The production of antibodies to coumarin and its major human metabolites by Killard, Anthony J.
THE PRODUCTION OF ANTIBODIES TO COUMARIN AND ITS 
MAJOR HUMAN METABOLITES
A thesis submitted for the degree of Ph.D.
by
Anthony Killard B.A. (Mod).
July 1998
Based on research carried out at 
School of Biological Sciences 
Dublin City University 
Dublin 9 
Ireland
Under the supervision of 
Prof. Richard O’Kennedy
To Mum, Dad, Jackie and Kieran.
"An expert is a man who has made all the mistakes which can be made in a very
narrow field."
Niels Henrik Bohr
"I think I must be an expert by now."
Anthony J. Killard
ii
I hereby certify that this material, which I now submit for assessment on the programme 
of study leading to the award of Ph.D. is entirely my own work and has not been taken 
from the work of others save and to the extent that such work has been cited and 
acknowledged within the text of my own work.
iii
ACKNOWLEDGMENTS
Although the previous page states that this work is all my own, no Ph.D. would be 
possible without the help and support of so many people; family, friends and colleagues. 
Many thanks to Richard for his patience and constant positive attitude. Thanks to my 
family for giving me all the support I needed to get through this. To all the lab gang, past 
(especially Mary, Teresa, Rob and Declan), and present (Stephen, Paul, Gary, Ciaran, 
Deirdre, Brian and John). You have all been an inspiration. Special thanks to Mike who 
helped me out of a few difficult patches. Also to the technical staff for putting up with 
my all too frequent visits for so long. Thank you everybody.
iv
CONTENTS
Publications and Presentations xvi
Abstract xviii
Abbreviations and symbols xix
1.0 INTRODUCTION 1
1.1 THE IMMUNE SYSTEM 1
1.1.1 The Lymphoid system 1
1.1.2 The humoral immune response 3
1.2 ANTIBODY STRUCTURE 8
1.3 ANTIBODY CHAIN GENE RECOMBINATION 11
1.4 MONOCLONAL ANTIBODY TECHNOLOGY 13
1.5 ANTIBODY ENGINEERING 15
1.6 COMBINATORIAL PHAGE DISPLAY LIBRARIES 21
1.6.1 The pComb3 System 24
1.6.2 The Nissim Library 30
1.6.3 Bacterial surface display 30
1.7 ANTIBODY CONJUGATES AND CHIMAERAS 33
1.8 HUMANISED ANTIBODIES 36
1.9 AFFINITY MATURATION 39
1.10 CATALYTIC ANTIBODIES 40
1.11 ENGINEERED ANTIBODIES IN THE TREATMENT OF DISEASE 44
1.12 INTRACELLULAR IMMUNISATION 45
1.13 BISPECIFIC ANTIBODIES 56
1.13.1 Bispecific antibody therapy in association with 
chemotherapeutic drugs 50
1.14 COUMARIN 50
1.14.1 The metabolism and pharmacokinetics of coumarin in man 51
1.14.2 Pharmacological role of coumarin and its metabolites 55
1.14.3 The analysis of coumarin and its metabolites 57
1.14.3.1 Physical methods of coumarin analysis 57
v
1.14.3.2 lmmunoanalytical techniques for coumarin analysis 57
1.14.4 Engineered antibodies for coumarin analysis 59
1.15 AIMS 61
2.0 MATERIALS AND METHODS 62
2.1 MATERIALS 63
2.2 EQUIPMENT 64
2.3 METHODS 66
2.3.1 General protocols 66
2.3.1.1 Culture media formulations 66
2.3.1.2 Standard molecular biology protocols 67
2.3.1.3 Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) 67
2.3.1.4 Coomassie blue staining 67
2.3.1.5 Silver staining 68
2.3.1.6 Western blotting 68
2.3.1.7 Dot blotting 68
2.3.1.8 Bicinchoninic acid (BCA) assay 69
2.3.1.9 Production of anti-VC SMI 3 antibody in rabbit 69
2.3.1.10 Production and purification of anti-c-myc antibody from 
mycl-9E10 70
2.3.1.11 Standard enzyme immunoassay protocol using polyclonal 
antibodies 70
2.3.1.11.1 Non-competitive enzyme immunoassay 70
2.3.1.11.2 Competitive enzyme immunoassay 71
2.3.1.12 Standard enzyme immunoassay protocol using single chain
Fv antibodies 71
2.3.1.12.1 Non-competitive enzyme immunoassay 71
2.3.1.12.2 Competitive enzyme immunoassay 72
2.3.1.13 Agarose gel electrophoresis 72
vi
2.3.2 Production of murine Fab antibody libraries to coumarin and 7- 
bydroxycoumarin 73
2.3.2.1 Production of a coumarin-thyroglobuttn conjugate 73
2.3.2.2 Characterisation of the coumarin-thyroglobulin conjugate 74
2.32.3 Spectrophotometric estimation of drug-protein coupling ratios 74
2.3.2.4 Immunisation of mice with coumarin-thyroglobulin and 7- 
hydroxycoumarin-thyroglobulin 74
2.3.2.5 Preparation of mouse spleen messenger RNA 75
2.3.2.6 Reverse transcription of mouse spleen mRNA 76
2.3.2.7 Amplification of antibody light and heavy chain genes using 
polymerase chain reaction 77
2.3.2.7.1 PCR Primers 77
2.3.2.7.2 PCR reaction 78
2.3.2.7.3 Purification o f PCR reaction products 79
2.3.2.8 Insertion of antibody heavy or light chain genes into the
pGEM-T plasmid vector 79
2.3.2.9 Preparation of electrocompetent Escherichia coli XLl-Blue cells 79
2.3.2.10 Measurement o f transformation efficiency of
electrocompetent E. coli XLl-Blue cells 80
2.3.2.11 Transformation of E. coli XLl-Blue with pGEM-T plasmid
vector containing light and heavy chain gene inserts 80
2.3.2.12 Isolation of light and heavy chain gene inserts from pGEM-T 81
2.3.2.13 Preparation of pComb3 phagemid vector for insert ligation
of antibody heavy chain genes 81
2.3.2.14 Transformation of E. coli XLl-Blue with pComb3 plasmid
vector containing light and heavy chain gene inserts 82
2.3.3 Production of single chain Fv antibodies to coumarin and 7- 
hydroxycoumarin 83
2.3.3.1 The Nissim library 83
2.3.3.2 Growth of the Nissim Library 83
2.3.3.3 Preparation of phagemid particles 83
vii
2.3.3.4 Affinity selection of scFv antibodies using the Nissim library 84
2.3.3.5 Affinity selection of antibodies using BlAcore™ 85
2.3.3.6 Screening of scFv antibodies by Phage ELISA 86
2.3.3.6.1 Preparation o f clones for phage ELISA 86
2.3.3.6.2 Phage ELISA 86
2.3.3.7 Transfer of pHENl to HB2151 for screening of soluble scFv 
antibody expression 87
2.3.3.8 Screening of scFv isolates for soluble antibody expression 87
2.3.3.9 Analysis of the cellular distribution ofscFv antibodies 88
2.3.3.10 Large scale scFv antibody production 88
2.3.3.11 Production ofscFv antibody from intracellular compartments 89
2.3.3.12 Large scale phage antibody production 89
2.3.3.13 BlAcore™ kinetic analysis of anti-coumarin scFv antibody
clones 89
2.3.4 The in vitro production of 7-hydroxycoumarin glucuronide 90
2.3.4.1 Preparation of porcine and bovine UDP-glucuronyl transferase 90
2.3.4.2 Initial analysis of the in vitro production of 7-hydroxy coumarin- 
glucuronide by HPLC 91
2.3.4.3 Repeat analysis of the in vitro production of 7-hydroxy coumarin- 
glucuronide by HPLC 92
2.3.4.4 Analysis of the in vitro production of 7-hydroxy coumarin- 
glucuronide by capillary electrophoresis (CE) 94
2.3.5 Purification of 7-hydroxycoumarin-glucuronide 95
2.3.5.1 Chromatographic separation of 7-hydroxycoumarin and 7- 
hydroxycoumarin-glucuronide 95
2.3.5.2 Chromatographic purification of 7-hydroxycoumarin-glucuronide 
from crude enzymatic reaction mixtures 95
2.3.5.3 Chromatographic purification of 7-hydroxycoumarin-glucuronide 
from coumarin-treated urine 95
viii
2.3.5.4 Development of a methodology for the extraction of 7- 
hydroxycoumarin-glucuronide from aqueous solutions 96
2.3.5.5 Extraction of 7-hydroxycoumarin-glucuronide from enzymatic 
reaction mixtures and coumarin-treated patient urine 96
2.3.5.6 Assessment of the thermal stability of 7-hydroxy coumarin- 
glucuronide at 6(fC 96
2.3.5.7 Assessment of the stability of 7-hydroxy coumarin-glucuronide to
a range of different pH conditions 96
2.3.5.8 In vitro enzymatic production of 3-amino-7-hydroxycoumarin- 
glucuronide 97
2.3.5.8.1 Preparation of 3-amino-7-hydroxycoumarin 97
2.3.5.8.2 In vitro enzymatic production o f 3-amino-7- 
hydroxy coumarin-glucuronide 97
2.3.5.9 Production of a 7-hydroxycoumarin-glucuronide-bovine serum 
albumin conjugate 97
3.0 PRODUCTION OF MURINE Fab ANTIBODY LIBRARIES TO 
COUMARIN AND 7-HYDROXYCOUMARIN USING THE pComb3 
SYSTEM 99
3.1 INTRODUCTION 100
3.1.1 Antibody phage display systems 100
3.1.2 Source and quality of material for library construction 100
3.1.3 Production of hapten-protein conjugates 101
3.1.4 T/A cloning vectors 101
3.2 RESULTS 103
3.2.1 Preparation of coumarin and 7-hydroxycoumarin protein conjugates 103
3.2.2 Production of coumarin-thyroglobulin (coumarin-THG) conjugate 103
3.2.3 Immunisation of mice with coumarin-THG and 7-hydroxycoumarin- 
THG 111
ix
3.2.4 Preparation of splenomic RNA 113
3.2.5 Selection of murine PCR primers based on homology plots 113
3.2.6 Murine PCR Primers 114
3.2.7 PCR optimisation 117
3.2.8 Preparation of pComb3 for heavy chain insert ligation 119
3.2.9 Measurement of the Electrocompetence of Escherichia coli XLl-Blue 119
3.2.10 Insertion of mouse 5 heavy chain genes into pGEM-T 119
3.2.11 Insertion of mouse 5 variable light chain genes into pGEM-T 120
3.3 DISCUSSION 124
3.3.1 Preparation of protein conjugates for immunisation 124
3.3.2 Characterisation of coumarin-thyroglobulin (coumarin-THG) 125
3.3.3 Mouse serum antibody titres following immunisation 125
3.3.4 PCR primer production 126
3.3.5 PCR optimisation 127
3.3.6 PCR fragment purification 128
3.3.7 Construction of light and heavy chain gene libraries in pGEM-T 128
3.3.8 Heavy and light chain gene insertion into pComb3 128
4.0 THE PRODUCTION OF SINGLE CHAIN Fv (scFv) ANTIBODIES TO 
COUMARIN AND 7-HYDROXYCOUMARIN USING THE N1SSIM 
LIBRARY 130
4.1 INTRODUCTION 131
4.1.1 Use of the Nissim library in the isolation of single chain scFv (scFv) 
antibodies 131
4.1.2 Affinity selection strategies 131
4.1.3 Affinity selection of antibodies from libraries using BIAcore™ 134
4.1.4 Induction of protein expression from phagemid pHENl 135
4.1.5 Screening of antibody clones from phage display libraries 135
x
4.1.6 Isolation and refolding of scFv antibody protein from insoluble 
inclusion bodies 137
4.1.7 Affinity purification of antibodies 138
4.1.8 Composition of affinity matrices 139
4.1.9 Concentration of purified antibodies 139
4.1.10 Immunoassay strategies for the measurement of drug-hapten 
concentrations 140
4.1.11 Antibody kinetics and equilibria 143
4.1.12 Analysis of antibody kinetics using BIAcore™ 145
RESULTS 146
4.2 PRODUCTION OF ANTI-COUMARIN ANTIBODIES FROM THE
NISSIM LIBRARY 146
4.2.1 Phage ELISA of anti-coumarin phage antibodies 146
4.2.2 Phage ELISA of anti-coumarin phage antibodies raised against 6- 
amino-coumarin coupled via N-oxysuccinimide ester 146
4.2.3 Screening of anti-coumarin positive clones for soluble scFv antibody 
production 146
4.2.4 Optimisation of affinity purification of anti-coumarin scFv clones 150
4.2.4.1 Effect of high pH on OrC14 elution from coumarin-BSA 150
4.2.4.2 Batch purification of a -C5 and OrC13 150
4.2.4.3 Optimisation of OrC13 affinity purification 154
4.2.4.4 Comparison of phosphate-buffered saline (PBS) and Tris as 
buffers in ELISA of U-C5 scFv 154
4.2.4.5 Purification of a-C5 and oc-C13 using NaCl gradient 158
4.2.4.6 Purification of c/j-C14 using NaCl gradient 158
4.2.4.7 Optimised purification of anti-coumarin scFv antibodies from 
culture supernatants and periplasmic lysates 159
4.2.4.8 Modification of scFv ELISA using anti-human F(ab’)2 antibody 159
4.2.5 Characterisation of anti-coumarin scFv antibodies 172
xi
4.2.5.1 Optimisation o f competition ELISA for the detection o f free
coumarin 172
4.2.5.1a Selection of optimal antibody concentration 172
4.2.5.1b Selection of optimal coumarin-BSA coating concentrations 172
4.2.5.1c Competition ELISA analysis o f free coumarin using anti-
coumarin scFv 172
4.2.6 Assessment of the effect of methanol and NaCl concentration on 
competition ELISA with a-C5, a-C13 and a-C14 172
4.2.7 The effect of NaCl concentration on anti-coumarin scFv binding to 
coumarin-BSA 174
4.2.8 Competition of anti-coumarin-BSA scFv antibodies against coumarin- 
BSA 174
4.2.9 Competition of a-C5 scFv with different coumarin-protein conjugates 174
4.2.10 Assessment of the multi-specificity of the anti-coumarin scFv 
clones to different coumarin derivative-BSA conjugates 175
4.2.11 Use of anti-coumarin-BSA scFv antibodies as western blot reagents 175
4.2.12 Characterisation and kinetic analysis of anti-coumarin-BSA scFv 
antibodies using BIAcore™ 185
4.3 PRODUCTION OF ANTI-7-HYDROXYCOUMARIN ANTIBODIES
FROM THE NISSIM LIBRARY 187
4.3.1 Phage ELISA screening of first anti-7-hydroxycoumarin library 187
4.3.2 Phage ELISA analysis of second anti-7-hydroxycoumarin library 187
4.3.3 Analysis of supernatant and periplasmic lysates of anti-7- 
hydroxycoumarin clones for the presence of scFv 187
4.3.4 Use of BIAcore for the affinity selection of anti-7-hydroxycoumarin 
clones from the Nissim library 188
4.3.5 Comparison of lysis methods in the isolation of scFv from intracellular 
compartments 193
4.3.6 Analysis of denatured and refolded anti-7-hydroxycoumarin clones 193
4.3.7 Induction and affinity purification of (X-70HC10 193
4.3.8 ELISA of purified OC-70HC10 199
4.3.9 Affinity purification of a-70HC9 199
4.3.10 Induction optimisation of (X-70HC10 204
4.3.11 Precipitation of purified and concentrated scFv preparations 204
4.3.12 Characterisation of anti-7-hydroxycoumarin phage antibodies 207
4.3.13 Reselection, screening and isolation of a-7-hydroxy coumarin scFv 
clones 207
DISCUSSION 212
4.4 PRODUCTION OF ANTI-COUMARIN scFv ANTIBODIES USING 
THE NISSIM LIBRARY 212
4.4.1 Selection of scFv antibodies to coumarin 212
4.4.2 Screening of scFv antibodies to coumarin 212
4.4.3 Purification of scFv antibodies to coumarin 213
4.4.4 Characterisation of scFv antibodies to coumarin 216
4.4.5 Summary 222
4.5 PRODUCTION OF ANTI-7-HYDROXYCOUMARIN scFv 
ANTIBODIES USING THE NISSIM LIBRARY 223
4.5.1 Selection and screening of scFv antibodies to 7-hydroxycoumarin 223
4.5.2 Isolation of scFv antibodies to 7-hydroxycoumarin from intracellular 
lysates 225
4.5.3 Production of phage antibodies to 7-hydroxycoumarin 227
4.5.4 Affinity selection of scFv antibodies to 7-hydroxycoumarin using 
BIAcore 227
4.5.5 Optimised affinity selection and screening of scFv antibodies to 7- 
hydroxycoumarin 228
4.5.6 Characterisation of scFv antibodies to 7-hydroxycoumarin 228
xiii
4.6 THEORIES AS TO WHY scFv ANTIBODY PRODUCTION 
STRATEGIES DID NOT RESULT IN ANTIBODIES WHICH 
SIGNIFICANTLY RECOGNISE FREE DRUG 229
4.7 CONCLUSION 232
5.0 7-HYDROXYCOUMARIN-GLUCURONIDE: PRODUCTION,
PURIFICATION, ANALYSIS AND CONJUGATION FOR THE 
PRODUCTION OF POLYCLONAL ANTIBODIES 233
5.1 INTRODUCTION 234
5.1.1 In vitro metabolic studies of 7-hydroxycoumarin 234
5.1.2 The use of HPLC for the analysis of coumarin metabolism 235
5.1.3 Reverse phase chromatography 236
5.1.4 Capillary electrophoresis (CE) 236
5.1.5 Liquid/liquid extraction 237
5.1.6 Conjugation strategies 237
RESULTS 240
5.2 The in vitro production of 7-hydroxycoumarin-glucuronide 240
5.2.1 Initial analysis of the in vitro production of 7-hydroxycoumarin 
glucuronide by HPLC 240
5.2.2 Repeat analysis of the in vitro production of 7-hydroxycoumarin- 
glucuronide by HPLC 245
5.2.3 Analysis of the in vitro production of 7-hydroxycoumarin-glucuronide
by capillary electrophoresis (CE) 248
5.3 Purification of 7-hydroxycoumarin-glucuronide 251
5.3.1 Separation of 7-hydroxycoumarin and 7-hydroxycoumarin-glucuronide
by reverse phase column chromatography 251
5.3.2 Purification of 7-hydroxycoumarin-glucuronide from crude enzymatic 
reaction mixtures by reverse phase column chromatography 255
xiv
5.3.3 Purification of 7-hydroxycoumarin from coumarin-treated patient 
urine using reverse phase column chromatography 258
5.3.4 Extraction of 7-hydroxycoumarin-glucuronide from urine in 
dichloromethane (DCM)rmethanol 258
5.3.5 Purification of 7-hydroxycoumarin-glucuronide from coumarin-treated 
patient urine and enzymatic reaction mixtures by reverse phase 
chromatography following extraction in dichloromethane 
(DCM): methanol (70:30 v/v) 261
5.4 Characterisation of 7-hydroxycoumarin-glucuronide 264
5.4.1 Thermal stability of 7-hydroxycoumarin-glucuronide at 60°C 264
5.4.2 Stability of 7-hydroxycoumarin-glucuronide with respect to pH 265
5.5 In vitro enzymatic production of 3-amino-7-hydroxycoumarin- 
glucuronide 266
5.5.1 Production of 3-amino-7-hydroxycoumarin 266
5.5.2 In vitro enzymatic production of 3-amino-7-hydroxycoumarin- 
glucuronide 266
5.6 Production and analysis of a 7-hydroxycoumarin-glucuronide-bovine 
serum albumin conjugate prepared by EDC/NHS coupling chemistry 272
DISCUSSION 275
5.8 In vitro production of 7-hydroxycoumarin-glucuronide and analysis by 
HPLC 275
5.9 In vitro production of 7-hydroxycoumarin-glucuronide and analysis by
CE 277
5.10 Purification of 7-hydroxycoumarin-glucuronide 278
5.11 Physical analysis of 7-hydroxycoumarin-glucuronide 282
5.12 Conjugate production 282
6.0 OVERALL CONCLUSIONS 286
7.0 REFERENCES 290
APPENDIX Prize winning essays in Biochemistry 319
xv
PUBLICATIONS AND PRESENTATIONS
Killard, A.J., O’Kennedy, R., and Bogan, D.P. (1996). Analysis of the glucuronidation 
of 7-hydroxycoumarin by HPLC. J. Pharm. Biomed. Anal., 14:1585-1590.
Bogan, D.P., Killard, A.J., and O’Kennedy, R. (1995). The use of capillary 
electrophoresis for studying the in vitro glucuronidation of 7-hydroxycoumarin. J. 
Capillary Electrophoresis, 2(5):241-245.
Killard, A.J., Deasey, B., O’Kennedy, R., and Smyth, M.R. (1995). Antibodies: 
Production, functions and applications in biosensors. Trends in Analytical Chemistry, 
14(6):257-266.
McCormack, T., Keating, G.J., Killard, A.J., and O’Kennedy, R. Biomaterials for 
Biosensors in "Sensors and Signals", John Wiley and Sons, New York, 1998.
Roben, P., Killard, A.J., and O’Kennedy, R. Immunoanalytical techniques: Concepts and 
applications in "Bioanalysis", Ellis Horwood, In Press.
Killard, A.J., Keating, G.J. and O’Kennedy, R. (1997). Production and characterization 
of anti-coumarin scFv antibodies. Biochem. Soc. Trans. 26: S33.
Killard, A., How the antibody army kills what could kill us. The Irish Times, June 3rd 
1996, p.2.
Killard, A. PCR and its uses in genetic engineering of antibodies, Modem Techniques in 
Molecular Life Sciences. An Occasional Symposium Series for Researchers. Royal Irish 
Academy National Committee for Biochemistry, Trinity College, Dublin, May 24th 1995.
xvi
Killard, A.J., Keating, GJ. and O’Kennedy, R , Production and characterization of anti- 
coumarin scFv antibodies, Biochemical Society, 663rd Meeting, University College 
Galway, 3-4 Sep. 1997.
Daly, S.J., Killard, AJ., Dillon, P.P., Smyth, M.R. and O’Kennedy, R., Single chain 
antibodies to 7-hydroxycoumarin and towards a bispecific scFv, Biochemical Society, 
663rd Meeting, University College Galway, 3-4 Sep. 1997.
Killard, A.J., Smyth, M.R. and O’Kennedy, R., The production of single chain Fv 
antibodies to small, hydrophobic haptens, Biochemical Society Meeting, Dublin City 
University, 9-10 Sep. 1998.
ABSTRACT
Two strategies were applied to the production of antibodies to coumarin and its phase I 
metabolite, 7-hydroxycoumarin. One system was the production of Fab antibody fragments 
using the combinatorial phage display library, employing the phagemid vector, pComb3. 
Although a library of murine heavy and light chain genes was established following 
immunisations with coumarin and 7-hydroxycoumarin conjugates, preparation of the 
library in pComb3 was not possible due to associated problems with this vector.
An alternative antibody library system was obtained. This was the naive semi-synthetic 
human scFv library of Nissim et al. (1994). The production of antibodies to both 
coumarin and 7-hydroxycoumarin was investigated. Various production and isolation 
techniques were explored. Best results were obtained by isolating correctly folded scFv 
protein from the periplasm or culture supernatants of E. coli. In the case of coumarin, 
three soluble antibody clones were isolated and characterised. These clones showed the 
characteristics of poor affinity for free coumarin, but did bind well to coumarin-protein 
conjugates. Isolated anti-7-hydroxycoumarin clones also showed the same characteristics 
of no binding to free drug. It was theorised that, due to the structural simplicity of these 
molecules, affinity selection and screening is biased against the detection of clones with 
high affinity for free drug. This conclusion was in broad agreement with other findings 
(Danilova, 1994). Recommendations are made as to how the selection and screening 
procedures can be improved to isolate antibodies to such molecules.
Techniques for the in vitro production of the phase II metabolite 7-hydroxycoumarin- 
glucuronide were developed. These were accompanied by the development of analytical 
methods (capillary electrophoresis and HPLC) for the glucuronide. Purification 
methodologies using 7-hydroxycoumarin present in these metabolic mixtures and in urine 
were also developed. The coupling of 7-hydroxycoumarin-glucuronide to proteins for the 
production of antibodies was also explored. A 7-hydroxycoumarin-glucuronide-bovine 
serum albumin conjugate was successfully synthesised for use in further antibody 
production strategies.
ABBREVIATIONS AND SYMBOLS
a  Alpha - denoting anti, i.e. anti-7-hydroxycoumarin (a-7-hydroxycoumarin)
Ab Antibody
Ag Antigen
BSA Bovine serum albumin
bp base pairs
Cb Carbenicillin
cDNA copy (complementary) DNA
CDR Complementarity determining region
CE Capillary electrophoresis
CEA Carcinoembryonic antigen
cfu colony forming units
CIP Calf intestinal phosphatase
CMV Cytomegalovirus
DCM Dichloromethane
DEAE Diethyl-aminoethyl
DEPC Diethyl-pyrocarbonate
DMSO Dimethyl sulphoxide
dNTP deoxynucleotidyl triphosphates
dsFv disulphide Fv
DTT Dithiothreitol
EBV Epstein-Barr virus
EDC 1-ethyl-3 (3-dimethylaminopropyl)carbodiimide
ELISA Enzyme-linked immunosorbent assay
ER Endoplasmic reticulum
Fab Antigen binding fragment
FCA Freund’s Complete Adjuvant
Fv Variable fragment
Gdn Guanidine
HAMA Human anti-mouse antibody
HEL Hen egg lysozyme
HEV High endothelial venule
hGH human growth hormone
HTV Human immunodeficiency virus
HPLC High performance liquid chromatography
HRP Horseradish peroxidase
HSV Herpes simplex virus
IFN Interferon
IG Intergenic region
Ig Immunoglobulin
IPTG Isopropyl-P-D-thiogalactopyranoside
IR Infrared
ITAM Immunoreceptor tyrosine-based activation motif
KLH Keyhole limpet haemocyanin
Kn Kanamycin
LOD Limit of detection
xix
LPS Lipopolysaccharide
MeOH Methanol
MHC Major histocompatibility complex
mlg membrane Ig
mRNA messenger RNA
NHS N-hydroxysuccinimide
OD Optical density
70HC 7-hydroxycoumarin
7OHCG 7-hydroxyc oumarin-glucuronide 
OPDA o-phenylene diamine
d> Phi - denoting attachment of antibody to phage
PAGE Polyacrylamide gel electrophoresis
PBL Peripheral blood lymphocyte
PBS Phosphate-buffered saline
PCR Polymerase chain reaction
PDA Photodiode array
pfu plaque forming unit
PMSF Phenyl methyl sulphonylfluoride
PVDF Polyvinylidene difluoride
RSV Respiratory syncitial virus
RT Room temperature
RU Response unit
scFv Single chain Fv
SDS Sodium dodecyl sulphate
SPR Surface plasmon resonance
Tc Tetracycline
TCR T cell receptor
tfu titre forming unit
TGF T cell growth factor
THG Thyroglobulin
TLC Thin layer chromatography
TNF Tumour necrosis factor
Tris Tris(hydroxymethyl)aminomethane
UDP Uridine diphosphate
UDPGT UDP-glucuronyl transferase
VSV Varicella Zoster virus
X-Gal 5-bromo-4-chloro-3-indolyl-p-D-galactoside
xx
1. INTRODUCTION
1.1 THE IMMUNE SYSTEM
The mammalian immune system is composed of a group of organs distributed throughout 
the organism called the lymphoid system. These structures give rise to, and harbour 
specialised cells which produce polypeptide signals called cytokines that control the 
immune response. These cells, associated proteins and cytokines orchestrate the 
surveillance, detection and removal of all foreign materials from the organism (Kuby, 
1997; Roitt et al., 1998).
1.1.1 The Lymphoid system
The lymphoid system is a collection of organs scattered throughout the body. The primary 
lymphoid organs comprise the bone marrow and the thymus. Bone marrow is the initial 
source of pluripotent haemopoietic stem cells which differentiate into lymphoid or 
myeloid progenitor cells. Lymphoid cells that mature in the bone marrow are called B 
cells. These develop the property of antibody production. Other lymphoid cells migrate 
to the thymus gland where they develop into various classes of T cell which possess the 
ability to recognise foreign antigenic epitopes via a surface immunoglobulin structure 
known as the T cell receptor (TCR). These cells are considered part of the adaptive 
immune response because they selectively recognise foreign structures in the body. Other 
cells of the immune system which develop from myeloid precursors go on to form 
phagocytic cells such as monocytes and macrophages as well as lytic cells such as 
neutrophils, basophils and eosinophils. These have no ability to differentiate between self 
and non-self, but respond non-specifically to damage and injury. These, in conjunction 
with soluble immune components such as complement and interferons comprise the innate 
immune system.
Many organs possess a secondary lymphoid function. The most important organ in this 
regard is the spleen. Also important are the lymph nodes which are scattered along the 
median line of the body and are connected to each other and the spleen via a network of 
lymphatic vessels. Although differing in structure, both organs act as sites at which T and 
B cells can interact with one another at high concentrations to bring about effective T
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cell-dependent B cell activation. Other important secondary lymphoid organs are the 
mucosa-associated lymphoid tissues (MALT) present in the g astro-intestinal, urinogenital 
and respiratory tracts and the skin-associated lymphoid tissues (SALT). These all show 
similar structures as those found in the spleen and lymph nodes comprising areas of high 
B and T cell density. Lymphoid cells can circulate freely between the cardiovascular 
system and the lymphatic system either through the lymphoid organs themselves or across 
high endothelial venules (HEV).
1.1.2 The humoral immune response
Immune responses are normally initiated at a site of damage or injury, as a result of skin 
abrasions, for example, or tissue necrosis brought about by microbial infection. 
Polymorphonuclear cells are attracted to the site of damage via chemotaxis, either via 
complement C5a release by damaged cells or via the alternative complement cascade 
whereby bacteria bring about the release of complement C3. This infiltration is rapidly 
followed by other phagocytic cells that digest damaged tissues, necrotic cells and other 
foreign components such as bacteria. This infiltration of immune cells in a localised area 
leads to the symptoms of inflammation: heat (calor); pain (dolor); redness (rubor); and 
swelling (rigor). Opsonization is triggered by attachment of bacteria to non-specific 
receptors or via complement C3b receptors. Opsonization can also be carried out by other 
antigen presenting cells such as monocytes and macrophages. Normally for an effective 
adaptive response, both B and T cells must become stimulated via antigen presentation. 
T cell-independent activation of B cells, however, can be brought about by the cross- 
linking of surface Ig with a polyvalent antigen, or via a mitogenic antigen such as 
lipopolysaccharide (LPS), which cross-links surface Ig with a B cell mitogen receptor. The 
response brought about by T cell-independent antigens is poorer than T cell-dependent 
responses, resulting in limited class switching and affinity maturation, yielding 
predominantly low affinity IgM responses. Antigen presentation primarily takes place in 
the secondary lymphoid tissues, whether in the skin via Langerhan’s cells or dendritic 
cells, in Peyer’s patches in the gastrointestinal mucosa and other mucosal surfaces, or via 
circulating monocytes in the lymph nodes or spleen. These macrophages, or naive B cells 
- which recognise antigen via surface expressed mlgM and IgD - endocytose antigen.
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Macrophages are attracted to the site of damage or infection by chemotactic factors such 
as complement components, blood clotting factors and cytokines. Large organisms and 
dead cells adhere to the surface of the macrophages and are phagocytosed. Naive B cells 
endocytose in response to the attachment of antigen to surface immunoglobulins. Once 
internalised, the process of phagocytosis takes place. Here, highly hydrolytic enzymes, 
peroxidases and lysozyme are secreted into the phagolysosome contaning the endocytosed 
antigen. Most of the antigen is then expelled from the cell by exocytosis. Some parts of 
the antigen such as short peptides are presented at the cell surface in association with 
class IIMHC (Fig. 1.1). Antigen cross-linking of mlg on naive B cells also results in the 
first of the competence signals which drives the naive B cell from resting G0 into Gt. 
Signal transduction is facilitated by the B cell receptor complex comprising mlg and two 
signal transducing Ig-oc/Ig-P heterodimers. Immunoreceptor tyrosine-based activation 
motifs (ITAMs) present on the cytoplasmic side of Ig-a and Ig-p interact with members 
of the Src family of tyrosine kinases and Syk kinase, activating them. These phosphorylate 
tyrosine residues on the cytoplasmic tails of Ig-oc/Ig-P, activating three pathways that 
bring about transcriptional modifications.
Although antigen presenting cells are involved in activation of TH cells, B cells recognise 
and internalise antigen specifically and present antigen at concentrations of hundreds to 
thousands of times lower than other antigen presenting cells, and so are probably more 
important at lower antigen concentrations. The other cell types principally involved in 
antigen processing and presentation are dendritic cells and macrophages. All three cell 
types express MHC class n , but dendritic cells and B cells do so constitutively. 
Macrophages are activated by the phagocytosis of large antigens such as microorganisms, 
before MHC class II expression is induced.
TH cells recognise antigen in the presence of the B cell or macrophage in association with 
MHC class II via their T cell receptor complex. When this occurs, the T and B cell form 
a complex. This causes the expression of CD40L on the surface of the activated TH cell. 
CD40L interacts with the B cell surface glycoprotein CD40, which triggers the second B 
cell competence signal, which in turn triggers the B cell to express receptors for various 
cytokines. TH cells also undergo internal rearrangements which result in the targeted
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secretion of cytokines towards the B cell. TH cells produce IL-2, IL-4 and IL-5 which 
drive the B cells into S phase, mitosis and B cell proliferation. These activated B cells are 
referred to as centroblasts. TH cells form two distinct populations based on their cytokine 
secretion characteristics and are referred to as TH1 and TH2. TH2 cells act most effectively 
as helper cells in B cell activation. TH1 cells are primarily responsible for the activation 
of cytotoxic T cells.
Activated centroblasts now undergo a process of affinity maturation which involves 
somatic hypermutation and high affinity selection. Somatic mutation involves the 
introduction of point mutations, deletions and insertions in the rearranged VHJ segments 
of genes, most of which occur in the CDR regions. This mutation rate is estimated at 1 
in 1000 base pairs per division and is 106 fold greater than normal mutation rates. This 
occurs late in the primary response. This mutation rate will bring about a single mutation 
in each antibody clone. Most mutations will result in decreased affinities. The few that 
are of higher affinity are positively selected by binding to antigen complexes on the 
surface of follicular dendritic cells. This interaction brings about a signal which induces 
up regulation of Bcl-2, so preventing apoptosis. Those that have decreased affinity and 
do not bind to antigen on follicular dendritic cells undergo apoptosis.
Many mutations are required to bring about the large increases in affinity seen in a mature 
immune response. Following a period of cellular rest, the centrocyte undergoes cycles of 
proliferation and mutation, followed by further rounds of positive selection via antigen 
binding on follicular dendritic cells.
Another important part of the differentiation of B cells is class switching. These events 
are also TH cell-dependent and require the competence signals triggered by CD40/CD40L 
interactions, as well as cytokine induction. The proliferating, high affinity centrocyte will 
be triggered to form different isotypes as a result of the type of cytokine signalling it 
receives, which is, in turn, dictated by its local environment. B cells maturing in MALT 
will form IgA antibodies under the influence of TGF-(3. B cells from non-mucosal 
lymphoid tissues such as the spleen, tonsils and lymph nodes will produce IgG subtypes
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under the influence of IFN-y or IL-4. Exposure to these various cytokines make certain 
switch sites on the CH domains of genes accessible to recombinase enzymes.
High level soluble antibody production in plasma cells is triggered by IL-1 and CD23 
secretion from the follicular dendritic cell. CD23 binds to CR2 on the plasma cell and 
switches off production of mlg with up-regulation of soluble antibody production. For 
memory B cell production, the centrocyte internalizes antigen and displays it in 
association with MHC class II to TH cells, resulting in CD40/CD40L interactions 
necessary for memory cell formation. This high affinity antibody producing, fully 
differentiated cell circulates for long periods and is readily induced to form antibody- 
producing plasma cells following subsequent rounds of antigenic challenge.
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Antigen in form of iccosomes Plasma cell
Figure 1.1. Tn cell-dependent B cell maturation in the humoral immune response. 
Antigen presentation via the B cell, in combination with surface cross-linking of 
antibodies at the B cell surface and interaction between the B and Th cell via 
CD40/CD40L brings about the competence signals which trigger the B cell to enter the 
cell cycle. Expression of cytokine receptors by the B cell and production of cytokines 
by the T„ cell drives the proliferation of the B cell. The activated B cell (centroblast) 
producing antibody of good affinity interacts with antigen released from the surface of 
follicular dendritic cells in the form of immune complexes called iccosomes. Cytokine 
signals from the follicular dendritic cell drives the B cell into rapid division and somatic 
mutation. High affinity variants go on to interact with follicular dendritic cells, while 
low affinity B cells are apoptosed. After many rounds of affinity maturation, high 
affinity antibody producing B cells either become antibody-producing plasma cells or 
circulating memory B cells.
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1.2 ANTIBODY STRUCTURE
Antibody molecules have come to symbolise the immense power of the mammalian 
immune system. Their power comes primarily from three characteristics; specificity, 
affinity and their ability to recruit effector functions. These characteristics are a result of 
their structure and ontogeny.
The structure of antibody molecules varies depending on their isotype, but are typified by 
the immunoglobulin G (IgG) molecule. (Roitt et al., 1998) (Fig. 1.2). The basic four 
polypeptide chain model was proposed by Rodney Porter (Porter et al., 1966). IgG 
consists of two identical heavy (H) and two identical light (L) chains. The H chain is 
some 450 amino acids (approximately 50 kDa) and the L chain is 212 amino acids 
(approximately 25 kDa) in length. The two H chains are held together by interchain 
disulphide linkages at the hinge region. The number and arrangement of these disulphide 
bonds varies between classes and subclasses (Edelmann and Poulik, 1961). L and H chains 
are also divided into distinct structural domains possessing intrachain disulphide bonds.
Antibodies are glycoproteins. All classes are glycosylated at the CH2 domain and 
additional glycosylation occurs at the CH1, hinge region and CH2 domains, again 
depending on isotype. Glycosylation may also occur in the V region. The H chain constant 
domains are class-specific. IgG molecules possess three C domains. IgM has an additional 
constant domain which, in combination with a cross-linking component, the J chain, 
results in cross-linking between adjacent constant domains, yielding the pentameric IgM 
structure. IgA has only three C domains with a distinctive c-terminal octapeptide 
sequence. IgA can form dimers with the presence of a secretory piece and J chain 
component anchoring adjacent Ca2 and Ca3 domains. IgE has an additional C domain 
which results in the oblation of the hinge region. There is a single constant L chain 
domain which can be of two isotypes, either k  or X.
Isotypic variation primarily results in changes in effector function of the various antibody 
types. The properties of antigenic recognition, specificity and affinity are as a result of the 
structure of the variable (V) domains present on both the L and H chains. Denoted by
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their high sequence variability, these variable domains are further subdivided into 
framework regions and complementarity determining regions based on levels of sequence 
variability. The four framework (FR) regions possess relatively low levels of sequence 
variation. These flank the three complementarity determining regions (CDRs) which 
possess high levels of sequence variability, with most variability being found in the third 
CDR region, CDR3. The CDRs of both L and H chain form six hypervariable loop 
structures on a beta sheet framework resulting in a three dimensional structure that is the 
antigen binding site. It is the sum total of hydrophobic and electrostatic interactions, van 
der Waals forces and hydrogen bonding between the amino acid side chains of the CDR 
regions and the antigen molecule that results in the high affinity interaction between the
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Figure 1.2. The immunoglobulin IgGl molecule. The antibody is composed of four 
peptide chains: two identical light and two identical heavy chains. H chains possess five 
distinct domains, variable (V), three constant (C) and a hinge (H) region. Light chains 
possess a single V and C domain. H chains and adjacent L and H chains are held 
together by interchain disulphide bridges. Two of these connect H domains of IgGl. 
Intrachain disulphide bridges also exist in V and C regions, resulting in the folded 
globular structure characteristic of antibodies. Areas of high sequence variability termed 
complementarity determining regions (CDR) form six hypervariable loop structures on 
a series of sequence frameworks, known as framework regions (FR). This is known as 
the antigen binding site and is the site of antigen attachment to the antibody.
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1.3 ANTIBODY CHAIN GENE RECOMBINATION
The variability present in the V regions of both L and H chains, and the differences in C 
region structure are a result of the genetic nature of antibody L and H chain germline 
genes (Tizard, 1995). Variable H chain regions are composed of sequences from three 
distinct loci, known as V, D and J regions. In L chain variable genes there are only V and 
J regions. The V region forms the 5’ end of the variable region, the D sequence, a central 
region and the J region, the 3’ end of the sequence. These genes are also found in this 
sequence on the germ line genes. V region sequences have evolved from common 
sequence ancestors to contribute to diversity. These V sequences have been grouped into 
families based on their 5’ sequence similarity. Different groupings were originally 
proposed, based both on DNA and protein sequence data (Brodeur and Riblet, 1984; 
Dildrop, 1984).
Variability results primarily from the presence of multiple V, D and J region sequences 
on the germline gene, of which there are several hundred VH, twelve DH and four JH 
segments. It is the recombination that occurs between these three regions that contributes 
further to variability. As a consequence of B cell maturation, recombination of VDJ (H 
chain) and VJ (L chain) sequences takes place. For a D region to become adjacent to a 
V region, an intervening sequence of other V and D regions is removed. This is done by 
a process of looping out. Here, intervening heptameric and nonameric complementary 
sequences form stem-loop structures and are removed (Fig. 1.3). This recombination is 
essentially random, with any V region recombining with any D and J region. The resulting 
VDJ or VJ sequence is now functional at the transcriptional level. Further diversity results 
from base shifts during recombination, somatic mutation and assortment between different 
H and L chain genes. Not surprisingly, the interface between V and D genes results in the 
CDR3 region in the VH chain as a result of these factors contributing to diversity. 
Antibody class is also determined by recombination as a result of B cell ontogeny. 
Constant H region genes are found in sequence downstream from the variable region 
genes. These are in a specific order; |i, 8, y, e, and a. At the 5’ end of each of these 
sequences, except 8, there is a switching sequence. In response to B cell maturation, C 
region genes are looped out at these switching sequences. IgM- and IgD-producing B cells
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V region germline DNA
Figure 1.3. Antibody variable heavy chain gene recombination. Multiple VH, VD and Vj 
regions present on the variable heavy region of the antibody germline gene recombine 
with one another in an essentially random fashion by the formation of stem-loop 
structures of intervening sequences, created by areas of complementarity in distinctive 
heptameric and nonameric stretches. Recombinase enzymes remove the intervening 
stem-loop, introducing further variability due to variations at the site of cleavage. The 
adjacent VDJ region now forms a functional B cell variable heavy chain gene.
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go on to produce IgG, IgA and IgE, depending on the individual environmental conditions 
to which that particular B cell is exposed. The resulting functional H chain transcripts now 
comprise VDJ and C region sequences in the case of H chains and VJC sequences in light 
chains, which result in the translation and assembly of intact immunoglobulin molecules.
1.4 MONOCLONAL ANTIBODY TECHNOLOGY
Prior to the advent of monoclonal antibody technology, antibody sera was mainly 
polyclonal in nature. These were made up of many antibody isotypes with various 
specificities to epitopes on the antigen of interest. Although such heterogeneous 
populations were useful in many serological applications, this heterogeneity also limited 
their potential in many areas. The development of monoclonal antibodies described by 
Kohler and Milstein in 1975 meant that a permanent source of homogeneous antibody 
with defined specificity and affinity could be produced. The homogeneity of the resulting 
monoclonal antibodies also allowed the elucidation of antibody structure by 
crystallographic techniques. The versatility of the antibody-antigen interaction has resulted 
in the use of monoclonal antibodies permeating almost every area of the biological 
sciences and beyond.
One area in which monoclonal antibodies have found widespread application is in the 
detection and therapy of neoplastic disease (von Mehren and Weiner, 1996; Bodey et a i, 
1996; Karius and Marriott, 1997) where their properties of specificity and high affinity 
have led to them being described as ’magic bullets’, with the ability to selectively target 
and destroy cancer cells. Many monoclonal antibodies have been developed with the aim 
of targeting tumour cells via tumour-specific or tumour-associated antigens. These cell 
surface markers assist in the differentiation between healthy and abnormal cells. In 
therapy, having selectively targeted the tumour, various means can be employed to destroy 
the cells. Antibodies alone can recruit natural effector functions. However, most 
monoclonal antibodies for clinical application are murine in origin, whose Fc portions do 
not effectively recruit human effector functions. Responses have been improved by the use
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of mouse/human chimaeras which possess human Fc portions fused to murine variable 
regions to improve effector activity (Motmans et al., 1996).
The enhancement of traditional radiotherapy and chemotherapy has been brought about 
by the use of monoclonal antibodies conjugated to radionuclides, toxins and other 
chemotherapeutic agents. Linkage of these components to an antibody increases their 
concentration at the site of action, resulting in reduced damage to healthy tissues while 
increasing the efficacy of the applied agent. Combining antibody and radionuclide also 
facilitates tumour imaging (Britton, 1996). Cancer detection and diagnosis are also 
facilitated by the use of monoclonal antibodies in immunocytochemistry (Beaty et al, 
1997).
Further improvements in the recruitment of cytotoxic cells for tumour destruction have 
been brought about by the linkage of two monoclonal antibodies to one another in a 
bispecific antibody. Here, one portion of the bispecific construct targets the tumour cell 
and the other targets cytotoxic cells via a suitable surface marker (Lindhofer et al., 1996; 
Clark et al., 1997). Prior to this, chemotherapeutic drugs had to be covalently linked to 
antibodies to target them effectively, which could affect the performance of the drug. 
Bispecific antibodies allow drug targeting without the requirement to conjugate the 
chemotherapeutic agent to the antibody.
In a further advance on combined antibody-chemotherapeutic treatment, antibodies are 
being coupled to enzymes which catalyse the breakdown of a non-toxic prodrug to a toxic 
component at the site of action in a system referred to as antibody-dependent enzyme 
prodrug therapy (ADEPT). A development of this technique utilises antibody catalysts to 
convert prodrug to drug. This catalytic antibody has been referred to as an ’abzyme’ and 
the technique labelled antibody-dependent ’abzyme’ prodrug therapy (ADAPT) 
(Wentworth et al., 1996). The use of monoclonal antibodies is also widespread in other 
therapeutic fields, such as the control of sepsis (Wheeler and Bernard, 1996), treatment 
of viral disease and control of allergic responses (Lebecque et al., 1997).
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Although there is an abundance of in vitro and animal model data for the benefit of 
antibody-based reagents in the treatment of cancer, only limited numbers of treatments 
have proved successful enough to reach full scale human clinical trials.
The use of monoclonal antibodies as a therapeutic tool in humans has, however, been 
severely limited because the vast majority are murine in origin. The in vivo use of such 
antibodies in humans leads to a human anti-murine antibody (HAMA) response. This 
limits the number of times the antibody can be used in a single patient. The human 
response reduces the antibody serum half-life and can, in the worst cases, lead to 
anaphylaxis.
Attempts have been made to produce human monoclonal antibodies in the same manner 
as murine hybridomas. However, there are fewer suitable myeloma fusion partners of 
human origin, some of which secrete antibody fragments which results in mixed antibody 
populations. Also, immunization is difficult and normally relies upon accidental 
immunization via infection or disease. In vitro immunization protocols for human 
lymphocytes have improved in recent times but are still fraught with difficulties. The 
source of B lymphocytes is also a problem. Although tonsils and peripheral blood 
lymphocytes are quite readily available, they do not equal the spleen in terms of the 
quality and quantity of lymphocytes (Ohlin and Borrebaeck, 1996). Attempts have also 
been made to immortalize specific B lymphocytes using the Epstein-Barr Virus (EBV), 
again with only limited success (Kozbor and Roder, 1983). In an attempt to overcome 
these obstacles, various molecular genetic techniques have been applied to make murine 
antibodies more ’human’ and so avoid anti-species responses when administered in man.
1.5 ANTIBODY ENGINEERING
Improved therapeutic and analytical applications of antibodies depended upon the 
development of techniques to genetically produce and manipulate antibody proteins 
through the field of study which is now broadly termed antibody engineering. Traditional 
molecular genetic techniques did not allow for the correct functional expression of whole 
antibody molecules. Most expression vectors are derived from plasmids that propagate
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in Escherichia coli (E. coli), and although correct expression of recombined light (L) and 
heavy (H) chain genes is possible, glycosylation does not take place. This affects the 
serum half-life and other characteristics of the antibody molecule. Full glycosylation 
requires the use of eukaryotic expression systems (Wright and Morrison, 1997). Antibody 
fragments are, however, easily manipulated using the expression vectors available. Work 
has thus concentrated on those parts of the antibody involved in the antibody-antigen 
interaction, namely the Fab fragment and its subcomponents. Various portions of this 
region have been manipulated in numerous protocols. These include the whole Fab 
(antigen-binding fragment) region, F(ab')2 (two antigen-binding fragments joined via the 
hinge region), Fd (VH and CH1 domains), Fv (variable fragment) and CDRs, the Fv region 
being the smallest fraction required to result in the complete antigen-antibody interaction 
(Fig. 1.4). It is believed that these small fragments may be more useful in many 
applications than whole antibody molecules as they possess improved tumour penetration 
characteristics, better pharmacokinetic properties (they are removed from the body more 
rapidly) and have reduced immunogenicity.
As stated, the absence of a reliable system to produce human antibodies was a significant 
problem for monoclonal antibody technology. The developing field of molecular genetics 
started to produce tools that could be applied to the problems encountered by those 
involved in antibody technology. An understanding of the processing of antibody 
messenger RNA (mRNA) (Schibler et al., 1978) was fundamental to being able to 
manipulate these species in vitro. Early work also established the familial nature of 
antibody genes (Brodeur and Riblet, 1984; Dildrop, 1984). With the advent of the 
polymerase chain reaction (PCR), systems for amplifying specific DNA or RNA 
sequences soon became available. (Saiki et al., 1985). It had been noted that large areas 
of antibody chain genes were conserved. Even in the variable regions, conserved 
sequences can be established when genes are divided into their respective families. These 
sequences proved ideal for the production of oligonucleotide primers that could flank the 
nucleic acid sequence of interest which could then be amplified and used for cloning 
(Orlandi et al., 1989). In early work, systems for the expression of these amplified genes 
in prokaryotes were inadequate. Initial studies involved transfection of antibody genes into 
myeloma cells using viral vectors. For example, an Abelson murine leukaemia virus
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Figure 1.4. Fragments of the antibody molecule. Various fractions of the whole 
antibody molecule may he generated either through genetic or enzymatic and chemical 
manipulation. Digestion with enzymes such as papain and pepsin yield either Fab 
(antigen-binding fragment) or F(ab,)2 (two antigen binding fragments linked by a hinge 
region) fragments and Fc (crystalline fragment) regions. Antibody chain gene 
manipulation has resulted in whole Fab fragments, Fv (variable fragment) moieties, 
some stabilised using a synthetic linker (scFv - single chain Fv), VH and CH1 chains 
(Fd) or equivalent VL chain sequences, as well as single CDR regions which have all 
been shown to be capable of binding antigen.
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(AMuLV)-transformed lymphoid cell line resulted in the stable expression of a kappa (k ) 
L chain gene from a plasmid using an SV40 early promoter with selection via 
mycophenolic acid resistance (Rice and Baltimore, 1982). Full antibody production was 
restored in a non-L chain-secreting mutant hybridoma cell line when transfected with a 
trinitrophenyl-specific k chain gene, again using the SV40 promoter and with selection 
using neomycin resistance (Ochi et al., 1983). An IgGjiq antibody was also secreted 
intact in a similar system in a J558L myeloma cell line (Oi, et a l, 1983). In a later 
development, Briiggemann et a l (1989) used a human H chain gene DNA to produce a 
transgenic mouse. DNA rearrangements had been found to occur at a high frequency in 
the thymus and spleen when compared to other cells demonstrating that the cloned genes 
were under the same cellular control as the mouse’s wild type antibodies. Briiggemann 
and Neuberger (1996) have developed this transgenic mouse to possess near complete 
human germline genes which undergo normal rearrangement and hypermutation. Such 
animals could be used to generate human monoclonal antibodies via mouse immunization.
Parallel improvements in the understanding of processing and transport systems in 
prokaryotes, especially E. coli gradually allowed the more efficient expression of foreign 
genes in prokaryotes using phage and plasmid vectors. The smallest antibody fragment 
required for complete antigen binding is the Fv fragment. Thus, for ease of cloning, much 
work concentrated on this portion. Skerra and Pliickthun (1988) expressed the VH and the 
VL domains of the murine anti-phosphorylcholine IgA antibody McPC603 in E. coli. To 
target VH and VL chain genes to the periplasm, ompA and phoA leader sequences were 
used, respectively. Expression of the genes could be controlled via the isopropyl-(3-D- 
thiogalactopyranoside (IPTG)-inducible lac promoter/operator. This system did appear to 
result in functional Fv assembly. Skerra and Pliickthun saw the translocation of protein 
to the E. coli periplasm as functionally equivalent to eukaryotic protein transport to the 
lumen of the endoplasmic reticulum. Others, however, had found the stable expression 
of Fv fragments a little more difficult (Glockshuber et al., 1990). Fv fragments 
dissociated at low protein concentrations and were unstable under physiological 
conditions. This was because the interchain disulphide bonds present in the CH1 and the 
CL regions were missing. Various strategies have been explored to improve this situation. 
Three methods have been investigated. The first was glutaraldehyde cross-linking of VH
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and VL while in the presence of antigen. The second method was the incorporation of 
cysteine residues into the VH and VL regions to yield a disulphide linkage (dsFv). The 
third method involved construction of a single chain fragment (scFv) using a 15 amino 
acid linker (Gly-Gly-Gly-Gly-Ser)3. These systems did not improve yields of Fv but did 
improve the stability of the resulting product. It was established that the yield is 
determined by the correct folding of Fv and not V chain association. Brinkmann et al. 
(1993) also found a disulphide-stabilized Fv-toxin chimaera to be as stable as the amino 
acid-linked scFv.
The scFv is a popular means of producing stable Fv fragments as this does not require 
any additional steps once the VH and VL chain genes have been cloned into a vector with 
a linker present. It also avoids the necessity to insert cysteine residues into the V 
sequences which may affect the conformation of the binding site and also requires correct 
redox conditions for disulphide bond formation. The scFv fragment can also be purified 
in a single step. The presence of the linker may still, however, affect the conformation 
of the antigen-binding site and the function of the antibody molecule. Tang et al. (1996) 
demonstrated that randomisation of an 18 amino acid linker led to the selection of higher 
affinity scFvs and restored catalysis to a scFv version of a catalytic monoclonal antibody.
The ability to produce scFv fragments by recombinant methods has improved significantly 
in recent times and has allowed the system to move beyond E. coli as an expression host. 
Tavladoraki et al. (1993) successfully produced a transgenic artichoke that produces a 
scFv antibody directed against the artichoke mottled crinkle virus. The scFv is 
constitutively expressed and leads to reduced infection rates and a slower onset of disease. 
Streptomyces is used for the production of many extracellular components. It would be 
of more use than E. coli for antibody production as Gram negatives only secrete into the 
periplasm and require lysis of the outer membrane. Streptomyces lividans was used as a 
host for the extracellular production of VH and VL chains to hen egg-white lysozyme 
(HEL) (Ueda et al., 1993) using suitable codon preferences. The cloned genes were 
placed in a Streptomyces multi-copy plasmid vector pIJ702 using the signal for the 
subtilisin inhibitor (SPssi), a major extracellular protein. Yields of 1 (ig/ml of V chains 
resulted. In the absence of HEL, VH and VL dissociated. It is clear that this system would
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have benefit greatly by scFv stabilisation. Chesnut et al. (1996) have developed systems 
which transiently express scFv antibody anchored to the eukaryotic cell surface which can 
be used to select cells expressing antibody from the rest of the cell population. The 
importance of eukaryotic expression is growing as the desire to produce whole, correctly 
expressed human antibodies continues. Persic et al. (1997) have developed several 
eukaryotic expression vectors that allow both transient and stable expression of either Fab 
fragments, or whole human antibodies, with specificity selected by insertion of V region 
genes. The use of E.coli cell-free translation systems was also exploited by Ryabova et 
al. (1997) which showed the requirement of protein disulphide isomerase and chaperones 
for correct disulphide bond formation and protein folding for improved levels of soluble 
scFv.
A potentially useful therapeutic scFv was produced by Savage et al. (1993). This murine 
scFv recognizes placental alkaline phosphatase (PLAP) which is expressed on many 
tumours and is used in the screening of ovarian and testicular cancer. The scFv was 
specific for PLAP and could be more useful in diagnosis if it were of human origin as this 
would minimise or totally remove the associated HAMA response.
Other fragments of the antibody molecule have been assessed for their possible uses. It 
was noted early in the study of antibody-antigen interactions that the H chain was the 
most important part of the antibody-antigen binding interaction and that the binding 
affinities of L chains are about 100-fold lower than H chains (Utsumi and Karush, 1964). 
However, there are instances where the light chain has been found to be dominant in the 
antibody-antigen interaction (Sun et al., 1994). The use of the VH/CH1 (Fd) fragment 
provides a molecule with good binding activity without the difficulties associated with the 
expression of two antibody peptide chains (Kouki et al., 1997). Other work has 
concentrated on larger fragments; the Fab or even F(ab’)2 portions of the antibody 
molecule. These fragments are still much smaller than the entire antibody, and so still 
possess advantages relating to tissue penetration and pharmacokinetics. These fragments 
can also be efficiently expressed in prokaryotic vectors and do not have the difficulties 
relating to stability experienced with Fv fragments. The absence of any interference in 
the structure of the antigen-binding site ensures that the original binding characteristics
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of the antibody are retained. Many Fab antibodies have been cloned from whole antibody 
molecules. One such example is a human anti-rabies Fab antibody that was expressed in 
a bacteriophage lambda (X) vector system using the E. coli pelB (pectate lyase) leader. 
The Fab was capable of binding to the rabies virus coat glycoprotein in a manner similar 
to whole antibody (Cheung et al., 1992).
It is clear that, due to the ease in which they can be cloned and expressed in various 
hosts, and due to their improved characteristics, antibody fragments have a large role to 
play in various areas of therapy and diagnosis. Every useful fraction of the antibody 
molecule has been explored to assess its individual characteristics. Even the CDR region 
alone has now been explored as an antigen-binding tool (Levi et al., 1993). In this 
system, the CDR-H3 region from a murine anti-HIV-1 V3 loop antibody was found to be 
capable of competing with whole antibody for the V3 loop. When the peptide was 
cyclized, it was also found to be capable of inhibiting HIV-1 replication and syncytium 
formation in infected cells. A single CDR is probably the limit in size reduction that 
useful antibody fragments can reach.
1.6 COMBINATORIAL PHAGE DISPLAY LIBRARIES
The development of the technique known as phage display - a system capable of the 
production of human antibody fragments - began back in 1985 when Smith (1985) 
demonstrated that a foreign peptide could be expressed on the surface of a virion by 
fusing it to a coat protein gene. The phage he used was a filamentous one, a member of 
the M13 family. These possess two distinct coat proteins, pin and pVIII derived from 
corresponding coat protein genes gill and gVIII, respectively. The pVHI coat protein is 
the major component expressing many thousands of copies. The pill protein is a minor 
component of the virion coat expressed at only 5 copies per virion but with the important 
function of binding to the E. coli F pilus via its N terminus. Initial attempts were made 
to insert a peptide between the C and N termini of pill to prevent disruption of terminal 
functions. This still severely reduced the infectivity and, thus, the efficiency of the virion. 
Parmley and Smith (1988) improved the methodology slightly by placing the inserted 
peptide at the very N terminus of the pin protein. This interfered with function to a
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lesser degree than central insertion but efficiency was still poor. Parmley and Smith also 
improved vector design by using a tetracycline resistance fd phage (fd-tet) that could 
propagate as a plasmid and did not need to reinfect to generate high titres. They also 
demonstrated that the phage particles could be affinity-purified in a process now known 
as panning. In their early version, phage was selected using biotinylated antibody to the 
foreign virion epitope attaching to a streptavidin-coated plate. Subsequent rounds of this 
enrichment procedure dilutes out weaker affinities and enriches higher affinity ligands.
Ward et al. (1989) were the first to use an M13 vector system to produce antibody chains 
in E. coli. To achieve this, mouse spleen VH mRNA was amplified using PCR. These 
early attempts only assessed the ability to clone a single chain in vectors of poor 
efficiency.
Some early work concentrated on expressing antibody fragments using a X vector as this 
phage was well understood and several suitable vectors were available. Huse et al (1989) 
were the first to produce a combinatorial Fab antibody library using just such a vector. 
The A.zapII vector allowed in vitro packaging of the cloned H and L chain genes following 
amplification using PCR. H and L chains were cloned separately in vectors ?iHc2 and 
A,Lcl, respectively, before being combined randomly. A library of 2.5 x 107 pfu was 
established, 1 x 106 of which were screened using plaque lifts - a far less efficient 
screening procedure than that allowed by filamentous phage display. Even so, 100 
plaques were found that bound the KLH-/?-nitrophenyl phosphonamidate antigen with 
affinities of 10-100 x 10'9 M.
Some workers persisted with the X phage system. Persson et al. (1991) generated a 
combinatorial library to tetanus toxoid using human lymphocytes from peripheral blood 
(PBLs), 5 litres of which had undergone leukapheresis to produce 1 x 109 lymphocytes. 
They assessed the effect stimulation of the B cells with antigen in vitro prior to cloning 
and the effect of panning would have on generating greater yields of specific antibody. 
Unstimulated cells produced a library of 1 x 105, stimulated cells 6 x 105 demonstrating 
little improvement from antigen stimulation. This may be due to the inefficiency of in 
vitro stimulation.
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As methods based on X could only produce comparatively small libraries (106) and the 
screening procedures were poor, work progressed on systems based on filamentous phage 
display. Several groups looked at the ability of phage to display non-antibody proteins 
such as hormones and random peptides. Bass et al. (1990) improved the M13 system in 
several ways to efficiently display human growth hormone (hGH) as a pIH fusion. They 
introduced the M13 intragenic (IG) region into the M13 plasmid to produce a ’phagemid’, 
an entity capable of propagating as both a plasmid (using E. coli ori and tetracycline 
resistance) or as a phage by becoming packaged via the IG region. The problem with the 
protein pm  being inactivated resulting in a phage incapable of F pilus infection was 
circumvented by the introduction of a helper phage M13K07. This phage possesses an 
in tact copy of gill, but has a non-functional IG region and so cannot transcribe its genes 
unless in the presence of the phagemid. Thus, following cloning of the hormone gene, 
coinfection of phagemid and helper results in the production of phage particles expressing 
cloned and intact pin  and so are still capable of reinfecting E. coli efficiently. Virions 
expressing a single cloned pin would be particularly desirable when cloning antibody 
genes as this would rule out avidity effects due to the presence of more than one antigen 
binding site per virion and would allow for the selection of high affinity antibodies 
amongst lower affinity molecules.
Several papers also reported similar phage display systems for the expression of random 
peptide sequences (generated by oligonucleotide synthesizers) on the surface of phage to 
identify important epitopes in antibody-antigen binding (Cwirla et al., 1990; Devlin et al., 
1990; Scott and Smith, 1990).
The antibody Fv domain was first cloned and expressed in a filamentous phage by 
McCafferty et al. (1990) who used the VH and VL fragment genes from murine anti- 
lysozyme antibody and linked them via the (Gly-Gly-Gly-Gly-Ser)3 linker to the gill of 
fd phage.
Some attempts were made to exploit a similar technique based on the pVffl protein 
instead of pill (Kang et al., 1991a). This also used a helper phage designated VCSM13 
and a phagemid vector pComb8. Still better than X vectors in generating larger libraries,
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this system makes it difficult to separate high affinity binders from lower affinity 
molecules due to avidity effects and has been superseded by the p in  system in most 
applications.
1.6.1 The pComb3 System
A single phagemid vector system capable of efficiently expressing intact Fab fragments 
in E. coli has now been established (Barbas et al., 1991) (Fig. 1.5). This vector is known 
as phagemid pComb3 and contains a (3-lactamase resistance gene (bid) and origin of 
replication for E. coli from plasmid pBluescript. It contains the IG region of the M l3 
phage and has directional cloning sites for PCR-amplified H and L chain genes. Both of 
these are placed downstream of pelB leader sequences for efficient E. coli periplasmic 
transport and the dicistronic message is under the control of the IPTG-inducible lacZ 
promoter. The H chain gene is placed C terminal to the gill gene sequence where, upon 
expression it forms a fusion protein. This system has the potential to generate libraries 
that are capable of cloning the entire human immunological repertoire which is estimated 
to be in the region of 108 different specificities. With the helper phage VCSM13, the 
phagemid can propagate as a phage particle. By removing the gill gene and in the absence 
of helper phage, it propagates as a plasmid and soluble Fab antibody fragments can be 
generated by induction with IPTG.
An outline of the pComb3 system is shown in Fig. 1.6. The first step in cloning the 
human immunological repertoire is the extraction of mRNA from approximately 108 B 
lymphocytes. This should theoretically contain the full repertoire of antigen specificities. 
Having done this, complementary DNA (cDNA) can be synthesized from the mRNA using 
oligo(dT) primers which complement the 5' end of the RNA messenger and using reverse 
transcriptase to convert mRNA to its cDNA strand. This DNA is then used as the template 
for the PCR amplification of the antibody L and H chain genes. The 5' ends of the CH1 
region and the CL region are conserved and a single primer is required for each of these. 
Several primers are required to complement the 3' ends of both the L and H chains as
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Figure 1.5. The pComb3 phagemid vector. Replication in E. coli is via the Col E l on. 
Resistance is via the (5-lactamase resistance gene, bla. For phage packaging, pComb3 
carries the intragenic region from f l  phage. Directional insertion of light and heavy 
chain genes is via Sacl/Xbal and XhoIISvel sites, respectively, each of which is 
downstream from a LacZ promoter/operator and a velB leader sequence. Downstream 
of the heavy chain gene insertion is g/ZZ. for phage surface expression of the 
heavy /light chain Fab fragment.
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these fall into specific groupings based on their DNA homologies. For PCR amplification, 
aliquots of cDNA are mixed with a single 5’ and 3’ primer of either the L or H chain 
which then undergoes thermal cycling to amplify these fragments. All the L chain 
aliquots and all the H chain aliquots are then pooled. The PCR primers are so designed 
that they also introduce restriction sites at the ends of the amplified L and H genes so 
they can be ligated into the vector. H chain genes are cloned into the vector first. The 
ends of the amplified sequences are cut with restriction enzymes and ligated into the 
phagemid. This is transformed into E. coli and propagated as a plasmid. The plasmid is 
repurified and then the L chain genes are inserted in a similar fashion. The phage is then 
used to coinfect E. coli along with the helper phage. The IG region on the phagemid 
allows the expression of phage genes, which assemble as a virion. The gene fusion of 
pin and H chain is incorporated into the phage coat along with functionally correct pin. 
Due to its non-functioning IG region, phage DNA cannot be packaged into the virion and 
so only phagemid is packaged. This results in an intact virion particle displaying wild 
type and recombinant pffl protein on its surface. During periplasmic transport, the L 
chain is able to reassociate with the H chain to form an intact Fab fragment expressed on 
the virion surface, while within the virion are the genes coding for the antibody L and H 
chains. The linkage of phenotype and genotype has been achieved. As E. coli is 
propagated, virions are secreted into the culture medium. When separated from whole 
cells by centrifugation, these can be used for panning. The antigen of interest is coated 
to a microtitre plate either chemically or as a protein conjugate. Phage is then added. 
Washing is used to remove those phage that are not expressing Fab capable of binding 
with antigen leaving the high affinity binders still attached (Fig. 1.7). These are then 
removed by more vigorous treatment and can then be propagated again in E. coli. 
Normally about three rounds of panning are performed to select Fabs of suitable affinities. 
Following purification of individual phage particles, soluble Fab antibody fragments can 
then be prepared by plasmid propagation of the phagemid and induction using IPTG. This 
generates H and L chains that are transported to the periplasm and can be recovered by 
lysis of the bacterial outer membrane or culture supernatant. The soluble antibody 
fragment can then be purified by affinity chromatography.
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With the advent of a methodology powerful enough to potentially clone the complete 
immunological repertoire of humans, it has been used to generate human antibody 
fragments of clinical benefit. The system has also been used as a means of dissecting the 
immune response but not without some controversy over its ability to truly mimic a 
natural immune response. The generation of a phage display library must start with B 
lymphocytic material. For the generation of human antibodies, obtaining this material still 
remains the main difficulty. To generate murine antibodies, spleen cells are available. The 
most readily available source of B lymphocytes in humans is from peripheral blood. This 
has been used on several occasions to generate libraries (Persson et al., 1991; Walker et 
al., 1992). Peripheral blood has, however, only a low concentration of B lymphocytes 
(15-20% of cells) so large volumes of blood (approximately 0.5 1) are required to produce 
sufficient numbers of B cells to clone the entire repertoire. Various strategies have been 
applied to enriching the B cell concentration of peripheral blood. Most steps involve 
separation of the whole blood on a suitable gradient (Persson et al., 1991). Also the 
blood contains only a small population of differentiated B cells reacting to recent 
antigenic challenge. Such a population could be greatly biased towards particular antigens 
making it extremely difficult to select antibody chains against the antigen of interest.
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Figure 1.6. (previous page). Production of antibody Fab fragments using the pComb3 
system. Antibody chain RNA is isolated from a suitable source, normally B lymphocytes. 
The RNA undergoes reverse transcription and PCR amplification using families of 
variable 5 ’ primers and constant 3 ’ primers, encoding restriction sites. Vector and PCR 
product are digested, ligated and transformed into E. coli. The heavy chain library is 
composed first and then recombined with light chains. Phage expression is brought 
about by infection with helper phage, and affinity selection takes place against the 
desired antigen immobilised to a solid support. When specific clones have been isolated, 
soluble antibody may be expressed by removing s i l l  and inducing high level expression 
from the LacZ promoter.
Figure 1.7. Affinity selection or panning. Polyclonal phage is allowed to bind to antigen 
on a solid support. Specific phage bind to the surface, and the rest of the material is 
removed by vigorous washing. Specific phage is then eluted from the antigen and this 
enriched material used to retransfect E. coli for screening or further rounds of affinity 
selection.
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1.6.2 The Nissim Library
Nissim et al. (1994) produced a scFv phage display library of human origin from the 
peripheral blood lymphocytes of an unimmunised donor. To further enhance the diversity 
of the library, they inserted random nucleotide sequences from 4-12 residues in length at 
the CDRH3 site. This library also used a single L chain sequence (VA3), so diversity was 
only as a result of the H chain. This semi-synthetic human library was combined with 
libraries established by Hoogenboom and Winter (1992), resulting in a ’single-pot’ library 
with very large diversity (>108). The Nissim scFv system is based on the phagemid vector 
pHENl. This bears similarities to pComb3 in terms of resistance mechanism, M13 IG 
region, E.coli ori, as well as the presence of lacZ promoter/operators and pelB leader 
sequences. Significant differences exist at the site of antibody chain gene insertion. As the 
scFv is a single sequence, insertion at only one site is required, upstream from pill. 
Soluble and phage surface expression are controlled by means of an amber mutation at 
the 3’ of p ill which can either be suppressed or expressed depending on the E.coli host 
strain employed. Detection of the scFv is facilitated by the presence of a c-myc tag 5' to 
the scFv.
The Nissim library offers the potential to produce human scFv antibodies against an 
antigen of interest without the need for prior in vivo immunisation, or the establishment 
of a combinatorial antibody library. Such a system exploits the concept that high affinity 
antibody species can be derived from so-called ’naive’ repertoires if the diversity is great 
enough. The fact that the antibodies are of human origin is also an important consideration 
for their use in any form of in vivo therapy. The Nissim library has been shown to be 
capable of generating high affinity scFvs to antigens such as foreign or self proteins and 
various haptens.
1.6.3 Bacterial surface display
As well as phage and eukaryotic display systems, the bacterial cell surface has also been 
put forward as a means of displaying antibody libraries (Little et al., 1993) with fusion 
to several cell surface components, e.g., lipoproteins, outer membrane proteins, secretory
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proteins, as well as flagellae and fimbriae. Robert et al. (1996) used Staphylococcal 
species to assess their ability to display a viral coat protein via fusion to several surface 
components. Such a system would find it hard to match the numbers of phage particles 
that can be generated by bacteriophage infection, but might be adequate for the display 
of previously established monoclonal antibodies.
31
Figure 1.8. The Nissim library. The library is a semi-synthetic human scFv library. It 
consists of a phagemid backbone, with f l  IG region and bla resistance gene (not 
shown). Induction is via the lacZ promoter/operator (P/O) and secretion via the velB 
leader sequence. The insert consists of a library of human variable heavy chain genes 
possessing a synthetic CDR3 region. The variable heavy chain is linked to a Vx3 
variable light chain gene via a (Gly-Gly-Gly-Gly-Ser)3 synthetic linker. Downstream of 
the variable light chain gene is an amber codon which allows production of scFv with 
or without p i l l  by expression in suppressor and non-suppressor strains of E. coli.
1.7 ANTIBODY CONJUGATES AND CHIMAERAS
Chimaeric antibodies can be formed by linkage of two antibody species, such as human 
and mouse. Antibodies have also been fused with proteins (toxins, enzymes, etc.) and 
solid supports (Fig. 1.9). Such constructs have a myriad of uses. The most obvious use 
that presents itself is in the area of antibody therapy of cancer. Examples of antibody 
conjugates in areas of imaging, radiotherapy, chemotherapy and toxin therapy are 
widespread (Reading et al., 1989; Adair, 1992; LoBuglio and Saleh, 1992).
A bacterial toxin that has proven popular as an antibody conjugate component is the 
Pseudomonas aeruginosa exoenzyme S. A truncated protein derived from this known as 
PE40 lacks the binding domain of the toxin. This has been genetically fused to a scFv 
antibody directed against Tac, the p55 subunit of the human IL-2 receptor (Chaudhary 
et al., 1989) and was found to be selectively cytotoxic to cells bearing the IL-2 receptor. 
Such a conjugate could have application in immunosuppressive therapy. The same toxin 
fragment was also linked to a scFv fragment constructed from the PR1 monoclonal 
antibody which targets normal prostate or adenocarcinoma prostate cells (Brinkmann et 
al., 1993). Such a targeting system might be useful post-prostectomy to destroy remaining 
carcinoma cells.
A novel strategy using an antibody conjugate has been developed to remove blood clots 
(Holvoet et al., 1992). Here, an scFv to fibrin is linked to a urokinase-type plasminogen 
activator. This activates the declotting cascade concentrating it to the area of the clot and 
was found to be 6-15 times more effective than plasminogen activator alone in an in vitro 
clotting system.
A metallothionein-antibody conjugate has also been established (Sawyer et al., 1992) that 
could be used to deliver radioactive metal isotopes to tumours for therapy or imaging. A 
novel luminescent probe has been developed based on an antibody fusion with a 
photoprotein called apoaequorin (Casadei et al., 1990). Such a construct was specifically 
targeted to hapten and exhibited Ca2+-dependent bioluminescence.
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As all the above examples demonstrate, antibody conjugates are extremely versatile and 
their uses are as widespread as there are examples of a need to target one substance to 
another.
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Chemical linkage
Figure 1.9. Antibody conjugates and chimaeras. Antibody conjugates may be produced 
by the joining of antibodies with proteins, enzymes and toxins by chemical or genetic 
methods. Chimaeras may be formed by the joining of variable regions from a mouse 
antibody with the constant regions of a human antibody.
1.8 HUMANISED ANTIBODIES
As has been stated, the production of human monoclonal antibodies has proved difficult. 
The relative potential of the applications that have been described above for therapies are 
drastically reduced because most of these are of murine or rat origin. In an attempt to 
find a path around the problems of human antibody production, the antibody engineer has 
turned to molecular genetic techniques.
It was postulated that most of the HAMA response was directed at the constant regions 
of the antibody molecule. Much of this part of the molecule can be discarded in some 
applications, e.g., removal of the Fc region. This cannot be done if antibody effector 
functions are required. Also, removal of Fc alone still leaves CH1 and CL regions. If the 
constant regions of a murine antibody could be replaced with those of a human antibody 
while retaining the variable regions for antigen binding, much of the HAMA response 
against the antibody would be lost. The body would see the molecule as less foreign. 
Also, human antibody effector functions are more efficient than murine functions when 
administered in man. Surfus et al (1996) produced a human/mouse chimaera composed 
of mouse V regions from an anti-renal-cell carcinoma antibody fused to a human IgGl 
antibody that was shown in vitro to enhance the antibody-dependent cellular cytotoxicity 
of renal cell carcinoma cells with IL-2 treated peripheral blood monocytes, showing 
possible in vivo therapeutic potential against renal cell carcinoma.
The resulting mouse/human chimaeras generated like that described above were better 
than completely murine antibodies with respect to immunogenicity. These chimaeras still 
carried long stretches of murine-specific sequences in the V regions, however, and so are 
still potentially immunogenic. It had long been established that most of the antigen 
binding of the antibody molecule was due to the three hypervariable regions, the CDRs 
present in the L and H chain V regions. The next stage in the ’humanization’ process was 
to remove the murine CDRs and graft them into a human framework (FR) region. Such 
chimaeric antibodies have been termed ’humanized’ antibodies. This approach appears 
to be proving popular. Early attempts used CDR sequences from established hybridomas 
like the Bl-8 anti-4-hydroxy-3-nitrophenacetyl caproic acid antibody (Jones et a l, 1986).
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This system dealt with the H chain CDRs only. This did not appear to bring about any 
reduction in hapten binding affinity in this instance. Fiorentini et al. (1997) produced a 
humanized Fab antibody using overlap PCR that recognises a surface marker over-exposed 
on most breast tumours. This was derived from a previously established murine 
monoclonal antibody, H23 with specificity to the Muc-1 peptide.
In a further example of the usefulness of humanized antibodies, blocking of CD11/CD18 
on the surface of leucocytes using an antibody chimaera has been accomplished (Sims et 
al., 1993). CD11/CD18 normally promotes the interaction of leucocytes with one another 
and with endothelial cells and may play a role in disorders such as adult respiratory 
distress syndrome and allograft rejection. Blocking these interactions without cell 
destruction may lead to treatments in these cases by preventing the associated tissue 
destruction characteristic of these disorders.
A diagnostic antibody already showing clinical benefits is a humanized version of the 
anti-placental alkaline phosphatase single chain antibody used in the detection of ovarian 
and testicular cancer (Savage et al., 1993). Humanization will allow it to be administered 
a greater number of times in a single patient without the onset of a HAMA response.
With all these examples of clinically useful humanized antibodies, it might be assumed 
that there is little problem with them in terms of design and application. This is not the 
case. Problems with humanized antibodies stem from two incorrect assumptions. The 
first is that the FR regions do not have a role to play in the shaping of the antigen binding 
site. The second is that murine CDRs, when grafted onto a human FR will not be 
immunogenic in humans.
Taking the first assumption: although the CDRs play the most important role in the 
antibody’s interaction with the antigen, the FR region does provide critical residues that 
place the CDRs in a correct conformation. Although good affinities may be obtained 
without recourse to the structure of the FR region, this is a hit and miss approach and may 
lead to unpredictable results. Several approaches have been taken for improving the 
affinity of humanized antibodies after CDR grafting. One system relies on the
37
introduction of FR amino acids adjacent to the CDRs in an iterative fashion (Co and 
Queen, 1991) until the binding affinity of the original antibody is restored. This is a 
thorough but time-consuming approach. A less thorough but less lengthy method is to test 
a suite of antibodies with different FR regions against the particular CDRs of interest 
(Kao and Sharon, 1993). Although not guaranteed to restore the full affinity of the parent 
antibody, it may considerably reduce the time taken to establish a useful chimaera of at 
least moderately high affinity. Molecular modelling of the antigen binding site is reducing 
the guess work involved in CDR grafting still further by allowing the identification of 
specific framework residues crucial to the restoration of full binding in a humanized 
antibody (Mateo et a l, 1997). They also found that residues selected by modelling 
restored original mouse sequences in the framework region. Baca et al. (1997) have used 
random mutagenesis of the framework regions, followed by selection of high affinity 
antibodies via phage display and have produced antibodies with affinities greatly in excess 
of the parent molecule.
The problem of the second assumption is, however, more difficult to circumvent. 
Roguska et al. (1996) have compared the use of CDR grafting to variable domain 
resurfacing in which only the crucial surface residues of the antigen-binding site are 
replaced, instead of whole CDR regions. This method could be shown to restore full 
binding of an antibody with the use of fewer murine residues than can be achieved with 
CDR grafting. The epitopes generated by CDR grafting onto a human framework will be 
many and varied. It is by no means certain whether the body will see these epitopes as 
foreign or not. If they resemble ’self’ antigens then they will escape immunological 
attack. If they do not, however, the immune system may raise an anti-idiotypic response 
against them. Thus, to assess the fate of a particular humanized antibody in a particular 
patient would be impossible. For this reason, the holy grail of antibody engineering still 
remains the production of completely human antibody molecules.
1.9 AFFINITY MATURATION
It is accepted that one of the best sources of material for the generation of human libraries 
is bone marrow. Here, the whole spectrum of B cells should be present, awaiting 
triggering and maturation. Obtaining such material is not as simple as for blood, so, in 
obtaining the marrow, there should be some degree of certainty that the clones of interest 
can be derived from it. A debate has arisen as to whether combinatorial phage display 
is capable of selecting antibody fragments of the required specificity and affinity without 
prior stimulation of the immune system with the antigen in what has come to be known 
as a ’naive’ library. (This is probably a misnomer as no immune system is ever truly 
naive.) Such a process is the ultimate aim of many interested in the generation of human 
monoclonal antibodies. There is a desire to be able to begin each round of selection by 
using the same library that should potentially have all combinations of specificity present, 
e.g., the Nissim library (Nissim et al., 1994). From this it would then be possible to 
select high affinity binders. With this system, however, one encounters the problems of 
antibody affinity maturation.
In a natural immune response, the initial first line of antibody defence is via IgM 
antibodies. These are of relatively low affinity compared to their IgG siblings but their 
decavalency increases their potential. Individual B cells undergo a process of affinity 
maturation to convert a low affinity antibody to a high affinity one as a result of antigenic 
challenge in vivo. Such fine tuning involves somatic mutation and gene rearrangements 
from which high affinity molecules are selected and expanded. Without this maturation 
process, naive libraries will result in mainly low affinity antibodies. Many have 
concentrated on developing in vitro methods to further mimic antibody maturation. Further 
L and H chain recombination in a process called ’chain shuffling’ has been used to 
improve affinities (Kang et al., 1991b; Ohlin et al., 1996). Most maturation processes 
involve the mutation of the V region followed by rounds of panning in an iterative 
process to select higher affinity molecules. To increase affinity to the V3 loop of the HIV 
gpl20 coat protein, Thompson et al. (1996) used the sequential replacement of L and H 
chains in an scFv construct. L chain variations did not result in significant improvements 
in affinity, but H chain variations did, the mutations mapping to the CDR2 and CDR3
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regions. The highly mutatable mutD strain of E. coli has a defective proofreading enzyme 
which results in increased rates of single base substitutions (Fowler et al., 1986). Such 
a mutation system lacks specificity and would be an extremely inefficient way of 
generating mutations. Mutations would only rarely occur in the H and L chain genes. 
A more specific random mutagenic method is that of error-prone PCR (Gram et al., 1992). 
Here, primers can be used to amplify the areas of concern, i.e., the V region, or more 
precisely the CDRs alone. By manipulating the conditions for PCR, the cycling can be 
induced to introduce errors. Such a technique has the potential to generate large numbers 
of mutations at the antigen-binding site. PCR is also employed in random oligonucleotide 
synthesis (Barbas et al., 1992b), again targeting important areas such as the CDR region, 
with the ability to generate as many as 1020 sequence combinations.
The more precise method of site-directed mutagenesis has also been applied to the 
maturation of an antibody in vitro (Sharon, 1990). This demonstrated that most mutations 
leading to higher affinity were in the H chain and the majority of these were in CDR 
regions. This strengthens the idea that the H chain is the major component in the antigen 
binding interaction, the CDRs being of greatest importance. This would be useful for 
studying the effect individual amino acid changes may have on affinity leading to detailed 
information about the residues involved but would have limited use for generating large 
numbers of recombinants for affinity maturation and selection.
1.10 CATALYTIC ANTIBODIES
In chemical synthesis, rarely can the chemist match the ability of biological processes to 
produce a desired product in the enantiomeric form in which it is required. A case in 
point is the famous thalidomide drug controversy where one racemate suppressed nausea, 
the other caused teratogenesis in developing foetuses. Chemists also have to search long 
and hard for an organic or inorganic compound that will promote or catalyse a particular 
chemical reaction. Attempts have been made to turn to natural enzymes, but these have 
a tendency to be unwilling to catalyse reactions other than those for which they have been 
strictly evolved (Danishefsky, 1993). Consequently, chemists have turned their attention 
to nature’s ability to synthesize vast combinations of peptides that interact with an antigen
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in a specific way. In this manner, many millions of possible catalysts could be generated, 
screened and selected in a rapid process.
The area of catalytic antibodies has been extensively reviewed (Schultz et al., 1990; 
Lemer et a l, 1991; Paul, 1996; Wade and Scanlan, 1997). For a chemical reaction to 
occur, a certain amount of free energy is required (entropy). The higher the entropic 
barrier, the less likely the reaction is to take place. Catalysts can lower this entropic 
barrier by increasing the stability of the reactive intermediate in the reaction. These 
chemical species are usually very short-lived. The concept of catalytic antibodies revolves 
around the theme that an antibody specific for this unstable intermediate could reduce the 
amount of free energy required for the reaction and, thus, accelerate it. Due to the short­
lived nature and rarity of this intermediate, this brings about obvious difficulties in 
developing immunization protocols to raise a monoclonal antibody to such a substance as 
well as difficulties with screening. Attempts have been made to screen for catalytic 
antibodies raised against the substrate, but this approach has had limited success. Kohen 
et al (1980) used an antibody to 2,4-dinitrophenyl hapten to enhance the ester hydrolysis 
of a dinitrophenyl aminohexanoxyl-coumarin conjugate. Although with only limited 
improvements in hydrolytic rates, it clearly demonstrated the potential of antibodies as 
catalysts.
Most work has concentrated on raising monoclonal antibodies to stable transition-state 
analogues of the unstable intermediate (Partridge et al, 1993). Antibodies raised using 
such analogues can increase reaction rates 103-fold over the uncatalysed reaction.
Initial attempts at the production of catalytic antibodies were based on chemical reactions 
that were already well understood. The Diels-Alder reaction is a very useful 
transformation that allows the production of complex natural compounds. It involves the 
concerted addition of a conjugated diene to an olefin resulting in a cyclohexene derivative. 
This reaction has a high entropic barrier but has a highly ordered bicyclic adduct 
intermediate. A suitable analogue to the intermediate was produced and was used to raise 
monoclonal antibodies (Hilver et al., 1989). A single catalytic monoclonal antibody was 
derived that increased the bicyclisation of the two compounds. Meekel et al. (1996) also
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showed that antibodies to transition state analogues for the Diels-Alder cycloadditions of 
trans- and cis- piperylenes to 4-nitroso-N-propylbenzamide were greater than 95% in 
favour of a single regioisomer.
Phosphoryl transfer reactions involving the amino acids threonine, tyrosine and serine are 
important in biological regulation and signalling and catalytic phosphorylation or 
dephosphorylation of these amino acids would be useful as an investigative tool. A first 
step to generating such catalytic antibodies is to produce antibodies capable of aryl 
phosphate monoester hydrolysis (Scanlan et al., 1991; Tawfik et al., 1997) as in the 
conversion of ¿»-nitrophenyl phosphate to nitrophenol and phosphate. Monoclonal 
antibodies were raised against a suitable intermediate analogue, a-hydroxyphosphonate 
conjugated to keyhole limpet haemocyanin (KLH) via a diazo linkage or nitrobenzyl- 
phosphonate. Several antibodies isolated from both transition state analogues proved to 
be catalytic for the hydrolysis of p-nitrophenyl phosphate.
In their search for catalytic antibodies that catalyse acyl transfer reactions, Jandra et al. 
(1991) describe a technique called ’Bait and Switch’. This is concerned with inducing the 
inclusion of certain amino acids in the antigen binding pocket. Using charged groups on 
the analogue of the reactive intermediate that match those on the natural intermediate 
results in the inclusion of amino acids at the antigen binding site that possess a 
complementary charge. Such charge complementarity was found to bring about catalytic 
antibodies. When neutral analogues were used, catalysis was not induced (Kikuchi and 
Hilvert, 1996).
A further target for those investigating the uses of catalytic antibodies has been the 
peptide bond. Some peptide bonds are extremely stable. The Gly-Phe peptide bond has 
a half-life of about 7 years (turnover of 3 x 10‘9.s-1). Iverson and Lemer (1989) have 
produced a metal-binding antibody that catalyses this reaction. The antibody was 
produced using a Co(m) triethylenetetraamine (trien)-Gly-Phe as antigen. The resulting 
metalloantibody was capable of binding cobalt and other metals and considerably 
increased the turnover of this reaction to 6 x lO^.s'1.
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The importance of metal-binding groups in enzymatic catalysis was further illustrated by 
Roben (1993) and Roben et al. (1993), who produced ’metalloantibodies’ by combining 
light chains which were capable of binding metal ions with gp 120-specific heavy chains, 
producing a Fab fragment with enhanced viral neutralisation capabilities, demonstrating 
a possible therapeutic use of catalytic antibodies in the treatment of HIV and AIDS. 
Blackburn and Deng (1993) have used the pComb3 system to derive metalloantibodies 
mimicking the action of zinc pro teases.
In an attempt to deactivate proteins in vivo, catalytic antibodies have also been produced 
that partake in the two-step conversion of asparaginyl-glycyl to isoaspartyl-glycyl via an 
aspartyl-glycyl intermediate (Gibbs et al., 1992). Wagner et al. (1996) have focused on 
the design of haptens for transition-state analogues of peptide cleavage sites to develop 
several catalytic antibodies to selectively target peptide bonds.
In a rather more unusual application, catalytic antibodies have been produced that are 
capable of the enzymatic degradation of cocaine to the non-narcotic ecgonine methyl ester 
and benzoic acid (Landry et al., 1993). These were produced using phosphonate 
monoester transition state analogues and could be useful in the treatment of drug 
addiction.
The strength of catalytic antibody production relies on the efficiency with which the 
immunological repertoire can be exploited to yield as great a variety of antibody 
combinations as is possible. Cloning the immunological repertoire in E. coli can simplify 
the selection procedure greatly. Early work combining the search for catalytic antibodies 
with phage display expression systems in E. coli concentrated on the VH chain gene alone 
(Sastry et al., 1989) as it has been shown that the H chain still has significant binding 
affinities in the absence of the L chain (Utsumi and Karush, 1964). Chen et al. (1993) 
used both L and H chains to clone a Fab library to phosphonamidate in a X vector. Three 
Fab antibodies were isolated that could hydrolyse a p-nitrophenyl substrate.
These examples clearly illustrate the ability of correctly selected antibody molecules to 
catalyse unfavourable reactions by stabilizing the reaction transition state. Catalytic
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antibodies become a more powerful concept when combined with advances in 
combinatorial phage display libraries.
1.11 ENGINEERED ANTIBODIES IN THE TREATMENT OF DISEASE
Engineered antibody fragments are replacing monoclonal antibodies in many areas, most 
notably in cancer treatment and other forms of potential in vivo therapy, where 
developments such as antibody chimaerisation and humanisation, as well as other 
characteristics of antibodies, such as their size, tissue penetration and pharmacokinetic 
characteristics can be of greatest benefit. Hu et al. (1996) produced a disulphide-linked 
bivalent VH-VL-CH3 construct against the carcinoembryonic antigen (CEA), a popular 
tumour target that is found on colon neoplasms. These have been shown to be effective 
in targeting human colon cancer xenografts in athymic mice, allowing effective tumour 
imaging when labelled with 123I. An scFv to the testicular and ovarian cancer marker, 
PLAP was derived from a monoclonal antibody (Deonarain et a l, 1997). However, 
problems with solubility and folding serve to illustrate some of the difficulties in 
converting established monoclonals to scFv, which can result in misfolding and 
insolubility.
Pereira et a l (1997) have exploited the full potential of combinatorial phage display 
technology to isolate a library of anti-melanoma Fab antibodies from the PBLs of a 
remissive melanoma patient treated with allogenic melanoma vaccinations. This resulted 
in Fab capable of binding to melanoma as well as some other tumour and normal cell 
types.
In a search for new therapies for viral disease, human combinatorial libraries are being 
greatly exploited. Research has concentrated on the most serious and chronic forms of 
viral disease such as AIDS (Burton et a l, 1991; Barbas et al., 1992a), and hepatitis B 
(Zebedee et al., 1992) and secondary viral infections closely related to HIV, respiratory 
syncytial virus (RSV) and herpes simplex virus (HSV) (Ping et al., 1996; Barbas and 
Burton, 1996). Other viruses to receive serious attention have been influenza virus (Caton, 
1990), cytomegalovirus (CMV) and varicella zoster virus (VSV) (Williamson et a l, 1993).
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Many human high affinity antibodies have been generated using phage display 
technologies that show high affinity viral neutralisation properties that require clinical 
evaluation in the fight against AIDS, hepatitis and other viral diseases.
1.12 INTRACELLULAR IMMUNISATION
Another interesting application to emerge from the eukaryotic expression of antibody 
fragments is that of intracellular targeting. Here, the antibody molecule is produced inside 
a host cell using a suitable vector, probably viral. Intracellular production of the antibody 
could allow it to target within the cell. An IgM antibody to the 4-hydroxy-3- 
nitrophenacetyl hapten was targeted to the nucleus of a mammalian cell using the SV40 
large T nuclear antigen as the L chain leader sequence (Biocca et al., 1990). The 
plasmids for L and H chain genes were based on human cytomegalovirus (CMV) and the 
Drosophila heat shock protein hsp70, respectively, using a murine secretory piece and 
eukaryotic selectable marker genes gpt (guanine phosphoribosyl transferase) and neo 
(neomycin acetyl transferase). This system resulted in assembled and nuclear targeted 
molecules. Such a system could have great therapeutic potential for the destruction of 
intracellular pathogens such as viruses by producing antibody from within the cell where 
these organisms are normally hidden from the immune system. Such a system has been 
described for a scFv antibody against the gpl20 coat protein of HIV-1 (Marasco et al.,
1993). The scFv was stably expressed and retained in the endoplasmic reticulum. It 
bound to HTV-1 gpl20 inside the cell and inhibited processing of envelope precursor and 
syncytium formation. Thus, HIV-1 infectivity from these cells could be reduced and its 
spread to neighbouring cells slowed.
Intracellular targeting can also be used to block and deactivate oncoproteins with the 
potential to arrest malignant growth (Chen and Marasco, 1996). Wright et al. (1997) 
exploited this potential using an anti-erb-2 scFv antibody targeted to several breast 
carcinoma cell lines via recombinant adenovirus. This achieved high efficiency down- 
regulation of erb-2 and resulted in apoptosis in cell lines overexpressing the protein. 
Transfection of carcinoma cells with such antibodies may be extremely effective in 
arresting cancerous growth where erb-2 plays a regulatory function.
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McMahon and O’Kennedy (1997) have developed a vector system for the intracellular 
expression of antibody libraries within eukaryotic cells. Clones conferring cytotoxic effects 
on the cell can be identified and selected from this population. Such intracellular cytotoxic 
antibodies may have many potential applications such as in therapies for cancer and viral 
infections such as HIV.
1.13 BISPECIFIC ANTIBODIES
Antibodies are bivalent (bind at two sites, and monospecific (bind a single species). This 
is for an important reason. Binding of the two Fab arms of the antibody molecule brings 
about conformational changes in the Fc portion. It is this signal that triggers the effector 
functions of the antibody molecule, e.g., complement activation or recognition by 
macrophages. Bivalency also results in the formation of immune complexes. For the 
antibody engineer, however, who tends only to be interested in the antibody-antigen 
interaction, such duplication sometimes seems wasteful and serves no additional purpose. 
It was envisaged that, rather than having a monospecific bivalent molecule, combining 
Fabs from two heterologous antibodies could result in a bispecific molecule capable of 
attaching to two different epitopes simultaneously. Such molecules have been termed 
’bispecific’ antibodies.
The production of bispecific antibodies has been reviewed (Nolan and O’Kennedy, 1990; 
Nolan and O’Kennedy, 1992). Production can be via either biological, chemical or 
genetic processes. Two distinct methods exist for biological production of monoclonal 
bispecific antibodies. The first involves the fusion of two hybridomas expressing 
antibodies of different idiotypes. Upon fusion, chromosomal mixing occurs and a further 
hybrid may result which produces H and L chains of both antibody types. This cell has 
been termed a quadroma because it descends from 4 original parents (two myelomas and 
two splenocytes). Because of this, yields of bispecific antibody can be low. Such cells 
also have poor chromosomal stability and may loose the ability to produce some chains.
A second method for the biological production of bispecific monoclonal antibodies uses 
the fusion of a hybridoma raised against one antigen with splenocytes from an animal
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immunized with the second antigen. Such cells are called triomas as they are descended 
from three parent cells (one myeloma and two splenocytes). The quadroma system is 
more popular as it is easier to work with, although it does require unpredictable back 
selection procedures.
Chemical methods have also been developed for bispecific antibody production. Various 
strategies have been developed with varying degrees of success. An efficient and popular 
system involves the use of the cross-linking reagent o-phenylene dimaleimide, which, 
under conditions that prevent intersulphide bond formation between SH groups can be 
linked to one Fab type and then cross-linked to a second Fab when introduced. This 
system tends to produce yields of up to 50-70% bispecific antibody.
The nature of bispecific antibodies endows them with potential therapeutic efficacy (Nolan 
and O’Kennedy, 1990). Before bispecific antibodies, chemotherapeutic agents could only 
be targeted using antibodies via conjugation of the effector molecule directly to the 
antibody. Such conjugation could have detrimental effects on the antibody or effector 
substance by altering the therapeutic agent or the antigen-binding site. With bispecific 
antibodies, one Fab could be directed to the target, the other to the effector molecule. 
Such a system has several advantages over alternative therapies. As well as having no 
deleterious effects on the antibody or the drug this system also allows the bispecific 
antibody and the therapeutic agent to be administered separately. Administering bispecific 
antibody alone would allow it to target specific areas and non-specific interactions could 
be allowed to clear before administration of the therapeutic drug. The drug would be 
delivered more specifically and more safely to the target area.
Antibody engineering has facilitated the production of bispecific antibodies by genetic 
methods (Holliger and Winter, 1993; Pack et al., 1992; Pliickthun and Pack, 1997). Some 
researchers have found spontaneous assembly of bivalent scFv fragments (McGregor et 
al., 1994). However, this is a result of dimérisation of non-adjacent L and H chain pairs 
and is not a reliable means of linking heterologous antibody fragments. Two strategies 
have exploited natural heterodimeric proteins or amphipathic helices with helix-tum-helix 
motifs (Pack and Plückthun, 1992). Both methodologies result in the production of stable
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heterodimers. One popular heterodimeric protein pair are the leucine zippers, Jun and Fos 
(Kostelny et al., 1992). The two proteins have a series of leucine residues down one side 
of an alpha helix which can interdigitate with each other forming a stable protein 
heterodimer. De Kruif and Logtenberg (1996) developed a bispecific antibody from scFv 
derived from the Nissim library (Nissim et al., 1994) by mixing separately expressed 
scFv-Jun or scFv-Fos fusions following expression of the individual fusion products. 
Bispecific constructs have also been created from single chain Fvs by the fusing the VH 
and VL domains of two distinct scFvs and expressing them in a single host (Holliger et 
al., 1993). This results in the association of the original VH and VL pairings, forming a 
bispecific ’diabody’. Other less successful linking methods have employed the direct 
linkage of two antibodies through another protein, e.g. cellulase (Mallender and Voss, 
1994).
Many effector substances can be used and have been proposed for use in conjunction with 
bispecific antibodies. Bacterial and plant toxins are extremely potent cytotoxic agents. 
Nature has created them in a particular way. Most toxins are divided into two fragments 
or functional domains: the A (activity) fragment and B (binding) fragment. Only in 
combination can the toxin bring about its cytotoxic effects. The binding fragment 
mediates the cellular uptake of the A fragment normally either by mediated endocytosis 
or by forming a pore in the cell membrane. The A fragment then targets specific cell 
functions to bring about the destruction of the cell. Without the B moiety, the A chain 
is completely innocuous. Bispecific antibodies, however, also appear to mediate 
endocytosis of the A chain. This allows the toxin to be precisely targeted via an anti- 
tumour Fab arm present as one half of the antibody and the toxin held by the other Fab 
arm. Such a system has been applied using ricin A chain in prostatic carcinoma (Webb 
et al., 1985).
Such bispecific antibody systems can also be used to retarget the cytotoxic functions of 
the immune system itself to tumours rather than using foreign toxins. Just such a 
bispecific antibody was produced with specificity for the c-erbB-2 protooncogene product 
and the Fcylll receptor (FeyRIII) (CD16) (Hsieh-Ma et al., 1992). The c-erbB-2 
protooncogene product is found on human breast cancer cells such as the SK-Br-3 cell
48
line. FcyRIII is found on mononuclear cells and stimulates cytotoxic activity. The 
bispecific antibody brought about significant lysis of SK-Br-3 cells in the presence of 
human monocytes. No significant lysis occurred with mixtures of the two parent 
antibodies demonstrating the bispecificity of the antibody was key in the cytolytic process. 
Bispecific F(ab’)2 fragments derived from the anti-cerfcB-2 protooncogene anti-FcyRIII 
bispecific antibody were also as effective as whole antibody.
Clearly, the most popular bispecific construct for tumour therapy combines an anti-tumour 
marker antibody with an anti-CD3 antibody to bring about T cell lysis of the tumour. This 
has been done with the tumour antigen HER2 (Shalaby et al., 1992), the multidrug- 
resistant glycoprotein (van Duk et al., 1989) and uncharacterised antitumour antibodies 
(Weiner et al., 1994). Other cytotoxic components of the immune system have also been 
redirected to tumours such as tumour necrosis factor a  (TNFa) in combination with anti- 
CEA in human colon carcinoma Robert et al., 1996). All these treatments show improved 
targeting of cytotoxic agents over monoclonal antibodies alone.
Some, not content with the bispecificity of antibodies took the system a step further and 
produced ’trispecific’ antibodies composed of three heterologous Fab moieties (Tutt, et 
al., 1991). F(ab’)3 molecules were assembled, all of which had an anti-CD37 arm (used 
to target to CD37+ tumour cells) and an anti-CD3 arm (to target T cells). The third arm 
was to a series of cluster designation factors such as CD2, CD4 or CD8. Only trispecific 
antibodies containing anti-CD2 demonstrated strong cytotoxic targeting to CD37+ tumour 
cells in the presence of resting T cells. Being able to bring about the targeting and 
stimulation of resting T cells to tumour cells gives such a trispecific molecule therapeutic 
potential. Tetraspecific moieties have also been put forward as viable constructs (Adair 
and Bright, 1993; Pack et al., 1995), with the possibility of targeting more than one 
tumour marker for greater target specificity, or several cluster designation factors to more 
effectively recruit immune effector cells.
49
1.13.1 Bispedfic antibody therapy in association with chemotherapeutic drugs
It is becoming clear that for more effective cancer therapies, several strategies must be 
combined. Antibodies directed to tumours alone are only poorly effective. Bispecific 
antibodies that target chemotherapeutic and other agents to tumour cells are more effective 
and reduced the side effects associated with such treatments. Such therapies can be further 
improved by using engineered antibody fragments from human origin and of smaller size 
to remove anti-species responses and result in improved pharmacodynamics of the 
antibody molecule. An engineered human bispecific antibody targeting chemotherapeutic 
drugs to tumour cells is a tool with great potential for therapeutic success. According to 
the presently available literature, however, most bispecific therapeutic reagents are still 
being derived from murine monoclonal antibodies with fusion systems based on quadroma 
or chemical linkage technology. Either work to date in this area is too young to yield 
results, has produced data too poor to publish, or is successful enough to warrant secrecy 
in the interests of patenting such therapies. Indeed, methodologies based on leucine zipper 
production of bispecific scFv and Fab antibodies have already been patented (Tso et al., 
1993; Curtis, 1992). This will limit, or at least slow the development and application of 
such systems until non-patented strategies can be developed.
1.14 COUMARIN
Coumarin is a ubiquitous secondary plant metabolite found in abundance in plants of the 
Rutaceae and Umbelliferaceae genus (Keating and O’Kennedy, 1997). In the past, it has 
had several industrial applications, mostly as a result of its odorous properties, such as a 
flavouring enhancer and odour stabiliser (Egan et al., 1990). Coumarin has also been 
found to have several therapeutically useful applications, such as in the treatment of high 
protein lymphoedema (Casley-Smith and Casley-Smith, 1997), the treatment of bum 
injuries (Piller, 1997), and the treatment of chronic infections associated with immune 
suppression, e.g., brucellosis (Egan et al., 1990). However, most research interest in 
coumarin and its metabolites has focused on their apparent immunomodulatory and anti- 
carcinogenic effects. To this end, most experimental cancer therapy using coumarin and 
its derivatives has been concentrated on neoplasias that were traditionally unresponsive
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to existing treatments and would normally result in a high percentage of mortality. Three 
such cancers are prostate cancer (Mohler et al., 1997), renal cell carcinoma (Ebbinghaus 
et al., 1997) and malignant melanoma (Mohler et al., 1997). The high mortality of these 
cancers is generally associated with their metastatic properties. Even following radical 
surgery in all three cases, either by nephrectomy, prostectomy, or skin grafting, the 
patients are at high risk of developing metastatic lesions which respond poorly to 
chemotherapeutic intervention or radiotherapy.
Coumarin and its metabolites (principally 7-hydroxycoumarin) have been found to have 
pleiotropic effects in such treatments (Seliger, 1997). They have been shown to have 
immunostimulatory properties, such as increasing the proteolytic activity of macrophages, 
interference with prostaglandin synthesis and their ability to stimulate cytokine production 
(Zlabinger, 1997), as well as having more direct effects on tumour cell growth and 
development (Seliger, 1997). Such properties have made the coumarins an important target 
for anti-cancer chemotherapy research.
Coumarin has other research applications such as its use as a measure of cytochrome P450 
activity in liver samples for the monitoring of liver activity and liver damage (Cooke et 
al., 1997). Coumarin metabolism via the cytochrome P450-dependent pathway can be 
induced in the presence of other xenobiotic agents such as phénobarbital, cocaine, carbon 
tetrachloride, caesium and cobalt chlorides and others (Pelkonen, et al., 1997). Use of 
coumarins in cytochrome P450 assays provides a sensitive fluorimetric substrate. 
Coumarin metabolism itself has been used in conjunction with lignocaine metabolism as 
a measure of overall liver function with analysis of the phase I metabolites, 7- 
hydroxycoumarin and monoethylglycinexilyde in urine (Sotaniemi et a i, 1995).
1.14.1 The metabolism and pharmacokinetics of coumarin in man
With its widespread presence in the natural environment and occurrence in foodstuffs, as 
well as its potential in vivo therapeutic applications, the metabolism of coumarin in man 
and other species has been extensively studied (Pelkonen et al., 1997). Coumarin is 
metabolised in man primarily via a cytochrome P450-dependent monooxygenase system,
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CYP2A6 to the phase I metabolite, 7-hydroxycoumarin (Fig. 1.9). However, this is not 
the only pathway that exists in man and 3-hydroxylation may take place (Fentem and Fry,
1993). It is believed that at low coumarin concentrations, 7 hydroxylation is most 
important, but at high doses, the 3 hydroxylation pathway may predominate. The extent 
and rate of this phase I metabolism in humans is dependent on several factors such as 
genetics, tissue-type, sex, hormonal activity, chemical induction and the presence of liver 
disease and damage. This is important because 3-hydroxylation is linked to hepatotoxicity 
which takes place as a result of coumarin administration. Hepatotoxicity as a result of 
coumarin administration is rare (0.2-0.4%) (Cox et al, 1989). 3-hydroxylation is the 
predominant phase I pathway in the rat, where administration is linked to hepatotoxicity 
(Fentem and Fry, 1993). Although 7-hydroxylation is the predominant pathway in man 
differences in its metabolism due to the factors outlined above may vary the degree of 7- 
hydroxylation taking place. In the absence of this pathway, 3-hydroxylation may become 
a significant metabolic route, leading to hepatotoxic symptoms in such individuals (Van 
Iersel et al., 1994). Phase I metabolism is rapid and extensive following first pass through 
the liver. Coumarin has a half-life of 1 h following peroral or intravenous administration 
and as little as 4% reaches the circulatory system following oral administration.
7-hydroxycoumarin is metabolised to the phase II metabolite 7-hydroxycoumarin-P-D- 
glucuronide via a UDP-glucuronyl transferase (Ritschel et al., 1977) (Fig. 1.10). This 
highly hydrophilic metabolite is rapidly excreted in the urine. The other more minor 
secondary metabolic pathway is o-sulphation via sulphotransferase enzymes which may 
predominate if the glucuronidation pathway is blocked or absent (Clarke and Burchell,
1994). Due to the combination of rapid phase I and phase II metabolism, both coumarin 
and 7-hydroxycoumarin have low levels of bioavailability with near 100% excretion of 
a range of oral or intravenous doses taking place within 24 h.
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Figure 1.10. The major metabolic pathway of coumarin in man. Phase I metabolism is 
via a cytochrome P450-dependent monooxygenase liver enzyme which rapidly converts 
coumarin to 7-hydroxycoumarin. This is then metabolised to 7-hydroxycoumarin- fkD- 
glucuronide by an endoplasmic reticulum enzyme system, UDP-glucuronyl transferase, 
with the cosubstrate UDP-glucuronic acid.
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Figure 1.11. Phase II metabolism of coumarin via UDP-glucuronyl transferase. 7- 
hydroxycoumarin enters the lumen of the endoplasmic reticulum across the 
phospholipid bilayer. UDP glucuronic acid enters via a specific transporter. Conjugation 
takes place at the lumenal surface of the ER as the UDP-glucuronyl transferase is 
anchored in the membrane. The glucuronidated 7-hydroxycoumarin is transported via 
an aglycone glucuronide transporter for excretion.
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1.14.2 Pharmacological role of coumarin and its metabolites
Due to its rapid metabolism to 7-hydroxycoumarin and its low bioavailability it has been 
suggested that coumarin is a prodrug. Although it has been shown to possess 
immunomodulatory and anti-proliferative effects on cells (Ebbinghaus et al, 1997), its 
non-availability has led many to suspect that it may not play a significant pharmacological 
role (Weinmann, 1997). 7-hydroxycoumarin has been shown to have greater cytostatic 
properties than coumarin and it is suggested by many to be the active form of the drug 
(Seliger, 1997).
However, it could be equally well argued that, due to its rapid phase II metabolism, the 
bioavailability of 7-hydroxycoumarin is also quite low. Its ability to cross membranes via 
passive diffusion and enter cells is comparable to coumarin, so this does not offer 7- 
hydroxycoumarin an advantage over the parent molecule. Further investigation is still 
required to show the relative contribution of these components in the in vivo situation.
Glucuronidation is a major detoxification pathway for many xenobiotics. The increase in 
hydrophilicity normally leads to properties of decreased intracellular localisation due to 
the inability to traverse membranes and stick to other hydrophobic components such as 
lipids and proteins. It is thus mostly assumed that glucuronide metabolites do not play any 
pharmacologically significant roles. However, some glucuronides have been shown to have 
some pharmaceutical relevance, namely ibuprofen glucuronide (Niemeijer et al., 1989), 
morphine glucuronide (Salem and Hope, 1997) and ferullic acid glucuronide (Ohta et al. 
1997) and retinoid glucuronides (Abou-Issa et al., 1997; Biesalski and Schaffer, 1997), 
and although no direct role for 7-hydroxycoumarin glucuronide has yet been shown to 
exist, it may exert its effect indirectly via a conjugation-deconjugation cycling mechanism 
(Casley-Smith and Casley-Smith, 1986, Kauffman, 1994) (Fig. 1.11). 7-hydroxycoumarin 
glucuronide may enter cells, possibly via a specific transport mechanism, where it 
becomes deconjugated intracellularly via p-glucuronidase and exerts its cytostatic or 
cytotoxic effects before being removed from the cells and reconjugated via the liver. 
Indeed, all body tissues have been shown to possess such P-glucuronidase activity (Bogan 
et al., 1997). It is clear that
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Figure 1.12. Proposed hypothetical cycling mechanism for 7-hydroxycoumarin- 
glucuronide. 7-hydroxycoumarin-glucuronide circulating in the system prior to excretion 
enters cells via a hypothetical glucuronide transport mechanism. On entering the 
cytoplasm, it is deconjugated by the ubiquitous (3-glucuronidase enzyme, whereupon, the 
released 7-hydroxycoumarin exerts its pharmacological effects, before leaving the cell 
probably by passive diffusion.
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further investigation of coumarin, 7-hydroxycoumarin and its glucuronide is still necessary 
for a full understanding of the mechanisms at work in their effects on cells. To study the 
use of coumarin as a chemotherapy, monitoring of its metabolism and elucidation of its 
mode of action, analytical methods must be available to monitor and measure these 
metabolites, both in vitro and in vivo, in various matrices, such as blood, urine, faeces, 
tissues and enzyme preparations.
1.14.3 The analysis of coumarin and its metabolites
1.14.3.1 Physical methods of coumarin analysis
As with most analyses, the techniques available to analyse coumarins has evolved with 
the technologies available (Bogan et al., 1997). For qualitative analyses, early 
methodologies used paper chromatography (Swain, 1953; Berlingozzi, 1954), and then thin 
layer chromatography based on the fluorescent characteristics of coumarin and 7- 
hydroxycoumarin (Cholerton et al., 1992). Quantitative methods applied have been 
spectrofluorimetry (Egan and O’Kennedy, 1993a), high performance liquid 
chromatography (with detection using UV absorbance and limits of detection for 7- 
hydroxycoumarin as low as 0.3 ng/ml (Bogan and O’Kennedy, 1996) and coumarin as low 
as 0.6 ng/ml) (Archer, 1988), gas chromatography/mass spectroscopy of coumarin (7.7 
ng/ml LOD) (Hawthorne et al., 1988) and capillary electrophoresis using UV detection 
with LOD of 1 (ig/ml (Bogan et al., 1996). Traditionally, 7-hydroxycoumarin glucuronide 
was measured indirectly via deconjugation of the glucuronide via either chemical or 
enzymatic treatment to 7-hydroxycoumarin which was then analysed by HPLC (Egan and 
O’Kennedy, 1992).
1.14.3.2 Immunoanalytical techniques for coumarin analysis
As an alternative to solid state physical methods of analysis, several immunoanalytical 
procedures have been developed for the analysis of coumarin and its metabolites. 
Although the immunoanalytical systems so far developed are not yet comparable with 
physical methods in terms of limit of detection and precision and accuracy, they still have
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the potential to be significantly improved. They also offer other advantages such as not 
requiring large amounts of capital equipment. These can be prepared cheaply, easily and 
relatively quickly in most laboratories with only a limited amount of technical skill as 
compared to that required to run HPLC and CE systems. Several enzyme immunoassay 
strategies have been developed using polyclonal antibodies capable of detecting free 
coumarin and 7-hydroxycoumarin. These assays are heterogeneous competition ELISAs 
in which the antibody competes for bound protein-hapten conjugate and free drug. Best 
limits of detection have been achieved using alkaline phosphatase assay systems with 
LOD as low as 40 ng/ml (Egan, 1993; Egan and O’Kennedy, 1993; Bogan et al., 1997).
A bispecific antibody was also developed to measure 7-hydroxycoumarin using polyclonal 
antibodies to 7-hydroxycoumarin and alkaline phosphatase in a chemically cross-linked 
construct (Reinartz et al., 1996). This measured 7-hydroxycoumarin in the linear range of
0.1 to 1 ng/ml with a LOD of 30 ng/ml and illustrates the usefulness of a bispecific 
antibody in the immunoanalysis of coumarins.
Polyclonal anti-sera have also been used to measure 7-hydroxycoumarin concentrations 
using immunosensors. In these electroanalytical systems, protein-hapten conjugates of 7- 
hydroxycoumarin can be immobilised onto an electrode surface (Deasey et al., 1994). 
Anti-7-hydroxycoumarin antibody labelled with HRP competes with the immobilised 7- 
hydroxycoumarin and free 7-hydroxycoumarin. After washing away unbound material, 
HRP-labelled anti-7-hydroxycoumarin antibodies are left bound to the electrode surface 
at a concentration inversely proportional to the quantity of free drug. In the presence of 
hydrogen peroxide, HRP becomes oxidised. This becomes reduced again at the expense 
of an electron from the mediator, hydroquinone, which itself becomes oxidised and is 
again reduced by drawing electrons from the electrode surface. Binding of antibody to the 
immobilised antigen thus results in an increase in the steady state current which can be 
measured amperometrically.
Another widely used immunosensor technology is bispecific interaction analysis using the 
Pharmacia Biosensor BIAcore™ system, based on the concept of surface plasmon 
resonance. Here, a narrow wedge of light is focused onto a fine gold surface at a range
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of incident angles. The reflected light is detected by a series of photodetectors. At a 
certain critical angle known as the SPR angle, a component of the incident light is 
coupled through the gold film as an evanescent wave. The intensity of the reflected 
component at this critical angle is greatly reduced and can be measured by the detector. 
The angle at which SPR takes place, amongst other things is dependent on the mass of 
the gold film. Increasing the mass of the gold layer will change this SPR angle. Change 
in mass is proportional to change in SPR angle which is measured in response units. A 
reactive dextran matrix coupled to the sensor surface facilitates attachment of antibody or 
antigen components whos mass interaction may be monitored. This system has also been 
used in the design of a competitive immunoassay for 7-hydroxycoumarin (Bogan et al., 
1997). Here, 7-hydroxycoumarin-BSA was immobilised to the sensor surface via 
EDC/NHS coupling chemistry (Hermanson, 1997). A rabbit polyclonal anti-7- 
hydroxycoumarin antibody was mixed with a range of free 7-hydroxycoumarin 
concentrations and was found to be linear and quantifiable from 0.5 to 80 ng/ml. Sensor 
surfaces could be reused many times with surface regeneration in 5mM NaC)H-20mM 
HC1-5 mM NaOH.
The bispecific antibody of Reinartz et al. (1996) was also evaluated using BIAcore™, 
which confirmed that the antibody was bispecific in nature.
1.14.4 Engineered antibodies for coumarin analysis
As is clear, many physical and immunological methods have been developed for the 
analysis of coumarin and its metabolites, principally 7-hydroxycoumarin. 
Immunoanalytical techniques have proved to be cheaper, and simpler, without the 
associated problems of sample preparation required for HPLC. The success of any 
immunoassay procedure relies predominantly on the quality of the antibodies being used.
Polyclonal antibody sera are cheap and relatively easy to prepare. However, it is the 
variation in the quality of polyclonal sera that is normally the problem in immunoassay 
development. Hybridoma production has given rise to the availability of homogeneous 
antibody preparations of fixed and measurable properties, but time and cost often limit
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their use, and the outcome can often be a limited number of antibody species with 
unpredictable characteristics that may not be suitable for the analytical system in which 
it will be used.
Production and selection of antibodies through phage display libraries offers the potential 
of producing a broader range of monoclonal reagents than hybridoma technology in less 
time and with less cost. Their genetic nature means that they can also be further 
manipulated to improve their characteristics, either improving antibody affinity, or by the 
production of bispecific antibody reagents. If isolated from human origin, their potential 
clinical use is of great importance, along with their improved pharmacodynamics resulting 
from their smaller size. As bispecific reagents, novel analytical and therapeutic 
applications also become possible.
When applied to coumarin research, such benefits from antibody engineering are clear. 
The availability of reagents that recognise coumarin and its metabolites, 7- 
hydroxycoumarin and 7-hydroxycoumarin glucuronide would be very useful in their direct 
analysis without the need for sample preparation and deconjugation etc. As bispecific 
antibodies with both drug and enzyme specificities, more rapid immunochemical systems 
could be developed, either for enzyme immunoassays or for use in conjunction with 
immunosensor systems. Such reagents may also offer therapeutic potential. Bispecific 
antibodies utilising anti-tumour and anti-coumarin specificities may more effectively target 
these drugs to the site of action, combatting their low bioavailability. Development of an 
ADAPT system capable of 70HCG deconjugaton might also show clinical benefit if 
conjugation-deconjugation cycling mechanisms are important in the pharmacology of these 
drugs. In all, recombinant antibodies in coumarin research have the prospect of delivering 
improved reagents with both analytical and clinical potential.
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1.15 AIMS
The specific aims of this thesis were:
1. The development of combinatorial phage display systems for the production of 
antibodies that detect coumarin and 7-hydroxycoumarin, having the potential for the 
analysis of these drugs, either alone, or as bispecific antibodies, or in combination with 
other detection systems. Such bispecific antibodies also have the potential to be used as 
chemotherapeutic agents.
2. The study of 7-hydroxycoumarin glucuronide: its in vitro and in vivo metabolism, 
purification and development of drug conjugates for antibody production. Such antibodies 
could be applied to the development of immunoassays to 7-hydroxycoumarin-glucuronide 
to aid in the investigation of its relative contribution in the pharmacokinetics of coumarin 
and 7-hydroxycoumarin administration.
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2. MATERIALS AND METHODS
2.1 MATERIALS
Unless otherwise stated, all standard laboratory reagents were purchased from Sigma 
Chemical Co., Poole, Dorset, England.
Solvents were purchased from Labscan, Unit T26, Stillorgan Industrial Park, Co. Dublin.
Restriction enzymes were purchased from Boehringer Mannheim UK Ltd, Bell Lane, GB- 
Lewes, East Sussex England.
Enzyme immunoassay microtitre plates (96 well) were purchased either from Nunc, PO 
Box 280-Kamstrup DK, Roskilde, Denmark, or Costar, 1 Alewife Ctr, Cambridge MA 
02140, USA.
Antibodies were purchased either from Sigma Chemical Co. or Pierce and Warriner (UK 
Ltd, 44 Upper Northgate Street, Chester, Cheshire, England.
HPLC columns were supplied by Phenomenex, Melville House, Queens Avenue, 
Hurdsfield Industrial Estate, Macclesfield, Cheshire, SK10 2BW, England.
Molecular biology reagents were purchased from Promega Corporation (2800 Wood 
Hollow Road, Madison WI 53711-5399), Strategene, Qiagen Ltd (Unit 1, Tillingboume 
Court, Dorking Business Park, Dorking, Surrey, RH4 1HJ, England), Gibco BRL Life 
Technologies Inc. (8400, Helgerman Court, Gaithersburg, MD 20877), Genosys 
Biotechnologies (Europe) (London Road, Pamisford, Cambridgeshire, CB2 4EF, England), 
or Molecular Biologische GmbH (Wagenstieg 5, D-37077, Gottingen, Germany) as stated.
Bacterial growth media was supplied by Oxoid, unless otherwise stated.
Cell lines were obtained from the European Collection of Animal Cell Cultures, 
Department of Animal Cell Resources, Centre for Applied Biology, Porton Down, 
Salisbury SP4 OJG, England.
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BRIclone was supplied by Bioresearch Ireland Ltd, Dublin City University, Glasnevin, 
Dublin 9.
Coumarin, 7-hydroxycoumarin, and 7-hydroxycoumarin glucuronide were supplied by 
Schaper and Brummer, Salzgitter, Germany. 7-hydroxycoumarin-BSA and 7- 
hydroxycoumarin-THG conjugates were both gifts of Declan Bogan (Dublin City 
University), and coumarin-BSA and 3-acetylamino-7-acetocoumarin were supplied by 
Denise Egan (Dublin City University). Anti-7-hydroxycoumarin antibody was a gift of 
Gary Keating (Dublin City University).
The plasmid vector pComb3 was supplied by The Scripps Institute, Department of 
Immunology, 10666 North Torrey Pines Road, La Jolla, CA 92037, USA.
The Nissim library was supplied by The Medical Research Council, Centre for Protein 
Engineering, MRC Centre, Hills Road, Cambridge CB2 2QH, England.
The plasmid vector pJuFo was supplied by the Swiss Institute of Allergy and Asthma 
Research, Obere Strasse 22, CH-7270, Davos, Switzerland
2.2 EQUIPMENT
Standard spectrophotometric measurements were taken using a Shimadzu UV160A 
(Shimadzu Corp., 1 Nishinokyo-Kwabaracho, Nakagyo-Ku, Kyoto 604, Japan).
Ultracentrifugation was performed on a Beckman L8-70M ultracentrifuge (Beckman 
Instruments Inc., Bioindustrial Business Unit, Fullerton, CA 92634-3100, USA). High 
speed centrifugation was carried out on a Sorvall RC-5B (DuPont Instruments, Newton, 
CT, USA). Bench centrifugation was performed using a Heraeus Sepatech (Heraeus 
Instruments Inc., 111-A Corporate Blvd, South Plainfield, NJ 07080, USA) and 
centrifugation of 1.5 ml test tubes was performed using a Heraeus Biofuge 13.
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All pH measurements were taken using a Jenway 3015 pH meter (Jenway Ltd, Gransmore 
Green, Felsted, Dunmow, Essex CM6 3LB, England.
Agarose gel electrophoresis and polyacrylamide gel electrophoresis were carried out using 
the Atto AE-6100 horizontal gel electrophoresis and AE-6450 vertical gel electrophoresis 
systems, respectively (Atto Corp., 2-3 Hongo 7-chome, Bunkyo-Kui, Tokyo 113, Japan).
Infrared analyses were performed using a Nicolet infrared spectrophotometer (The Nicolet 
Instrument Corp., 525-1 Verona Road, Madison, WI 53711, USA).
Freeze drying was performed using Hetosicc, Hetofrig and Hetovac (Heto Laboratory 
Equipment, A/S Gyderang 17-19 DK 3450, Allerod, Denmark.
High performance liquid chromatographic (HPLC) analysis was performed using either 
Beckman System Gold 507 autosampler, 126 pump, 166 UV detector and 168 photo diode 
array (PDA) detector, or Waters Corp. PDA detector (Waters Corp., 34 Maple Street, 
Milford, MA 01757, USA).
Analysis of microtitre plates was performed using the Titertek Multiscan Twinreader 
(Flow Laboratories Ltd., Woodcock Hill, Harefield Road, Rickmans worth, Hertfordshire, 
WD3 IPG, England).
Electrotransformations were performed using a BioRad Gene Pulser (BioRad Laboratories, 
BioRad House, Maylands Avenue, Hemel Hempstead, Hertfordshire HP2 7TD, England).
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2.3 METHODS
2.3.1 General protocols
2.3.1.1 Culture media formulations
LB medium SOC medium
For the growth of E. coli XLl-Blue For the recovery of cells following
electrotransformation
Tryptone 10 g/1 Tryptone 20 g/1
NaCl 10 g/1 Yeast extract 5 g/1
Yeast extract 5 g/1 NaCl 0.5 g/1
Bacteriological agar 1% (w/v) KC1 2.5 mM
MgCl2 20 mM
Glucose 20 mM
pH 7.0
Glucose and MgCl2 added separately 
following autoclaving.
2xTY medium
For the growth of E. coli HB2151 and TGI 
Tryptone 16g/l
Yeast extract 10 g/1
NaCl 5g/1
TYE medium
For the growth of HB2151 and TGI 
Tryptone 10 g/1
Yeast extract 5 g/1
NaCl 8 g/1
Bacteriological agar 15 g/1
Terrific Broth
For the growth of E. coli XLl-Blue.
Prepared according to manufacturer’s instructions with 0.8 % (v/v) glycerol.
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Phosphate-buffered saline
All phosphate-buffered saline (PBS) used was according to Dulbecco ‘A’ formulation 
(Oxoid), as follows:
Potassium chloride
Sodium chloride 8 g/1 
0.2 g/1
Disodium hydrogen phosphate 1.15 g/l
Potassium dihydrogen phosphate 0.2 g/l
PH 7.3
2.3.1.2 Standard molecular biology protocols
Standard molecular biology protocols were performed as described in Sambrook et al.,
2.3.1.3 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
Polyacrylamide separating gels from 10% to 20% (w/v) were prepared from 30% 
acrylamide (29.2% (w/v) acrylamide, 0.8% (w/v) bis-acrylamide) in separating buffer from 
a 4X stock (1.5 M Tris-HCl, pH 8.8, 0.4% (w/v) SDS). Stacking gels were prepared at 
5% (w/v) polyacrylamide in stacking gel buffer from a 4 X stock (0.5 M Tris-HCl, pH 
6.8, 0.4% (w/v) SDS). Samples were prepared in 5 X sample buffer (60 mM Tris-HCl, 
pH 6.8, 25% (w/v) glycerol, 2% (w/v) SDS, 14.4 mM 2-mercaptoethanol, 0.1% (w/v) 
bromophenol blue) by boiling for 5 min. Samples were run on an Atto AE-6450 minigel 
gel until samples had reached the base of the stacking gel and then at 20 mA per gel until 
the dye front had reached the base of the gel. Gels were stained with Coomassie blue, or 
by silver staining, or were used for western blotting.
2.3.1.4 Coomassie blue staining
Gels were stained in Coomassie blue staining solution (0.2% (w/v) Coomassie blue R250 
in 30:10:60 (v/v/v) methanol:acetic acid:water) for 30 min and destained overnight in 
destaining solution (10:7:53 (v/v/v) methanol:acetic acid:water).
(1989).
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2.3.1.5 Silver staining
Gels were fixed for 30 min at room temp, or overnight at 4°C in 40:10:60 (v/v/v) 
methanol:acetic. acid:water. Protein was oxidised on 0.1% (w/v) potassium dichromate in 
100 ml water acidified with 27 (xl of 65% (w/v) nitric acid for 5 min while shaking. 
Following three 5 min washes in water, 0.2% (w/v) silver nitrate was added to the gel for 
20 min under shaking, washed for 1 min with water and developed in 29.65% (w/v) 
sodium carbonate, 0.5% (v/v) formaldehyde, by adding and removing stain as desired. The 
staining was stopped using fixative solution.
2.3.1.6 Western blotting
Proteins were transferred from acrylamide gels to nitrocellulose using a BioRad semi-dry 
blotter in the same running buffer for 25 min at 15 V and blocked with blocking solution 
(5% (w/v) non-fat milk powder, 0.01% (v/v) antifoam A, 0.02% (w/v) sodium azide in 
PBS for 2 h at room temperature or overnight at 4°C. Intermediate, non-enzyme-labelled 
antibodies were added in blocking solution for 1.5 h, shaking at room temperature, 
followed by three 10 min washes in PBS. The nitrocellulose was washed with phosphate- 
free, azide-free blocking solution (150 mM NaCl, 50 mM Tris-HCl, pH 7.5) three times 
for 10 min. Alkaline phosphatase-labelled anti-mouse IgG antibody was added to the filter 
in 5% (w/v) fat-free milk powder in phosphate-free, azide-free blocking solution for 1.5 
h, shaking at room temperature. Final washing was four 10 min washes in phosphate-free, 
azide-free blocking solution, prior to development with 5-bromo-4-chloro-3’- 
indolylphosphate (BCIP) and nitro blue tetrazolium chloride (NBT) reagents (Promega) 
in alkaline phosphatase buffer (100 mM NaCl, 5 mM MgCl2, 100 mM Tris-HCl, pH 9.5) 
according to manufacturer’s instructions. Colour development was stopped by the addition 
of 0.002M EDTA in PBS.
2.3.1.7 Dot blotting
Samples of 3 1^ were dotted on to nitrocellulose filters, marked off in 0.9 cm x 0.9 cm 
squares and blotted as for western blots (section 2.3.1.6).
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2.3.1.8 Bicinchoninic acid (BCA) assay
10 1^ of protein sample were placed in wells of a 96 well microtitre plate (Nunc). 190 jol 
of BCA assay reagent (Pierce) (50 parts reagent A to 1 part reagent B) were added and 
incubated at 60°C for 1 h. The absorbance was read on a Titretek Twinreader Plus at 562 
nm and compared to a set of protein standards from 0 to 2 mg/ml.
2.3.1.9 Production of anti-VCSM13 antibody in rabbit
VCSM13 phage was used to infect TGI cells and phage particles isolated according to 
section 2.3.3.3. 0.5 ml of VCSM13 phage, at lmg/ml, was mixed with 0.5 ml Freund’s 
Complete Adjuvant and used to inoculate a New Zealand White rabbit at five sites i.d. 
Three similar boosts were performed in Freund’s Incomplete adjuvant at 22, 42 and 124 
days. The rabbit was sacrificed by exanguination and the serum prepared according to 
section 2.3.2.4. 40% (v/v) saturated ammonium sulphate was added to the serum and 
antibody allowed to precipitate. The precipitate was centrifuged at 4,000 x g for 10 min. 
and resuspended in PBS. Saturated ammonium sulphate was again added to 40% (v/v) 
saturation and antibody allowed to precipitate. This was again centrifuged at 4,000 x g for 
10 min. The precipitate was finally redissolved in PBS and dialysed overnight at 4°C 
against 50 volumes of PBS. The sample was applied to a 1 ml protein G column 
equilibrated using PBS. The column was washed using 5 ml of PBS and the antibody was 
eluted in 0.1 M formate buffer, pH 2.8. One millilitre fractions were collected into 1.5 ml 
tubes containing 100 jol of 0.1 M Tris-HCl, pH 8.7. The fractions were analysed for the 
presence of antibody by measuring the absorbance at 280 nm. Fractions containing protein 
were pooled and dialysed against 50 volumes of PBS overnight at 4°C.
Rabbit serum was analysed five days subsequent to each immunisation by ELISA with 
10 ng/ml VCSM13 phage and 1 in 10,000 horseradish peroxidase-conjugated anti-rabbit 
IgG antibody according to Campbell (1986).
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2.3.1.10 Production and purification of anti-c-myc antibody from mycl-9E10
Mycl-9E10 hybridoma (ECACC) was cultured in Dulbecco’s Modification of Eagle’s 
Medium with 10% (v/v) foetal calf serum and 5% (v/v) BRIClone with 100 U/ml 
penicillin, 0.1 mg/ml streptomycin and 50 |ig/ml gentamycin. Culture supernatants were 
precipitated with 40% (v/v) saturated ammonium sulphate, centrifuged at 2,500 x g for 
30 min, resuspended in 10 mM phosphate buffer, pH 7.2 and dialysed against 50 volumes 
of the same buffer. Antibody was either used directly in enzyme immunoassays, or 
purified further by DEAE-cellulose chromatography. For DEAE-cellulose chromatography, 
a column was prepared. 4 g DEAE-cellulose were prepared in 10 mM phosphate buffer, 
pH 7.2 and used to pour a 15 ml column (3 cm x 2.5 cm diameter). Antibody was applied 
to the column in 1 ml fractions and washed with 10 column volumes of buffer. Antibody 
was eluted in 10 mM phosphate buffer, pH 7.2, with a linear gradient from 0 to 0.2 M 
NaCl. Fractions were collected, assayed, pooled and dialysed against 50 volumes of 10 
mM phosphate buffer, pH 7.2.
The titre of anti-c-myc antibody was determined using chequerboard ELISA (Campbell, 
1986) with doubling dilutions of antibody starting at 1 in 100 dilution, against doubling 
dilutions of horseradish peroxidase-labelled anti-mouse IgG beginning at 1 in 100 dilution 
with 1 in 100 anti-human IgG as control.
2.3.1.11 Standard enzyme immunoassay protocol using polyclonal antibodies
2.3.1.11.1 Non-competitive enzyme immunoassay
Protein-drug conjugates of appropriate type (coumarin-thyroglobulin, coumarin-bovine 
serum albulin, 7-hydroxycoumarin-bovine serum albumin, 7-hydroxycoumarin-ovalbumin) 
and concentration (up to 500 (a.g/ml) were coated onto immunoassay microtitre plate 
(Nunc) in 100 fil volumes for 2 h at room temperature. Wells were emptied and rinsed 
once with PBS, dried and blocked overnight with 1% (w/v) BSA at 4°C. The plates were 
washed once with PBS and dried. Dilutions of antibody were added to wells in 100 (ol 
volumes and allowed to bind for 90 min at room temperature. Plates were washed three
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times with PBS/Tween 20 (0.05 %, v/v) and once with PBS and tapped dry. Anti-species 
antibody conjugated to horseradish peroxidase, in PBS, was added to wells in 100 (ul 
volumes and allowed to incubate at room temperature for 90 min. Plates were again 
washed with three time PBS/Tween and once with PBS. 0.04 mg/ml o-phenylenediamine 
in 50 mM sodium citrate, 0.15 M sodium phosphate buffer, pH 6.0 with 0.32 |al/ml H20 2 
was added to each well and incubated at room temperature for 30 min. Substrate reactions 
were terminated by the addition of 50 ul 4 M H2S04 per well. Absorbance was read at 
492 nm.
2.3.1.11.2 Competitive enzyme immunoassay
Competitive enzyme immunoassays were performed as described in section 2.3.1.11.1, 
except that concentrations of free analyte (coumarin or 7-hydroxycoumarin) of up to 500 
Hg/ml were mixed with coumarin-protein or 7-hydroxycoumarin-protein conjugate as 
appropriate at a concentration predetermined by enzyme immunoassay and added to 
microtitre plate wells following coating and blocking of wells with drug-protein conjugate. 
Addition of primary and secondary antibodies was also as described in section 2.3.1.11.1.
2.3.1.12 Standard enzyme immunoassay protocol using single chain Fv antibodies
2.3.1.12.1 Non-competitive enzyme immunoassay
Protein-drug conjugates of appropriate type and concentration as described in section
2.3.1.11.1 were coated onto immunoassay microtitre plate (Nunc) in 100 |il aliquots for 
2 h at room temperature. Wells were emptied and rinsed once with PBS, dried and 
blocked overnight at 4°C with 1% (w/v) BSA, ovalbumin or 5% (w/v) non-fat milk in 
PBS as appropriate. The plates were washed once with PBS and dried. Appropriate 
dilutions of scFv antibody in either 50 mM Tris, pH 7.4 or PBS were added to wells in 
100 (il volumes and allowed to bind for 90 min at room temperature. (All washes and 
dilutions of anti-coumarin scFv clones took place in 50 mM Tris, pH 7.4 and all anti-7- 
hydroxycoumarin scFv clones took place in PBS. Wells were washed three times with 
either 50 mM Tris, pH 7.4 or PBS and 100 fil of a 1 in 400 dilution of anti-c-myc
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antibody was added to each well for 90 min at room temperature. The wells were again 
washed and dried as before and 100 |al of a 1 in 5,000 dilution of horseradish peroxidase- 
conjugated goat anti-mouse IgG antibody added to each well and incubated for 90 min 
at room temperature. Following washing, substrate was added as described in section 
2.3.1.11.1.
2.3.1.12.2 Competitive enzyme immunoassay
Competitive enzyme immunoassay was performed as section 2.3.1.12.1, except that free 
analyte was mixed with antibody following coating and blocking of wells with drug- 
protein conjugate.
2.3.1.13. Agarose gel electrophoresis
Samples from 10 to 20 nl were prepared in 6x loading buffer (0.25% (w/v) bromophenol 
blue, 40% (w/v) sucrose). Samples were loaded into wells of agarose gels, typically 
between 0.8 and 1.2%. Gels were prepared using 50x TAE (242g/l Tris, 57.1 ml/1 glacial 
acetic acid, 100 ml/10.5 M EDTA, pH 8.0) and SeaKem GTG agarose (FMC BioPoducts). 
Ethidium bromide was added to gels at 0.25 (J.g/ml. Samples were electrophoresed at 8 
V/cm for 0.5 to 1.5 h.
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2.3.2 Production of murine Fab antibody libraries to coumarin and 7- 
hydroxycoumarin
2.3.2.1 Production of a coumarin-thyroglobuUn conjugate
Production of the coumarin-thyroglobulin (THG) conjugate was performed according to 
Egan (1993), and involved the production of 6-aminocoumarin diazonium salt from 
coumarin via the intermediates, 6-nitrocoumarin and 6-aminocoumarin. Briefly, 6- 
nitrocoumarin was prepared by adding 25 ml concentrated nitric acid to 25 g of coumarin 
dissolved in 50 ml concentrated sulphuric acid, mixed for one hour and precipitated on 
ice, and the precipitate filtered and dried at 37°C. The 6-nitrocoumarin was analysed by 
melting point, thin layer chromatography (TLC) (silica stationary phase, diethyl ether : 
petroleum ether (90:10 v/v) mobile phase, and infrared (IR) spectral analysis.
6-aminocoumarin was prepared by suspending 4 g of 6-nitrocoumarin in 100 ml hot 
distilled water, acidified with 4 ml concentrated hydrochloric acid, and reduced by the 
addition of 8 g reduced iron filings (May and Baker Ltd), maintained at 70°C with mixing 
for three hours and made alkaline by the addition of solid sodium hydrogen carbonate (pH 
8). The hot mixture was filtered and precipitated on ice and dried at 37°C. Melting point, 
TLC and IR analyses were performed as above.
To conjugate 6-aminocoumarin to THG, 0.25g 6-aminocoumarin was mixed in 25 ml 
concentrated hydrochloric acid, followed by the addition of 2 ml distilled water, and 
cooling to 4°C. 2.5 ml of a cold 10% (w/v) sodium nitrite solution was added dropwise 
and mixed. This was then added dropwise to a solution of 0.2 g THG in 5 ml water, 
maintaining the pH at 7.0 with the addition of 0.5 M sodium hydroxide and stored at 4°C 
for two hours. The resulting coumarin-THG conjugate was dialysed extensively against 
distilled water at 4°C. A control reaction, containing no 6-aminocoumarin, was also 
performed with THG.
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2.3.2.2 Characterisation of the coumarin-thyroglobulin conjugate
The resulting coumarin-THG conjugate was dissolved in dimethyl sulphoxide 
(DMSO) rmethanol:water (1:1:1) and analyzed spectrophotometrically. The conjugate was 
also analyzed by size exclusion chromatography using a Phenomenex SEC 4000 size 
exclusion column on a System Gold HPLC system using an ultra pure water mobile phase 
at a flow rate of 0.5 ml/min. Detection was via PDA. The THG control was analyzed on 
a Waters HPLC with PDA under identical conditions. The conjugate was also analyzed 
by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) (section 
2.3.1.3) on a 10% (w/v) reducing gel. The conjugate was also analyzed by enzyme-linked 
immunosorbent assay (ELISA) as follows: coumarin-THG was coated onto a microtitre 
plate (Nunc) at 50 ng/ml PBS, overnight at 4°C, washed with PBS, blocked with 10 jig/ml 
bovine serum albumin (BSA) in PBS. Detection of coumarin was via a rabbit anti- 
coumarin-BSA antibody (Egan, 1993), 1 in 100 dilution, and a horseradish peroxidase 
(HRP) conjugated anti-rabbit immunoglobulin G (IgG) (1 in 10,000). The ELISA format 
followed was that of Campbell (1986).
2.3.2.3 Spectrophotometric estimation of drug-protein coupling ratios
Spectrophotometric scans were taken of drug-protein conjugates of known concentration. 
Protein concentration was estimated at 280 nm as 1 AU = 0.741 mg/ml. A standard curve 
of drug concentration from 1 to 10 (ag/ml was prepared and measured at 320 nm. The 
concentration of coumarin or 7-hydroxycoumarin in the drug-protein conjugates was 
calculated from the standard curve. These concentrations were converted to molarities and 
the molar ratios of drug to protein calculated.
2.3.2.4 Immunisation of mice with coumarin-thyroglobulin and 7-hydroxycoumarin- 
thyroglobulin
Balb/c mice were immunised with either coumarin-THG or 7-hydroxy coumarin-THG 
(70HC-THG). Conjugates were prepared at 50|ig in 50|il in sterile PBS. Initially, 
conjugate was mixed with 100 jol Freund’s Complete Adjuvant (FCA). Mice were
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immunised at several sites intradermally (i.d.). Mice were boosted after three weeks with 
50(xg of conjugate in 50^1 sterile PBS and 100|xl FCA intraperitoneally (i.p.). A final boost 
three weeks later was made using 250|ag of immunogen in 250^1 sterile PBS four days 
prior to the removal of the spleen. A control mouse was not immunised with immunogen.
0.2 ml blood samples were taken five days prior to each immunisation and serum 
prepared. Blood was allowed to clot for 3 h at room temperature (RT), and the clot 
allowed to shrink overnight at 4°C. The blood samples were centrifuged (Heraeus Biofuge 
13) at 2,000 rpm for 30 minutes and the sera stored at -20°C.
Serum titre was analyzed by ELISA. Nunc microtitre plates were coated with doubling 
dilutions of either coumarin-bovine serum albumin (BSA) or 70HC-BSA, starting at 
50^g/ml in PBS and coated overnight at 4°C. Doubling dilutions of mouse sera, beginning 
at 1 in 100 were prepared in PBS, after blocking with BSA. Finally, HRP-conjugated anti­
mouse IgG was added at 1 in 5,000 in PBS/BSA. A 1 in 100 dilution of serum from the 
control mouse was used as the control. Following o-phenylenediamine (OPDA) substrate 
addition and development, plates were read at 405 nm (Titretek Twinreader Multiscan) 
according to Campbell (1986).
2.3.2.5 Preparation of mouse spleen messenger RNA
Following immunisation, mice were sacrificed by exsanguination and blood serum stored 
as previously described. Mouse spleens were removed and transferred to a 5 ml chilled 
sterile 0.9% (w/v) NaCl solution. Messenger RNA (mRNA) was isolated from the spleens 
according to the method of Chomezynski and Saachi (1987) as follows. All glassware and 
reagents were prepared using diethyl-pyrocarbonate (DEPC)-treated ultrapure water and 
autoclaved at 121°C, 15 p.s.i. for 15 min. This was required to remove all contamination 
resulting from RNAse enzymes.
Spleens were placed in a glass hand homogeniser in 10 ml denaturing solution (4.0 M 
guanidine isothiocyanate, 0.25 M sodium citrate, pH 7.0, 0.1 M 2-mercaptoethanol) and 
gently homogenised. This was followed by the addition of 1 ml 2 M sodium acetate, pH
4.0 and mixed thoroughly, followed by 1 ml saturated phenol and 2 ml
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chloroform/isoamyl alcohol (24:1), mixed vigorously for 10 seconds and placed on ice for 
15 min.
The homogenate was transferred to a polypropylene tube and centrifuged at 10,000 x g 
for 20 min at 4°C. The upper layer was transferred to a fresh tube and mixed with an 
equal volume of isopropanol and incubated for 1 h at -20°C. The precipitated RNA was 
centrifuged at 10,000 x g for 20 min at 4°C and the pellet resuspended in 3 ml denaturing 
solution. The RNA was reprecipitated with 3 ml isopropanol at -20°C for 1 h and 
centrifuged at 10,000 x g for 20 min at 4°C. The pellet was washed in 70% (v/v) ethanol 
and dried under vacuum for 15 min. Finally, the pellet was resuspended in 3 ml sterile, 
ultrapure water.
2.3.2.6 Reverse transcription of mouse spleen mRNA
Reverse transcription was performed using the Promega PCR-related Reverse 
Transcription System. 10(al mRNA preparations were incubated with 5|jg (10|al) oligo(dT) 
primer, and 25 U of rRNAsin ribonuclease inhibitor in a total volume of 40(il at 70°C for 
10 min and then cooled on ice. This was added to a mixture of 50fjl 10 X reverse 
transcription buffer, 50^1 deoxynucleotide triphosphates (dNTPs) mix, (10 mM each 
dATP, dCTP, dGTP, dTTP), lOOfol MgCl2 (25 mM) and 6pJ AMV reverse transcriptase 
(25 U/|iJ) in a total of 500|al, incubated at RT for 10 min, 42°C for 2 h and 90°C for 5 
min. 1^ 1 RNase H was added and incubated for 2 h at 37°C.
76
23.2.7 Amplification of antibody light and heavy chain genes using polymerase chain
reaction
2.3.2.7.1 PCR Primers
PCR primers were obtained from the Genetics Department, Trinity College, Dublin. 
Primer stock concentrations were 0.2 mM. Primers used were as follows:
Variable Heavy Chain - 5' Primers
VhIB 5'-CAG GTG CAG CTC GAG GAG TCA GGA-3'
VhIIB 5'-CAG GTC CAA CTC GAG CAG CCT GGG-3'
VHIIIB 5'-GAG GTG AAG CTC GAG GAG TCT GGA-3' 
V„IIID 5'-GAA GTG ATG CTC GAG GAG TCT GGG-3' 
VhVA 5'-GAG GTT CAG CTC GAG CAG TCT GGA-3'
Variable Kappa Chain - 5' Primers
KI 5'-GAC ATT GAG CTC ACT CAG TCT CCA-3'
KVI 5'-CAA ATT GAG CTC ACC CAG TCT CCA-3'
Constant Heavy Chain 1 - 3 '  Primer
CGI 5'-GCA AGG ACT AGT ACC ACA ATC CCT-3'
Constant Kappa Chain - 3' Primer
Ckl 5'-ACA CTC TCT AGA GTT GAA GCT CTT-3'
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2.3.2.7.2 PCR reaction
A stock PCR reaction mixture was prepared as follows:
5^1 each 10 mM dNTP stock (dATP, dCTP, dGTP, dTTP)
60m1 25 mM MgCl2
100|al 10 X Taq polymerase reaction buffer (Promega)
Sterile ultrapure water to 1 ml
Standard PCR reaction mixture was as follows:
lpl mouse spleen cDNA (0.5-ljj.g) 
l^il each primer stock (20 i^M)
2.5 U (0.5 pi) Taq polymerase (Promega)
97(il stock PCR reaction mixture
PCR conditions varied depending on individual DNA and primer conditions (Innis and 
Gelfind, 1990), but typical thermal cycling conditions were as follows:
1. 95°C 5 min
2. 58°C 1.5 min
3. 72°C 1.5 min
4. 95°C 1 min
Steps 2-4 repeated 30 times
5. 58°C 2 min
6. 72°C 5 min
All ramping rates were at 2 s/°C.
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23.2.7.3 Purification o f PCR reaction products
PCR reaction products were precipitated with sodium acetate and isopropanol according 
to Sambrook, et al. (1989), resuspended in 20^1 sterile ultrapure water and run on a 1.5% 
(w/v) agarose gel (SeaKem GTG, FMC BioProducts, 191 Thomaston Street, Rockland, 
ME 04841, USA) containing 0.5|ig/ml ethidium bromide for 1 h at 80 V. The 700 base 
pair (bp) band was cut from the gel with a sterile scalpel and the DNA purified from the 
agarose using a Qiaex II purification System (Qiagen), according to manufacturer’s 
instructions.
23.2.8 Insertion of antibody heavy or light chain genes into the pGEM-T plasmid vector
Gel purified light or heavy chain genes were ligated into the pGEM-T plasmid vector 
(Promega) as follows:
50 ng (1 1^) pGEM-T vector 
2^1 gel purified antibody chain genes 
l(jl 10 X reaction buffer 
l|il ligase (Promega)
5|al sterile ultrapure water
Incubation was for 3 h at 15°C and overnight at 4°C.
23.2.9 Preparation of electrocompetent Escherichia coli XLl-Blue cells
Escherichia coli (E. coli) XLl-Blue (Stratagene) was streaked onto LB medium with 
10(j.g/ml tetracycline (Tc) and grown for 24 h at 37°C. Single colonies were used to 
inoculate 10 ml of Terrific Broth (TB) (Sigma), with 2% (w/v) glucose and 10|j.g/ml Tc 
and grown overnight at 37°C, 200 rpm. The 10 ml was overnight culture was used to 
inoculate 1000 ml (2 x 500 ml) Terrific Broth, 2% glucose and 10 |ag/ml Tc and grown 
at 37°C, 200 rpm to an optical density (OD) at 550 nm of 0.8 absorbance units (AU). The 
culture was chilled on ice for 15 min and centrifuged at 2,500 x g for 15 min at 4°C. The
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media was thoroughly decanted and the cells resuspended in an equal volume of ice-cold 
10% (v/v) glycerol in sterile ultrapure water, and centrifuged at 2,500 rpm for 15 min at 
4°C. This was repeated using half a volume of 10% (v/v) glycerol (500 ml), and the cells 
were resuspended in a final volume of 20 ml 10% (v/v) glycerol. Cells were aliquoted in 
300^1 lots, snap frozen in liquid nitrogen and stored at -80°C.
2.3.2.10 Measurement of transformation efficiency of electrocompetent E. coli XLl-Blue 
cells
300|il of electrocompetent E. coli XLl-Blue cells were thawed on ice for 5 min. 2 jil of 
supercoiled pUC18 plasmid DNA (Stralagene) (100 ng/ml) was added, mixed gently by 
pipetting and allowed to incubate on ice for 1 min. Cells were pulsed in a BioRad Gene 
Pulser at 2.5 kV, 200 Q, 25 (iF in a 0.2 cm electroporation cuvette. 1 ml of prewarmed 
(37°C) SOC medium was added to the cells and pipetted gently, before transfer to a 
further 2 ml SOC medium and shaking at 200 rpm, 37°C for 1 h. Transformants were 
plated on LB agar supplemented with 10 (ig/ml Tc and 100 ng/ml carbenicilin (Cb) and 
grown for 24 h at 37°C.
Electrocompetence was calculated as the number of positive transformants per microgram 
of pUC18 supercoiled plasmid DNA.
2.3.2.11 Transformation of E. coli XLl-Blue with pGEM-T plasmid vector containing 
light and heavy chain gene inserts
An appropriate volume of ligation mixture from 232.1  (2, 5 or 10 jol) was added to a 
300|jl aliquot of electrocompetent XLl-Blue cells and transformed according to section
2.3.2.10. Following 1 h incubation at 37°C, 200 rpm, the material was centrifuged at 2,500 
x g, cells were resuspended in a minimal volume of liquid and spread on plates of LB 
containing 10 ng/ml Tc and 100 ng/ml Cb. Self-ligated pGEM-T vector was distinguished 
from insert ligation by the addition of 20 nl of 50 mg/ml 5-bromo-4-chloro-3-indolyl-P-D- 
galactoside (X-Gal) (Promega) with 100 nl 100 mM isopropyl-p-D-galactoyranoside 
(IPTG) to plates of LB agar 30 minutes prior to use. Plates were incubated for 24 h at 37°C.
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2.3.2.12 Isolation of light and heavy chain gene inserts from pGEM-T
Transformed E. coli XLl-Blue carrying light or heavy chain inserts were resuspended 
from LB agar plates in 1 ml sterile distilled water and transferred to 25 ml sterile vials 
(Sterilin). Cells were pelleted at 2,500 x g for 20 min and plasmid DNA minipreps carried 
out using Wizard miniprep (Promega) according to manufacturer’s instructions. pGEM-T 
plasmid vector was digested with restriction enzymes, either for the removal of heavy or 
light chain gene inserts as follows (figures given for the digestion of 1 \ig plasmid DNA 
in 10 fil reaction volumes):
Heavy Chain Light Chain
Samples were incubated for 2 h at 37°C. The digested plasmid DNA was electrophoresed 
and the 700 bp band excised and purified according to section 2.3.2.7.3.
2.3.2.13 Preparation of pComb3 phagemid vector for insert ligation of antibody heavy 
chain genes
pComb3 (Scripps Institute) was transformed into E. coli XLl-Blue according to section
2.3.2.10. Individual colonies were used to inoculate TB with 2% glucose, 10 (ag/ml Tc, 
100 ng/ml Cb, and cultures grown overnight at 200 rpm, 37°C. Plasmid minipreps were 
prepared using Wizard Plus Minipreps (Promega). Plasmid DNA was digested as follows 
(figures given for the digestion of 1 |ig of plasmid DNA in 10 (il reaction volumes):
Heavy chain Light chain
10 U Xhol 
3 U SpeI
1 Ml 10 X Buffer H
10 U Xbal
5 U Sac I
1 Ml 10 X Buffer A
10 U Xhol 
3 U Spe I 
1 Ml 10 X Buffer
5 U Sacl
10 U Xbal
1 Ml 10 X Buffer
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Samples were incubated for 2 h at 37°C. The digested plasmid DNA was electrophoresed 
and the 700 bp band excised and purified according to section 2.3.2.7.3.
Ligation of heavy and light chain genes into pComb3 was performed using the Rapid 
DNA Ligation Kit (Boehringer Mannheim) according to manufacturer’s instructions,
2.3.2.14 Transformation of E. coli XLl-Blue with pComb3 plasmid vector containing 
light and heavy chain gene inserts
Transformation was performed according to section 2.3.2.11.
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2.3.3 Production of single chain Fv antibodies to coumarin and 7-hydroxycoumarin
2.3.3.1 The Nissim library
The human synthetic phage antibody single chain Fv (scFv) library (Nissim library) was 
obtained from the Medical Research Council, Cambridge (Nissim et a l, 1994). This 
consisted of the synthetic scFv library in E. coli TGI cells. All bacterial stocks were 
maintained at -80°C as 10% glycerol stocks.
2.3.3.2 Growth of the Nissim Library
50 ml 2xTY with 100 ng/ml Cb was inoculated with 50 pi of library cells (approx. 108 
cells). The culture was grown in a shaking incubator (at 200 rpm) at 37°C, until the OD 
at 600 nm had reached 0.5 AU. 10 |al VCSM13 helper phage (Stratagene) (1011 pfu/ml), 
were added to 10 ml of culture and incubated at 37°C, static for 30 min, centrifuged at 
2,500 x g for 10 min and the cells transferred to 300 ml 2xTY with 100 ng/ml Cb and 25 
Mg/ml kanamycin (Kn) and incubated overnight at 30°C, 200 rpm.
2.3.3.3 Preparation of phagemid particles
The overnight culture from section 2.3.3.2 above was centrifuged at 5,000 x g for 10 min. 
The culture supernatant was transferred to l/5th volume of PEG/NaCl (20% (w/v) 
polyethylene glycol 8000 in 2.5 M NaCl), mixed and incubated at 4°C for 1 h. This was 
centrifuged at 5,000 x g for 30 min (Heraeus Sepatech) and the pellet resuspended in 40 
ml water. The phage particles were again precipitated with l/5th volume of PEG/NaCl for 
20 min at 4°C and centrifuged at 2,500 x g for 30 min. The supernatant was thoroughly 
removed and the pellet resuspended in 2.5 ml water, centrifuged at 2,500 x g for 10 min 
and the supernatant stored at -20°C.
Phage preparations were titred by adding 50 1^ serial dilutions of phage preparation to 50 
|il TGI cells grown to an OD at 600 nm of 0.5 AU in 2xTY, 1% (w/v) glucose, incubated 
for 30 min at 37°C and plated on TYE with 100 |ag/ml Cb. Phage titre was calculated as
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titre-forming units (TFU) per ml.
2.3.3.4 Affinity selection of scFv antibodies using the Nissim library
16 wells of a Costar microtitre plate were coated with antigen at the appropriate 
concentration. For 7-hydroxycoumarin, 10 ng/ml 7-hydroxycoumarin-bovine serum 
albumin, for coumarin, 10 ng/ml coumarin-bovine serum albumin. All antigen was coated 
in PBS. An N-oxysuccinimide-activated binding plate (Nunc) was coated directly with 10 
mg/ml 6-amino coumarin in PBS. All plates were coated overnight at 4°C. The plates 
were washed three times with PBS and blocked with 1% (w/v) BSA in PBS for 2 h at 
37°C. Plates were then washed three times in PBS and 0.5 ml of library (approx. 1012 
TFU) was placed in 3.5 ml 1% (w/v) bovine serum albumin in PBS and dispensed into 
16 wells. The plates were shaken gently at RT for 30 min, followed by static incubation 
for 90 min.
Unbound phage was removed from wells by shaking the plate over a sink and the plates 
were washed 10 times with PBS-Tween (0.05 mg/ml Tween 20 in PBS) and 10 times with 
PBS.
250 [ol of sterile elution buffer (1.6 ml 12 M HC1 in 150 ml water, adjusted to pH 2.2 
with solid glycine and made up to 250 ml) were added to each well and left for 10 min. 
Eluted phage was transferred to an equal volume of 2 M Tris-HCl pH 8.0 for 
neutralisation and stored at -20°C. Eluted, neutralised phage was used to transfect 10 ml 
cultures of TGI (grown to an OD at 600 nm of 0.5 AU in 2xTY, 1% (w/v) glucose), for 
30 min at 37°C. This was transferred to 100 ml of 2xTY, 1% (w/v) glucose and 100 (ig/ml 
Cb overnight at 37°C. Cells were pelleted by centrifugation at 2,500 x g for 30 min and 
resuspended in 1 ml of 10% (v/v) glycerol and stored at -20°C. This material was used 
in repeated rounds of growth and selection as described (section 2.3.3.4).
Second and third affinity selection strategies were performed for the production of 
antibodies to 7-hydroxycoumarin. Three rounds of affinity selection were performed as 
above using 70HC-BSA, 70HC-0VA and 70HC-BSA in rounds 1 to 3 of affinity
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selection, respectively. The blocking solutions in rounds 1 to 3 were BSA, ovalbumin and 
non-fat milk respectively.
2.3.3.S Affinity selection of antibodies using BIAcore™
Phage antibody particles from section 2.3.3.3 at a concentration of 5.5 x 109 tfu/ml were 
passed across a sensor chip surface immobilised with 7-hydroxycoumarin-BSA for 5 min 
at a flow rate of 10 ^l/min. The sensor chip surface was washed with HEPES-0.5 M 
NaCl, pH 7.4 at 100 jd/min for 13.4 min. Glycine buffer, pH 2.2, was passed across the 
sensor surface at 10 |ol/min for 20 min and the eluent was neutralised with an equal 
volume of 2 M Tris, pH 8.0. Aliquots of eluent were analysed by phage titre at various 
time periods and the phage counts performed according to section 2.3.3.3.
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2.3.3.6 Screening of scFv antibodies by Phage ELISA
Glycerol stocks of affinity-selected scFv antibody were serially diluted in 2xTY and plated 
onto TYE with 100 |ig/ml Cb and grown overnight at 37°C. Viable counts were 
determined as the number of cfu/ml of stock culture.
2.3.3.6.1 Preparation of clones for phage ELISA
Single colonies were selected from plates and used to inoculate individual wells of a 96 
well cell culture dish containing 200 (xl 2xTY, 1% (w/v) glucose and 100 ng/ml Cb. The 
plate was shaken (150 rpm) overnight at 37°C and used as a master plate to inoculate an 
identical plate. 30 |xl of 60% (w/v) glycerol was added to each well of the master plate 
and stored at -20°C. The second plate was grown (shaken at 150 rpm) for 8 h at 37°C. 25 
1^ of 2xTY containing 1% (w/v) glucose, 100 |xg/ml Cb and 109 VCSM13 helper phage 
per ml was added to each well and allowed to stand at 37°C for 30 min followed by 
shaking (150 rpm) for 1 h at 37°C. Plates were centrifuged at 2,000 x g for 10 min. The 
supernatant was discarded and replaced with a mixture of 200 (ol 2xTY, 100 (ig/ml Cb and 
25 (ig/ml Kn and grown at 150 rpm overnight at 30°C. The plates were centrifuged at
2,000 x g for 10 min and 75 1^ of supernatant was used in the following phage ELISA. 
An anti-NIP clone (Nissim et a l, 1994) was used as a positive and negative control for 
the phage ELISA as outlined in section 2.3.3.6.2.
2.3.3.62 Phage EUSA
Enzyme immunoassay plates (Costar) were coated with 100 (il of either 10 ng/ml 7- 
hydroxycoumarin-bovine serum albumin, 7-hydroxycoumarin-OVA or 10 |ag/ml coumarin- 
bovine serum albumin, as appropriate and left overnight at 4°C. A positive control well 
was coated with 10 fig/ml 3-nitro-4-hydroxy-iodophenylacetic acid (NlP)-bovine serum 
albumin in PBS. A negative control well was coated with 7-hydroxycoumarin-bovine 
serum albumin or coumarin-bovine serum albumin as appropriate. Plates were washed 
once with PBS. Plates were blocked with 100 (jJ 1% (w/v) bovine serum albumin in PBS
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(or ovalbumin in the case of the second anti-7-hydroxycoumarin library) for 1 h at RT. 
The plate was washed three times with PBS-Tween. 75 (ol supernatant and 25 pi 4% (w/v) 
bovine serum albumin (or ovalbumin) in PBS were added to each well for 2 h at RT. 
Plates were washed three times with PBS-Tween and incubated with 100 pi per well of 
1 in 400 dilution of anti-M13 antibody (sheep or rabbit IgG, Genosys, Sigma or raised in 
rabbits (section 2.3.1.9)). This was followed by a 1 in 800 dilution of HRP-labelled anti­
sheep or anti-rabbit IgG. This was incubated for 2 h at RT and plates were washed three 
times in PBS-Tween. 100 pi substrate (0.04 mg/ml o-phenylenediamine in 50 mM sodium 
citrate, 0.15 M sodium phosphate buffer, pH 6.0 with 0.32 pl/ml H20 2) was added to each 
well and incubated at RT for 30 min. Substrate reactions were stopped by addition of 50 
pi of 4 M H2S04 per well. Absorbance was read at 492 nm.
2.3.3.7 Transfer of pHENl to HB2151 for screening of soluble scFv antibody 
expression
Positive isolates from phage ELISA were identified and 100 pi of the phage supernatant 
was used to transfect 10 ml cultures of HB2151 grown in 2xTY with 1% (w/v) glucose 
and 100 pg/ml Cb. Transfection was performed according to section 2.3.3.2.
2.3.3.8 Screening of scFv isolates for soluble antibody expression
Glycerol stocks of HB2151 clones from section 2.3.3.7 were plated onto TYE with 100 
pg/ml Cb, 1% (w/v) glucose in a 96 well tissue culture plate, and grown shaking (150 
rpm) overnight at 37°C. This was used as a master plate to inoculate a second plate 
containing 200 pi 2xTY per well, 0.1% (w/v) glucose and 100 pg/ml Cb. This was grown, 
while shaking, until the absorbance was approximately 0.9 AU. 25 pi 2xTY with 100 
pg/ml Cb and 9 mM IPTG were added and the plates grown for 16 h at 37°C and 150 
rpm to induce soluble antibody production.
Enzyme immunoassay plates were coated with antigen as appropriate (see section 
2.3.3.5.2), blocked and washed. 75 pi culture supernatant and 25 pi 4% (w/v) bovine
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serum albumin in PBS were added to each well, mixed and incubated at RT for 90 min. 
Plates were washed three times with PBS-Tween and three times with PBS. 100 (ol of a 
1 in 400 dilution of anti-c-myc antibody in PBS was added to each well at RT for 90 min. 
The plates were washed again, three time with PBS-Tween and three times with PBS. 100 
|il of a 1 in 100 dilution of a horseradish-peroxidase labelled anti-mouse IgG antibody was 
added and incubated for 90 min at RT. The plates were washed again as before and 
developed with o-phenylenediamine substrate as in section 2.3.3.5.2.
2.3.3.9 Analysis of the cellular distribution of scFv antibodies
Cultures of HB2151 selected for expression via phage ELISA were grown in 2xTY, 1% 
(w/v) glucose, 100 (ig/ml Cb and induced as described in 2.3.3.8. Cell pellets were 
analysed for periplasmic expression of scFv by resuspending in 100 (jl of PBS, 0.1% (w/v) 
phenyl methyl sulphonylfluoride (PMSF) and 1.5% (w/v) streptomycin sulphate. They 
were then subjected to three freeze-thaw cycles and centrifuged at 2,000 x g for 10 min 
(Heraeus Sepatech). Lysates were analysed by dot blotting (section 2.3.1.7).
2.3.3.10 Large scale scFv antibody production
E. coli HB2151 expressing appropriate antibody clones were inoculated into 5 ml cultures 
of 2xTY, 1% (w/v) glucose and 100 (ig/ml Cb and shaken (200 rpm), overnight at 37°C. 
These were used to inoculate 500 ml cultures of the same media which were grown to an 
OD of 0.8 at 600 nm, centrifuged at 2,500 x g for 20 min at RT and resuspended in an 
equal volume of 2xTY, warmed to 30°C. The culture was again centrifuged at 2,500 x g 
for 2 min and resuspended in an equal volume of 2xTY, 1 mM IPTG and incubated at 
200 rpm overnight at 30°C. Cells were harvested by centrifugation at 10,000 x g for 10 
min. Antibody was isolated from culture supernatant, periplasm or intracellular 
compartments, as appropriate, and this is described in section 2.3.3.11.
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2.3.3.11 Production of scFv antibody from intracellular compartments
The centrifuged bacterial pellet from above was resuspended in ice cold 50 mM Tris, pH 
8.0, 1 mM EDTA, 100 mM KC1, 0.1 mM PMSF. Cells were disrupted, either by 
sonication or use of a beadbeater with 50% (v/v) 0.1 mm glass beads and three 1 min 
pulses followed by 1 min cooling time, on ice. The lysate was centrifuged at 25,000 x g 
for 20 min at 4°C and the pellet resuspended in either 7.5 M guanidine hydrochloride 
(Gdn HC1) or 8 M urea with gentle mixing for 2 h at RT. The denatured lysate was 
centrifuged at 25,000 x g for 20 min at 4°C and dialysed against several changes of 0.1 
M Tris, 0.4 M arginine, 2 mM EDTA, pH 8.0 at 4°C over periods of time ranging from 
2 days to 2 weeks. The refolded lysate was finally centrifuged at 25,000 x g for 20 min 
at 4°C.
2.3.3.12 Large scale phage antibody production
E. coli TGI cells expressing appropriate antibody clones were prepared according to 
sections 2.3.3.2 and 2.3.3.3.
2.3.3.13 BIAcore™ kinetic analysis of anti-coumarin scFv antibody clones
A 5 min injection at 20 (xL/min of scFv antibody at a concentration of 1 nM was passed 
over both a coumarin-BSA sensor chip surface (1,600 RU) and a BSA control surface 
(6,000 RU) in HEPES buffer, pH 7.4. After 10 min dissociation phase, the surface was 
regenerated using HEPES, 0.15 M NaCl, pH 7.4. Observed association and dissociation 
rates were calculated using BIAevaluation 2.1™ software (Pharmacia Biosensor).
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2.3.4 The in vitro production of 7-hydroxycoumarin glucuronide
2.3.4.1 Preparation of porcine and bovine UDP-glucuronyl transferase
Porcine or bovine UDP-glucuronyl transferase (UDPGT) was prepared according to 
Tegtmeier et al. (1988). Fresh liver was cut into small pieces and washed in ice cold 0.9% 
(w/v) NaCl until the supernatant was clear. The supernatant was discarded and the liver 
was mixed with four times its mass (4 x) of 0.25 M sucrose (20%, w/v). The liver was 
homogenised (Ultra-Turrax) and centrifuged at 10,000 x g at 4°C for 15 min (Sorvall RC 
5B). The collected supernatant was centrifuged at 190,000 x g, 4°C for 90 min (Beckman 
L8-70M). The resulting microsomal pellet was resuspended in 4 x the mass of ice cold 
0.1 M Tris-HCl, pH 8.0, 0.1 mM dithiothreitol (DTT), 0.75% (w/v) sodium cholate, and 
shaken gently for 30 min. The homogenate was centrifuged at 190,000 x g for 1 h. 
Saturated ammonium sulphate to a final concentration of 40% (v/v) of saturation, was 
added gradually to the resulting clear supernatant while stirring. The resultant turbid 
solution was centrifuged at 10,000 x g at 4°C for 10 min, and saturated ammonium 
sulphate added to bring it to a final concentration of 70% (v/v) of saturation. The turbid 
solution was again centrifuged at 10,000 x g, for 10 min at 4°C and the precipitate 
resolubilised in 4 x its mass of 50 mM Tris-HCl, pH 7.4. It was dialysed against 50 
volumes of the same buffer and stored at -20°C. Protein concentrations were measured 
using the BCA assay (section 2.3.1.8).
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2.3.4.2 Initial analysis of the in vitro production of 7-hydroxycoumarin-glucuronide by 
HPLC
4 x 20 ml reaction mixtures, labelled A to D were prepared according to Table 2.1.
Table 2.1. Composition of reaction mixtures for the initial in vitro production of 7- 
hydroxycoumarin-glucuronide.
Component A B C D
UDP glucuronyl transferase 1.2 mg/ml 1.2 mg/ml 1.2 mg/ml 0 mg/ml
UDP glucuronic acid 2 mM 0 mM 2 mM 2 mM
Tris-HCl, pH 7.4 0.1 M 0.1 M 0.1 M 0.1 M
7-hydroxycoumarin 140 mM 140 mM 0 mM 140 mM
Ethanol 4% (v/v) 4% (v/v) 4% (v/v) 4% (v/v)
Saccharolactone 5 mM 5 mM 5 mM 5 mM
Magnesium chloride 5 mM 5 mM 5 mM 5 mM
Water To 20 ml To 20 ml To 20 ml To 20 ml
Sample A was the test sample, containing enzyme and both substrates, 7-hydroxycoumarin 
and UDP glucuronic acid. Sample B lacked UDP glucuronic acid, sample C lacked 7- 
hydroxycoumarin and sample D lacked UDP glucuronyl transferase. Saccharolactone was 
present as a (3-glucuronidase inhibitor and magnesium ions was act as a cofactor for UDP 
glucuronyl transferase.
The samples were placed at 37°C revolving at 80 cycles per min, and 100 fil samples 
removed at various time intervals, precipitated with 20% (w/v) trichloroacetic acid and 
centrifuged at 13,000 rpm for 10 min at room temperature.
HPLC analysis conditions
HPLC analysis was performed on a System Gold chromatography station with System 
Gold software, using a Phenomenex Bondclone 10 C-18 reverse phase column (25 cm)
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with a flow rate of 2 ml/min and a mobile phase of 700:300:2 water:methanol:acetic acid. 
Samples of 20 fil were injected with detection at 324 nm. Samples were compared against 
glucuronide standards from 0 to 100 |ig/ml prepared in the same matrix.
2.3A.3 Repeat analysis of the in vitro production of 7-hydroxycoumarin-glucuronide 
by HPLC
For the repeat analysis of the in vitro production of 7-hydroxycoumarin glucuronide, 
bovine UDP glucuronyl transferase was prepared according to section 2.3.4.1. A reaction 
mixture was prepared in triplicate according to Table 2.2.
Table 2.2. Composition of the reaction mixture for the repeat in vitro production of 
7-hydroxycoumarin glucuronide.
Component Concentration
7-hydroxycoumarin 0.77 mM
UDP glucuronyl transferase 1 mg/ml
Magnesium chloride 6.25 mM
Saccharolactone 6.25 mM
UDP glucuronic acid 1.25 mM
Ethanol 4% (v/v)
Tris-HCl, pH 7.4 125 mM
Water To 4 ml
The reactions were carried out at 37°C in open 10 ml glass tubes. 200 (ol samples were 
removed and 40 |il 20% (w/v) trichloroacetic acid added, mixed and centrifuged at 13,000 
rpm for 10 min. Standards were also prepared (n=4) containing 0 to 1000 pg/ml 7- 
hydroxycoumarin glucuronide in the reaction components after treatment with 
trichloroacetic acid. 190 jol of sample was then added to 10 pi of a 1 mg/ml 4- 
hydroxycoumarin internal standard. These were analysed by HPLC.
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HPLC conditions
Chromatography was performed on a System Gold chromatography station using System 
Gold software, with a Phenomenex Bondclone 10 C-18 column. This analysis used a 
gradient method to increase the retention time of 7-hydroxycoumarin-glucuronide, and 
allow for the simultaneous analysis of 7-hydroxycoumarin, 7-hydroxycoumarin- 
glucuronide and the internal standard 4-hydroxycoumarin. Solvent A was 950:50:2 
water:methanol acetic acid (v/v/v). Solvent B was 100% methanol. The flow rate was 1 
ml/min with detection at 320 nm. The gradient was as follows (all percentages are v/v):
0-14 min: Solvent A (100%) to Solvent A (50%)/Solvent B (50%)
14-22 min: Solvent A (50%)/Solvent B (50%)
22-23 min: Solvent A (50%)/Solvent B (50%) to Solvent A (100%)
23-32 min: Solvent A (100%)
7-hydroxycoumarin-glucronide concentration was calculated by calculating the peak height 
ratios of 7-hydroxycoumarin-glucuronide and the internal standard, 4-hydroxycoumarin.
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2.3.4.4 Analysis of the in vitro production of 7-hydroxycoumarin-glucuronide by 
capillary electrophoresis (CE)
An enzymatic reaction mixture was prepared according to Table 2.2 to a total volume of
1.6 ml. Reactions were carried out in open 2.0 ml test tubes. Fractions were removed and 
analysed by CE. A standard curve of 7-hydroxycoumarin-glucuronide was prepared (n=3) 
in the same matrix as the reaction mixture, except that the enzyme solution was denatured 
prior to addition to the reaction mixture by boiling for 5 min.
CE separation conditions
Separation was carried out on a Beckman capillary electrophoresis instrument, P/ACE 
System 5500 using System Gold software according to the method developed by Bogan 
et al. (1996) for the analysis of 7-hydroxycoumarin and 7-hydroxycoumarin-glucuronide. 
The capillary used was a 57 cm x 50 |im i.d. untreated silica capillary with a capillary-to- 
detector distance of 50 cm. The capillary was conditioned each day by 10 min rinses with 
0.1 M hydrochloric acid, followed by 0.1 M sodium hydroxide, then deionised water and 
finally electrolyte buffer. Between each run, the capillary was rinsed for 0.8 min with 0.1 
M NaOH, then a 2.5 min rinse with electrolyte solution. Samples were applied by 10 
second pressurised injections at 0.5 p.s.i. Separation was achieved at 30 kV (rise time 0.2 
min) at 25°C with detection at 320 nm. Typical running current was 170 (jA.
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2.3.5 Purification of 7-hydroxycoumarin-glucuronide
2.3.5.1 Chromatographic separation of 7-hydroxycoumarin and 7-hydroxycoumarin- 
glucuronide
A series of chromatographic experiments were performed using a Lichroprep RP-18 
reverse phase silica column, 15 cm x 1 cm i.d. prepared in methanol. Buffer flow was 
maintained via a peristaltic pump with flow rates in the order of 0.2 to 0.4 ml/min. 
Various mobile phases, pump speeds and fraction intervals were assessed for the effective 
separation of pure mixtures of 7-hydroxycoumarin and 7-hydroxycoumarin-glucuronide. 
Fractions were analysed spectrophotometrically at 320 nm.
2.3.5.2 Chromatographic purification of 7-hydroxycoumarin-glucuronide from crude 
enzymatic reaction mixtures
Chromatographic conditions utilising a mobile phase of 50:50 methanol:water (v/v) was 
selected for the separation of 7-hydroxycoumarin and 7-hydroxycoumarin-glucuronide in 
crude enzymatic reaction mixtures derived from section 2.3.4, with flow rates typically 
in the order of 0.2 ml/min. Various sample volumes were assessed for their ability to be 
effectively separated under the given conditions. Relevant fractions of purified 7- 
hydroxycoumarin-glucuronide were analysed by HPLC according to section 2.3.4.2.
2.3.5.3 Chromatographic purification of 7-hydroxycoumarin-glucuronide from 
coumarin-treated urine
A healthy human volunteer was administered a 1 g p.o. dose of coumarin in 10 x 100 mg 
tablet doses subsequent to provision of a control urine sample. Urine from the treated 
volunteer was collected at 2 h. Control and treated urine samples were stored in aliquots 
at -20°C until use. Thawed samples were centrifuged and filtered through 0.45 (am sterile 
acetate filters.
Chromatographic separation of 100 pi aliquots of control urine, control urine spiked with
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7-hydroxycoumarin-glucuronide and treated urine samples were performed as described 
in section 2.3.5.2.
2.3.5.4 Development of a methodology for the extraction of 7-hydroxycoumarin- 
glucuronide from aqueous solutions
4 ml of coumarin-treated urine was extracted with 2 ml of DCM:methanol at varying 
ratios from 10:90 to 95:5 (v/v) in 10 ml glass tubes. Tubes were rotated on a blood tube 
mixer for 30 min at room temperature. The organic phase was removed and extracted into 
a further 1 ml of 1 M KC1. The organic layer was dried and resuspended in 400 |il water 
and analysed spectrophotometrically at 320 nm.
2.3.5.5 Extraction of 7-hydroxycoumarin-glucuronide from enzymatic reaction mixtures 
and coumarin treated patient urine
Further extractions of either urine samples or enzymatic reaction mixtures were performed 
using a DCM:methanol ratio of 70:30 (v/v). Extracted samples underwent chromatography 
according to section 2.3.5.2.
2.3.5.6 Assessment of the thermal stability of 7-hydroxycoumarin-glucuronide at 60°C
A 1 mg/ml solution of purified 7-hydroxycoumarin-glucuronide was prepared in distilled 
water and maintained at 60°C in a water bath. Aliquots were taken and analysed by HPLC 
according to section 2.3.4.2. The 7-hydroxycoumarin-glucuronide peak area was monitored 
over time.
2.3.5.7 Assessment of the stability of 7-hydroxycoumarin-glucuronide to a range of 
different pH conditions
Samples of purified 7-hydroxycoumarin-glucuronide were prepared in aqueous solution 
over a range of pH values from 2 to 12.
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2.3.5.8 In vitro enzymatic production of 3-amino-7-hydroxycoumarin-glucuronide
2.3.5.8.1 Preparation o f 3-amino-7-hydroxycoumarin
3-amino-7-hydroxycoumarin was prepared from 3.5 g 3-acetylamino-7-acetocoumarin 
according to Bogan (1996). Briefly, 3.5 g 3-acetylamino-7-acetocoumarin was refluxed 
in 250 ml of 3 M hydrochloric acid for 30 min until all the solid present had reacted and 
turned orange. The pH was neutralised with solid NaHC03. The resultant yellow 
compound was filtered under vacuum, dissolved in a minimal volume of boiling water and 
an equal volume of methanol, added and the whole solution placed on ice. The 
recrystallised orange-yellow compound was filtered and tested by HPLC (section 2.3.4.2) 
employing photodiode array detection and infrared spectral analysis.
2.3.5.8.2 In vitro enzymatic production of 3-amino-7-hydroxycoumarin-glucuronide
0.1 g of 3-amino-7-hydroxycoumarin was dissolved in 1 ml water and placed in the 
reaction mixture described in Table 2.1. The mixture was incubated for 4 h at 37°C, 
precipitated with 1 ml 20% (w/v) trichloroacetic acid and centrifuged to precipitate 
protein. The sample was analysed by HPLC according to section 2.3.4.2 using photodiode 
array detection.
2.3.5.9 Production of a 7-hydroxycoumarin-glucuronide-bovine serum albumin 
conjugate
42 pmoles of 7-hydroxycoumarin-glucuronide (14.2 mg), 52 (¿moles N- 
hydroxysuccinimide (1.87 mg) and 42 pmoles EDC (19.17 mg) were added to 270 mg 
bovine serum albumin (20:1 molar excess of 7-hydroxycoumarin-glucuronide to BSA) in 
3 ml carbonate buffer, pH 9.6 and 1 ml dimethyl sulphoxide. The reaction mixture was 
stirred overnight at room temperature and dialysed against ultrapure water and freeze 
dried. The resulting conjugate was analysed by SDS-PAGE (see section 2.3.1.3) and 
HPLC size exclusion chromatography according to section 2.3.2.2 with photodiode array 
analysis. The reaction was also performed without 7-hydroxycoumarin-glucuronide.
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Further examples of 7-hydroxycoumarin-glucuronide-bovine serum albumin conjugates 
were synthesised. A second conjugate was synthesised using borate buffer at pH 8.5 with 
a 200:1 molar excess of 7-hydroxycoumarin-glucuronide and a third was also prepared at 
this molar ratio, at pH 7.0
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3. PRODUCTION OF MURINE Fab ANTIBODY LIBRARIES TO COUMARIN 
AND 7-HYDROXY COUMARIN USING THE pComb3 SYSTEM
3.1 INTRODUCTION
3.1.1 Antibody phage display systems
Combinatorial antibody phage display technology, such as that developed by the Scripps 
Institute. La Jolla, San Diego, CA, has the potential to produce and screen large libraries 
of monoclonal antibodies to an antigen of interest. The pComb3 system utilises the 
technique of phage display, to mimic antibody presentation on the surface of B cells, with 
the linkage of genotype and phenotype resulting from the presence of only a single light 
and heavy antibody chain combination present on a phagemid particle within that phage. 
The enrichment technique of affinity selection, or panning, allows the selective 
amplification of phage particles carrying antibody specificities of interest from the rest of 
the population. Association of a single light/heavy chain gene combination with the 
correct protein expression is guaranteed by the characteristics of filamentous phage 
infection of E. coli, in which only a single phage particle can infect a cell, ensuring the 
correct linkage of phenotype and genotype (section 1.6.1).
3.1.2 Source and quality of material for library construction
Antibody chain genes have, in the past been isolated from several sources, notably from 
areas containing high B cell populations such as lymphoid tissues and blood. For the 
production of human antibody libraries, this has posed greater difficulties, as the best 
organ for B cell isolation in terms of quality and quantity of B cells is bone marrow. 
Although donation of bone marrow for such methodologies has been arranged, such 
procedures if performed routinely would be difficult to justify on ethical grounds. This 
would apply to other lymphoid tissues also. The second problem encountered with human 
monoclonal antibody production is lack of immunisation. Although naive, unimmunised 
libraries have been created and used effectively, it is still thought that the most reliable 
means of isolating high affinity light and heavy chain recombinations from such libraries 
is facilitated by immunisation. During this process, the events giving rise to large numbers 
of B cells expressing antibodies of high affinity occur. Placed in the context of antibody 
library production, such immunisations may result in the more reliable selection of high
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affinity light and heavy chain recombinants. For the production of murine antibody 
libraries, the problems associated with immunisation are overcome. For the most effective 
library production from mice, immunisation would be recommended, followed by 
splenectomy, and isolation of B cell mRNA from this source.
3.1.3 Production of hapten-protein conjugates
For the development of an immune response to haptens such as coumarin and 7- 
hydroxycoumarin, the haptens must be coupled to a large, immunogenic component, 
normally a protein (see section 4.1.1). Traditionally, several proteins are used in this 
regard: BSA, THG, keyhole limpet haemocyanin (KLH), and ovalbumin (OVA). Each of 
these exhibit different characteristics, making them more or less suited to various 
applications. Traditionally, BSA has been reserved for use during screening because of 
its low cost, whereas THG is used for immunisations, having the advantage of creating 
slightly less soluble conjugates, which characteristically, provoke a better immune 
response (Hermanson, 1997).
3.1.4 T/A cloning vectors
T/A cloning vectors such as pGEM-T (Promega) have been developed for the 
simplification of the insertion of products from polymerase chain reaction into vectors. 
Polymerase chain reaction (PCR) of DNA fragments using Taq polymerase results in the 
characteristic 5' adénylation of the amplified fragments. This characteristic has been 
employed for PCR fragment cloning using T/A cloning vectors (Promega). The pGEM-T 
vector is a modification of pGEM, which has been linearised and blunt ended followed 
by thymidylation of both 5' blunt ends. Such vectors allow the direct insertion of PCR 
fragments without the need for restriction digestion of the PCR fragments prior to 
insertion. T/A cloning is generally less efficient than restriction/ligation using standard six- 
cutter restriction endonucleases, which result in four nucleotide overhangs. It does, 
however, circumvent problems associated with PCR fragment ligation in that effective 
restriction digestion at sites introduced close to both the 3' and 5' ends of the PCR 
fragment can not be easily validated due to the very small size change in the PCR
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fragment, and the small size of the cut ends. Insertion into pGEM-T, followed by 
restriction digestion should yield a PCR fragment, which has now been correctly digested 
and should be ideal for further cloning.
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3.2 RESULTS
3.2.1 Preparation of coumarin and 7-hydroxycoumarin protein conjugates
Diazo-coupled conjugates of coumarin and 7-hydroxycoumarin to BSA and 7- 
hydroxycoumarin coupled to THG were donated by Egan (1993). These conjugates had 
all been previously characterised by ETPLC size exclusion chromatography and photodiode 
array analysis. Estimation of the coupling ratios of drug to protein were performed. 
Coumarin-BSA was estimated to possess approximately 12 moles coumarin per mole of 
BSA. This compared excellently with the estimates made by Egan (1993) of 12 molecules 
coumarin per molecule of BSA. 7-hydroxycoumarin-BSA was estimated to have 
approximately 3 moles of 7-hydroxycoumarin per mole of BSA.
BSA conjugates of coumarin and 70HC were further analysed by ELISA using rabbit 
anti-coumarin and rabbit anti-70HC antibodies (Egan, 1993). Both showed specific 
responses for the drug-protein conjugate alone, but not to protein (Figs. 3.1 A and B)
3.2.2 Production of coumarin-thyroglobulin (coumarin-THG) conjugate
Coumarin-THG was prepared according to Egan (1993). This required the production of 
6-nitro-coumarin (6-N02-coumarin), which was then converted to 6-amino-coumarin (6- 
NH2-coumarin). These were analysed by infrared spectrophotometric, TLC and melting 
point analysis and identified as the correct species. The IR spectrum of 6-N02-coumarin 
(Fig. 3.2) shows a stretch at 1,736 cm'1 (-C=0), and 1,350 and 1,526 cm'1 (-N02 
symmetrical and asymmetrical stretch). The IR spectrum of 6-NH2-coumarin (Fig. 3.3) 
shows a stretch at 1,699 (-C=0) and 3,322 and 3,402 cm'1 (-NH2 asymmetrical and 
symmetrical stretch, respectively)
6-amino-coumarin was coupled to THG according to Egan (1993). Following freeze 
drying, the resulting conjugate exhibited particularly poor solubility in water and other 
aqueous buffers as well as in organic solvents such as methanol, ethanol and DMSO. This 
lack of solubility would make it difficult to analyse by HPLC. Eventually, an effective
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solute was found in the combined use of dimethyl sulphoxide (DMSO), methanol and 
water. C-THG was dissolved in 1:1:1 DMSO/MeOH/water (v/v/v), adding DMSO first, 
then MeOH and then water. A spectrophotometric scan showed characteristic peaks at 280 
and 320 nm (Fig. 3.4), indicating the presence of coumarin and protein in the same 
sample. In HPLC analysis and photodiode array detection, two major peaks occurred, one 
at approximately 13 minutes - as expected for THG, which has a molecular weight of 
approximately 300 kDa (Fig. 3.5). The PDA scans of both these peaks give similar 
profiles characteristic of protein conjugated to coumarin (Fig. 3.6). This is manifest in the 
shoulder at approximately 320 nm. which is not present in THG alone.
Analysis of the coumarin-THG conjugate was also performed using ELISA, again using 
a rabbit anti-coumarin antibody (Egan. 1993). This also showed specific response for the 
antibody to the conjugate, and not to protein alone (Fig. 3.7).
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Figure. 3.1 A  and B. Analysis o f coumarin-BSA and 7-hydroxycoumarin-BSA (70HC- 
BSA) conjugates by ELISA. The response o f the rabbit anti-coumarin antibody (A) was 
specific for the coumarin-BSA conjugate (50 fig/ml) (open circles), and did not 
recognise BSA alone (filled circles). The response o f the rabbit anti-7OHC antibody (B) 
was specific for the 70HC-BSA conjugate (50 fig/ml) (open circles), and did not 
recognise BSA alone (closed circles).
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Figure 3.2. Infrared spectrum o f 6-N02-coumarin from 600 to 4000 cm 1. This shows 
a stretch at 1,736 cm 1 (-C=0), and 1,350 and 1,526 cm'1 (-N02 symmetrical and 
asymmetrical stretch), indicating the presence o f an N 02 present on the coumarin 
molecule.
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Figure 3.3. Infrared spectrum o f 6-NH2-coumarin from 600 to 4000 cm 1. This shows 
a stretch at 1,699 (-C-O) and 3,322 and 3,402 cm 1 (-NH2 asymmetrical and symmetrical 
stretch, respectively).
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Figure 3.4. Spectrophotometric scan o f thyroglobulin (THG) (A), coumarin-THG (B) 
and coumarin (C) from 400 to 200 nm. Comparison o f the coumarin-THG with THG 
shows a distinct shoulder between 320 and 350 nm on the coumarin-THG sample that 
was not present on THG. This was indicative o f the linkage o f coumarin to THG.
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Figure 3.5. HPLC analysis o f coumarin-thyroglobulin by size exclusion 
chromatography. The chromatogram shows predominant 280 nm peaks at 9.967 (peak 
A) and 12.167 (peak B) minutes. The retention time o f 10 minutes corresponds to the 
retention o f a large molecular weight protein such as thyroglobulin (300 kDa).
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Figure 3.6. Photodiode array analysis o f coumarin-THG. Protein peaks at 9.967 (peak 
A, Fig. 3.5) and 12.167 minutes (peak B, Fig. 3.5) show an additional absorbance 
shoulder at 320 nm. This was not present on the thyroglobulin control, indicating 
attachment o f a coumarin-like molecule to the protein.
109
1/Antibody Dilution
Figure 3.7. Analysis o f coumarin-THG conjugate by ELISA with rabbit anti-coumarin 
antibody. The graph shows recognition o f the coumarin-THG conjugate (50 fig/ml) 
(open circles), but not THG alone (filled circles).
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3.2.3 Immunisation of mice with coumarin-THG and 7-hydroxycoumarin-THG
Titres of mouse serum were performed following initial and secondary immunization. 
Responses to coumarin and 70HC were made using the appropriate BSA conjugate. The 
two mice immunised with coumarin-THG, mice 2 and 3, showed titres in excess of 1 in 
10,000 following primary immunisation and 1 in 20,000 following secondary 
immunisation, as compared to a 1 in 100 dilution of control mouse serum (mouse 1) 
(Figs. 3.8A, B, C and D). Mice 4 and 5, immunised with 70HC-THG showed titres in 
excess of 1 in 200 following secondary immunisation, as compared with a 1 in 100 
dilution of control serum. These serum titrations were deemed high enough responses 
from which to prepare splenomic RNA following a final intravenous boost, as according 
to Campbell (1986).
I l l
1/A ntibody Dilution 1/A ntibody Dilution
1/Antibody Dilution 1/Antibody Dilution
Figure 3.8 A, B, C and D. Mouse serum titres following primary (open circles) and 
secondary (closed circles) immunisation with either coumarin-THG (A and B), or 
70HC-THG (C and D). Both mice immunised with coumarin-THG gave similar titres 
o f 1 in 12,800 as compared to 1 in 100 dilution o f mouse control serum (solid line) 
following first immunisation and rising to 1 in 25,600 as compared to 1 in 100 dilution 
o f mouse 1 control serum (dotted line) following secondary immunisation. In the case 
of mice 4 and 5 immunised with 70HC-THG, titres following primary immunisation 
were 1 in 400 as compared to 1 in 100 control serum (solid line) and between 1 in 200 
and 1 in 400 as compared to 1 in 100 control serum (dotted line) following secondary 
immunisation.
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3.2.4 Preparation of splenomic RNA
Splenomic RNA was isolated from spleens from mouse 2 (coumarin-THG) and mouse 5 
(70HC-THG), yielding mRNA concentrations of 924 (ig/ml and 720 pg/ml, respectively. 
Spleens from mice 3 and 4 were placed in storage at -80°C.
3.2.5 Selection of murine PCR primers based on homology plots
Homology plots of available murine 5' heavy and light chain gene family sequences 
(Kabat and Wu, 1986) (Figure 3.9) were prepared (Figure 3.10). Primers were selected 
according to levels of sequence homology. A sequence already closely represented by a 
homolog was excluded, as mismatching during annealing may give rise to amplification 
of these species also. Sequences with no similar homologs were included. Using heavy 
chain primer sequences VHIB, VHIIB, VHHIB, VHIIID and VHVA resulted in at least 83% 
homology with primers. For light chains, inclusion of primers VkI and VkVI gave at least 
83% homology with known sequences, except for VkII with only 75% homology. The 
ability of primers to amplify non-specific sequences was not tested further. This rationale 
was merely chosen to reduce the numbers of primers required for library preparation.
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Murine Heavy Chain 5' Primers:
v hia  5'-GAG c t g  c a g  c t c  g a g  GAG TCA GGA-3'
VhIB 5'-CAG GTG CAG CTG GAG GAG TCA GGA-3'
VhIIA 5'GAG GTC CAG CTC GAG CAG TCT GGA-3'
VHnB 5'-CAG GTC CAA CTC GAG CAG CCT GGG-3'
VHnC 5'-GAG GTT CAG CTC GAG CAG TCT GGG-3'
VhIIIA 5'GAG GTG AAG CTC GAG GAA TCT GGA-3'
VhIIIB 5'GAG GTG AAG CTC GAG GAG TCT GGA-3'
VHIIIC 5'-GAA GTG AAG CTC GAG GAG TCT GGA-3'
VhIIID 5'-GAA GTG ATG CTC GAG GAG TCT GGG-3'
VhVA 5' GAG GTT CAG CTC GAG CAG TCT GGA-3'
Murine Light Chain 5' Primers
VkI 5'-GAC ATT GAG CTC ACT CAG TCT CCA-3'
vkn 5'-GAT GTT GAG CTC ACC CAA ACT CCA-3'
Vkin  5'-GAC ATT GAG CTC ACC CAG TCT CCA-3'
VkIV 5'-GAA AAT GAG CTC ACC CAG TCT CCA-3'
VkV 5'-GAC ATC GAG CTC ACC CAG TCT CCA-3'
VkVI 5'-CAA ATT GAG CTC ACC CAG TCT CCA-3'
Figure 3.9. Murine heavy chain and light chain gene family-specific 5' PCR primers, 
incorporating the restriction sites (underlined) for Xhol and Xbal in the heavy and light 
chain genes, respectively.
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Murine Variable Heavy Chain
IA
IA 100 IB
IB 83 100 IIA
HA 83 79 100 HB
HB 62.5 71 83 100 IIC
n c 75 75 92 71 100 I II A
ILLA 71 75 75 58 71 100 IHB
TUB 79 71 75 58 71 83 100 m e
m e 79 75 75 58 71 83 83 100 HID
IHD 62.5 71 67 58 71 83 75 83 100
VA 92 75 92 75 92 71 72 79 62.5
VA
100
Murine Variable Light Chain
kl
kl 100 kH
kn 75 100 k m
k m 92 79 100 klV
klV 79 67 87.5 100 kV
kV 83 71 83 71 100
kVI 75 62.5 83 87.5 67
Figure 3.10. Homology plots o f murine variable heavy and variable light chain gene 
family-specific 5' primers, as described in Rabat and Wu (1986).
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The physical characteristics of the murine PCR primers selected are shown in Table 3.1.
3.2.6 Murine PCR Primers
Table 3.1. Characteristics of murine antibody gene PCR primers.
Name Absorbance 
(260 nm)
Concentration
(mg/ml)
2^60^ 2^80
ratio
kg/mole Concentration
(nM)
CGI 0.314 1.884 1.4004 7.353 0.26
VhIB 0.234 1.404 1.6731 7.530 0.19
VhIIB 0.352 2.112 1.4477 7.216 0.29
VnIIlB 0.356 2.136 1.6953 7.585 0.28
VhIIID 0.481 2.886 1.6230 7.576 0.38
v hv a 0.216 1.296 1.5791 7.496 0.17
CkI 0.385 2.310 1.5193 7.365 0.31
VkI 0.281 1.686 1.4535 7.045 0.24
VkVI 0.279 1.674 1.4628 7.304
. . .
0.23
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3.2.7 PCR optimization
Using the standard PCR protocol (section 2.3.2.7), single amplified bands of 
approximately 700 bp, corresponding to amplified variable region genes were achieved 
using the following specific PCR conditions:
VhIB/CG1 Annealing temp. 58°C
V„IIIB/CGl Annealing temp. 59°C
VhIIID/CG1 Annealing temp. 58°C, 10 |iM concentration of PCR primers
V„VA/CG1 Annealing temp. 58°C, 10 |iM concentration of PCR primers
VkI/Ckl Annealing temp. 58°C
VkII/Ckl Annealing temp. 58°C
Primers VHIIB/CG1 failed to amplify under a variety of conditions which involved the 
variation of annealing temperature, adjustment of MgClj concentration and variation of 
primer concentration (Fig. 3.11), so was excluded from the group.
117
1 2 3 4 5 6 7 8
2,645 ►
1,605^ 
1,198►
676► 
517^
Figure 3.11. Optimisation ofPCR conditions for the amplification o f murine heavy and 
light chain genes from mouse 5 immunised with 7-hydroxycoumarin-THG. Lanes: 1,5: 
pGEM molecular weight markers (bp); 2: VHIB; 3: VH1IID; 4: VHVA; 6: VnllIB; 7: 
VJ; 8: VJI. The gel shows specific amplification o f 700 bp fragments using primer 
combinations CG1/VJB, CG1/VHIIIB, CG1.VJ1ID, VnVA, C J /V J  and Ckl/V kVI under 
the conditions described in sections 2. and 3 ., but failed to amplify CG1/VHIIB over a 
variety o f conditions (not shown).
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3.2.8 Preparation of pComb3 for heavy chain insert ligation
Plasmid pComb3 was digested with either XhoVSpel or XbaUSacl restriction enzymes for 
either heavy and light chain insertion, respectively. Digestion with XbaUSacl is shown in 
Fig. 3.12. This resulted in a predominant fragment of approximately 4,000 bp, as expected 
for a linear fragment of pComb3. No difference in molecular weight could be detected 
between single digested (Xbal) and double digested (XbaUSacl) pComb3. This was also 
the case for digestion for heavy chain insertion and digestion with Xhol and SpeI (data 
not shown).
Restriction-ligation controls were performed on pComb3 using Xhol and Xbal/Spel (Fig. 
3.13). Digestion with these two enzymes resulted in two distinct fragments of 3,073 and 
956 bp. When the stuffer fragment was religated with the major fragment, significant 
ligation was observed, with the production of various multimers. When the fragments had 
been treated with calf intestinal phosphatase, however, there were only minor levels of 
ligation. This indicated both efficient ligation and dephosphorylation of plasmid DNA.
3.2.9 Measurement of the Electrocompetence of Escherichia coli XLl-Blue
Many batches of electrocompetent E. coli XLl-Blue were prepared with typical 
efficiencies of 2 x 108 transformants per microgramme plasmid DNA, using 100 pg 
supercoiled pUC18.
3.2.10 Insertion of mouse 5 heavy chain genes into pGEM-T
Test transformations of mouse 5 heavy chain genes ligated into E. coli showed 125 
transformants/pl of ligation mixture. The pooling and concentration of ligation mixture 
resulted in the production of approximately 2 xlO3 transformants. Transformations were 
repeated until a library of approximately 4.75 x 105 heavy chain inserts was built up.
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3.2.11 Insertion of mouse 5 variable light chain genes into pGEM-T
A variable light chain gene library in pGEM-T of approximately 3.2 x 105 light chain 
gene inserts was built up by pooling the results of several transformations. The plasmid 
library was analysed by restriction digestion (Fig. 3.14). Single digestion with Xbal 
yielded a single fragment of 3,700 bp and with Xbal and Sad, two predominant fragments 
of 2,950 bp, 700 bp and a small 50 bp fragment.
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Figure 3.12. Restriction digestion analysis o f pComb3. Lanes: 1: pGEM molecular 
weight markers (bp); 2: pComb3; 3: pComb3 Xbal digest; 4: pComb3 Xbal/SacI digest. 
pComb3 shows multiple bands indicating the presence o f covalently closed circular and 
open circular DNA. Following either single or double digestion, an approximately 4,000 
bp fragment resulted. No difference in molecular weight between single and double 
digest fragments could be detected.
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Figure 3.13. Plasmid pComb3 ligation and dephosphorylation controls. Lanes: 1 
Lambda molecular weight markers (bp); 2: pComb3; 3-6: Not treated with calf intestinal 
phosphatase (CIP); 7-10: Treated with CIP; 3,7: pComb3 Xhol digest; 4,8: pComb3 
Xhol digest following ligation; 5,9: pComb3 Xbal/Svel digest; 6,10: pComb3 Xbal/Spel 
digest following ligation.Digestion with the single enzyme Xhol resulted in a linear 
fragment o f approximately 4,000 bp. Double digestion with Xbal and Svel resulted in 
two fragments o f 3,073 and 956 bp. Ligation o f linearised Xhol-cut pComb3 resulted 
in several higher molecular weight bands, but following treatment with CIP, no ligation 
occurred. Ligation o f the two double-digest fragments resulted in several higher 
molecular weight bands. Following treatment o f both fragments with CIP, however, 
virtually no ligation took place.
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Figure 3.14. Restriction analysis o f the mouse 5 light chain gene library in pGEM- 
T.Lanes: 1: Lambda molecular weight markers (bp); 2: pGEM-T. V j  3: pGEM-T:VL 
Xbal digest; 4: pGEM-T:VL S a d  digest; 5: pGEM-T:Vh Xbal/SacI digest.Single 
digestion with Xbal resulted in a single digested band at approximately 3,700 bp. 
Digestion with S a d  produced three bands o f2,950, 3,650 and 750 bp. Double digestion 
with Xbal and SacI resulted in bands o f 2,950 and 700 bp.
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3.3 DISCUSSION
Production of an immunised library in the mouse begins with the preparation of a suitable 
antigen. Small haptens such as coumarin and 7-hydroxycoumarin are not immunogenic, 
and so require conjugation to a large protein, such as BSA or THG. Traditionally, the 
coupling methodology for coumarin and 7-hydroxycoumarin to these proteins was via 
diazo linkage between an amino group on the hapten and nitrogen or hydrogens on 
imidazole and phenolic ring structures such as those found on histidine and tyrosine 
residues respectively. Coumarin and 7-hydroxycoumarin possess no reactive side chains 
amenable for linkage, and so a linker must be chemically synthesized. The amino group 
is produced in a two step process. Initially, the benzene ring is nitrated at the 6 position, 
forming 6-nitro-coumarin. This is then reduced to 6-amino-coumarin, which is now 
amenable to linkage. The resulting aromatic amine can be converted to the highly reactive 
and unstable diazonium with sodium nitrite under acidic conditions at 0°C. The diazonium 
ion will now attack the aromatic rings on residues of tyrosine, histidine and tryptophan. 
Linkage via the diazonium bond produces distinctively coloured compounds. This results 
in distinctive visible spectral absorbances. Spectrophotometric analysis of the conjugate 
showed the presence of a shoulder between 320 and 350 nm. This is due to the presence 
of coumarin, which absorbs at 320 nm. No such shoulder is apparent with a sample of 
THG that has been through the same procedure in the absence of 6-NH2-coumarin. To 
establish that the two moieties are linked to one another, chromatographic separation is 
desirable. Although thoroughly dialysed to remove small molecular weight components 
from the mixture, it is still good practice to characterise the conjugate by HPLC and 
photodiode array analysis. Separation by size exclusion chromatography resulted in peaks 
corresponding to a high molecular weight component with short retention time (9 to 12 
min), which exhibited high absorbance at 280 nm, distinctive of proteins. Photodiode array 
scans show the shoulder between 320 and 350 nm as being concomitant with the protein 
peaks. The presence of two peaks may indicate some degradation in the protein sample 
or, possibly, different levels of conjugation.
3.3.1 Preparation of protein conjugates for immunisation
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3.3.2 Characterisation of coumarin-thyroglobulin (coumarin-THG)
Thyroglobulin tends to produce characteristically insoluble conjugates (Hermanson, 1997). 
This was also the case here. Insolubility was contributed to by the fact that coumarin is 
also extremely hydrophobic in nature. The conjugate proved very difficult to analyse due 
to this characteristic. Eventually, a solvent system was found to efficiently solubilise the 
conjugate, dissolving it sequentially in DMSO, methanol and water, which may have 
gradually released more hydrophobic interactions, allowing access to successively more 
hydrophillic ones. The presence of two peaks in the sample following PDA analysis is 
probably due to protein degradation over time. Initial PDA scans showed only a single 
peak, (data not shown). However, at this point, a solvent system was not available to 
produce large concentrations for effective analysis.
The insolubility of the conjugate was, however, advantageous during the immunisation 
procedure. Insoluble aggregates administered as immunogens elicit better immune 
responses than soluble antigens. This may be because they persist at the site of 
immunisation, prolonging immunological attack, rather than being rapidly cleared from 
the system. This may have contributed to the excellent immune response produced by 
mice immunised with coumarin-THG as evidenced by their titre, as compared to 70HC- 
THG which was very soluble (Fig. 3.8). Another factor may have been the level of 
conjugation of the two conjugates used for immunisation.
3.3.3 Mouse serum antibody titres following immunisation
Although the titre produced by immunisation with 70HC-THG was quite low, it must be 
measured against the control used (1 in 100 dilution of control serum) which is quite a 
stringent control, but is recommended by Campbell (1986) for the production of 
monoclonal antibodies. Titres in excess of 1 in 200 would typically be adequate for the 
setting up of a fusion, although titres in excess of 1 in 1,000 would be preferable.
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3.3.4 PCR primer production
For effective library production, it is necessary to amplify a large number of heavy chain 
and light chain genes. Due to their structure, heavy and light chain genes have conserved 
3' sequences and variable 5' sequences. However, the diversity of the 5' variable region 
results from V gene segments, of which there are an estimated 300 to 1,000 on the mouse 
heavy chain germline genes and 300 on mouse k  light chain germline genes. These 
sequences have evolved from common sequence ancestors to generate antibody diversity. 
Consequently, they share large degrees of sequence homology. Homology at the 5' end 
of these sequences has been analysed and used to divide sequences into families. These 
families allow the construction of sets of primers for PCR that are capable of amplifying 
groups of genes from these families.
The 5' sequences of available antibody light and heavy chain genes (Kabat and Wu) were 
used to construct a set of family-specific primers (Fig. 3.9). These were modified for the 
insertion of restriction digestion sites. Due to the large group of primers this generates, 
a rationale was constructed to reduce the numbers of primers used. Primer sequences were 
further grouped in homology plots (Fig. 3.10). Here, the sequence similarity between the 
primers was assessed. Primers which were similar to a selected homolog were excluded 
from the group to be used, and those that had no very similar sequence homolog were 
included. In this way, a set of primers that had high sequence similarities to unused 
sequences was built up. Any misannealing during amplification may result in the 
amplification of non-specific sequences, without the need for large numbers of primers. 
This phenomenon was never actually tested, but could be assessed by amplifying 
antibodies with known sequences with non-identical, but similar 5' primer sequences.
In the end, the selection of the heavy chain primers VHIB, VHIIB, VHIIIB, VHHID and 
VhVA yielded at least 83% homology with the other families. This meant that no more 
than 4 nucleotides differed between any two pairs of primers. Homology increased with 
the introduction of identical restriction sites into all primers. This strategy was also 
applied to light chain sequences which resulted in the choice of two primers VkI and VkVI 
which also resulted in at least 83% homology, except for VkII to which they only had
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75% homology.
The 3' heavy chain constant region primer sequence selected was a Crl sequence. All 
heavy chains of a C71 subtype would be amplified. These tend to be produced in largest 
abundance, with high affinity. A kappa chain-specific constant 3' primer was also selected 
for light chain amplification, as these comprise 95% of light chain subtype, compared to 
some 5% for lambda chains (Kuby, 1997).
3.3.5 PCR optimisation
PCR amplification was optimised, in most cases at standard MgCl2 and primer 
concentrations, with slight variations in annealing temperature, around 58°C and 59°C. 
However, amplifications involving VHIIID and VHVA, required a reduction in primer 
concentration to 10 |iM. Amplifications involving VHIIB failed to produce single defined 
700 bp bands over a range of PCR conditions.
3.3.6 PCR fragment purification
Several methods were assessed for the isolation and purification of PCR fragments from 
agarose gels such as phenol:chloroform cleanup (Sambrook et al., 1989), Wizard kits 
(Promega), Spin-X columns (Costar), or without clean up (data not shown). However, the 
most reliable system was found to be Qiaex gel purification kits (Qiagen). These produced 
clean, reproducible preparations of high yield.
All attempts to clone digested heavy and light chain PCR fragments into pComb3 
produced extremely low yields of transformants, or failed to work at all (data not shown). 
It was assumed that this failure was due to the inefficiency of the PCR fragments to 
digest. Inadequate overhangs can reduce the efficiency of restriction digestion. However, 
the design of these primers is similar to many others, with at least a 9 base overhang in 
the heavy chain primers (Roben, 1993). Several methodologies were also attempted to 
circumvent this problem. These involved concatamerisation of PCR fragments, followed 
by digestion, blunt end cloning (data not shown) and T/A cloning. Concatamerisation and
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blunt end cloning failed to remedy the problem. Both techniques still depended on 
enzymatic modification of the PCR fragments. T/A cloning removes the need for 
modification of the PCR fragments following amplification and purification. Although 
with a potentially lower efficiency than cloning using six-cutter enzymes, greater than 103 
transformants could be produced from a single ligation reaction. Repeated reactions could 
thus be used to establish a library of chains of high diversity. Some 104 heavy and 104 
light chains would be sufficient to generate a library of good size (108). After several 
transformations, a heavy chain library of 4.75 x 105 transformants and a library of 3.2 x 
105 light chains was produced, so large libraries are quite accessible via this methodology.
3.3.7 Construction of light and heavy chain gene libraries in pGEM-T
Insertion into pGEM-T also allowed the visualisation of correctly digested fragments, 
following double digestion with either Xhol and SpeI for heavy chains or XbaVSacl for 
light chains. These both yielded the expected 700 bp fragment, indicative of the inserted 
antibody chain gene. Bands produced in this way have also been efficiently restricted.
3.3.8 Heavy and light chain gene insertion into pComb3
Heavy chains derived from pGEM-T insertion were purified, and attempts were made to 
insert these into pComb3 (data not shown). However, these attempts also failed, or again, 
showed extremely low levels of transformation efficiency. It was concluded at this time 
that the limiting factor in the cloning procedure was not the PCR fragments, but the 
pComb3 vector. It had been assumed that efficient double digestion was taking place as 
these restriction sites are 57 bp and 12 bp apart for heavy and light chain insert sites, 
respectively. However, the stuffer fragment was never visualised by gel electrophoresis, 
and no differentiation could be made between single digested and double digested 
pComb3 on gels (Fig. 3.12). This is evidenced by the production of vectors based on 
modifications of pComb3 (Burioni et al., 1997). They also suggest that efficient cutting 
of pComb3 is difficult in that overdigestion will reduce cloning efficiency and limiting 
digestion poses the risk of interfering in the cloning procedure. It is likely from these 
observations, and those seen by this author, that the failure of the cloning strategy was as
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a result of the vector, either being inefficiently digested, or overdigested. The use of 
modified vectors, such as those proposed by Burioni et al. (1997) eould alleviate this 
situation and bring about the production of large Fab antibody libraries to coumarin and 
7-hydroxycoumarin.
129
4. THE PRODUCTION OF SINGLE CHAIN Fv (scFv) ANTIBODIES TO 
COUMARIN AND 7-HYDROXYCOUMARIN USING THE NISSIM LIBRARY
4.1 INTRODUCTION
The applications of coumarin in therapy and biochemistry have been discussed (Chapter 
1). The usefulness of phage display libraries for the production of antibodies to coumarin 
has also been explored. Here, the isolation of antibodies to coumarin and 7- 
hydroxycoumarin from the Nissim phage display library is discussed. It explores the use 
of scFv material from culture supernatant, periplasmic lysates and inclusion bodies, as 
well as the use of scFv displayed on the phage surface as immunological reagents. It 
investigates the affinity purification of these molecules, to yield pure, high titre, stable 
reagents for subsequent analyses. The physicochemical characteristics of the resulting 
monoclonal scFv antibodies are also analysed, and their applicability in various analyses 
is assessed. Consequently, the applicability of the Nissim library for the isolation of 
antibody reagents to these molecules is evaluated.
4.1.1 Use of the Nissim library in the isolation of single chain scFv (scFv) antibodies
Alternatives to the production of large, immunised combinatorial phage display libraries 
such as the pComb3 system do exist. One such library system is the Nissim library 
(Nissim et al., 1993). The concept behind the Nissim library was the creation of a naive 
human scFv library of very large size (108 clones) so as to make it highly probable that 
many scFv clones to any chosen antigen could be selected from it. Diversity was brought 
about using a library of variable heavy chain genes that had been mutagenised in the 
CDRH3 region, increasing diversity to 108. This library was further combined with 
previous scFv libraries (Hoogenboom and Winter, 1992) increasing the overall library size 
to much greater than 108.
4.1.2 Affinity selection strategies
Affinity selection can potentially be performed with antigen attached to a solid support. 
Matrices used have been in the form of immunoassay plates, immunoassay tubes and 
affinity columns (Kretzschmar et al., 1995). With the use of immunoassay dishes and 
immunotubes, protein antigens are normally adsorbed. For the selection of antibodies to
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peptides and haptens, these require linkage to a carrier protein to facilitate this adsorption. 
For this reason, optimal conjugate design is critical for efficient enrichment of phage 
antibodies to the hapten or peptide. Many conjugation chemistries are available for the 
coupling of haptens and peptides to carrier proteins, depending on their structure and the 
presence of suitable functional groups to facilitate linkage (Hermanson, 1997). Coumarin 
and 7-hydroxycoumarin lack such reactive functional groups, and must be derivatised in 
some way to make them amenable to conjugation (Egan, 1993). Aromatic ring conjugation 
can be performed by the formation of a diazonium derivative (Fig. 4.1). An active 
aromatic amine can react with the electron-rich nitrogens of the imidazole ring on 
histidine residues or ortho modification of the phenolic group of tyrosine residues. On 
BSA, there are 36 potential binding sites of this type. Efficient conjugate production 
involves the formation of conjugates with coupling ratios that maximise the number of 
haptens on their surface. This will encourage antigenic recognition of the hapten rather 
than the carrier protein and reduce interactions that rely on epitopes shared by hapten and 
carrier protein. High hapten coupling ratios, however, can have other practical difficulties. 
With many haptens, most notably hydrophobic molecules such as coumarin and 7- 
hydroxycoumarin, introduction of these to the surface of a protein may make it extremely 
insoluble, preventing its efficient use as an affinity ligand during affinity selection. It is 
likely that optimisation of conjugates is necessary for effective affinity selection strategies.
Another factor affecting the characteristics of affinity selection taking place on solid 
supports is the presence of a protein blocking agent. Heterogeneous protein mixtures such 
as non-fat milk are often used in such strategies. However, the presence of carrier protein 
free in solution may serve to remove interactions that take place between carrier protein 
and phage antibodies, resulting in enrichment of phage recognising hapten alone, rather 
than carrier protein epitopes.
An alternative strategy for selection of antibodies to haptens is the use of direct covalent 
attachment of activated hapten derivatives to solid supports. Many of the same coupling 
interactions available for the formation of hapten-carrier conjugates can be applied to solid 
supports. For example, N-oxysuccinimide is a highly active and unstable species that 
promotes the hydrolysis of amines with carboxyl groups. An amine such as
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Figure 4.1. Diazonium coupling reaction o f coumarin to histidine and tyrosine residues. 
A diazonium ion is formed by the reaction o f 6-amino-coumarin with sodium nitrite 
under acidic conditions at 0°C (reaction A). This reacts principally with nitrogen on the 
imidazole ring o f histidine residues (reaction B) or at higher pH  with the phenolic side 
chain o f tyrosine (reaction C).
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6-NH2-coumarin could thus be directly covalently linked to a solid surface. This strategy 
may oblate problems associated with the interaction of phage antibodies with the protein 
moiety of the hapten-carrier conjugate and avoid the need to produce and optimise the 
production of such conjugates.
4.1.3 Affinity selection of antibodies from libraries using BIAcore™
Selection and screening procedures using solid supports encourage the isolation of high 
affinity interactions over lower affinity ones (Kretzschmar et a l, 1995). In studies of 
antibody kinetics, it has been shown that the equilibrium affinity constant is mostly 
determined by the dissociation rate constant, kd (Tijssen, 1985). Selection in this way 
encourages the isolation of antibodies with low dissociation rate constants. Such antibodies 
are optimal for subsequent use in ELISA and other immunoassay formats. However, 
antibodies are being increasingly used in immunosensor systems (Turner, 1997). These 
employ the detection of an antibody-antigen interaction by transduction to an electrical 
signal using a physical property such as surface plasmon resonance (Stenberg et a l, 1991) 
or electrochemistry (Ghindilis et a l, 1998). As well as having the potential for rapid, 
‘real-time’ analysis, these systems also offer the possibility of the repeated use of the 
sensor surface. To accomplish this, the surface must be regenerable. That is, the antibody- 
antigen interaction that took place as a result of a previous analysis must be fully 
dissociated, leaving behind a re-usable sensor surface of either antigen or antibody, 
depending on the methodology employed. The ease of dissociation of the antibody-antigen 
interaction and, thus, the ease of regeneration of the sensor surface is primarily determined 
by the dissociation rate of the antibody used. Since most antibodies isolated via ELISA 
have low dissociation rates, they require more severe procedures to bring about full 
dissociation, making regeneration less efficient and more damaging to the sensor surface, 
reducing the number of regenerations possible.
As an alternative to enzyme immunoassay selection and screening procedures, some 
sensor devices, such as BIAcore™, facilitate using the sensor device to screen for clones 
with different dissociation rates, which would be of greater use subsequently in the same 
sensor and other devices (Malmborg et a l, 1996).
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4.1.4 Induction of protein expression from phagemid pHENl
As is also the case with pComb3, production of scFv antibody protein, and pill protein 
from the pHENl phagemid is controlled by the LacT, promoter/operator. LacL is a low 
level constitutive promoter that is repressed by glucose and greatly up-regulated by certain 
inducers such as lactose (Old and Primrose, 1980). Production of protein from pHENl is 
controlled by the incorporation of repressors and inducers in the growth medium. E. coli 
TGI (pHENl) and E. coli HB2151 (pHENl) are normally cultured in 1% (w/v) glucose 
to repress constitutive expression when not required. High level induction is brought about 
by the removal of glucose from the medium, and replacement with a non-metabolisable 
inducer analogue of lactose, isopropyl-|5-D-thiogalactopyranoside (IPTG). For scFv 
expression on the surface of phage, constitutive protein translation occurs in association 
with pill. For soluble scFv protein production, large yields of protein are preferable, and 
induction with IPTG is used following the initial growth of the cultures to mid-log phase. 
Inducer concentration can vary but a concentration of 1 mM is typical (Buchner and 
Rudolph, 1991).
Growth conditions normally employed for high level scFv induction require a culture of 
mid-log phase, grown at 37°C, cultured in 1% (w/v) glucose to be transferred to a medium 
containing 1 mM IPTG and growth at the lower temperature of 25-30°C. This has also 
been found to be optimal for protein yield (Skerra et al., 1991). Conditions of induction 
can affect the production and secretion characteristics of the proteins synthesised. 
Temperature, inducer concentration and growth phase may all affect the yield of protein. 
The age and condition of the cells may affect the release of antibody from the periplasm 
to the culture supernatant. Proteolytic degradation may also be a factor. Large scale 
protein production may also contribute to the overloading of protein production machinery 
and in the accumulation of protein as insoluble inclusion bodies.
4.1.5 Screening of antibody clones from phage display libraries
Screening of phage following affinity selection is performed using phage ELISA. This can 
be performed on polyclonal phage, showing the general level of enrichment occurring in
135
each round of selection, or on individual clones to identify antigen-binding recognition. 
Positive clones can be selected from the population and used for the production of soluble 
scFv antibody. In the Nissim library, soluble scFv production is achieved by the transfer 
of the pHENl scFv-containing phagemid from the amber suppressor E. coli strain TGI 
to the non-suppressor E. coli HB2151. In the absence of helper phage and pin, soluble 
scFv is produced (Hoogenboom et al., 1991).
Screening of positive clones has also been performed on blotting membranes (Pharmacia 
Biotech, 1996). Individual E. coli clones expressing scFv (either as phage or soluble 
antibody) were blotted onto nitrocellulose containing antigen. Following blocking of the 
membrane, binding was detected with secondary antibodies. Positive clones could then be 
selected from the original culture plate.
It has been noted that the translation of exogenous protein in E. coli does not always 
result in the formation of correctly folded, soluble protein. Several factors are involved 
in the efficient folding and secretion of proteins from intracellular matrices. One factor 
is the presence of a leader or signal peptide at the C terminus of the protein (Cheung et 
al., 1992). These characteristic sequences guide proteins across membranes, before being 
processed by enzymatic cleavage or resulting in the anchoring of the protein in a 
particular membrane. To facilitate secretion of scFv from the intracellular compartment 
of E. coli, upstream of the scFv is a leader sequence derived from the E. coli pectate lyase 
protein, pelB. Presence of the correct leader sequence is, however, no guarantee of 
transport. The ability of a protein to form a correctly folded, soluble molecule is 
sequence-dependant, and so difficult to predict. In eukaryotic cells, many chaperon 
proteins are present which guide the folding of proteins (Takagi et al., 1988; Pelham, 
1989). These mechanisms are not present in E. coli and so correct folding is solely 
dependant on the particular protein structure translated. It is thus likely that, while some 
clones may secrete into the periplasm and culture supernatant, others will not be capable 
of doing so. These may form misfolded, insoluble inclusion bodies within the E. coli 
cytoplasm (Buchner and Rudolph, 1991).
Analysis of positive scFv clones can be performed by ELISA. Here, culture supernatant
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from scFv clones is analysed for the presence of scFv binding to antigen. In the Nissim 
library, recognition is via a c-myc peptide tag of approx. 1.5 kDa, that is recognised by 
mycl-9E10 anti-c-myc antibody. Direct detection of scFv can also be facilitated using 
blotting membranes such as nitrocellulose and PVDF (Towbin and Gordon, 1984; Stott, 
1989). These do not indicate antigen binding activity, but merely the presence of scFv 
protein.
The presence of scFv material in the E. coli periplasm can also be detected by the gentle 
breaking of the outer membrane using freezing and thawing (Hughes et al., 1969). 
Soluble, active scFv otherwise incapable of passage across the outer membrane can thus 
be detected.
4.1.6 Isolation and refolding of scFv antibody protein from insoluble inclusion bodies
As has been stated, many scFv clones fail to secrete antibody, either due to misfolding 
of protein upon translation, or due to the overloading of the cellular machinery. It may 
not always be possible to isolate clones that secrete antibody. Protocols have been 
developed for the isolation of soluble protein from intracellular compartments (Hughes et 
al. 1969). These require the lysis of the inner membrane, the denaturation and 
solubilisation of the protein inclusion bodies and the controlled refolding of the denatured 
protein to the active form. Lysis requires more severe treatment of the cells than outer 
membrane rupture, such as physical disruption techniques, like sonication, explosive 
decompression (X-press) or shearing against glass beads.
Denaturation is brought about by the use of high concentrations of guanidine 
hydrochloride or urea. This results in linearised peptide chains, removing inter- and intra­
molecular interactions, with resulting protein solubility.
Refolding is performed by the gradual removal of denaturant from the protein 
environment, either by dialysis, or by the direct addition of a dilution buffer. Refolding 
begins from a point of low protein concentration. This dilute solution discourages 
intermolecular interactions during refolding. Gradual removal of denaturant allows
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intramolecular interactions to come about. Hydrophobic residues will associate and 
predominate on internal surfaces, whereas hydrophilic interactions will occur with the 
aqueous matrix. Some protein will refold correctly. Yields of up to 40% (w/w) correctly 
folded material has been produced (Buchner and Rudolph, 1991). Yield can be further 
enhanced by the purification of scFv prior to refolding (section 4.1.7).
The level of refolded antibody has been improved by the incorporation of arginine at 0.4 
M. This aids in the stabilisation of the protein during refolding. Refolding is a gradual 
process, taking up to 5 days to reach completion.
4.1.7 Affinity-purification of antibodies
For the production of high titre scFv material, without the presence of contaminants 
capable of the degradation of the sample, or causing problems associated with non-specific 
background interactions when used in assays, an efficient means of purification is 
required. Purification has been achieved using a protein A-scFv fusion protein system 
(Djojonegoro et al., 1994). Many protein purification systems now used employ the highly 
efficient technique of metal chelate affinity chromatography (Skerra et al., 1991; Vaughan 
et al., 1996). This exploits the highly specific interaction that occurs between nickel ions 
and sequences of histidine residues. This can be used to purify scFv of any specificity, 
whether correctly folded or not. This can be particularly useful for the isolation of 
antibody from intracellular lysates. The Nissim library, however, does not incorporate the 
(His)6 sequence tag necessary to do this. In the past, scFv from this library have been 
purified using anti-c-myc antibody (Kipriyanov and Little, 1997). This, however, was 
considered relatively inefficient. The traditional alternative is the use of antigen 
immobilised on a solid support in an affinity column (Hermanson et al., 1992). In this 
way, scFv may be introduced to the column under conditions which promote specific 
interaction while allowing the removal of other non-specific proteins in the sample. 
Conditions are then found which result in the dissociation of antibody from antigen, 
without permanent effect on the antibody species.
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4.1.8 Composition of affinity matrices
The range of affinity matrices available is broadly similar to the range of affinity ligands 
available for affinity selection. Carrier-hapten conjugates can be coupled to activated 
supports such as sepharose activated with CNBr (Pharmacia). Alternatively, haptens can 
be coupled directly via functional groups such as covalent linkage of 7-hydroxycoumarin- 
4-acetic acid to EAH-sepharose (Heiko Reinartz, Dublin City University, Personal 
Communication).
Traditionally, purification of polyclonal antibodies and many monoclonal antibodies using 
affinity columns containing antigen begins from a point of high ionic strength (0.5 M 
NaCl) to reduce non-specific background binding (Catty, 1989). Elution of antibody 
following sufficient washing is facilitated by the use of either high (11.5) or low (2.2) pH 
buffers that disrupt the antibody-antigen interaction, followed by immediate neutralisation 
of the purified species (Heiko Reinartz, Dublin City University, Personal Communication).
Monoclonal antibodies, however, exhibit specific individual characteristics that may differ 
significantly in a number of ways from the ’average’ characteristics of a polyclonal 
antibody population (Catty, 1989). As a consequence, more individual antibody 
purification strategies may need to be developed to take into account this nature. This 
principally involves optimising the environmental conditions used for purification such as 
temperature, pH, ionic strength, use of ionic and non-ionic detergents, the presence of 
non-polar organic solvents, and the use of chaotropic agents. Any of these factors may 
affect the efficiency of the affinity purification as well as the quality of the antibody 
material subsequently derived.
4.1.9 Concentration of purified antibodies
Protein isolated from affinity purification is normally in dilute solution and requires 
concentration if it is to be used as an effective reagent. Several methods such as reverse 
osmosis, ultrafiltration and membrane filtration can be applied.
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4.1.10 Immunoassay strategies for the measurement of drug-hapten concentrations
The quantitative analysis of drug haptens and other small molecules using antibodies is 
best facilitated by the heterogeneous competition immunoassay (Tijssen, 1985). Two 
competition strategies can be envisaged (Fig 4.2). In one scenario, antibody recognising 
the analyte is immobilised on a solid surface, such as the wells of an immunoassay plate. 
Enzyme-labelled analyte competes with free analyte present in standards and unknown test 
samples for binding to the antibody. The amount of enzyme label present is inversely 
proportional to the level of free analyte in the sample. This proportionality is log-linear 
over a range of analyte concentration which is usually determined by the antibody’s 
affinity. Higher affinity antibodies yield more sensitive assays (Asignal/Aconcentration) 
with lower limits of detection. This strategy requires the production of an enzyme-labelled 
conjugate of the analyte.
The second strategy involves competition of free antibody for bound analyte-protein 
conjugate and free analyte. The quantity of antibody binding to the surface is also 
inversely proportional to the level of free analyte over a specific concentration range. 
Detection this time is either via enzyme label directly attached to antibody, or the 
incorporation of intermediate antibody species to amplify the signal. Both strategies are 
equally acceptable. The latter, however, utilises hapten-protein conjugates that are 
normally synthesised as part of the antibody production strategy, and so requires no 
additional conjugates to be prepared.
The nature of competition immunoassays requires the optimisation of several parameters 
before it can perform effectively (Crowther, 1995). Since free analyte is competing with 
surface-bound analyte, the maximum concentration of free drug that can be measured is 
dependant on the amount of surface bound analyte. If only small concentrations of bound 
analyte are employed, antibody will saturate at a lower concentration, reducing the amount 
of free drug that can be bound. However, oversaturation of the surface will only result in 
wasted hapten-protein conjugate as excess amounts will not be adsorbed to the surface.
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To compete effectively between bound and free antigen, antibody must be present in 
limiting concentrations. Otherwise, it may be capable of saturating both bound and free 
antigen with the result that no decrease in signal is obtained when free antigen is 
introduced. Experimentally, the dilution of antibody which yields 70% maximal binding 
to surface-bound antigen in the absence of free antigen has been used as an effective 
working dilution in such immunoassays (Crowther, 1995).
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Antigen
Antibody
Figure 4.2. Competition ELISA strategies for the analysis o f haptens. A. Antibody 
competes for free and bound antigen. B. Enzyme-labelled and unlabelled antigen 
compete for binding to surface-bound antibody. The enzyme is detected with a suitable 
substrate or amplified with secondary antibodies.
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4.1.11 Antibody kinetics and equilibria
Antibody kinetic equilibria data may also be estimated using competition immunoassay 
strategies (Tijssen, 1985; Friguet et al., 1985). This can be deduced from equilibrium 
equations of antibody-antigen binding. The equilibrium is defined by the equation:
K
Ab + Ag ** A b . Ag  ( 1 )
k a
Where Ab is antibody and Ag is antigen and Ab.Ag is the antibody-antigen complex.
The on rate is defined by: 
ka[Ab].[Ag] in M'1 .s'1
The off rate is defined by: 
kd[Ab.Ag] in s’1
The association equilibrium constant, KA, is defined by:
Ka = —  = — ‘ — AT1 (2)
A k d [Ab] . [Ag\
The dissociation equilibrium constant, KD, is defined by:
K  = - i -  = = [A b] ■ [A g ] ^  ^ )
D k . {Ab.Ag] M (3)
The association equilibrium constant can be found experimentally. For binding to 
monovalent hapten, the point at which 50% binding occurs:
[Aby nbound] I B ound]
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Since [Ab] = [AbAg], then:
k a  = 4s = T T T  ( 4 )A k d [A g ]
This is performed experimentally according to Friguet et al. (1985). Antibody and a range 
of free antigen concentrations are allowed to reach equilibrium. At some antigen 
concentration, half of the antibody is bound at equilibrium. Samples from equilibration 
are then assayed against bound antigen to measure the quantity of unbound antibody. 50% 
binding can be calculated and the association equilibrium constant determined.
A non-equilibrated approximation of affinity measurement was used by Van Heyningen 
et al. (1983) and modified by Roben (1993). In this instance, [Ab] = [Ab.Ag] is estimated 
by competing antibody for free and surface-bound antigen. This assumes that at any given 
instant the rate constants for binding to free and surface-bound antigen are the same and 
that the amount of antibody not bound to either free or surface-bound antigen is 
negligible:
[A b .A g Fiee\ + [A b .A g sui£ace] -  lA b Tot3l\ *  0 ( 5 )
In this instance, when:
[Ab.AgFrJ  = [Ab.AgSurface]
This approximates to:
[Ab] = [AbAg]
thus yielding an estimate of the association equilibrium constant.
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4.1.12 Analysis of antibody kinetics using BIAcore™
BIAcore is an analytical device based on the optical property of surface plasmon 
resonance (SPR). BIAcore acts as a mass balance. A wedge of light is focused to a point 
on the surface of a gold film. The intensity of the reflected wedge of light is analysed at 
a photodiode array detector. At an angle of incidence to the gold film, known as the 
surface plasmon resonance angle, a component of the incident light is propagated through 
the gold film as an evanescent wave. This excites delocalised surface electrons in the gold 
film known as plasmons, which absorb energy from the incident light. This leads to a 
decrease in the intensity of the reflected light at this angle. The angle at which surface 
plasmon resonance occurs is dependent on the characteristics of the gold film, including 
the refractive index of the opposite face of the gold film. Changes in the bulk refractive 
index at this side of the gold film will change the resonance angle. This change in bulk 
refractive index can be related to the mass bound to the gold film. The resonance angle 
is converted to an electrical signal which is expressed as response units (RU). Attachment 
of affinity ligands to the gold surface results in detectable mass changes. Coupling is 
normally performed using a dextran matrix attached to the gold film. This can be used to 
couple most species, which it maintains in solution. Rate constants for antibody-antigen 
interactions can be calculated using kinetic results arrising from BIAcore analysis 
(O’Shannessy and Winzor, 1996), based on the reaction scheme described in Equation 1 
above.
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RESULTS
4.2 PRODUCTION OF ANTI-COUMARIN ANTIBODIES FROM THE NISSIM 
LIBRARY
4.2.1 Phage ELISA of anti-coumarin phage antibodies
The phage ELISA for the anti-coumarin clones taken from the second and third rounds 
of affinity selection is shown in Fig. 4.3. Five clones out of 42 were positive after two 
rounds of affinity selection. This had risen to 12 out of 42 after three rounds. No positive 
clones to coumarin were detected prior to affinity selection (Fig. 4.4). These were 
designated a-C l to a-C17 accordingly.
4.2.2 Phage ELISA of anti-coumarin phage antibodies raised against 6-amino- 
coumarin coupled via N-oxysuccinimide ester
The phage ELISA of clones screened following affinity selection against 6-NH2-coumarin 
directly coupled to an N-oxysuccinimide (NOS) 96 well microtitre plate, and screened 
using coumarin-BSA is shown in Fig. 4.5. Four positive clones out of 94 could be 
identified. These were designated a-C(NOS)l to a-C(NOS)4 accordingly.
4.2.3 Screening of anti-coumarin positive clones for soluble scFv antibody production
The results of dot blotting of individual anti-coumarin clones following affinity selection 
to either coumarin-BSA or 6-NH2-coumarin are shown in Fig. 4.6. Out of the 21 positive 
anti-coumarin phage antibodies, only three showed significant scFv present in periplasmic 
lysates (Fig. 4.6a), and two of these showed antibody present in the culture supernatant 
(Fig. 4.6b). 27 clones were selected at random from the anti-coumarin library following 
three rounds of affinity selection. Several showed good secretion into the periplasm, with 
some extracellular expression also. The three anti-coumarin secretors were all from the 
anti-coumarin library selected using coumarin-BSA. None of the four clones selected on 
6-NH2-coumarin showed any secretion. The blot was repeated (Fig. 4.7).
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Figure 4.3. Phage EUSA analysis of anti-coumarin library following 2 (P2) and 3 (P3) 
rounds of affinity selection against coumarin-BSA. Clones from the second round of 
affinity selection showed 5 positives out of 42, and clones following three rounds of 
selection showed 12 good positives (with some weaker positives) from the same number 
of clones. Negative control: H6. Positive control: H7. The positive control failed to 
work, but positive wells could be clearly denoted without it.
1 2 3 4 5 6 7 8 9 10 11 12
A 0.093 0.090 0.080 0.075 0.077 0.091 0.076 0.091 0.085 0.084 0.084 0.092
B 0.106 0.082 0.075 0.086 0.069 0.081 0.071 0.078 0.084 0.070 0.082 0.087
C 0.100 0.081 0.078 0.086 0.075 0.321 0.081 0.076 0.076 0.087 0.323 0.090
D 0.106 0.091 0.081 0.079 0.080 0.077 0.076 0.074 0.079 0.081 0.099 0.088
E 0.086 0.082 0.077 0.071 0.081 0.084 0.080 0.081 0.094 0.081 0.086 0.091
F 0.083 0.082 0.081 0.079 0.086 0.078 0.078 0.079 0.079 0.083 0.092 0.121
G 0.155 0.075 0.079 0.080 0.072 0.085 0.075 0.093 0.084 0.073 0.088 0.093
H 0.087 0.086 0.096 0.080 0.083 0.080 M i l 0.083 0.082 0.083 0.085 0.094
Figure 4.4. Phage ELISA data of 94 randomly selected clones from the original, 
unpanned Nissim library screened against coumarin-BSA. No clones were found to be 
positive in the 94 clones selected. Negative control (H6): a -NIP clone against coumarin- 
BSA. Positive control (H7): Or NIP clone against NIP-BSA.
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Figure 4.5. Phage ELISA of anti-coumarin clones selected using 6-NH2-coumarin 
coupled via N-oxysuccinimide-activated microtitre plates. Four clones out of 94 were 
found to be positive to the coumarin-BSA conjugate used for screening. The four clones 
selected were BIO (a-C(NOS)l), C4 (u-C(NOS)2), D9 (a-C(NOS)3) and H2 (a- 
C(NOS)4). Negative control: H6. Positive control: H7.
Periplasm Supernatant
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Figure 4.6. Dot blot analysis of periplasmic lysates (columns 1-6) and culture 
supernatants (columns 7-12) of 21 anti-coumarin clones selected on coumarin-BSA 
(Fig. 4.3) and 6-NH2-coumarin (Fig. 4.5). The 21 anti-coumarin clones (A1-D3 and A7- 
D12)Three clones from selection on coumarin-BSA proved positive for periplasm 
containing scFv. Two of the clones that were positive for periplasmic secretion were 
also found to be positive for secretion into culture supernatant. None of the four clones 
selected with 6-NH2-coumarin showed solubility in either periplasm or supernatant.
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Figure 4.7. Repeat analysis of dot blots of 21 anti-coumarin clones from phage EUSA. 
Clones were numbered sequentially a -Cl to (X-C21 in the order A l, Bl, Cl... for 
supernatants and A7, B7, C7... for periplasmic lysates, respectively. This confirmed the 
previous result of three clones secreting scFv, either into the periplasm or culture 
supernatant, or both. These were E1,E7 (a-C5), E2,E8 (OrC13) and F2,F8 (OrC14). 
Negative controls: G5 and G il. Positive controls H5 and H ll.
This again showed the same three positive clones, designated a-C5, a-C13 and a-C14. 
All three showed extracellular secretion of scFv, particularly a-C14, but only a-C5 and 
(X-C13 showed good levels of periplasmic scFv.
4.2.4 Optimisation of affinity purification of anti-coumarin scFv clones
4.2.4.1 Effect of high pH on OrC14 elution from coumarin-BSA
A 10 ml sample of culture supernatant from a-C14 was affinity purified on a coumarin- 
BSA column on a pH gradient from pH 7 to 12 (Fig. 4.8a). Dot blots of fractions showed 
six fractions to contain scFv antibody at pH between 8 and 10. This was repeated and 
positive fractions were obtained between pH 10.5 and 11.5 (Fig. 4.8b). A third gradient 
(Fig. 4.8c) showed a single positive fraction at pH 11.5. However, the signals achieved 
by dot blotting were extremely poor compared to controls, indicating small quantities of 
antibody binding to the coumarin-BSA column.
4.2.4.2 Batch purification of a -C5 and a-C13
5 ml volumes of periplasmic lysates of a-C5 and a-C13 were batch purified in 12.5 ml 
coumarin-BSA coupled to sepharose 4B which had been equilibrated with PBS. Washing 
was with 50 mM Tris/0.5 M NaCl, pH 8.5, and elution was with 50 mM Tris/0.5 M NaCl, 
pH 12, and concentration of the antibody by reverse osmosis. In both a-C5 and a-C13, 
purification of a 31 kDa scFv fragment did occur following elution and concentration (Fig. 
4.9). However, these purified fractions were no longer detected when analysed by western 
blotting using the anti-c-myc antibody, mycl-9E10 (Fig. 4.10). Also present in unpurified 
fractions was a lower molecular weight fragment of approximately 20 kDa which 
recognised anti-c-myc antibody, but was subsequently lost upon purification, and was not 
present in purified fractions in SDS-PAGE analysis. This loss of recognition was also 
associated with loss of activity on ELISA (Figs. 4.11a and 4.11b). These clearly showed 
excellent responses from periplasmic lysates to coumarin-BSA, but not to BSA. However, 
following purification, nearly all activity had been lost.
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Figure 4.8A, B, and C. Purification of a-C14 using pH gradient elution. Analysis of fractions from affinity purification of cirC14 on a pH  
gradient from 7 to 12 showed most antibody eluting between pH 10.5 and 11.5. Successive improvement in the control of pH showed elution 
to occur between 10.5 and 11.5. Positive fractions containing antibody are shown in a shaded circle. 4.8A shows antibody in several fractions 
across a range of pH values. Why this was so is not clear. In 4.8B only a single fraction at pH 11.4 is positive. 4.8C. Again, only a single 
fraction proves positive at pH 10.5.
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Figure 4.9. SDS-PAGE analysis of batch-purification of a-C5 and a-C13. Lanes: 1,6: 
Molecular weight markers; 2,7: Supernatant; 3,8: Periplasmic lysate; 4,9: Unbound 
fraction; 5,10: Affinity-purified fraction. In both cases, purification of a 31 kDa protein 
fragment can be seen following elution of scFv at pH 12. The concentrations of non­
specific protein in supernatants and periplasmic lysates was very high and led to 
overloading of the gel.
a-C5 a-C13
1 2 3 4 5 6 7 8
Figure 4.10. Western blot analysis of batch-purification samples of OrC5 and a-C13. 
Recognition was with a-c-myc antibody. Lanes: 1,5: Supernatant; 2,6: Periplasmic 
lysate; 3,7: Unbound fraction; 4,8: Affinity-purified fraction. In both cases, recognition 
of the 31 kDa scFv antibody is seen in periplasmic lysates, unbound fractions and 
column washings. However, only small responses are detected from the purified 31 kDa 
fraction.
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Figure 4.11 A and B. ELISA analysis of periplasmic lysate and affinity-purified samples 
from the batch purification of a rC5 (A) and a-C13 (B). Periplasmic lysates of both a- 
C5 and a-C13 exhibited titres in excess of 1 in 1,000 to coumarin-BSA (C-BSA), with 
no response to BSA alone. Only marginal responses were produced using samples of 
a -C5 and a -C13 which had been affinity-purified samples.
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4.2A.3 Optimisation of OrC13 affinity purification
A 5 ml sample of (X-C13 periplasmic lysate was dialysed with 10 mM Tris, pH 7.4, 
overnight at 4°C and affinity purified on a 12.5 ml coumarin-BSA column using three 
gradients:
1. Tris buffer gradient, pH 7.4, from 10 mM to 50 mM.
2. NaCl gradient in 50 mM Tris, pH 7.4, from 0 M NaCl to 0.5 M NaCl.
3. pH gradient in 50 mM Tris/0.5 M NaCl from pH 7.4 to 12.
10 x 10 ml fractions were collected on each of the three 100 ml gradients, and analysed 
by dot blotting (Fig. 4.12).
No antibody eluted as a result of increasing the ionic strength of the Tris buffer from 10 
mM to 50 mM. However, significant amounts of antibody eluted as a result of increasing 
the NaCl concentration fro 0 to 0.5 M. Only negligible amounts of antibody then 
continued to elute in response to an increase in pH. Another significant difference from 
previous affinity purifications using high pH elution was that very little antibody was lost 
in the ’unbound’ fraction of material when added to the column. The individual fractions 
from salt elution were analysed by western blotting (Figs. 4.13). Single purified 31 kDa 
bands were detected in samples 3 to 5. Analysis of these same fractions by dot blotting 
showed them to be detected by the anti-c-myc antibody (Fig. 4.12).
4.2 A A  Comparison of phosphate-buffered saline (PBS) and Tris as buffers in ELISA 
of a-C5 scFv
An ELISA of a-C5 was carried out according to section 2.3.1.12.1, using either 50 MM 
Tris, pH 7.4, or PBS as wash and diluent reagents throughout the assay. The assay using 
Tris gave titres greatly in excess of 1 in 1,000, whereas use of PBS reduced this to below 
1 in 1,000 (Fig. 4.14).
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Figure 4.12. Sequential elution of OrC13 from a coumarin-BSA sepharose affinity 
column using Tris buffer, NaCI and pH gradients. Increasing Tris buffer concentration 
from 10 mM to 50 mM did not bring about scFv elution. Material in fraction 1 is the 
result of unbound material present on the column. Elution did occur in NaCI gradient 
in the range of 0 to 0.5 M NaCI, predominating in fractions 3 to 6. Negligible but 
detectable amounts of scFv were eluted in fractions from pH  7.4 to 12.
Fraction No. 
8 7 6 5 4 3 2 1 mw
— ^  31 kDa
Figure 4.13. Western blot analysis of fractions from NaCl gradient elution of U-C13. 
Recognition of scFv was with a-c-myc antibody. This shows the presence of a 31 kDa 
protein fragment present in fractions 3 to 5.
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Figure 4.14. The titration of a-C5 antibody against coumarin-BSA (C-BSA) using either 
Tris buffer or PBS as wash buffers and diluent. Antibody diluted and washed with PBS, 
pH 7.2, greatly reduced scFv titre, as compared with the use of 50 mM Tris, pH 7.4, 
which yielded titres greatly in excess of 1 in 1,000. The absence of NaCl in the Tris 
buffer did not lead to an increase in the non-specific binding of scFv to BSA.
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4.2.4.5 Purification of a-C5 and OrC13 using NaCl gradient
10 ml samples of periplasmic lysate of a-C5 and a-C13 in 50 mM Tris, pH 7.4 were 
purified on a 12.5 ml coumarin-BSA column using a 50 mM Tris, pH 7.4, 0 to 0.5 M 
NaCl gradient, collecting 10 x 10 ml fractions. Dot blots of purification fractions for oc-C5 
and a-C13 are shown in Figs. 4.15 and 4.16, respectively. Both showed elution of 
significant levels of antibody in fractions 3 to 6. Later fractions contained lower yields 
of scFv also. The fractions containing the greatest yields of antibody were pooled, 
concentrated and analysed by SDS-PAGE and western blotting. SDS-PAGE showed 
purification of two bands, one at approximately 31 kDa, and the other at approx. 29.5 kDa 
(Figs. 4.17 and 4.18). The lower molecular weight band was present in large amounts in 
both samples following concentration. In the a-C13 sample, the higher molecular weight 
component was entirely lost following concentration of the affinity-purified sample. TTie 
31 kDa molecular weight fragment isolated from affinity purification and detected by 
SDS-PAGE was also detected on western blots which recognised the c-myc peptide tag 
(Fig. 4.18). However, loss of the 31 kDa fragment was associated with loss of recognition 
on western blots, the 29.5 kDa band showing no recognition by anti-c-myc. The loss of 
recognition on western blots was also accompanied by loss of activity in ELISA (Figs. 
4.19 and 4.20). Periplasmic lysates yielded titres in excess of 1 in 1,000. However, nearly 
all activity was lost following affinity purification, a-C5 being marginally better than a- 
C13. The 20 kDa fragment recognising anti-c-myc antibody was again present in 
unpurified samples.
4.2.4.6 Purification of a-C14 using NaCl gradient
Culture supernatant from cultures of a-C14 were filtered through sterile 0.45 (am filters 
and 0.15% (w/v) streptomycin sulphate added. Supernatant was diluted 1 in 4 with 50 mM 
Tris, pH 7.4, and purified on a 12.5 ml coumarin-BSA column. Antibody was washed and 
eluted as in section 4.2.4.5 and samples analysed by dot blotting (Fig. 4.21). Although 
overall yields were poorer than for previous purifications of a-C5 and a-C13, antibody 
did elute into fractions 4 to 6 on the salt gradient. Again, however, when analysed by
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4.22), significant activity was lost when the purified fractions were concentrated. This was 
again associated with loss of the western blot-active 31 kDa component and the 
appearance of the non-active 29.5 kDa component (Figs. 4.23 and 4.24).
4.2.4.7 Optimised purification of anti-coumarin scFv antibodies from culture 
supernatants and periplasmic lysates
Affinity purification of anti-coumarin clones was as previously described, with the 
additional incorporation of 1 mM PMSF into all buffers used in affinity purification and 
final samples. Culture supernatant from a-C14 production was concentrated 10-fold by 
ultrafiltration (Amicon) and dialysed into 50 mM Tris, pH 7.4. Purified antibody- 
containing fractions were pooled, dialysed into 50 mM Tris, pH 7.4 and concentrated on 
Centricon 10 units (Amicon). In all three cases, elution profiles were as previously 
described, with elution taking place in fractions 2 to 6 for a-C5 and a-C13, corresponding 
to 0.05 M to 0.15 M NaCl, and fractions 4 to 6 for a-C14, corresponding to 0.15 M NaCl 
(Fig. 4.25). All three samples showed elevated levels of the 31 kDa component over the
29.5 kDa fragment (Fig. 4.26). This also gave rise to titres in excess of 1 in 10,000 by 
ELISA (Figs. 4.27a, 4.27b and 4.27c), even after two weeks storage at 4°C. Typical yields 
of purified scFv were in the order of 1 mg scFv per litre of original culture.
4.2.4.8 Modification of scFv ELISA using anti-human F(ab’)2 antibody
The results of ELISA using a HRP-labelled anti-human F(ab’)2 antibody to detect scFv 
a-C5 and a-C13 are shown in Figs. 4.28a and 4.28b. Both periplasmic lysates showed 
decreased responses in association with decreases in antibody concentration. However, 
overall signals were typically very poor with absorbances no higher than 0.3 at 492 nm.
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Figure 4.15. Dot blot analysis of fractions of a-C5 purified in an NaCl gradient. 
Culture supernatant, periplasmic lysate, unbound material from the column and column 
wash were all analysed as were fractions eluted in NaCl gradient from 0 to 0.5 NaCl 
(Fractions 1 to 10). This was followed by a wash in glycine buffer, pH 2.2. Highest 
levels of scFv were found infractions 3 to 6. Lower concentrations of scFv was present 
in the supernatant, with a considerable amount in the periplasmic lysate. The unbound 
fraction was the material that passed through the column without binding. This 
contained appreciable amounts of scFv. Little antibody was present in the buffer wash 
prior to elution and also little eluted in glycine buffer, pH 2.2 which followed NaCl 
elution. Positive control: Or NIP.
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Figure 4.16. Dot blot analysis of fractions of a-C13 purified in an NaCl gradient. 
Highest levels of scFv were found in fractions 3 to 6. Quantities of scFv in supernatant, 
periplasm, unbound fraction, buffer and low pH washes was similar to that for a-C5 
(Fig. 4.16). Positive control: a-NIP.
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Figure 4.17. SDS-PAGE analysis of samples from the purification of a-C5 and a-C13 
by NaCl elution from a coumarin-BSA sepharose affinity column. Lanes: 1,6,7,12: 
Molecular weight markers; 2,8: Supernatant; 3,9: Periplasmic lysate; 4,10: Affinity- 
purified fraction; 5,11: Affinity-purified and concentrated. Affinity purification brought 
about the enrichment of a 31 kDa protein fragment. This had degraded to a 29.5 kDa 
protein band following concentration. This was more significant in the a -C13 sample 
than in a -C5. Although enrichment of the scFv was significant, several other molecular 
weight species were still present following purification.
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Figure 4.18. Western blot analysis of samples from the purification ofarC5 and a -C13 
by NaCl elution from a coumarin-BSA sepharose affinity column. Lanes: 1,5: 
Supernatant; 2,6: Periplasmic lysate; 3,7: Affinity-purified; 4,8: Affinity-purified and 
concentrated. Recognition of 31 kDa components by the anti-c-myc antibody are clearly 
present in the periplasmic lysates and affinity-purified samples of both OrC5 and QL-C13. 
Following concentration, the recognition of a-C13 is completely lost, associated with 
the complete loss of the 31 kDa band. However, the presence of significant levels of the 
a-C5 31 kDa component in the affinity-purified fraction has led to its recognition by 
anti-c-myc. High levels of protein in samples such as a-C13 periplasm led to non­
specific binding and smearing.
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Figure 4.19. Analysis of samples from the NaCl gradient purification of a-C5 by 
ELISA. Titres in excess of 1 in 1,000 were achieved for periplasmic lysate to coumarin- 
BSA (C-BSA). This had dropped to less than 1 in 100 in the affinity-purified sample. 
Only a negligible signal was obtained from culture supernatants.
1/A ntibody Dilution
Figure 4.20. Analysis of samples from the NaCl gradient purification of c/rC13 by 
ELISA. Titres in excess of 1 in 1,000 were achieved for periplasmic lysate to coumarin- 
BSA (C-BSA). Only negligible activity remained in the sample following affinity 
purification. Culture supernatant yielded a signal only marginally higher than 
background values.
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Figure 4.21. Dot blot analysis of OrC14 fractions purified by NaCl gradient elution on 
a coumarin-BSA sepharose affinity column. Antibody eluted primarily into fractions 4 
to 6. Recognition ofscFv was with a -c-myc antibody. Large concentrations ofscFv were 
present in the culture supernatant, and the diluted culture supernatant used for 
application of sample to the affinity column. Fractions of sample after passage through 
the column showed little unbound material upon initial application of sample, but 
significantly more at the end of sample application. Some ScFv also eluted in pH 2.2 
buffer. Positive control: u-NIP. Negative control: HB2151.
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Figure 4.22. ELISA analysis of samples from a-C14 purification by NaCl gradient 
elution. Culture supernatant gave a titre in excess of 1 in 10,000 to coumarin-BSA (C- 
BSA). This had decreased to 1 in 1,000following affinity purification. Signals were only 
marginally above baseline levels following concentration.
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Figure 4.23. SDS-PAGE analysis of samples from the purification of a-C14 by NaCl 
gradient elution on a coumarin-BSA sepharose affinity column. Lanes: 1,6: Molecular 
weight markers; 2: Supernatant; 3: Unbound fraction; 4: Affinity-purified fraction; 5: 
Affinity-purified and concentrated. The presence of a 31 kDa and a 29.5 kDa fragment 
are both clearly visible in the affinity-purified sample, but only the 29.5 kDa component 
is visible following concentration of the scFv.
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Figure 4.24. Western blot analysis of samples from the purification of a-C 14 by NaCl 
gradient elution. ScFv was detected with a-c-myc antibody. Lanes: Supernatant; 2: 
Unbound fraction; 3: Affinity-purified fraction; 4: Affinity-purified and concentrated. 
Recognition of the 31 kDa scFv is apparent in supernatant, unbound material and 
affinity-purified samples, but has again been lost in the concentrated affinity-purified 
sample. This blot corresponds to the SDS-PAGE gel in Fig. 4.23.
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Figure 4.25. Dot blot analysis of Fractions from the affinity purification of ctrC5, a-C13 
and a -C14 by NaCI gradient elution on a coumarin-BSA sepharose affinity column, 
with the incorporation ofPMSF. Recognition ofscFv was with a -c-myc antibody. o C 5  
and a -C13 show maximum scFv elution in fractions from 0.05 to 0.25 M NaCI and a - 
C14 shows maximum elution in fractions from 0.15 to 0.3 M NaCI.
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Figure 4.26. SDS-PAGE analysis of arC5, a-C13 and OrC14 affinity-purified and 
concentrated using NaCl gradient in the presence of PMSF. Lanes: 1,5: Molecular 
weight markers; 2: oC 5; 3: a-C13; 4: a-C M  All three scFv preparations show the 
greatly improved yield of 31 kDa fragment over the 29.5 KDa component.
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Figure 4.27. ELISA analysis of samples from the affinity purification of a-C5 (A), a-C13 (B) and a-C14 (C). Following affinity purification 
and concentration in the presence of PMSF, all three concentrated scFv samples yielded titres in the order of 1 in 10,000 to coumarin-BSA 
(C-BSA).
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Fig. 4.28A and B. ELISA analysis ofarC5 (A) and a-C13 (B) scFv using HRP-labelled 
anti-human F(ab')2 antibody. Response to decreases in antibody concentration were only 
achieved at high dilutions of conjugated antibody. However, signals were extremely low, 
the highest signals being less than 0.3 AU at 492 nm.
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4.2.5 Characterisation of anti-coumarin scFv antibodies
4.2.5.1 Optimisation of competition ELISA for the detection of free coumarin
4.2.5.1a Selection of optimal antibody concentration
Optimal antibody concentration was calculated according to (Crowther, 1995) from the 
titres yielded in Figs. 4.27a, b and c. This was selected as 70% maximum binding, and 
corresponded to 1 in 400, 1 in 200 and 1 in 100 dilutions of a-C5, a-C13 and a-C14 
antibodies, respectively.
4.2.5.1b Selection of optimal coumarin-BSA coating concentrations
The effect of coating concentration on signal for all three anti-coumarin scFvs is shown 
in Fig. 4.29. Levels above 150 (jg/ml did not increase signals, so 150 (ig/ml was selected 
as optimal coating concentration of coumarin-BSA.
4.2.5.1c Competition EUSA analysis of free coumarin using anti-coumarin scFv
The ability of the three anti-coumarin clones to compete between bound coumarin-BSA 
and free coumarin was assessed (Fig. 4.30). All three clones showed no recognition of 
free coumarin in the presence of 0.05% methanol, at coumarin concentrations ranging 
from 0.05 to 50 |ag/ml. Competition ELISAs were repeated over a range of antibody 
dilutions (Figs. 4.31 A, 4.32B and 4.32C), but these assays confirmed the original result 
that showed no recognition between the anti-coumarin scFv antibodies and free drug.
4.2.6 Assessment of the effect of methanol and NaCl concentration on competition 
ELISA with a-C5, a-C13 and a-C14
The effect of methanol concentrations up to 25%, and NaCl concentrations up to 0.5 M 
on the binding of a-C5, a-C13 and a-C14 to free coumarin were assessed at the 1 (ig/ml 
free coumarin level (Figs. 4.32, 4.33 and 4.34). NaCl significantly reduced the binding of
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all three scFv antibodies to surface coumarin-BSA. The presence of methanol appeared 
to enhance the interaction of antibody with coumarin-BSA significantly in the case of a- 
C14 (Fig. 4.34).
Data for different methanol concentrations were grouped, and student independent and 
paired t-tests performed, comparing the means of populations in the presence and absence 
of 1 |ig/ml coumarin. In the cases of a-C5 and a-C13, a significant difference in binding 
to coumarin-BSA in the presence and absence of free coumarin was detected at the 0 and
Table. 4.2. Mean (X) and standard deviation (s) of populations from ELISA results 
investigating the effect of NaCl concentration on the binding of anti-coumarin 
scFvs in the presence and absence of free coumarin (n=5).
NaCl concentration (M)
0 0.001 0.01 0.1 0.25 0.5
a-C5
1 ng/ml X 0.631 0.630 0.622 0.356 0.110 0.105
coumarin s 0.012 0.007 0.045 0.039 0.010 0.005
No free X 0.656 0.644 0.641 0.390 0.117 0.099
coumarin s 0.012 0.007 0.006 0.026 0.007 0.006
a-C13
1 ng/ml X 0.703 0.702 0.705 0.610 0.250 0.222
coumarin s 0.005 0.006 0.003 0.028 0.008 0.028
No free X 0.715 0.719 0.713 0.628 0.261 0.218
coumarin s 0.009 0.007 0.008 0.025 0.014 0.015
cc-C14
1 (ig/ml X 0.604 0.596 0.597 0.216 0.091 0.087
coumarin s 0.031 0.037 0.026 0.040 0.004 0.007
No free X 0.607 0.602 0.604 0.221 0.092 0.081
coumarin s 0.024 0.026 0.029 0.058 0.005 0.002
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0.001 M NaCl concentration levels (n=5). These were significant at the 95% confidence 
level (Table 4.2) and Figs. 4.35A, B and C. In most instances, the signal in the presence 
of 1 ng/ml free coumarin was lower than that with no free coumarin, but this was only 
statistically significant at the 0 and 0,001 M NaCl concentrations for a-C5 and a-C13.
4.2.7 The effect of NaCl concentration on anti-coumarin scFv binding to coumarin- 
BSA
The effect of NaCl concentration from 0 to 0.2 M on the binding of the three anti- 
coumarin-BSA clones is shown in Fig. 4.36. Maximum binding occurred at 0 M NaCl and 
this decreased rapidly to baseline levels when the NaCl concentration reached 0.2 M.
4.2.8 Competition of anti-coumarin-BSA scFv antibodies against coumarin-BSA
When normalised to a percentage of maximum binding, all three anti-coumarin-BSA scFv 
clones showed competition binding profiles to coumarin-BSA that were very similar to 
one another (Fig. 4.37). Relative affinities of the scFvs to coumarin-BSA were calculated 
as the molarity of free antigen which yielded 50% maximum absorbance, according to 
Roben (1993) and Tijssen (1985). This yielded relative affinities for the three clones of 
3 x 107 M'1, 4.5 x 107 M'1 and 2.5 x 107 M"1 for a-C5, a-C13 and a-C14, respectively. 
Since the coupling ratio of coumarin to BSA was 11.5:1, this would give relative affinities 
to the hapten of 3.45 x 108 M'1, 5.18 x 108 M'1 and 2.88 x 10s M'1 for a-C5, a-C13 and 
oc-C14 respectively. This resulted in an affinity ranking of a-C13>a-C5>a-C14.
4.2.9 Competition of a-C5 scFv with different coumarin-protein conjugates
The interaction of the a-C5 scFv clone with different coumarin-protein conjugates was 
assessed. Four conjugates were selected: three coumarin-BSA conjugates with different 
coupling ratios of coumarin to protein (11.5, 5.7 and 2.77 moles coumarin/mole BSA), 
and a coumarin-ovalbumin conjugate (7 moles coumarin/mole ovalbumin). These were 
used as competition reagents against bound coumarin-BSA (11.5 moles/mole) (Fig. 4.38).
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All conjugates showed that they had been recognised by a-C5 scFv. In the case of the 
three coumarin-BSA conjugates, the level of recognition was proportional to the level of 
conjugation. a-C5 also recognised coumarin when attached to ovalbumin, giving a 
response similar to that of the coumarin-BSA (11.5 moles/mole) conjugate. However, 
ovalbumin is a smaller protein than BSA, being only approximately 44 kDa, this would 
equate to a coupling ratio of 10.5 moles coumarin/mole BSA, very similar to the 11.5 
moles/mole conjugate.
4.2.10 Assessment of the multi-specificity of the anti-coumarin scFv clones to 
different coumarin derivative-BSA conjugates
Fig. 4.39 shows that the three anti-coumarin scFv antibodies bound specifically to 
coumarin-BSA, but not to 7-hydroxycoumarin-BSA or 7-hydroxycoumarin-glucuronide- 
BSA (see section 5). The level of binding to 7-hydroxycoumarin-BSA and 7- 
hydroxycoumarin-glucuronide-BSA was only fractionally higher than that for the control 
BSA.
4.2.11 Use of anti-coumarin-BSA scFv antibodies as western blot reagents
All three antibodies were used as western blot reagents on samples of coumarin-BSA, 
BSA, coumarin-OVA and OVA. However, due to their intolerance of NaCl, salt- 
containing buffers were substituted with 50 mM Tris, pH 7.4. The level of non-specific 
interaction between antibody and proteins on the surface of a membrane can be controlled 
by the incorporation of NaCl at different concentrations as well as detergents and the 
number of washing steps involved. Normally, a level is selected which reduces non­
specific binding to a negligible level, while still giving good interaction with the specific 
protein. Low stringency buffers containing no NaCl resulted in high levels of non-specific 
background staining (results not shown).
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Log C-BSA conc. (m g/m l)
Figure 4.29. The effect of coumarin-BSA coating concentration on signal for the 
optimisation of competition ELISA in the analysis of coumarin. Increasing coating 
concentration above 150 pg/ml did not result insignificant increases in the amount of 
scFv bound. Optimal coumarin-BSA coating concentration for competition ELISA was 
estimated to be 150 fig/ml.
Free coumarin (ug/m l)
Figure 4.30. Competition ELISA of free coumarin (in 0.05 % methanol) against 
coumarin-BSA using a-C5, a-C73 and OrC14. No competition with free coumarin was 
apparent at concentrations of free drug from 0.05 to 50 pg/ml.
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Figure 4.31 A, B and C. Repeat analysis of competition EUSAs using cl -C5, a-C13 and a-C14 for the detection of free coumarin using a 
range of scFv concentrations. No observable interaction between scFv and free coumarin was apparent at any of the drug concentrations 
or antibody dilutions analysed.
0.1  1 1 1 1----- 1—
0.001 0.01 0.1 1 10 100
Fr»« coumorfn (uM)
177
a. 1 /Lig/ml free coumarin b. No free coumarin
0.7
0.6
CM
2 0.4
€>o
0 0.3
■e
1 0.2
0.1
0.0 
0.
Figure 4.32. The effect of NaCl and methanol concentration on the binding of o.-C5 in the presence of 0 and 1 fig/ml coumarin. Increasing 
NaCl concentration drastically reduced the binding interaction between a-C5 and coumarin-BSA. Methanol concentration had no significant 
effect between 0.01 and 25 % (v/v) (as found by paired and independent student t-tests). Significant reduction in the binding to coumarin-BSA 
occurred in the presence of 1 fig/ml coumarin at the 0 and 0.001 M NaCl levels. (Values for 0 M NaCl not shown due to logarithmic scale 
used. See Table 4.2).
178
a. 1 /xg/m l free coumarin b. No free coumarin
NaCI (M) NaCI (M)
Figure 4.33. The effect of NaCI and methanol concentration on the binding of a-C/3 in the presence of 0 and 1 fig/ml coumarin. Increasing 
NaCI concentration drastically reduced the binding interaction between a-C13 and coumarin-BSA. Methanol concentration had no significant 
effect between 0.01 and 25 %(v/v). Significant reduction in the binding to coumarin-BSA occurred in the presence of 1 fig/ml coumarin at 
the 0 and 0.001 NaCI levels.
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Figure 4.34. The effect of NaCI and methanol concentration on the binding of a-C14 in the presence of 0 and 1 fig/ml coumarin. Increasing 
NaCI concentration drastically reduced the binding interaction between a-C14 and coumarin-BSA. Methanol concentration had a significant 
effect, increasing the level of interaction between a -C14 and coumarin-BSA between 0.01 and 25 %(v/v), most significantly on samples 
containing 0.01 M and 0.1 M NaCI (see insert). No significant reduction in binding to coumarin-BSA was observed in the presence of 1/ig/ml 
coumarin.
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Figure 4.35A, B and C. Competition immunoassay of OrC5 (A), a -C13 (B) and a-C14 (C) against 1 fig/ml free coumarin at different NaCI 
concentrations. All three scFv clones show slightly lower absorbances in the presence of 1 fig/ml coumarin compared to 0 fig/ml coumarin 
at the 0, 0.001, 0.01 and 0.1 M NaCI concentrations. This was significant for arC5 and a-C l3 at the 0 and 0.001 M NaCI concentrations 
(as determined by independent and paired t-tests).
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Figure 4.36. The effect of NaCI concentration on the binding of anti-coumarin-BSA 
scFvs to coumarin-BSA. All three scFvs show NaCI sensitivity from as low as 0.05 M. 
Baseline signals occur when NaCI concentration reaches 0.2 M.
Log C—BSA conc. (M)
Figure 4.37. Relative affinities of a-C5, a -C13 and a-C14. All three scFvs show 50% 
binding with free coumarin-BSA at approx. 5 x 107 M'1 coumarin-BSA, which 
corresponds to a molarity of coumarin of approximately 5.75 x 10s M'1.
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Figure. 4.38. Competition of OrC5 scFv for different coumarin-protein conjugates. 
Competition for coumarin-BSA (C-BSA) conjugates appears to be proportional to the 
level of conjugation of coumarin on the BSA carrier protein, oo-C5 also recognised 
coumarin-ovalbumin (C-OVA) to the same degree as coumarin-BSA (11.5 moles 
coumarin/mole BSA). Due to the lower molecular weight of ovalbumin, this would be 
equivalent to a 10.5:1 coupling ratio on BSA.
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Figure 4.39. ELISA of anti-coumarin scFv antibodies a -C5, a -C13 and a -C14 to 
coumarin and its derivatives 7-hydroxycoumarin (70HC) and 7-hydroxycoumarin- 
glucuronide (70HCG) conjugated to bovine serum albumin (BSA). Antibody bound only 
to the coumarin-BSA conjugate and showed only background binding to 70HC-BSA 
and 70HCG-BSA as compared with the BSA control
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The BIAcore sensorgrams for the three anti-coumarin scFv clones are shown in Fig. 4.40. 
Antibodies were analysed at 1 mM concentrations on a surface of coumarin-BSA (2.77 
moles/mole) of 1,600 response units (RU). Kinetic data was calculated for the three 
clones. Analysis showed that the three clones did not adhere perfectly to first order 
kinetics. However, all three clones gave affinity constants based on the observed on and 
off rates in the 109 M 1 range and were affinity ranked in the order a-C13>a-C5>a-C14. 
This affinity ranking corresponded with that found by competition immunoassay (Fig. 
4.37). Controls using BSA coupled to the sensor chip surface (6,000 RU) did show some 
background binding of the scFv antibody to the BSA-dextran matrix (Fig. 4.41) of 31.6 
RU, compared to 167.2 RU for the a-C5 clone.
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Figure 4.40. BIAcore sensorgrams of anti-coumarin clones a-C5, a -C l3 and a-C14 to 
a coumarin-BSA surface coupled to dextran and yielding 1,600 response units (RU). All 
three clones show association and dissociation phases of the three clones. Kinetic data 
based on these sensorgrams yielded affinity constants in the range of l ( f  M'1.
4.2.12 Characterisation and kinetic analysis of anti-coumarin-BSA scFv antibodies
using BIAcore™
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Figure 4.41. BIAcore sensorgrams of a-C5 scFv (1 mM) passed over a surface of 
coumarin-BSA (1,600 RU) linked to dextran and over bovine serum albumin (BSA) 
linked to dextran (6,000 RU). This showed some interaction of the scFv with the BSA- 
dextran surface (31. 6 RU) as compared to 167.2 RU over the coumarin-BSA surface.
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4.3 PRODUCTION OF ANTI-7-HYDROXYCOUMARIN ANTIBODIES FROM THE 
NISSIM LIBRARY
4.3.1 Phage ELISA screening of first anti-7-hydroxycoumarin library
93 clones from the first anti-7-hydroxycoumarin library, following three rounds of affinity 
selection on 70HC-BSA with BSA as blocking reagent, were screened on 70HC-BSA and 
BSA (Fig. 4.42). This showed that all the clones which were positive to 70HC-BSA were 
positive on the BSA control also. Positives were selected as those having values in excess 
of the positive control well, H7. This creates some discrepancies between the two plates. 
However, all clones which show values well in excess of the negative control on one 
plate, also did so on the other, indicating that these clones were also positive, if not 
reaching the positive control signal.
4.3.2 Phage ELISA analysis of second anti-7-hydroxycoumarin library
A second anti-7-hydroxycoumarin library was prepared with affinity selection using 
alternating 70HC-protein conjugates and different blocking proteins (see section 2.3.3.4 
and 2.3.3.6). Screening of 42 clones against 70HC-0VA and OVA showed no response 
to the OVA control, while showing good enrichment of positive clones to 70HC-0VA 
(Fig. 4.43).
A second phage ELISA of 96 clones was performed (Fig. 4.44). From this, 43 positive 
clones were selected and denoted a-70H Cl to a-70HC43 and used for further analysis.
4.3.3 Analysis of supernatant and periplasmic lysates of anti-7-hydroxycoumarin 
clones for the presence of scFv
Dot blot analysis of the periplasmic lysates and culture supernatants of the 43 positive 
anti-7-hydroxycoumarin clones is shown in Fig. 4.45. All 43 clones showed no secretion 
of antibody into periplasm or culture supernatant. Clones picked at random from the 
library showed secretion in 2 out of 5 clones. Since no individual clone exhibited better
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secretion characteristics than another, the first twelve clones, (X-70HC1 to a-70HC12 
were selected for further studies on antibody refolding. a-70H Cl to (X-70HC11 were 
analysed a second time and compared to controls and again showed poor scFv production. 
Clones (X-70HC6 to a-70H C ll appeared slightly better, with (X-70HC10 and a-70H C ll 
looking moderately better than the rest of the population.
4.3.4 Use of BIAcore for the affinity selection of anti-7-hydroxycoumarin clones from 
the Nissim library
To enrich for antibodies to 7-hydroxycoumarin-BSA, the phage antibodies of the original 
Nissim library were passed across a BIAcore chip surface immobilised with 7- 
hydroxycoumarin-BSA according to section 2.3.3.5. The phage counts eluting from the 
chip surface are shown in Fig. 4.46. A total of approximately 2.74 x 108 phage antibodies 
(tfu) from the original Nissim library were passed across the BIAcore chip surface. Phage 
antibody eluting in wash buffer fell to a level of approximately 5 x 102 tfu/ml. This level 
of phage elution was quite constant. Upon the addition of glycine buffer, however, 
specific elution of bound phage did occur. A total output of eluted phage of 1.26 x 104 
tfu was produced. This represented an enrichment in excess of 1 in 20,000. No signal was 
produced by this binding on BIAcore sensorgrams (data not shown).
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Figure 4.42. Phage ELISA analysis of anti-7-hydroxycoumarin library clones on 7- 
hydroxycoumarin-BSA and BSA surfaces following three rounds of affinity selection. 
Both ELISAs show similar patterns of positives (shaded) and negatives (unshaded). 
Discrepancies only occur for wells that fall slightly below the positive control value, but 
are still positive readings. Positive clones are shaded. Positive control: H7. Negative 
control: H6.
189
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Figure 4.43. Phage ELISA of anti-7-hydroxy coumarin library following three rounds 
of affinity selection on alternating protein conjugates of 7-hydroxy coumarin with 
different blocking proteins with screening on 7-hydroxycoumarin-ovalbumin (70HC- 
OVA) and ovalbumin (OVA). All clones when screened on 70HC-0VA showed elevated 
signals above background when compared to the same clones on OVA. None of the 
clones screened on OVA gave signals above the negative control (H6). Positive control:
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Figure 4.44. Phage EUSA analysis of anti-7-hydroxy coumarin library. 43 clones 
showing the highest responses were selected as positive from the phage ELISA. Positive 
control: H7. Negative control: H6.
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Figure 4.45. Dot blot analysis of supernatant and periplasmic lysates of anti-7- 
hydroxycoumarin positive clones from phage ELISA. The 43 positive clones (rows A to 
G and HI and H7) were compared to five clones taken at random from the library (H2 
to H6 and H8 to H12). All 43 clones failed to demonstrate any secretion into the 
periplasm or culture supernatant. The control clones tended to show higher levels of 
scFv production, especially H3 and H4.
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Figure 4.46. Use of BIAcore for the enrichment of anti-7-hydroxycoumarin positive 
clones from the Nissim library. Approximately 2.75 x l ( f  phage antibodies were injected 
onto the sensor ship immobilised with 7-hydroxycoumarin-BSA. The phage titres eluting 
from the sensor are shown. During washing with buffer, titres fell to 5 x 102 tfu/ml. 
When glycine elution buffer was applied to the sensor (pH 2.2), this titre increased to 
7 x 10* tfu/ml. Over the 20 minute elution period, this equated to 1.26 x 104 phage.
192
4.3.5 Comparison of lysis methods in the isolation of scFv from intracellular 
compartments
The effect of periplasmic and intracellular lysis of clones a-70HC10 and a-70H C ll is 
shown in Fig. 4.47. This showed that freeze-thawing again released no scFv into the 
periplasm, but some antibody present in the intracellular compartment following 
sonication. Dot blot signals were also improved when antibody was denatured in 7.5 M 
guanidine hydrochloride.
Clones a-70HC6 to a-70HC8 were also sonicated and denatured in 8 M urea, which was 
also found to improve signals on dot blots, but still showed very low production of anti-7- 
hydroxycoumarin scFv antibody (Fig. 4.48).
4.3.6 Analysis of denatured and refolded anti-7-hydroxycoumarin clones
Clones a-70HC6 to a-70H C ll were denatured and refolded in arginine buffer for two 
days. Refolding greatly improved dot blot signals (Fig. 4.49). This was particularly 
evident in clones a-70HC10 and a-70H C ll.
4.3.7 Induction and affinity purification of (X-70HC10
Analysis of the fractions from the affinity purification of a refolded intracellular lysate of 
a-70HC10 is shown in Fig. 4.50. Antibody eluted from the 7-hydroxycoumarin column 
(7-hydroxycoumarin-4-acetic acid coupled to EAH-sepharose 4B) in glycine buffer, pH
2.2 in fractions 3 to 5. Following pooling of these fractions, they were found to have 
enriched for a 31 kDa protein fragment as seen by SDS-PAGE analysis (Fig. 4.51), as 
well as a lower molecular weight fragment, the molecular weight of which could not be 
accurately determined from the gel. Only the 31 kDa fragment was recognised by anti-c- 
myc antibody on western blots (Fig. 4.52). Analysis under reducing and non-reducing 
conditions indicated that a-70HC10 was a single peptide. Recognition of the 31 kDa 
fragment only occurred on western blots following purification. Antibody may not have 
been present in sufficient quantities to yield a signal on western blots prior to purification.
193
Figure 4.47. Dot blot analysis of lysis methods in the release of scFv from a-70HC10 
and 0-70HC11. Positive clone a-NIP showed good release of scFv following freeze- 
thawing and sonication, as well as into the culture supernatant. TGI (pHENl) also 
showed secretion of c-myc peptide. No antibody was present in the periplasmic lysate 
following freeze-thawing, but was present following sonication and dénaturation. 
Dénaturation of (X-70HC10 and (X-70HC11 significantly improved signals.
Figure 4.48. Dot blot analysis of the sonication and dénaturation of U-70HC6, a- 
70HC7 and a-70HC8 clones. Low yields of scFv were produced following sonication. 
Signals were again enhanced following dénaturation in 8 M urea. The negative control, 
HB2151 showed no scFv production in all samples as expected. Positive assay controls: 
a -NIP and TGI (pHENl).
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Figure 4.49. Dot blot analysis of anti-7-hydroxy coumarin scFv clones a-70HC6 to a- 
70HC11 (a-70HC9 omitted). All five clones tested showed poor signals of scFv after 
sonication. This improved upon dénaturation and was significantly better following 
refolding in arginine. a-70HC10 was significantly better than the others and a- 
70HC11 was moderately better. Positive clones TGI (pHENl) and TGI (o NIP) showed 
good levels of c-myc peptide and soluble scFv, respectively. Negative control HB2151 
showed no scFv production as expected.
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Figure 4.50. Dot blot analysis of fractions from the elution of a-70HC10. ScFv eluted 
at pH 2.2 from the EAH-sepharose 7-hydroxycoumarin column primarily in fractions 
3 to 5 with some material in fractions 2 and 6 also. Positive control: OrNIP. Negative 
control: HB2151.
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Figure 4.51. SDS-PAGE analysis of a-70HC10 refolded scFv antibody before and after 
affinity purification. Lanes: 1-4: Reducing conditions; 5-8: Non-reducing conditions; 
1,5: a-NIP (positive control); 2,6: HB2151 (negative control); 3,8: Purified U-70HC10; 
4,7: Unpurified Or70HC10. Purification resulted in the enrichment of a 31 kDa 
fragment and a lower molecular weight band that was not recognised by western 
blotting (Fig. 4.52). Purification reduced the amount of non-specific protein in the 
sample. Analysis under reducing and non-reducing conditions showed that the 31 kDa 
protein was a single peptide fragment.
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Figure 4.52. Western blot analysis of Or70IIC10 refolded scFv antibody before and 
after purification. Detection of scFv was with a-c-myc antibody. Lanes: 1-4: Non­
reducing conditions; 5-8: Reducing conditions; 1,5: a-NIP; 2,6: HB2151; 3,8: 
Unpurified a-70HC10; 4,7: Purified Or70HC10. Purification led to the recognition of 
a 31 kDa fragment under both reducing and non-reducing conditions. No antibody 
could be detected in the unpurified samples.
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4.3.8 ELISA of purified (X-70HC10
The ELISA of the purified (X-70HC10 scFv against 70HC-BSA and BSA is shown in Fig. 
4.53. The antibody showed no response to BSA, but did respond to 70HC-BSA with a 
very poor signal which was proportional to the amount of 70HC-BSA on the surface, 
with signals on the 6.25 ng/ml 70HC-BSA wells still higher than controls at 1 in 20 
dilution of scFv.
4.3.9 Affinity purification of a-70HC9
Refolded a-70HC9 was affinity purified on 70HC-EAH-sepharose and analysed by dot 
blotting (Fig. 4.54). This showed a-70HC9 to be present in fractions 1 to 4. A sizeable 
amount did not bind to the column and passed through in the unbound fraction. Dot blot 
analysis also showed that antibody did not elute at pH 3.5 (Fig. 4.55). SDS-PAGE also 
showed that although enrichment of a 31 kDa fragment occurred, poor levels of 
purification were achieved (Fig. 4.56). Western blotting showed the presence of the 31 
kDa component in the refolded lysate material, the unbound fraction and the affinity- 
purified sample, detected by a-c-myc antibody. This was still present following 
concentration of a-70HC9 (Fig. 4.57), which was also shown by dot blotting (Fig. 4.58).
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Figure 4.53. ELISA analysis of purified a-70HC10 scFv. Antibody recognised 7- 
hydroxycoumarin-BSA (70HC-BSA) but not BSA alone. Signals were very low, even 
at low dilutions (0.17 AU at 1 in 10), but gave titres in excess of 1 in 100.
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Figure 4.54. Dot blot analysis of fractions from the purification of a-70HC9. Detection 
of scFv was with Orc-myc antibody. Positive control (+ve): Or NIP. Negative control (- 
ve): HB2151. A large proportion of the antibody did not bind to the column and passed 
through in the unbound fraction. Antibody eluted in fractions 1 to 4.
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Figure 4.55. Dot blot analysis showing elution of a-70HC9 in pH  2.2 and pH 3.5 
buffers. Detection of scFv was with Orc-myc antibody. Positive control (+ve): a-NIP. 
Negative control (-ve): HB2151.ScFv eluted at pH  2.2, but not at pH  3.5.
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Figure 4.56. SDS-PAGE analysis of affinity-purified Or70HC9. Lanes: 1: Molecular 
weight markers; 2: HB2151; 3: a-NIP; 4: Refolded Or70HC9; 5: Unbound fraction; 
6: Affinity-purified a-70HC9; 7: Concentrated column washings; 8: Concentrated 
affinity-purified fraction. Enrichment of a 31 kDa protein fragment can be seen 
following concentration of the affinity-purified sample.
Figure 4.57. Western blot analysis of affinity-purified Or70HC9. Detection of a 31 kDa 
fragment was seen in the refolded sample, the unbound fraction and in the concentrated 
affinity-purified sample, although the latter is extremely faint. No scFv was detected in 
column washings. Lanes: 1: Molecular weight markers; 2: a-NIP; 3: HB2151; 4: 
Refolded a-70HC9; 5: Unbound fraction; 6: Affinity-purified O.-70HC9; 7: 
Concentrated column washings; 8: Concentrated affinity-purified a-70HC9.
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Figure 4.58. Dot blot analysis of affinity-purified O-70HC9. ScFv material was detected 
in the unbound fraction and in the pooled affinity-purified fractions 1 to 4. The signal 
was significantly enhanced following concentration of the affinity purified fraction 
(Or70HC9 conc.). No antibody was detected in concentrated column washings (conc. 
eluate). Negative control (-ve): HB2151. Positive control (+ve): Or NIP.
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4.3.10 Induction optimisation of (X-70HC10
a-70HC10 culture supernatant, periplasmic lysates and intracellular lysates were analysed 
by dot blotting for the presence of scFv following induction with IPTG (Fig. 4.59). During 
induction, several parameters were monitored. These were growth period prior to induction 
(4, 8 and 16 h), IPTG concentration (0.01, 0.1 and 1 mM) and growth period after 
induction. No scFv was present in culture supernatant or periplasmic lysate under any of 
the conditions tested. ScFv was present in most intracellular lysates, but no great 
differences in scFv yield were evident due to the changes in growth conditions. In general, 
8 h growth pre-induction showed the overall highest levels of antibody, with 0.1 mM 
IPTG and 16 h post-induction growth being marginally better. Also, the 1 mM IPTG with 
16 h pre-induction growth was very good at 0 and 4 h post-induction. These two scenarios 
were analysed a second time, this time also looking at the effect of growth temperature 
post-induction. This now showed 8 h growth pre-induction with 0.1 M IPTG and 2 h post­
induction growth at 25°C to be optimal for scFv antibody yield (Fig. 4.60). However, 
further scale ups using these induction conditions failed to significantly increase scFv 
yield (data not shown).
4.3.11 Precipitation of purified and concentrated scFv preparations
Following denaturation and refolding of a-70HC9 and a-70HC10, these were 
characterised by the precipitation of protein material following affinity purification and 
concentration. When analysed, no viable titres were obtained for a-70HC9 (data not 
shown).
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Figure 4.59 (previous page). Analysis of culture supernatants, periplasmic lysates and 
intracellular lysates of (X-70HC10 for the presence of scFv following induction under 
different conditions. All show pre-induction growth periods of 4, 8 and 16 h, IPTG 
inducer concentrations of 0.01, 0.1 and 1 mM IPTG and post-induction growth periods 
of 0 to 48 h at 3(fC. No scFv was found in periplasm or supernatant, but was present 
in intracellular lysates, generally most significantly following 8 h pre-induction culture 
growth, but samples of 8 h pre-induction growth, 0.1 mM IPTG, 16 h post-induction 
growth and 16 h pre-induction growth, 1 mM IPTG, and 0 h post-induction growth 
showing slightly elevated levels above the others.
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Figure 4.60. Dot blot analysis of the induction of a-70HC10. Induction was performed, 
either with 16 h preincubation growth period and 1 mM IPTG, or 8 h preincubation 
growth and 0.1 mM IPTG, both with post-induction growth up to 24 h at 25, 30 and 
37°C. Maximum yields of scFv from the 16 h pre-induction sample was at 4 h and 25°C. 
However, most scFv resulted from 8 h pre-incubation after 2 h, also at 25°C. Negative 
control: HB2151. Positive control: a-NIP.
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4.3.12 Characterisation of anti-7-hydroxycoumarin phage antibodies
Six anti-7-hydroxycoumarin clones positive from affinity selection were prepared for the 
production of phage-expressed antibody (section 2.3.3.3). These phage antibody 
preparations were characterised by ELISA (Fig. 4.61). All six clones showed very similar 
profiles of recognition of 70HC-BSA, but with high responses to BSA also. These were 
designated a-70H C 0 to denote them as phage antibody clones, rather than soluble scFv 
antibodies.
4.3.13 Reselection, screening and isolation of a-7-hydroxycoumarin scFv clones
A further library of anti-7-hydroxycoumarin clones was prepared. Phage ELISA was 
performed using 7-hydroxycoumarin-OVA and OVA as control (Fig. 4.62). This showed 
that most clones bound to 70HC-0VA, but not to ovalbumin alone. These clones were 
also tested against a 70HC-BSA conjugate synthesised using EDC/NHS coupling 
chemistry (Keating, 1998) (Fig. 4.63). No response was seen to this conjugate. The clones 
were also tested for the presence of periplasmic or extracellular scFv production. Seven 
clones showed good levels of periplasmic scFv production (Fig. 4.64). These were in 
positions B2, B4, G4, A5, B5, D5 and H5, with B5 and D5 being the poorer secretors of 
the group. Nearly all the clones showed some level of extracellular expression, with C4, 
D5 and G4 being better than average (Fig. 4.64). Large scale periplasmic lysates of two 
clones, A5, and B4, were prepared and competition immunoassays performed using the 
periplasmic lysate. (Figs. 4.65 and 4.66). Both clones only showed poor responses on 
ELISA, but in both cases, competition with free drug could not be detected. In both 
instances, the presence of larger concentrations of 7-hydroxycoumarin increased the signal.
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Figure 4.61. ELISA analysis of anti-7-hydroxycoumarin phage antibodies. Phage 
antibody clones were designated a-70HC<£> to indicate attachment of the antibody to the 
phage particle. AU six clones showed near identical titration profiles, with good 
responses to 70HC-BSA, but were also characterised by unacceptably high background 
responses to BSA alone. Open circles: 70HC-BSA; Filled circles: BSA.
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7-hydroxycoumarin-ovalbumin Ovalbumin
1 2 3 4 5 6 7 8 9 10 11 12
A 0.259 0.319 0.186 0.177 0.166 0.258 0.070 0.173 0.116 0.096 0.096 0.161
B 0.289 0.230 0.319 0.357 0.209 0.250 0.139 0.134 0.201 0.205 0.124 0.146
C 0.216 0.279 0.247 0.279 0.250 0.251 0.141 0.169 0.144 0.155 0.143 0.137
D 0.172 0.305 0.322 0.211 0.344 0.230 0.123 0.203 0.185 0.122 0.222 0.136
E 0.183 0.233 0.277 0.285 0.250 0.204 0.145 0.134 0.151 0.179 0.152 0.140
F 0.232 0.283 0.227 0.288 0.275 0.299 0.142 0.174 0.152 0.179 0.152 0.140
G 0.307 0.163 0.272 0.305 0.144 0.251 0.176 0.114 0.149 0.173 0.144 0.151
H 0.312 0.210 0.228 0.298 0.261 0.104 0.195 0.147 0.146 0.164 0.128 0.424
Figure 4.62. Phage ELISA analysis of anti-7-hydroxycoumarin library. 42 clones were 
analysed against 7-hydroxycoumarin-ovalbumin and ovalbumin. Clones did not bind to 
ovalbumin, but most bound to 7-hydroxycoumarin-ovalbumin. Positive control: H12. 
Negative control: H6.
7-hydroxycoumarin-BSA (EDC/NHS) BSA
1 2 3 4 5 6 7 8 9 10 11 12
A 0.091 0.100 0.084 0.080 0.077 0.097 0.070 0.076 0.086 0.072 0.080 0.086
B 0.081 0.089 0.111 0.142 0.088 0.091 0.069 0.079 0.088 0.086 0.079 0.080
C 0.076 0.098 0.079 0.105 0.094 0.092 0.065 0.076 0.071 0.092 0.075 0.069
D 0.078 0.108 0.134 0.105 0.142 0.086 0.073 0.089 0.080 0.106 0.117 0.072
E 0.079 0.085 0.094 0.104 0.136 0.083 0.082 0.071 0.101 0.080 0.101 0.070
F 0.082 0.106 0.090 0.107 0.103 0.106 0.072 0.084 0.073 0.076 0.075 0.066
G 0.111 0.096 0.099 0.113 0.094 0.088 0.083 0.066 0.085 0.080 0.080 0.064
H 0.131 0.096 0.082 0.125 0.102 0.140 0.100 0.081 0.072 0.087 0.080 0.452
Figure 4.63. Phage ELISA analysis of anti-7-hydroxy coumarin library. Clones that were 
positive on 7-hydroxycoumarin-ovalbumin (Fig. 4.62) were not positive for the 7- 
hydroxycoumarin-bovine serum albumin (BSA) conjugate prepared by EDC/NHS 
coupling chemistry. Positive control: H12. Negative control: H6.
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Figure 4.64. Dot blot analysis of supernatants and periplasmic lysates of 42 clones from  
the anti-7-hydroxycoumarin scFv library. Recognition of scFv was with a-c-myc 
antibody. All the culture supernatants showed some level of scFv secretion, with clones 
at positions D5 and G4 showing particularly good levels of secretion. In periplasmic 
lysates, several clones showed secretion of scFv, wit clones at positions B2, B4, G4, A5, 
B5, D5 and H5 with B5 and D5 being the poorest secretors.
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Figure 4.65. Competition enzyme immunoassay of Or70HCA5periplasmic lysate against 
free 7-hydroxycoumarin (70HC) and 7-hydroxycoumarin-ovalbumin. No competition 
occurred. At high free 7-hydroxycoumarin concentrations, the signal was elevated, 
indicating enhanced binding to the bound conjugate.
Free 70HC (ug/ml)
Figure 4.66. Competition enzyme immunoassay of Or70HCB4periplasmic lysate against 
free 7-hydroxy coumarin (70HC) and 7-hydroxy coumarin-ovalbumin. As in the case of 
Or70HCA5, no competition was noted, and signals were heightened at elevated 7- 
hydroxycoumarin concentrations.
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DISCUSSION
4.4 PRODUCTION OF ANTI-COUMARIN scFv ANTIBODIES USING THE 
NISSIM LIBRARY
4.4.1 Selection of scFv antibodies to coumarin
Phage ELISA analysis of rounds of affinity selection clearly showed the library enriching 
for antibodies recognising the coumarin-BSA conjugate. No anti-coumarin clones were 
detected in the library prior to affinity selection. 12% of clones were positive after two 
rounds of selection and 28.5% after three rounds. Selection using 6-NH2-coumarin coupled 
to plates was less efficient. However, since no detailed work was performed on optimising 
the coupling chemistry involved, enrichment may not have been as efficient as might be 
possible using direct coupling chemistries.
4.4.2 Screening of scFv antibodies to coumarin
Screening of positive scFv-producing clones can be performed using ELISA. This would 
simultaneously show the recognition of scFv for antigen, while also demonstrating 
extracellular expression if culture supernatant were used. However, many scFv clones 
positive by phage ELISA, prove negative when culture supernatant is analysed. Many 
clones may not be efficiently secreted due to particular protein structures that result in 
misfolding and intracellular aggregation. Others may secrete efficiently into the periplasm, 
but do not reach the extracellular matrix. Nissim et al. (1993) suggested that failure of 
detection using ELISA was due to a reduced sensitivity of the ELISA assay system as 
compared with phage ELISA. This is probably not the reason for their failure to detect 
scFv positive clones. Considering the problems associated with ELISA screening of 
clones, dot blotting was employed as a more reliable and sensitive technique for detecting 
scFv. Although dot blotting does not demonstrate interaction of the scFv with its antigen, 
recognition of antigen had already been shown to occur by phage ELISA.
Screening of clones was also extended to include periplasmic lysates of scFv-carrying E.
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coli clones. Such lysates can yield concentrated scFv material (Roben, 1993) and do not 
have the liquid handling problems associated with large volumes of culture supernatant. 
They are thus, an important source of antibody material. Also, many clones that do not 
efficiently secrete into supernatants may secrete efficiently into the periplasmic space.
The inability of many scFv clones to secrete efficiently was borne out in section 4.1.3 
where only three out of 21 clones showed efficient secretion, two of these into periplasm 
and supernatant (a-C5 and a-C13) and a-C14 solely into culture supernatant. Clones 
selected at random from the coumarin library after three rounds of affinity selection 
showed a variety of good and poor secretors with higher levels of expression than clones 
already selected as positive to coumarin. This may suggest that clones recognising 
coumarin excrete less efficiently from E. coli than clones not recognising the conjugate. 
The four clones screened as positive from selection using 6-NH2-coumarin all failed to 
secrete. However, the fact that positive clones were detected using phage ELISA may be 
very important for the future production of anti-hapten antibodies without the requirement 
for drug-protein conjugates, as will be discussed in more detail.
Having selected three clones and elucidated their secretion characteristics, it was decided 
to treat a-C5 and a-C13 as periplasmic lysates and a-C14 as a culture supernatant for the 
purposes of antibody production.
4.4.3 Purification of scFv antibodies to coumarin
Initial attempts to affinity purify the anti-coumarin scFv a-C14 were carried out in a 
fashion typical of that used for polyclonal antibody purification and many monoclonal 
antibodies (Catty, 1989, Heiko Reinartz, Dublin City University, Personal 
Communication), employing high pH elution of antibody from a coumarin-BSA affinity 
column. Initially, extremely small quantities of scFv bound to the affinity column and 
following high pH elution, only small quantities of antibody were recovered. This did not 
improve following careful optimisation of pH conditions used for washing and elution, a- 
C5 and a-C13 were also tested under similar conditions, except this time using batch 
purification with periplasmic lysate being allowed to mix for a period of time with the
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affinity matrix. This again failed to improve the yield of scFv. It also served to identify 
another characteristic of the affinity purification, namely that although a 31 kDa scFv 
component was purified which was detected by western blots, subsequent concentration 
resulted in its breakdown to a 29.5 kDa fragment that was no longer recognised by dot 
blotting, or detected by ELISA, suggesting the disappearance of the short c-myc peptide 
tag of approximately 1.5 kDa from the scFv molecule. A 20 kDa molecular weight 
fragment recognising anti-c-myc antibody, but incapable of binding to antigen was also 
formed. There appears to be two sites of significant proteolytic cleavage on the three scFv 
antibody clones (Fig. 4.67), which leads to the formation of the characteristic protein 
fragments as seen on western blots and SDS-PAGE gels. The 29.5 kDa fragment is 
purified by affinity chromatography, but is not detected by western blotting, whereas the 
20 kDa fragment is detected by blotting, but because it lacks the major part of the VH 
chain, is not affinity purified.
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Figure 4.67. Major protein fragments produced by the proteolytic cleavage of the anti- 
coumarin antibodies (X-C5, U-C13 and a-C14. Cleavage at two sites produces a 29.5 
kDa fragment not detected by western blotting, but recognising antigen and a 20 kDa 
fragment detected by anti-c-myc antibody, but incapable of recognising antigen.
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The ionic conditions of affinity purification were more thoroughly investigated due to 
early difficulties in the establishment of an effective affinity purification strategy. 
Periplasmic lysate of a-C13 was dialysed into 10 mM Tris, pH 7.4, prior to interaction 
with the affinity column, this time, with 10 mM Tris buffers used for equilibration instead 
of PBS. The effects of three gradients were investigated sequentially. Firstly, an increase 
in Tris buffer concentration from 10 to 50 mM showed no affect on the antibody-antigen 
interaction. Antibody did elute on the second gradient, however, when an increase in NaCl 
concentration from 0 to 0.5 M was employed. It was clear that large amounts of antibody 
had bound in the absence of, and eluted in the presence of approx. 0.15 M NaCl, a similar 
ionic strength as is found in PBS which contains a mixture of KC1 and NaCl. Culture 
supernatants of 2xTY media contain approx. 0.85 M NaCl. These antibodies in the 
presence of PBS or 2xTY would be significantly inhibited from binding to the affinity 
matrix. The levels obtained following high pH elution were the result of small quantities 
of scFv remaining attached to the affinity column. This was further confirmed when a-C5 
was assayed by ELISA using both PBS and Tris as buffers, resulting in greatly differing 
titres for the two systems. Subsequent purification and analysis of these scFvs was 
modified to allow for this salt intolerance and 50 mM Tris, pH 7.4, was used instead of 
PBS.
Subsequent purifications of anti-coumarin scFv were performed with an NaCl gradient 
between 0 and 0.5 M NaCl. This resulted in the efficient purification of the 31 kDa scFv 
fragment. However, degradation of the scFv, associated with loss of c-myc activity 
continued to be a problem. This was more significant when antibody was concentrated 
after affinity purification. It was suspected that degradation might be enzymatic due to the 
presence of protein contaminants from periplasm or culture supernatant. Such proteolysis 
should be inhibited by the presence of PMSF in lysis buffers. During affinity purification, 
however, protective PMSF may be removed during washing and elution. This may allow 
the reactivation of serine protease contaminants in the sample which coelute with the 
scFv. When concentrated, this activity may be greatly increased, bringing about an 
acceleration in the degradation of the antibody. If this was the case, then the inclusion of 
PMSF in wash buffers, elution buffers and purified fractions should reduce the level of 
degradation.
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All three scFvs were repurified taking into account all the characteristics of these 
antibodies. This resulted in the more efficient enrichment of the active 31 kDa scFv 
component that was detected by western blotting and gave ELISA titres of 1 in 10,000 
to coumarin-BSA with no detection of BSA alone. Antibody activity was also found to 
be stable upon storage at 4°C over several weeks at least.
The anti-c-myc antibody (mycl-9E10) used for recognition of scFv in ELISA and western 
blots would only be capable of detecting the 31 kDa fragment. An antibody recognising 
scFv, however, might recognise both 31 kDa and 29.5 kDa species, and so loss of the c- 
myc peptide tag during purification would not affect use of the antibody in assays. 
However, no anti-scFv antibodies were commercially available. The closest antibody 
recognising human scFv that was available was an anti-human F(ab’ )2 antibody. This was 
used in conjunction with scFv in ELISA. Although a result was obtained, it was extremely 
poor. This is likely to be because only a fraction of the anti-human F(ab’)2 antibody is 
being used in scFv recognition, as there is only a single heavy and light chain variable 
region sequence. The synthetic nature of the CDRH3 region and the presence of a 
synthetic linker may all contribute to reduce the amount of anti-human F(ab’)2 antibody 
specific for the scFv to a very small proportion of the total polyclonal mixture, thus 
making it insensitive and non-viable in ELISA.
4.4.4 Characterisation of scFv antibodies to coumarin
To serve its purpose, an antibody must be applicable in the assay system for which it was 
developed. The three anti-coumarin clones isolated here were produced for the detection 
of the drug coumarin in a competition immunoassay, in which antibody would compete 
for the free analyte coumarin and the surface bound coumarin-BSA conjugate. For a 
competition assay to function effectively, several parameters must be optimised (Tijssen, 
1985). Firstly, the scFv antibody concentration used in the assay must be optimised so as 
to make it limiting. If antibody is capable of binding to free and bound antigen in excess, 
this will not result in a measurable signal. Optimal antibody concentration was determined 
from titres of the three scFvs and taken at 70 % of maximum binding. At this level, they
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will be limiting, but still provide enough antibody to bind antigen at a range of 
concentrations. Surface coumarin-BSA coating concentration was also maximised in this 
instance so as to effectively compete with free analyte and provide a high blank signal. 
Only as much antigen is used when increasing concentration does not result in an increase 
in signal. In the case of all three scFvs, this was found to be 150 ^g/ml.
oc-C5, a-C13 and a-C14 were tested in competition ELISA assays with free coumarin 
concentrations from 50 to 0.05 (ig/ml. All three antibodies showed no detectable 
interaction with free drug at any of these concentrations. Coumarin was present in 0.05% 
methanol for efficient dissolution. Repetition of the assays varying antibody concentration 
again failed to show interaction with free drug.
The three anti-coumarin scFvs had displayed particular physicochemical characteristics. 
Significantly, they were capable of binding to the conjugate, coumarin-BSA. They did not, 
however, show any interaction with BSA alone. This suggested that interaction of 
antibody and antigen was absolutely dependent on the presence of the coumarin moiety. 
However, the lack of significant recognition of free drug indicated that interaction with 
the coumarin moiety alone was not capable of forming a high affinity antibody-antigen 
complex.
The NaCl sensitivity of the three scFv antibodies suggested that an ionic or electrostatic 
interaction between antigen and antibody was significantly important for the stabilisation 
of the antibody-antigen interaction. However, the extent of this type of interaction in the 
overall stabilisation of the complex must be limited due to this sensitivity. Coumarin is 
extremely hydrophobic and possesses no structures that would bring about electrostatic 
interactions with the scFv. Therefore, it must be concluded that this essential stabilising, 
but weak electrostatic force must be as a result of an interaction with the antibody and 
some component of the BSA carrier protein, probably a component of the amino acid by 
which coumarin is coupled, i.e. histidine or tyrosine. Complete stabilisation of the 
antibody-antigen interaction requires both hydrophobic interactions between scFv and 
electrostatic interactions between scFv and amino acid present on the parent protein. The 
three scFv antibodies thus probably principally recognise a combined hapten-protein
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epitope of the coumarin-BSA conjugate.
The fact that coumarin was required to stabilise the antibody-antigen interaction suggested 
that there must be some affinity between the scFvs and free coumarin. Since the principle 
interactions between coumarin-BSA or coumarin and scFv appeared to be either 
electrostatic and/or hydrophobic in nature, then it might be suggested that adjustment of 
the ionic and polar environment in which the competition between coumarin-BSA and 
coumarin takes place, may enhance the interaction between free coumarin and scFv over 
coumarin-BSA and scFv. This was attempted by looking at the combined effects of NaCl 
and methanol concentration present during the antibody-antigen competition. However, 
increasing NaCl concentration only succeeded in destabilising coumarin-BSA-scFv 
interaction, without enhancing interaction with coumarin alone. Increasing methanol 
concentration also succeeded in only having a positive effect on the interaction of 
coumarin-BSA with scFv. This effect was only significant in the case of a-C14, but not 
a-C5 or a-C13. The effect of NaCl concentration on the interaction between scFv and 
coumarin-BSA was examined more closely and seemed to confirm earlier observations 
that antibody-antigen interaction was all but prevented at an NaCl concentration of 0.2 M. 
In the cases of a-C5 and a-C13, as the effect of methanol concentration was not 
significant, these data were used as replicates (n=5) from which to calculate means and 
standard deviations of absorbance for each NaCl concentration used. When populations 
in the presence and absence of coumarin were compared, significant differences were 
detected at the 0 and 0.001 M NaCl levels for a-C5 and a-C13, showing that binding to 
surface coumarin-BSA was reduced in the presence of 1 fig/ml coumarin in the case of 
<x-C5 and a-C13. This was not so for a-C14. However, since there was greater standard 
deviation in this population due to the significant effect of methanol, the presence of an 
effect showing binding to free coumarin may have been lost.
Since the scFvs could not be effectively characterised using free coumarin to measure 
affinity, relative affinity measurements were made using coumarin-BSA conjugate. The 
method used was an approximation of the affinity equilibrium constant according to Van 
Heyningen et al. (1983) and Roben (1993). All three scFvs yielded very similar results,
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3 x 107 M'1, 4.5 x 107 M'1 and 2.5 x 107 M'1 for a-C5, a-C13 and a-C14, respectively. 
This figure represents moderate affinity, but was calculated based on a single mole of 
coumarin-BSA. With a multivalent hapten, the formula for KA becomes:
K*  = T d = n [ A g \  M  1
where n is the valence of the antigen. Up to 11.5 scFv molecules may bind to a single 
coumarin-BSA molecule. If this were the case, relative affinities would be 3.5 x 108 M \  
5.18 x 108 M'1 and 2.88 x 108 M'1 for a-C5, a-C13 and a-C14, respectively, under the 
conditions used.
Further confirmation of the characteristics of the three scFv antibodies resulted from their 
interaction with other coumarin-protein conjugates. The level of interaction between scFv 
and coumarin-BSA conjugates was directly related to the extent of drug conjugation on 
the BSA protein, again indicating the requirement for a shared coumarin-BSA epitope. 
Interaction with coumarin-OVA to the same extent as coumarin-BSA again suggested that 
the epitope did not depend on topographically proximal amino acid structures, but on the 
amino acid to which the coumarin molecule was linked, namely tyrosine and tryptophan. 
This could be further confirmed by the use of other coumarin-protein conjugates 
(coumarin-THG), enzymatic digests of coumarin-BSA and conjugates of coumarin- 
histidine and coumarin-tyrosine.
a-C5, a-C13 and a-C14 could not be effectively used for the analysis of free coumarin, 
but were capable of the characterisation of coumarin-protein conjugates by ELISA. Their 
use as reagents on western blots was, however, limited by their NaCl sensitivity. Blotting 
incorporates stringent washing steps using PBS and other salt buffers to prevent 
background staining. When these buffers were substituted with buffers suitable for the 
scFv interaction with coumarin-protein conjugates, the lack of stringency resulted in high 
background. Their use as reagents in blots is limited by this sensitivity, but may be 
optimised by careful control of NaCl concentration and the use of other agents such as 
non-polar detergents like Tween 20.
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The multi-specificity of the three clones was also assessed using conjugates of coumarin, 
7-hydroxycoumarin and 7-hydroxycoumarin-glucuronide coupled to BSA. This showed 
that the three antibodies were specific for the coumarin hapten and showed no significant 
specificity for the other haptens. This is not surprising as coumarin and 7- 
hydroxycoumarin were coupled in opposing orientations to the carrier protein, coumarin 
at the 6-position and 7-hydroxycoumarin at the 3-position (Fig. 4.68). When these are 
presented to the scFv, they are bound to present significantly different surfaces. This may 
have been less significant if the haptens had been free. 7-hydroxycoumarin-glucuronide 
possesses the intervening glucuronic acid molecule, and a stable interaction between the 
coumarin moiety and the amino acid to which it was linked was unlikely to take place.
BSA
Coumarin-BSA
0H
7-hydroxycoumarin-Q lucuronide-BSA
Figure 4.68. Orientation of coumarin, 7-hydroxycoumarin and 7-hydroxycoumarin- 
glucuronide on the carrier protein. Coumarin was coupled at the 6-position, 7- 
hydroxycoumarin at the 3-position and 7-hydroxycoumarin-glucuronide via the carboxyl 
group of the glucuronide moiety.
The three anti-coumarin scFv clones were also analysed by BIAcore. Kinetic analysis was 
performed on the three clones and the relative affinities for the three clones calculated.
220
Kinetic analysis showed that the three clones deviated from pseudo-first-order kinetics. 
This could occur for two main reasons (Nieba et al., 1996; O’Shannnessy and Winzor, 
1996). One is that binding is taking place with the matrix rather than the haptens present 
on the protein. This was demonstrated as occurring on the control surface. Since no 
binding to the BSA control occurred in ELIS As, it is probable that most of this interaction 
was a non-specific one between the antibody and the charged dextran matrix. This, 
coupled to the ionic sensitivity of these clones would suggest that some electrostatic 
interaction may occur between the dextran matrix and the scFv. Also, first order kinetics 
can be distorted by the presence of high concentrations of surface ligand. In this instance, 
rebinding may take place. Efforts were made to greatly reduce the amount of bound ligand 
(1,600 RU), but a lower concentration may have been more optimal.
Using the data from the observed on and off rates, all the clones had affinity 
measurements in the nanomolar range, with an affinity ranking of a-C13>oc-C5>a-C14. 
These affinity measurement were strongly dependent on the matrix used for the 
measurement, ie., HEPES buffer without NaCl was used. The use of the standard 
phosphate-buffered saline buffer would have significantly reduced the affinity 
measurements. Indeed, 0.15 M NaCl was incorporated into the HEPES buffer to serve as 
a regeneration buffer. Such an easily regenerable sensor surface could have applications 
in sensor technology where an easily regenerable surface is an ideal characteristic of the 
assay system.
The calculated affinities were an order of magnitude greater than that found by 
competition enzyme immunoassay, which were calculated using equilibrium data. This 
may suggest a significant error in the kinetic data as generated by BIAcore analysis and 
demonstrates some of the possible inadequacies of the kinetic models used for such 
analyses. However, both studies yielded affinity rankings for the three clones in the order 
of a-C13>a-C5>a-C14.
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4.4.5 Summary
The three anti-coumarin scFv antibodies a-C5, a-C13 and a-C14 all exhibited 
characteristics very similar to one another. All three possessed NaCl sensitivity and bound 
to coumarin-BSA with high affinity in the absence of NaCl, but to free coumarin with 
poor affinity. None of the antibodies bound to BSA alone. All three showed relative 
affinity measurements in the subnanomolar and nanomolar range by ELISA and 
BIAcore™ respectively. Major differences were observed in their secretion characteristics, 
a-C5 and a-C13 secreting into periplasm and supernatant in roughly equal quantities, 
whereas (X-C14 secreted more efficiently into culture supernatant, bypassing the periplasm. 
This could lead to the suggestion that the structure of the antigen binding sites may be 
very similar, if not identical, then at least exhibiting certain critical polar and non-polar 
regions. a-C5 and a-C13 appear so alike that they may be derived from the same clone. 
a-C14 may possess sequence variations that do not affect antigen binding but aid in more 
efficient release of protein from the periplasm across the outer membrane. Nucleic acid 
sequence analysis of the three clones would confirm or refute this.
Screening of anti-coumarin antibodies using the Nissim library resulted in the isolation 
of three scFv antibodies that were capable of recognising coumarin with low affinity and 
a combined coumarin-BSA epitope with relatively high affinity. These also had a 
characteristic sensitivity to greater than 0.05 M NaCl which made them unsuitable as 
western blot reagents, but made them easily regenerable on the BIAcore sensor chip 
surface. This electrostatic interaction also resulted in some interaction with the BIAcore 
sensor chip dextran matrix, which contributed to non-linearity when kinetic parameters for 
the scFvs were measured.
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4.5 PRODUCTION OF ANTI-7-HYDROXYCOUMARIN scFv ANTIBODIES USING 
THE N1SSIM LIBRARY
4.5.1 Selection and screening of scFv antibodies to 7-hydroxycoumarin
Production of the anti-7-hydroxycoumarin scFv library began with affinity selection 
against a 7-hydroxycoumarin-BSA (70HC-BSA) conjugate using BSA as blocking reagent 
and free in solution to remove non-specific BSA binders. In principle, this methodology 
should have been capable of the removal of anti-BSA clones from the phage population, 
while enriching for clones recognising 7-hydroxycoumarin only. Initially, however, this 
did not occur, and the library enriched for anti-BSA clones instead. It is clear that the use 
of soluble protein to remove reactivity with surface BSA, either as blocking reagent or as 
carrier protein is not sufficient. This may be as a result of the very large numbers of 
phage particles in the phage population used for affinity selection. If enough phage is 
present, binding of clones to free BSA and surface BSA may reach an equilibrium. Even 
following washing, many anti-BSA phage may be still adhering to the surface. Since the 
number of epitopes available to anti-BSA binders is greater than those to anti-7- 
hydroxycoumarin binders, and since the number of sites available to bind to BSA is far 
greater than to 7-hydroxycoumarin (the 70HC-BSA conjugate used possessed 2.7:1 moles 
7-hydroxycoumarin to BSA), then the numbers of anti-BSA clones enriched could greatly 
exceed the number of anti-7-hydroxycoumarin clones, even following a single round of 
affinity selection. With subsequent rounds of enrichment, this bias may only be 
exacerbated, until a point is reached where the population consists almost entirely of anti- 
BSA clones, making it impossible to screen anti-7-hydroxycoumarin clones.
The enrichment methodology was modified so as to avoid this enrichment to the carrier 
protein or blocking reagent. Changing the carrier protein and the blocking protein used 
on each round of affinity selection would ensure that enrichment of phage antibody to 
carrier protein or blocking protein on a previous round of selection would be removed in 
the following round. This was very successful, and all clones subsequently screened were 
not positive to the carrier protein or blocking reagent.
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This phenomenon did not arise in the case of enrichment of anti-coumarin clones (section 
4.2). What may have been crucial here was the level of conjugation of hapten to carrier 
protein. In the coumarin-BSA conjugate, the coupling ratio was 11.5:1 moles coumarin 
to BSA, whereas for 70HC-BSA, this was only 2.7:1. Such a reduction in the number of 
hapten epitopes may bias affinity selection too much in favour of the carrier protein.
A high hapten:protein coupling ratio would be ideal for such affinity selection strategies. 
With peptides, approximately 10:1 molar ratio will effectively cover the surface of the 
protein, so revealing very few carrier protein epitopes for antibody binding (Andrew 
Williams, Cambridge Antibody Technology, personal communication). However, haptens 
such as coumarin and 7-hydroxycoumarin, having much lower molecular masses, would 
require much higher coupling ratios to achieve this near total occlusion of the carrier 
protein. Such an attempt would result in problems associated with the physical 
characteristics of such a conjugate. The hydrophobicity of these molecules would lead to 
an extremely insoluble conjugate that could not function as a useful affinity ligand 
(Hermanson, 1997). For effective selection of antibodies to 7-hydroxycoumarin, 
modification of the enrichment procedure in the way performed seems appropriate. 
Alternatively direct coupling of haptens to solid supports may also be another viable 
strategy. This was tested briefly for anti-coumarin antibodies which did appear to result 
in levels of enrichment. No optimisation of these methodologies was performed and 
significantly better levels of enrichment may be achievable.
As has been stated, not all clones positive by phage ELISA result in the secretion of scFv. 
Indeed, in most cases, this seems to be a relatively small proportion of the overall 
population. In the case of the 7-hydroxycoumarin screening, however, all 43 clones 
positive to 70HC-BSA were found to be incapable of secretion. Clones taken at random 
from the population, i.e., not necessarily anti-7-hydroxycoumarin clones, showed greater 
levels of secretion. This phenomenon was also true of the coumarin library. It was initially 
suggested that such a result might be a consequence of the production of scFv molecules 
to hydrophobic haptens. The presence of hydrophobic residues in the scFv to bind to the 
hydrophobic hapten may result in difficulties associated with refolding where large areas 
of hydrophobicity are not normally exposed on the external surfaces of such globular
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proteins. However, later rescreening found there to be populations of soluble anti-7- 
hydroxycoumarin clones, and that the earlier difficulties with insolubility might have been 
artefacts of the original affinity selection.
4.5.2 Isolation of scFv antibodies to 7-hydroxycoumarin from intracellular lysates
Prior to reselection and rescreening, however, the possibility of isolating scFv from 
intracellular lysates was investigated. In the conversion of whole monoclonal antibodies 
into antibody fragments for prokaryotic expression () it has been found that many of the 
resulting molecules are insoluble due to incorrect folding, so preventing secretion and 
resulting in intracellular inclusion bodies. The development of protocols to solubilise, 
denature and then refold these molecules into their correct conformation allowed the 
possible use of these molecules. Lysis of the inner membrane was normally performed by 
sonication or physical disruption techniques such as the use of a Beadbeater apparatus 
(Hughes et al., 1969). Neither was significantly better than the other in terms of the yield 
of scFv released. In practical usage, however, sonication was the simpler of the 
techniques.
Following cell lysis, denaturation was performed in either 7.5 M guanidine hydrochloride 
or 8 M urea. Again, these performed equally well, and both resulted in elevated signals 
of scFv on blots. Denaturation may have resulted in the greater availability for recognition 
of the c-myc peptide by anti-c-myc antibody.
Efficient refolding is a lengthy procedure and can take up to 5 days (Buchner and 
Rudolph, 1991). Refolding also requires large concentrations of arginine which has been 
found to assist in the refolding of the antibody protein.
When applied to the anti-7-hydroxycoumarin clones a-70HC9 and (X-70HC10, the 
refolding methodology did result in scFv that was capable of binding to 7- 
hydroxycoumarin coupled to EAH sepharose, indicating recognition of 7- 
hydroxycoumarin. Much scFv material did not attach, however. Actual yield could not be 
measured due to the presence of non-specific protein, but yields of up to 40% correctly
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folded antibody have been achieved with these protocols (Buchner and Rudolph, 1991). 
Surprisingly, however, for affinity purification, much non-specific protein material was 
still present following extensive washing of the column prior to elution. Intracellular 
lysates contain very high concentrations of protein in comparison to periplasmic lysates 
and more extensive optimisation of washing and elution procedures would be required to 
improve the level of enrichment.
The main obstacle in the efficient use of scFv refolded from intracellular lysates was the 
initial yield of scFv from the cells. Yields of exogenous protein can be dramatically 
effected by the growth conditions of the culture such as growth temperature (Cabilly, 
1989; Takagi et al, 1988) and inducer concentration (Takagi et a l, 1988). For this reason, 
optimisation of the yield of scFv from a-70HC10 was attempted by varying several 
factors: growth period prior to induction; inducer concentration; growth period post­
induction and growth temperature post-induction. All these have been shown in the past 
to be factors important in determining antibody yield. In this instance, however, although 
small variations in yield could sometimes be noted when growth periods and inducer 
concentrations were varied in small scale tests, for full scale antibody production, yields 
were not seen to be visibly improved upon previous analyses. This poor yield may relate 
to the build up of these antibodies as inclusion bodies within the cell. Such deposits may 
inhibit the correct functioning of the cell, maybe even causing cell death before large 
yields of protein have built up.
Purified antibodies were also found to be prone to precipitation following concentration. 
This predisposition to precipitate may be connected with their inability to refold correctly 
during translation. This, in combination with an initial low yield of scFv, resulted in very 
low yields of correctly folded, soluble antibody. a-70HC10 managed to show selective 
recognition of 70HC-BSA over BSA on ELISA, but with extremely poor signals. This 
combination of characteristics meant that the production of scFv anti-7-hydroxycoumarin 
antibodies from intracellular lysates was not a viable option for the isolation of antibody 
material useful in immunoassays or other applications.
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4.5.3 Production of phage antibodies to 7-hydroxycoumarin
If antibody could not be efficiently secreted, then antibody on the surface of phage - so- 
called ’phage antibodies’- might be used as an alternative source of antibody material. 
Secretion of scFv attached to pill and assembled on the surface of the virion is assured, 
and large yields of phage antibody can be isolated. Six such clones were isolated and 
analysed by ELISA. Although supernatants from clones were shown to have no reactivity 
to the carrier protein, when used as concentrated phage stocks, a sizeable response to BSA 
was detected in all six clones, below the signal for 70HC-BSA. The presence of large 
amounts of virion protein in these concentrated phage stocks may have resulted in 
significant degrees of non-specific interaction between virion and BSA, contributing to a 
high background and a very poor signal:noise ratio. In this form, such phage antibodies 
would have little use as affinity reagents. Application of these molecules may be found 
in a pVIII-type system (Kang et al., 1991) for scFvs. Here, the copy number of scFv on 
each virion would be considerably increased. This would also in turn decrease non­
specific interaction between phage and surface coatings, improving the signalrnoise ratio 
of the assay and allowing the use of higher dilutions.
4.5.4. Affinity selection of scFv antibodies to 7-hydroxycoumarin using BIAcore
The potential of using BIAcore to select phage antibody clones to 7-hydroxycoumarin 
from the Nissim library was explored. Malmborg et al. (1996) had demonstrated that 
BIAcore could be used to select positive clones from a mixture of positive and negative 
phage clones. Malmborg et al. (1996) crucially demonstrated that below a specific phage 
titre of 3 x 108 tfu/ml, BIAcore was not capable of detecting a binding signal. Thus, it 
would be unlikely that any signal would result from a population of unselected phage such 
as the Nissim library used here. However, absence of a sensorgram signal did not mean 
that selection was not taking place. By monitoring phage counts, it was clear that elution 
of bound phage could be brought about after attachment to the BIAcore sensor chip 
surface. The level of enrichment was significant, yielding in excess of 1 in 20,000 
enrichment of specific phage. This was well in excess of the 5-fold enrichment 
experienced by Malmborg and Borrebaeck (1995). However, since they began with a
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mixture of 1:10 specific antibody and non-specific phage stock, the mixture was already 
significantly enriched and unlikely to result in large enrichment factors. Malmborg et al. 
(1996) also found that antibodies isolated in the early part of the elution phase had higher 
dissociation rate constants than those isolated later. It was demonstrated that specific 
phage could be selected from a large, diverse, unpanned antibody library in much the 
same way as has been achieved on solid supports. Such a selection procedure also has the 
potential to be used to select antibodies with high dissociation rates with the potential for 
use in regenerable immunosensor systems.
4.5.5 Optimised affinity selection and screening of scFv antibodies to 7- 
hydroxycoumarin
The affinity selection of antibodies to 7-hydroxycoumarin using the conjugates available 
was eventually achieved. This was done using rounds of affinity selection with different 
carrier proteins and different blocking reagents. In this way, two problems with the 
enrichment were eradicated. Firstly, the enrichment of antibodies to the blocking protein 
were prevented as a different one was used each time. Secondly, responses to the protein 
carrier were minimised also. This strategy did indeed result in clones that did not respond 
to the carrier protein alone, or the blocking solution. However, when tested against a 
conjugate of 7-hydroxycoumarin in which the drug was attached to the protein via a 
different linker at the 4-position rather than the 3-position, no response from the antibody 
occurred. Although some clones were now found to be secretors of soluble scFv, when 
tested against free 7-hydroxycoumarin, no competition was seen. A similar effect was 
noted as had occurred with anti-coumarin clones. That is, at higher free drug 
concentrations, the response to the bound conjugate was enhanced.
4.5.6 Characterisation of scFv antibodies to 7-hydroxycoumarin
Although further analysis of these clones was not performed, and they were only used in 
an unpurified form, they seemed to possess certain characteristics in common with the 
previously screened anti-coumarin scFv clones. Firstly, they did bind to the drug-protein 
conjugate to which they were raised, but not to the free drug or carrier protein alone.
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They also showed that the increasing hydrophobicity of the test matrix due to the presence 
of high concentrations of 7-hydroxycoumarin, enhanced the interaction of the antibody 
with the drug-protein conjugate. This may indicate that an electrostatic interaction between 
the antibody and the antigen is a major stabilising influence. Since there are no polar or 
ionic components present on 7-hydroxycoumarin, it could also be concluded that a 
component of the protein provides this interaction. It might be concluded then, that the 
production of antibodies to coumarin and 7-hydroxycoumarin resulted in the selection of 
clones which did not bind to the free drug with high affinity , but selected antibodies to 
a drug-amino acid conjugate.
4.6 THEORIES AS TO WHY scFv ANTIBODY PRODUCTION STRATEGIES DID 
NOT RESULT IN ANTIBODIES WHICH SIGNIFICANTLY RECOGNISE FREE 
DRUG
Keating (1998) used hybridoma technology for the production of antibodies to 7- 
hydroxycoumarin. Similar results were encountered in which clones selected using 7- 
hydroxycoumarin conjugates coupled to proteins differing from that used for immunisation 
did not result in the selection of clones that were capable of binding free drug.
Danilova (1994) also obtained similar results in the isolation of hybridomas to small 
haptens such as digoxin and thyroxine. These exhibited all the characteristics of the anti- 
coumarin and anti-7-hydroxycoumarin clones described. That is, they bound thyroxine- 
BSA, but not BSA or free thyroxine with high affinity, but were capable of showing 
competition with the free thyroxine-BSA conjugate. Danilova concluded that these clones 
also bound to a combined epitope of the hapten-carrier and that this was not dependent 
on the carrier protein as antibody bound equally well to other protein-hapten conjugates, 
as did the anti-coumarin clones.
A mechanism can be proposed as to why, in the case of selection and screening using 
antibody scFv libraries, clones were selected that were not capable of binding to the free 
haptens, coumarin and 7-hydroxycoumarin, but bound to a combined epitope of the drug- 
hapten conjugate. This mechanism can also be extended to explain why this phenomenon
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also occurs in the case of hybridoma screening.
In the selection of scFv to these haptens, selection was performed using, in one instance, 
the same coumarin-BSA conjugate throughout selection and screening. In the other case, 
selection used different conjugates, differing by their protein, but not their mode of 
attachment. In the case of coumarin, the coupling ratio was high, and this resulted in 
enrichment of clones to the drug-carrier conjugate, rather than to the protein alone. At 
lower coupling ratios, as was initially the case with 7-hydroxycoumarin-BSA, however, 
enrichment to the carrier came to predominate, and so coupling ratio is crucial in 
removing these effects. However, the alternative strategy of alternating the carrier protein 
and the blocking solution also circumvented this.
Affinity selection is performed using immobilised antigen on immunoassay plates. Such 
methodologies have the potential to select for clones with the highest affinities to the 
antigen. Such high affinities are based on the sum of attractive and repulsive forces, based 
on hydrophobic interactions, Van der Waals forces, ionic bonds and hydrogen bonding 
taking place between the antigen and the antibody. Since coumarin and 7- 
hydroxycoumarin are small, hydrophobic molecules, they would have a tendency to 
interact by a small number of hydrophobic forces alone. Such interaction may be of only 
low affinity. This molecule would occupy only a small pocket of the antigen binding site. 
Other interactions between the antibody and the antigen may provide higher affinity 
interactions. Such might involve interactions, not with the drug alone, but with parts of 
the protein, namely that part of the protein that is proximal to the hapten: the amino acid 
to which it is linked. Indeed, even a single electrostatic interaction can contribute 
significantly to the overall affinity of such an interaction (Tijssen, 1985). Enrichment of 
these clones over those that interact with hapten alone thus result in difficulties during 
screening anti-hapten antibodies from the enriched population. Again, during the screening 
process, which is an ELISA-based technique, these lower affinity binders are passed over 
for the higher affinity clones which yield the highest signals.
In the case of hybridoma technology, similar events may occur both in vivo and in vitro 
to bring about the same effects. In the antibody response following immunisation, affinity
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maturation takes place, where high affinity clones are selected from lower affinity clones, 
which are apoptosed (Kuby, 1997). Indeed, it was shown by Reinartz (Dublin City 
University, Personal Communication) that only a small percentage of a polyclonal 
antibody response was found to be to the hapten, and the rest to components of the carrier 
protein. Already, the population of B cells may already be heavily biased in favour of 
high affinity clones not recognising the free hapten, but a hapten-carrier combination. Use 
of a hapten-protein conjugate during screening that just differs by the protein used is then 
not sufficient to prevent the selection of clones that recognise the hapten-amino acid 
epitope, as this is the same in both instances. The use of different protein carriers was 
again shown to be of no significance in the case of anti-7-hydroxycoumarin antibodies, 
as the resulting clones still recognised both conjugates.
It is clear, then, that the use of conjugates differing by the protein, but using the same 
coupling methodology are not sufficient for the selection of antibodies to these small 
haptens. Danilova’s assertion - that the orientation of the hapten should be changed, along 
with the coupling methodology and the carrier, between, in the case of hybridomas, 
immunisation and screening, and in the case of scFv antibodies, during affinity selection 
and screening - is a valid one. Changing the orientation of the hapten and changing the 
coupling methodology would reduce the bias towards selecting and screening clones that 
relied on a certain interaction with the carrier, or, indeed, the linker. Also, antibodies 
would be selected that simultaneously bound different orientations of the same hapten, 
perhaps in different parts of the antigen binding site, which might significantly affect the 
resulting affinity.
Other viable alternatives for selection and screening are the use of direct covalent 
attachment of the haptens to solid phases. This would remove problems associated with 
the carrier protein, but may not remove problems associated with the linker, or the 
orientation of the hapten. Steric hindrance may also be a concern in this instance. 
Selection and screening using BIAcore may also be a viable alternative. Its ability to 
select low affinity binders may show that many of these are capable of interacting with 
the hapten and not the hapten-carrier combination. Another alternative would be the 
development of a screening method based on a competitive immunoassay in which
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binding to free drug could be detected. Such work was attempted (data not shown), but 
was found not to be feasible. Several parameters of a competition assay require 
optimisation prior to the assay itself, such as optimum antibody, antigen and free analyte 
concentrations (Catty, 1989). Such analyses cannot be performed simultaneously on large 
numbers of clones as occurs with phage ELISA. This would further diminish the chances 
of detecting clones that were capable of binding to free antigen.
4.7 CONCLUSION
Antibody scFv fragments were screened from a naive library against coumarin and 7- 
hydroxycoumarin. The resulting clones were incapable of binding with high affinity to the 
free drug due mainly to the nature of the conjugates used to select and screen them. For 
the effective selection and screening of monoclonal antibodies to these haptens, either by 
genetic or hybridoma technology, the development of more sophisticated conjugates is 
desired. These conjugates should differ, not only by their carrier proteins, but also by their 
linker methodology and thus, the orientation of the hapten. It is felt that this will remove 
the problems encountered in these antibody production strategies.
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5. 7-HYDROXYCOUMARIN-GLUCURONIDE: PRODUCTION, 
PURIFICATION, ANALYSIS AND CONJUGATION FOR THE PRODUCTION
OF ANTIBODIES
5.1 INTRODUCTION
In vitro metabolic studies are useful for several reasons. They can be used to assess the 
relative contributions of various tissues and organs in the metabolism of a particular 
pharmaceutical component. The data gathered in this way can be compared to what is 
known of its metabolism in the in vivo situation. In the case of coumarin (Pelkonen et al., 
1997), there exists large interspecies differences in its metabolism. Such in vitro models 
can establish which organs are responsible for these variations in metabolism. Such 
variations may have significance for the toxicity or therapeutic effects of coumarin, 7- 
hydroxycoumarin and their metabolites.
In vitro studies of the human metabolism of coumarin have also been performed using 
tissue biopsies (Deasey et al., 1995). This can yield important data as to the relative 
contribution of human organs in the metabolism of coumarin in man. Inter-individual 
differences in man may also have relevance for such factors as toxicity and therapy. 
Coumarin is also a useful model for the metabolism of a simple organic substrate.
The phase I metabolism of coumarin has been very well investigated (Pelkonen et al. 
1997). However, for the reasons described in section 1.14, its phase II metabolism has 
been unjustifiably ignored. Although less important in terms of toxicity as phase I 
metabolism, phase II metabolism may play a significant role in the effectiveness of 
coumarin therapy. The development of in vitro metabolic methodologies and allied 
analytical techniques for 7-hydroxycoumarin-glucuronide are essential for such studies. 
Also, the development of suitable derivatives for the purpose of antibody production lead 
to the possibility of developing immunoanalytical tools to complement the solid state 
methods used. The production of 7-hydroxycoumarin-glucuronide also has the potential 
to be used in further pharmacological studies.
In the case of Tegtmeier (1988) and Brunner and Tegtmeier (1994), the purpose of their 
metabolic studies was the detoxification of chemical agents in an in vitro metabolic
5.1.1 In vitro metabolic studies of 7-hydroxycoumarin
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system incorporating hollow fibre membrane technology. Glucuronidation is often 
correctly described as a major detoxification pathway for many xenobiotic substances. 
This has applications for environmantal clean up as well as the pharmacological 
applications described.
The metabolism of 7-hydroxycoumarin to its glucuronide has been described (section 
1.14.1). It was assumed that the techniques used by Tegtmeier (1988) for the in vitro 
metabolism of lignins would be applicable to 7-hydroxycoumarin also. Here, the enzyme 
UDP-glucuronyl transferase was isolated from porcine liver. This was incubated with the 
necessary substrates: the aglycone and UDP-glucuronic acid. Other reaction components 
were also required. The presence of magnesium ions were necessary as an enzyme 
cofactor, Saccharolactone is an inhibitor of P-glucuronidase activity. This stops the reverse 
reaction of the removal of glucuronic acid from the glycone derivative, in our case, 7- 
hydroxycoumarin-glucuronide.
As well as the production of the glucuronide by in vitro means, analytical methods have 
to be applied to the study. Two methodologies were used: HPLC and CE.
5.1.2 The use of HPLC for the analysis of coumarin metabolism
In HPLC, the separation of components in a matrix is dependent on their partition in a 
mobile and a stationary phase (Fallon et al., 1987). In the case of HPLC, the stationary 
phase is a narrow bore column solid phase, and the mobile phase is liquid. In the type of 
chromatography used here, called reverse phase chromatography, the solid phase is a 
hydrophobic material produced by the fusing of silica with long chain aliphatic 
hydrocarbon chains of 18 carbons in length (C l8). Separation of relatively hydrophobic 
components is then brought about by adjusting, amongst other conditions, the composition 
of the mobile phase. A very hydrophobic mobile phase will encourage hydrophobic 
components to travel with it, whereas a less hydrophobic phase would cause these to be 
retarded on the hydrophobic stationary phase. In general, more hydrophobic phase will 
migrate more slowly than less hydrophobic components. Egan and O’Kennedy (1994) 
deveoloped HPLC conditions for the analysis of coumarin and 7-hydroxycoumarin. This
235
employed an isocratic mobile phase of methanol:water and acetic acid, with UV detection 
at 320 nm
Detection of the analytical species is normally performed by a single wavelength 
ultraviolet detector. For coumarin analysis, this is typically 320 nm. However, photodiode 
array analysis can also be applied to the separation of such components for the more 
detailed analysis that this technique yields.
5.1.3 Reverse phase chromatography
Reverse phase chromatographic separation can be applied to large scale chromatography 
in semi- and fully preparative separations. The principal is the same as that described 
above, except that only low pressures are used to perform the separation, and large 
column volumes are used to achieve larger yields.
5.1.4 Capillary electrophoresis (CE)
CE is a relatively modem analytical technique. It is a development of other electrophoretic 
systems such as gel electrophoresis (Beckman, 1991). Analytical mixtures are separated 
by the application of a high electrical potential to a sample in an ionic buffer in a narrow 
bore capillary. The fused silica capillary is negatively charged and attracts positively 
charged ions from the buffer. Cations in the buffer migrate towards the cathode, carrying 
water with them. This results in a net flow of buffer towards the cathode. Most solutes 
will migrate towards the cathode, regardless of their charge due to this electroosmotic 
flow. Dectection is via a detector window close to the cathodic terminal of the capillary. 
UV absorption is again the detection method most commonly employed. CE results in 
near instantaneous, high speed separations. This alters the requirements for sample clean 
up in certain analytical procedures, often simplifying the methodology. Also, unlike 
HPLC, it is capable of analysis in aqueous environments, so extractions with organic 
solvents is not required. Bogan et al. (1996) developed a CE separation strategy for the 
analysis of urine samples for the presence of 7-hydroxycoumarin-glucuronide.
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5.1.5 Liquid/liquid extraction
Liquid extractions are commonly used for the isolation of organic hydrophobic 
components from aqueous mixtures. The imiscibility of organic solvents with water makes 
this possible. The extracted species partitions between the two phases, normally with 
much higher partition in the organic phase. The extraction of more water miscible solutes 
is more difficult, however, with such techniques and is normally far less efficient. Phases 
of various polarity can be constructed to attempt to partition the solute more efficiently 
into the organic phase. In this way, moderately hydrophobic components may be extracted 
into organic phases.
5.1.6 Conjugation strategies
The diazonium coupling methodology of haptens containing an aromatic amine have been 
described in section 4.1.2. The resulting conjugates are chemically robust. They do, 
however, require the chemical synthesis of the aromatic amine if one is not naturally 
available. This is performed under relatively severe chemical conditions. Such conditions 
may not be compatible with a compound such as 7-hydroxycoumarin-glucuronide. 
Alternatively, it might be conceived that an amine be introduced to 7-hydroxycoumarin 
prior to in vitro conjugation with glucuronic acid. In this way, production of an amino 
conjugate of 7-hydroxycoumarin-glucuronide might be possible.
Alternatively, coupling chemistries such as 1-ethyl-3-(3-dimethylamino- 
propyl)carbodiimide / N-hydroxysuccinimide (EDC/NHS) could be applied to 7- 
hydroxycoumarin-glucuronide (Hermanson, 1997). This requires the presence of a 
carboxyl group, one of which is present on the glucuronic acid moiety of 7- 
hydroxycoumarin-glucuronide. This strategy tends to result in less stable conjugates, but 
is simple to perform. The carbodiimide, EDC can react with carboxyl groups, forming a 
very short-lived o-acylisourea intermediate. This is then capable of the interaction with 
primary amines, forming an amide bond. The reaction can be improved by the 
introduction of NHS. This results in the formation of a much more stable NHS ester
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intermediate of the carboxyl-containing compound, which can then react with the primary 
amine (Fig. 5.1).
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Figure 5.1. EDC/NHS reaction chemistry with 7-hydroxy coumarin-glucuronide. The carboxyl group of the glucuronic acid moiety of 7- 
hydroxycoumarin-glucuronide reacts with EDC to form the ubstable and short-lived o-acylisourea reactive intermediate. This can react 
directly with primary amines on proteins, but these are normally at a relatively low concentration in solution. Addition of NHS results 
in the production of higher concentration of more stable reactive intermediates which can react with primary amines over several hours.
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5.2.1 Initial analysis of the in vitro production of 7-hydroxycoumarin glucuronide by 
HPLC
All the individual components of the reaction mixture were first analysed by HPLC under 
the conditions described (section 2.3.4.2). These components were shown not to have 
absorbances or retention times that would interfere with the analysis of 7- 
hydroxycoumarin-glucuronide (data not shown).
Figs 5.2 A to 5.2 D show chromatograms of all 4 reaction mixtures taken at 0 and 23 h. 
All chromatograms (except the samples lacking 7-hydroxycoumarin) show peaks at 
approximately 9 to 9.5 min, corresponding to 7-hydroxycoumarin, and a smaller peak at 
11 min, corresponding to coumarin which is a contaminant of 7-hydroxycoumarin. Smaller 
peaks between 1.52 min and 2.5 min correspond to the other reaction components.
In sample A which contained all the reaction components, a peak between 2.98 and 3.26 
min, corresponding to 7-hydroxycoumarin-glucuronide was apparent. This was not present 
in the other three reaction mixtures. The area of this peak increased over time (Fig. 5.2 
A). Reaction mixture A was also spiked with 7-hydroxycoumarin-glucuronide, which led 
to a further increase in the peak at 3.26 min in the sample after 23 h incubation (data not 
shown).
RESULTS
5.2 The in vitro production of 7-hydroxycoumarin-glucuronide
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Fig. 5.2 A and B. HPLC chromatograms of enzymatic reaction mixtures from the initial 
analysis of in vitro 7-hydroxycoumarin production at 0 and 23 h. A contained all 
reaction components and B lacked the substrate UDP-glucuronide acid. All 
chromatograms show peaks A,B, and C, components of the reaction mixture, Tris, 
saccharolactone and magnesium chloride, respectively, and peaks E and F, the 7- 
hydroxycoumarin and coumarin contaminant, respectively. Both chromatograms showed 
shifts in the retention times of the components over time. In the case o f A, the retention 
times increased marginally, and in B, decreased. Only in sample A was there seen the 
appearance of peak D, 7-hydroxy coumarin-glucuronide, which increased over time.
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Fig. 5.2 C and D. HPLC chromatograms of enzymatic reaction mixtures from the initial 
analysis of in vitro 7-hydroxy coumarin production at 0 and 23 h. C lacked the substrate 
7-hydroxycoumarin, and as a consequence, lacked peak E. Also, the coumarin 
contaminant (peak F) was not present. No production of 7-hydroxycoumarin- 
glucuronide was observed in either sample. In sample D, which lacked UDP-glucuronyl 
transferase enzyme, no shift in retention times was observed for the 7-hydroxycoumarin 
(peak E) and coumarin (peak F) peaks.
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The rate of formation of 7-hydroxycoumarin-glucuronide in sample A is shown in Fig. 
5.3. Production of 7-hydroxycoumarin-glucuronide had an initial rate of 7.93 x 10'2 
jiM/min, and a specific activity of 3.3 x 10'3 (iM/min/mg protein. Approximately 14.4 foM 
7-hydroxycoumarin-glucuronide had been formed after 23 h. This corresponded to a yield 
of 7-hydroxycoumarin-glucuronide of 0.29 nmoles or 0.097 i^g. The level of 7- 
hydroxycoumarin-glucuronide production was calculated from a standard curve of 7- 
hydroxycoumarin-glücuronide concentration as shown in Fig. 5.4.
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Figure 5.3. In vitro production of 7-hydroxycoumarin-glucuronide from the enzymatic 
conjugation of 7-hydroxycoumarin to glucuronic acid via porcine liver UDP glucuronyl 
transferase as analysed by HPLC. The initial rate of product formation was 
approximately 7.93 x Iff2 fiM/min (r*=0.99) (dashed line).
Figure 5.4. Standard curve of 7-hydroxy coumarin concentration prepared in enzymatic 
reaction mixture according to section vs. peak area as analysed by HPLC (n=2) 
(r*=0.99).
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5.2.2 Repeat analysis of the in vitro production of 7-hydroxy coumarin-glucuronide by 
HPLC
The in vitro production of 7-hydroxycoumarin-glucuronide was repeated using bovine 
UDP glucuronyl transferase, isolated according to section 2.3.4.1. The formulation of the 
reaction mixture was adjusted according to section 2.3.4.3, and HPLC analysis conditions 
were adjusted according to section.
Table 5.1 shows the mean peak absorbance ratio for the 7-hydroxycoumarin-glucuronide 
standards and their percentage relative standard deviation (n=4).
Table 5.1. Concentration of 7-hydroxycoumarin-glucuronide vs. the peak absorbance 
ratio for 7-hydroxycoumarin-glucuronide and 4-hydroxycoumarin.
7-hydroxy coumarin- 
glucuronide (jiM)
Peak absorbance ratio 7- 
hydroxycoumarin- 
glucuronide/4- 
hydroxycoumarin +/- 
standard deviation (n=4)
Standard Error (%)
0 0 0
1.47 0.006+/- 0.0002 1.3
2.96 0.01+/- 0.0002 3.0
5.92 0.02+/- 0.0015 8.3
14.79 0.02+/- 0.0015 3.2
29.58 0.09+/- 0.003 3.2
59.15 0.19+/- 0.0069 3.7
147.89 0.46+/- 0.0099 2.2
236.62 0.73+/- 0.0407 5.6
295.77 0.88+/- 0.059 6.7
The reaction mixture was monitored over 150 min. Fig. 5.5 shows chromatograms for the 
reaction mixture at 0, 20 and 70 min. It was clear that an increase in the 70HCG peak 
at 13.2 min (peak A) occurred over time. A decrease in the 7-hydroxycoumarin peak at
16.2 min (peak B) could also be observed over time.
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Table 5.2 shows the mean 7-hydroxycoumarin-glucuronide concentration over time. This 
is illustrated in Fig. 5.6. It can again be seen that the reaction follows a typical enzyme 
reaction kinetic, and that the initial rate of reaction was found to be 4.127 (iM/min and 
a specific activity of 1.03 ^M/min/mg of protein. A yield of 1.35 |xmoles (0.46 ^g) of 7- 
hydroxycoumarin-glucuronide resulted after 150 min incubation. This also compared 
favourably with results determined by capillary electrophoresis (see section 5.2.3).
Table 5.2. Concentration of 7-hydroxycoumarin-glucuronide vs. time for the repeat 
production of 7-hydroxycoumarin-glucuronide by bovine UDP glucuronyl transferase.
Time (min) 7-hydroxycoumarin- 
glucuronide (fiM) +/- 
standard deviation (n=4)
Standard Error (%)
0 0 0
10 47.1+/- 0.7 1.6
20 92.6+/- 5.5 5.9
30 122.4+/- 3.1 2.5
40 153.8+/- 3.1 2.0
50 177.8+/- 3.9 2.2
60 200.5+/- 5.5 2.7
70 233.1+/- 12.4 5.3
85 262.3+/- 4.7 1.7
90 280.4+/- 3.8 1.4
105 287.2+/- 3.0 1.1
120 302.6+/- 10.6 3.5
135 331.3+/- 0.6 2.0
150 336.7+/- 5.0 1.5
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Figure 5.5. HPLC chromatograms of the repeat production of 7-hydroxycoumarin- 
glucuronide. Shown are offset chromatograms at 0, 20 and 70 min. This shows an 
increase in the 7-hydroxycoumarin-glucuronide peak at 13.2 min (peak A) over time. 
A decrease in the 7-hydroxy coumarin peak at 16.2 min (peak B) could also be observed 
over time.
Time (min)
Figure 5.6. In vitro production of 7-hydroxycoumarin-glucuronide from the enzymatic 
conjugation of 7-hydroxy coumarin to glucuronic acid via bovine liver UDP glucuronyl 
transferase as analysed by HPLC. The initial rate of product formation was linear 
between 0 and 40 min and was estimated to be approximately 4.13 pM/min (r2=0.995).
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5.2.3 Analysis of the in vitro production of 7-hydroxy coumarin-glucuronide by capillary 
electrophoresis (CE)
Overlayed CE electropherograms of the metabolic solution for the production of 7- 
hydroxycoumarin-glucuronide are shown in Fig. 5.7. All electropherograms showed the 
presence of neutral compounds (A) at approximately 3.8 min, and magnesium chloride and 
7-hydroxycoumarin peaks (B) at approximately 4.6 min. At 12, 47, and 82 min is the 
presence of a peak at 8.6 min, which corresponded to 7-hydroxycoumarin-glucuronide. 
This increased over time. The production of 7-hydroxycoumarin-glucuronide over time is 
shown in Table 5.3 and Fig. 5.8.
Table 5.3. Concentration of 7-hydroxycoumarin-glucuronide vs. time for the 
production of 7-hydroxycoumarin-glucuronide by bovine UDP glucuronyl transferase.
Time (min) 7-hydroxycoumarin- 
glucuronide (|iM) +/- 
standard deviation (n=4)
Standard Error (%)
0 0 0
12 35.1 +/- 4.3 12.3
23 72.8 +/- 4.6 6.3
35 112.3 +/- 6.0 5.3
47 140.9 +/- 11.5 8.2
58 189.4 +/- 4.2 2.2
70 207.6 +/- 2.0 1.0
82 222.1 +/- 7.9 3.6
The initial rate of 7-hydroxycoumarin-glucuronide production in this instance was found 
to be 3.23 (iM/min, with a specific activity of 2.02 (iM/min/mg protein. A yield of 0.36 
(amoles (0.12 jag) of 7-hydroxycoumarin-glucuronide was produced from this reaction 
mixture after only 82 min incubation.
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Fig. 5.7. CE electropherograms from the in vitro elucuronidation of 7-hydroxycoumarin 
to 7-hydroxy coumarin-glucuronide by bovine UDP-glucuronyl transferase. 
Electropherograms at 12, 47 and 82 min have been offset to show the increase in 7- 
hydroxycoumarin-glucuronide peak (C) at 6.5 min. All electropherograms showed 
typical peaks of neutral reaction components (peak A) and a magnesium chloride peak 
(B).
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Figure 5.8. In vitro production of 7-hydroxycoumarin-glucuronide from the enzymatic 
conjugation of 7-hydroxycoumarin to glucuronic acid via bovine liver UDP glucuronyl 
transferase as analysed by CE. The initial rate of product formation was linear between 
0 and 35 min and was estimated to be approximately 3.23 fiM/min (r2=0.995).
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5.3 Purification of 7-hydroxycoumarin-glucuronide
5.3.1 Separation of 7-hydroxycoumarin and 7-hydroxycoumarin-glucuronide by reverse 
phase column chromatography
Initially, pure samples of both 7-hydroxycoumarin (100 (il of 10 mg/ml) and 7- 
hydroxycoumarin-glucuronide (100 (il of 1 mg/ml) were analysed using a methanol mobile 
phase with flow rates of approximately 0.3 ml/min with fractions collected every 2.5 min 
(Figs. 5.9 A and B). These showed the elution of 7-hydroxycoumarin at between 4 and 
8 ml and 7-hydroxycoumarin-glucuronide at about 3 to 6 ml, showing considerable peak 
overlap. A mobile phase of 700:300:2 water:methanol:acetic acid (v/v/v) resulted in 7- 
hydroxycoumarin eluting immediately from the column (fractions 1 to 5, and the 7- 
hydroxycoumarin at fractions 20 to 25 (Fig. 5.10). Using a simple combination of 
methanol and water and varying the ratio of the two, increasing quality of separation of 
both components could be achieved, with increasing separation occurring by increasing 
the ratio of water to methanol, so making the mobile phase more polar (Fig. 5.11 A, B 
and C.). Good separation was achieved when the ratio of water to methanol was in excess 
of 40:60 (v/v).
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Figure 5.9 A and B. Elution of 100 /il of 10 mg/ml 7-hydroxycoumarin (A) and 100 fil 1 mg/ml 7-hydroxycoumarin-glucuronide (B)from 
a Lichroprep RP-18 reverse phase silica column in methanol mobile phase at approx. 0.3 ml/min (flow rate shown in dashed line). 
Fractions were collected over 2.5 min intervals and analysed at 320 nm (hatched box and solid line). 7-hydroxy coumarin eluted primarily 
in 4 to 8 mis and 7-hydroxy coumarin-glucuronide between 3 and 6 ml.
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Figure 5.10. Elution of 100 fil 0.5 mg/ml 7-hydroxycoumarin/0.5 mg/ml 7- 
hydroxycoumarin-glucuronide from a lichroprep RP-18 reverse phase silica column 
using a 700:300:2 water:methanol:acetic acid (v/v/v) mobile phase. Fractions were 
collected over 2.5 min (fractions 1 to 5), 5 min (fractions 7 to 8) and 10 min (fractions 
9 to 45) intervals. Fractions were analysed spectrophotometrically at 320 nm (hatched 
box). 7- hydroxy coumarin-glucuronide eluted immediately from the column (peak A) in 
fractions 1 to 4 and 7-hydroxycoumarin eluted infractions 20 to 27 (peak B).
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Figure 5.11 A, B and C. Separation of 100 fil 7-hydroxycoumarin/7-hydroxycoumarin-glucuronide (0.5 mglml/0.5 mg/ml) on a Lichroprep 
RP-18 reverse phase silica column in a mobile phase of 80:20 (A), 60:40 (B) and 50:50 (C) methanol:water (v/v). Flow rate was 
approximately 0.2 mUmin and fractions were collected over 2.5 min intervals and analysed spectrophotometrically at 320 nm. Separation 
of peaks of 7-hydroxy coumarin-glucuronide (peak A) and 7-hydroxy coumarin (peak B) increased with the increase in the ratio of water 
to methanol, with good separation being achieved at 50:50 methanol:water (v/v).
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5.3.2 Purification of 7-hydroxycoumarin-glucuronide from crude enzymatic reaction 
mixtures by reverse phase column chromatography
Enzymatic reaction mixtures from the in vitro production of 7-hydroxycoumarin- 
glucuronide were applied to the reverse phase column according to the conditions 
described in section 2.3.5.2. Increasing volumes of reaction mixture were applied to the 
column from 100 to 400 pi (Figs. 5.12 A, B, C and D). All showed complete separation 
of the 7-hydroxycoumarin-glucuronide peaks from the 7-hydroxycoumarin peaks, up to 
a sample volume of 400 pi, although this did result in the peaks becoming less well 
resolved from one another.
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Figure 5.12 A and B. Purification of 7-hydroxycoumarin-glucuronide from 100 p i (A), 
200 pi (B) of enzymatic reaction mixture on a Lichroprep RP-18 reverse phase silica 
column in a 50:50 methanol: water (v/v) mobile phase, with a flow rate o f approximately 
0.2 ml/min and fractions collected over 5 min intervals and spectrophotometric analysis 
at 320 nm. Separation of 7-hydroxycoumarin-glucuronide (peak A) and 7- 
hydroxycoumarin (peak B) was complete at 100 and 200 p i of sample.
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Figure 5.12 C and D. Purification of 7-hydroxy coumarin-glucuronide from 300 fit (C), 
400 fil (D) of enzymatic reaction mixture on a Lichroprep RP-18 reverse phase silica 
column in a 50:50 methanol:water (v/v) mobile phase, with a flow rate of approximately 
0.2 ml/min and fractions collected over 5 min intervals and spectrophotometric analysis 
at 320 nm. Separation of 7-hydroxy coumarin-glucuronide (peak A) and 7- 
hydroxycoumarin (peak B) was still complete at 300 and 400 fil o f sample.
257
5.3.3 Purification of 7-hydroxycoumarin from, coumarin treated patient urine using 
reverse phase column chromatography
100 pi samples of control urine, control urine spiked with 100 ng/ml 7-hydroxycoumarin- 
glucuronide and coumarin-treated volunteer urine were applied to the reverse phase 
column as described in section 2.3.5.2. (Fig. 5.13 A, B and C). All three samples showed 
the presence of glucuronides, as indicated by the large absorbance at 254 nm. This was 
present in all samples in elution volumes between 6 and 12 mis. The spiked sample 
showed an elevation in the 320 nm signal over the control urine. This 320 nm absorbance 
was much greater in the sample of coumarin-treated urine and is indicative of the presence 
of 7-hydroxycoumarin-glucuronide. No other significant peaks were noted in the urine 
samples tested.
5.3.4 Extraction of 7-hydroxycoumarin-glucuronide from urine in dichloromethane 
(DCM): methanol
The absorbance of the extracted samples of treated urine at 320 nm are shown in Fig. 
5.14. This showed a clear increase in the 320 nm absorbance at a DCMrmethanol ratio 
of 70:30 (v/v), indicating the highest extraction efficiency for 7-hydroxycoumarin- 
glucuronide from urine.
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Figure 5.13 A, B and C. Purification of 7-hydroxycoumarin-glucuronide by reverse phase column chromatography from control (A), 
spiked (B) and treated (C) urine. Flow rate: (dotted line). A shows the presence of quantities of glucuronides in the urine, as observed 
by the absorbance at 254 nm (hatched bars). When spiked with 7-hydroxy coumarin-glucuronide (B), an increase in the 320 nm 
absorbance was observed at the same place in which the glucuronides were eluting (solid line). C clearly shows a further elevation in 
the ratio of 320/254 nm absorbance from the treated urine sample, indicating the presence of 7-hydroxycoumarin-glucuronide in 
association with other glucuronides in the urine.
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Figure 5.14. Extraction of 7-hydroxycoumarin-glucuronide into different proportions 
of DCM:methanol. Samples were analysed by HPLC. This shows that the greatest 320 
nm absorbance was found in samples extracted with an approximate ratio of 
DCM'.methanol of 70:30 (v/v).
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5.3.5 Purification of 7-hydroxycoumarin-glucuronide from coumarin treated patient 
urine and enzymatic reaction mixtures by reverse phase chromatography following 
extraction in dichloromethane (DCM):methanol (70:30 v/v)
The chromatograms of the extracted enzymatic reaction mixtures are shown in Figs. 5.15 
A and B. In both chromatograms, where 100 pi (5.15 A) and 400 pi (5.15 B) of extracted 
enzymatic sample were used, it would appear that significant concentration of 7- 
hydroxycoumarin taken place. However, the ratio of 7-hydroxycoumarin-glucuronide to 
7-hydroxycoumarin had clearly decreased, indicating inefficient extraction of the 
conjugated 7-hydroxycoumarin. This methodology showed a decreased efficiency over the 
direct application of enzymatic reaction mixture to the column.
Chromatography of the extracted treated urine sample also showed a decrease in 
efficiency as compared with unextracted samples applied directly to the reverse phase 
column, indicating significant losses of 7-hydroxycoumarin-glucuronide during the 
extraction procedure (Fig. 5.16).
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Figure 5.15 A and B. Purification of 7-hydroxycoumarin-glucuronide from crude 
enzymatic mixtures by reverse phase column chromatography following extraction in 
DCM'.methanol. Application of both 100 fil of sample (A) and 400 fil (B) showed the 
separation of 7-hydroxy coumarin-glucuronide (peak 1) from 7-hydroxy coumarin (peak 
2). However, both samples showed significant enrichment of the 7-hydroxy coumarin 
over its glucuronide, with no real increase in the concentration of 7-hydroxycoumarin- 
glucuronide as compared with previous, unextracted samples.
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Figure 5.16. Chromatographic separation of extracted treated urine sample. This shows 
that 7-hydroxycoumarin-glucuronide predominated in the sample, but some 7- 
hydroxycoumarin had also become extracted and concentrated in the sample (peaking 
infraction 13). The overall yield was also relatively low with maximum absorbances at 
320 nm less than 0.3.
263
5.4.1 Thermal stability of 7-hydroxycoumarin-glucuronide at 60°C
The peak area for samples of 7-hydroxycoumarin-glucuronide over time when incubated 
at 60°C is shown in Fig. 5.17. No apparent decrease in peak area was noted after 80 min 
incubation indicating good thermal stability of the compound at 60°C.
5.4 Characterisation of 7-hydroxycoumarin-glucuronide
Time (min)
Figure 5.17. Analysis of 7-hydroxycoumarin-glucuronide by HPLC during incubation 
at 6(fC over time. No reduction in 7-hydroxycoumarin-glucuronide peak size were 
observed over the 160 min incubation period.
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5.4.2 Stability of 7-hydroxycoumarin-glucuronide with respect to pH
The peak height for samples of 7-hydroxycoumarin-glucuronide in aqueous solvent at 
different pH is shown in Fig. 5.18. Samples showed good stability at pH 7 and below, but 
began to decrease above pH 7 indicating instability in basic environments. However, 
degradation of the sample only became significant above pH 10.
pH
Figure 5.18. Analysis of 7-hydroxycoumarin-glucuronide by HPLC following 
preparation in different pH  buffers. From pH  2 to 7, no reduction in peak is observed. 
However, above pH 7, significant decreases in the peak size of 7-hydroxycoumarin- 
glucuronide were observed. This became substantial at pH in excess of 10.
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Production of a 3-amino derivative of 7-hydroxycoumarin-glucuronide was investigated 
for its potential use in the conjugation of 7-hydroxycoumarin-glucuronide to proteins. This 
first required the production of 3-amino-7-hydroxycoumarin from the precursor 3- 
acetylamino-7-acetocoumarin, followed by the enzymatic glucuronidation of the 3-amino- 
7-hydroxycoumarin.
5.5.1 Production of 3-amino-7-hydroxycoumarin
The infrared spectrophotometric scan of 3-amino-7-hydroxycoumarin is shown in Fig. 
5.19. This compares exactly with equivalent IR scans by Bogan (1996), indicating the 
production of 3-amino-7-hydroxycoumarin from the 3-acetylamino-7-acetocoumarin 
derivative. HPLC analysis shows the synthesised compound to be mostly 3-amino-7- 
hydroxycoumarin, with a small amount of unreacted 3-acetylamino-7-acetocoumarin (Fig. 
5.20).
5.5.2 In vitro enzymatic production of 3-amino-7-hydroxycoumarin-glucuronide
Components in the production of 3-amino-7-hydroxycoumarin-glucuronide were analysed 
by HPLC according to section 2.3.4.2 using dual channel spectrophotometric monitoring 
at 320 and 254 nm as well as photodiode array analysis between 200 and 400 nm.
Fig. 5.21 shows the chromatogram and the photodiode array scan for 7-hydroxycoumarin- 
glucuronide. Worthy of note is the retention time of 3.33 min and the absorbance maxima 
at 320 nm, with a peak rising to 200 nm. When analysed by HPLC and PDA analysis, 3- 
acetylamino-7-acetocoumarin (Rt= 5.45 min) and 3-amino-7-hydroxycoumarin (Rt=4.32 
min) both contained the coumarin absorbance maxima at 320 nm (Fig. 5.22). However, 
3-acetylamino-7-acetocoumarin possessed a UV absorbance peak rising to 200 nm, 
whereas 3-amino-7-hydroxycoumarin showed a dip at 200 nm. When the enzymatic 
reaction mixture was analysed by HPLC, 5 distinct components could be identified. Two 
of these at 4.3 and 5.42 min could be clearly identified as the original components of the
5.5 In vitro enzymatic production of 3-amino-7-hydroxycoumarin-giucuronide
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mixture, 3-amino-hydroxycoumarin and 3-acetylamino-7-acetocoumarin (Fig. 5.23). Three 
new components, all with greater polarity than the parent compounds were also present. 
Two of them closely resembled one of the parental compounds with respect to their 
photodiode array scan, with the peak at 2.7 min resembling 3-amino-7-hydroxycoumarin 
and the peak at 2.9 min resembling 3-acetylamino-7-acetocoumarin. A third peak at 3.6 
min also possessed the characteristic absorbance peak at 320 nm typical of coumarins. Its 
UV absorbance ridge, however, did not resemble the other components in the mixture. No 
further identification of these components was performed.
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Figure 5.19. Infrared spectra of 3-amino-7-hydroxy coumarin. This shows a spectra 
typical of that expected for 3-amino-7-hydroxy coumarin, according to Bogan (1994).
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Figure 5.20. HPLC and photodiode array analysis of 3-amino-7-hydroxycoumarin. 
Absorbance at 254 nm (solid line). Absorbance at 320 nm (dotted line). Two peaks were 
present in the sample. The reaction product 3-amino-7-hydroxycoumarin at 4.32 min 
predominated in the sample with the presence of a smaller quantity of unreacted 3- 
acetylamino-7-acetocoumarin (5.45 min) also present. These showed typical PDA scans, 
both with absorbances at the 320 nm region, with one showing a rise in absorbance to 
200 nm, the other showing a decrease in the same region.
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Figure 521. HPIC and photodiode array analysis of 7-hydroxycoumarin-glucuronide. 
Absorbance at 254 nm (solid line). Absorbance at 320 nm (dotted line). A single peak 
of 7-hydroxycoumarin-glucuronide was obtained at 3.33 min. This had the typical PDA 
scan as shown, with a peak at 320 nm, a ridge at 280 nm, and a rise up to 200 nm.
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IFigure 522. HPLC and photodiode array analysis of the in vitro metabolic production 
of 3-amino-7-hydroxycoumarin-glucuronide. Absorbance 254 nm (solid line). 
Absorbance at 320 nm (dashed line). Five components were present in the reaction 
mixture. Two at 4.20 and 5.42 min were the original reaction components, 3-amino-7- 
hydroxycoumarin and 3-acetylamino-7-acetocoumarin, respectively. Three new 
components, all showing decreased hydrophobicity were produced at 2.69,2.99 and 3.59 
min. The PDA scan of peak 2.69 min resembled 3-amino-7-hydroxycoumarin, whilst 
peak at 2.9 min resembled that of 3-acetyl-7-acetocoumarin. The peak at 3.59 min did 
not particularly resemble either of the starting components.
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5.6 Production and analysis of a 7-hydroxycoumarin-glucuronide-bovine serum 
albumin conjugate prepared by EDC/NHS coupling chemistry
The 7-hydroxycoumarin-glucuronide-bovine serum albumin conjugate was analysed by 
SDS-PAGE (Fig. 5.23). This indicated the presence of a protein component of 
approximately 66 kDa, corresponding to bovine serum albumin. When analysed by size 
exclusion chromatography and photodiode array analysis (Fig. 5.24), this showed a 
predominant protein peak at 21.9 min. Concomitant with the protein absorbance maxima 
at approximately 280 nm was a second absorbance maxima at 320 nm indicating the 
presence of a coumarin moiety attached to the protein component. When compared to the 
spectrophotometric scan of bovine serum albumin alone, no such absorbance maximum 
could be seen at 320 nm.
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Figure 5.23. Analysis of bovine serum albumin and 7-hydroxycoumarin-bovine serum 
albumin conjugate by SDS-PAGE. Lanes: 1: bovine serum albumin; 2: 7- 
hydroxycoumarin-bovine serum albumin. The gel shows that both samples contained 
protein with a molecular weight of approximately 66 kDa, corresponding to the 
molecular weight of bovine serum albumin.
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Figure 5.25. Photodiode array scans of 7-hydroxycoumarin-glucuronide-bovine serum 
albumin conjugate (solid line) and bovine serum albumin control (dot-dash line). Both 
samples exhibited the typical 260 nm absorbance peak indicating the presence of a 
protein (peak A). However, the 7-hydroxycoumarin-glucuronide-bovine serum albumin 
conjugate exhibited a second peak at 320 nm (peak B), indicating the presence of a 
coumarin-type molecule attached to the protein. This was not present in the bovine 
serum albumin control sample.
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DISCUSSION
The purpose of studying the production, analysis, purification and conjugation of 7- 
hydroxycoumarin-glucuronide were outlined in section 1.14.
The study of the in vitro metabolism of 7-hydroxycoumarin-glucuronide served several 
purposes. The need for information on the pharmacokinetics of 7-hydroxycoumarin are 
important in its use as a therapy in several conditions such as high protein lymphoedema, 
brucellosis and experimental cancer therapies. Variations in phase II metabolism of the 
drug may relate to differences in the efficiency of the treatment regime. Inadequacies in 
phase II metabolism may also relate to sporadic cases of hepatotoxicity during such 
therapies. Studying individual differences in their ability to metabolise 7-hydroxycoumarin 
in liver samples such as liver biopsies may further confirm in vivo analyses, pointing to 
deficiencies in phase II metabolism in the liver. Such procedures have been used in the 
phase I metabolism of coumarin (Deasy, et al., 1995). Interspecies studies have also 
served to elucidate the metabolic pathways of different organisms, leading to a fuller 
understanding of the development of these pathways. Studies of in vitro metabolism in 
different organs has also yielded information about the sites that are important in the 
drug’s metabolism, and consequently its distribution in the organism. In vitro metabolism 
is also a source of the glycone for purification and use in other methodologies, such as 
in standards, and its application in the development of a conjugate for the production of 
antibodies to the glucuronide. Such antibodies would themselves be applied in various 
studies of phase II metabolism.
5.8 In  vitro production of 7-hydroxycoumarin-glucuronide and analysis by HPLC
For the in vitro production and analysis of 7-hydroxycoumarin-glucuronide, an effective 
enzymatic reaction had to be developed as well as a method or methods of analysis of the 
reaction product formed. Tegtmeier et al. (1988) and Brunner and Tegtmeier (1984) had 
developed methods of in vitro glucuronidation using hollow fibre membrane systems for 
the biochemical detoxification of lypophilic compounds in which suitable reaction 
conditions for porcine UDP-glucuronyltransferases had been elucidated. Egan and
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O’Kennedy (1994) had also developed HPLC conditions capable of the direct detection 
and resolution of 7-hydroxycouraarin and coumarin. These two methodologies were used 
as starting points for the analysis of the in vitro metabolism of 7-hydroxycoumarin by 
porcine UDP-glucuronyltransferase enzymes isolated from liver. HPLC analysis showed 
that the 7-hydroxycoumarin substrate and 7-hydroxycoumarin-glucuronide could be 
separated using this methodology. It also illustrated very clearly that all the reaction 
components (substrates and enzyme) were necessary to detect formation of the 
glucuronide product. Analysis of initial rates of product production (v0) showed the rate 
to be very slow at 3.3 x 10'3 pM/min/mg under the initial reaction conditions used.
In subsequent experimentation, changes were made to both the enzymatic reaction mixture 
and the analytical methodology employed. With respect to the reaction mixture, UDP- 
glucuronyltransferase enzyme was isolated from bovine liver. The other notable alteration 
was the reduction of the 7-hydroxycoumarin substrate concentration. The analytical 
methodology also underwent some notable changes. The separation methodology used a 
gradient system. This was done primarily to increase the retention time of the glucuronide 
species, bringing it further from the void volume, while still giving good resolution of all 
components. Calculation of 7-hydroxycoumarin-glucuronide concentration was determined 
by ratio analysis against an internal standard, 4-hydroxycoumarin, which was also 
effectively resolved by the methodology applied. As a result v0 of the bovine enzyme was 
found to be 4.13 pM/min (1.03 pM/min/mg protein). This was an increase in over 300- 
fold specific reaction rate over the initial reaction. It is not clear whether this is due 
primarily to the change in the source of liver enzyme, or due to substrate inhibition in the 
original reaction mixture due to the very high concentration of 7-hydroxycoumarin 
employed.
With respect to the HPLC methodologies used, no direct comparison can be made 
between the two methodologies with regard to precision, since the initial experiment was 
not performed with replicates. However, internal standardisation has been shown to be 
superior in terms of precision over direct measurements (Christian, 1986), so it might be 
assumed that this was also the case here. The standard errors of the standards used for 
analysis were all below 8% and typically below 5%, indicating acceptable precision. The
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analytical methodology was, however, slower than the original chromatographic 
separation, requiring 25 min, as opposed to approximately 16 min for the original isocratic 
separation. However, due to sample stability and automation of sampling, this was not an 
inconvenience.
In terms of the overall yields of these methodologies for the production of 7- 
hydroxycoumrin-glucuronide, the initial methodology produced just less than 0.1 pg of 
conjugate in the 23 h reaction period, compared to nearly 0.5 |ig for the second reaction 
within 2.5 h. Thus, the enzymatic methodologies employed were shown to be capable of 
yielding microgram quantities of 7-hydroxycoumarin-glucuronide.
5.9 In vitro production of 7-hydroxycoumarin-glucuronide and analysis by CE
The technique of capillary electrophoresis was applied to the analysis of the enzymatic 
reaction mixture. As has been discussed, CE offers rapid separations of reaction 
components based on their electrophoretic mobility in certain ionic solvents in high 
electrical potentials. A method had been developed by Bogan et al. (1996) for the analysis 
of 7-hydroxycoumarin-glucuronide in urine samples. This methodology was applied to the 
analysis of 7-hydroxycoumarin-glucuronide in crude enzymatic reaction mixtures. 
Crucially, treatment of the reaction mixtures for CE analysis with trichloroacetic acid was 
not appropriate and was not required. Changes in pH brought about by such treatments 
would significantly alter the separation characteristics of the assay. However, 
electrophoresis brings about instantaneous separation of the reaction components, at which 
point, the reaction ceases. To perform this analysis then, samples must be taken and 
analysed immediately. This is not a difficulty, since separation takes just 7.5 min, a 
periodicity quite convenient for regular sampling of the enzymatic reaction mixture. Use 
of this methodology for the analysis of enzymatic reaction mixtures demonstrated the 
resolution of 7-hydroxycoumarin-glucuronide from other reaction components.
The initial rate of reaction in the CE study was comparable to the HPLC study using 
bovine liver UDP-glucuronyltransferase, with a v0 of 3.23 fxM/min, but with a specific 
activity of 2.02 (jM/min/mg protein, yielding only 0.12 |ig of 7-hydroxycoumarin-
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glucuronide in the 82 min incubation, with the rate of reaction dropping more rapidly than 
in the study which used HPLC. The reasons for these discrepancies could be several fold. 
Mostly, they might relate to the quality of the liver material used, its treatment and 
preparation and the yield of UDP-glucuronyltransferase enzyme protein in the sample. 
This does illustrate a very important consideration when extrapolating data from such 
experiments to the actual in vivo enzyme reaction rates of intact whole organs. It is 
probable that specific activities of in vitro prepared enzyme mixtures are lower than that 
in whole, in tact tissues. However, no significant studies comparing in vivo and in vitro 
metabolic rates have been performed to illustrate this.
The establishment of an in vitro metabolic reaction mixture for the conversion of 7- 
hydroxycoumarin to its glucuronide, accompanied by two reliable analytical methodologies 
by which to analyse the reaction products yielded a system that could be used to probe 
the phase II metabolic characteristics of different organs and species with respect to 7- 
hydroxycoumarin. These methodologies have been successfully exploited by Bogan et al. 
(1997) and Duffy et al. (1997) for the analysis of phase II metabolism of 7- 
hydroxycoumarin in rabbit tissues. It also resulted in a third source of 7-hydroxycoumarin- 
glucuronide, in addition to chemical synthesis and in vivo isolation from treated urine.
5.10 Purification of 7-hydroxycoumarin- glucuronide
Two metabolic sources of 7-hydroxycoumarin-glucuronide were available. Firstly, the 
enzymatic synthesis methodologies outlined in section 5.2, and secondly, 7- 
hydroxycoumarin-glucuronide from treated volunteer urine samples.
In the case of the enzymatic reaction mixtures, 7-hydroxycoumarin-glucuronide was in the 
presence of quantities of 7-hydroxycoumarin, coumarin and protein material. If 7- 
hydroxycoumarin-glucuronide from such a source was to have any application as a 
standard, or for the production of conjugates, it must first be separated from these other 
components.
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Since 7-hydroxycoumarin-glucuronide was successfully separated from 7-hydroxycoumarin 
and coumarin using reverse phase chromatography by HPLC, it was assumed that such 
a reverse phase system might be applicable to the column chromatographic preparative- 
scale separation of these components also.
A reverse phase column with C-18 packing was prepared (section 2.3.5.1). Initially, pure 
samples of both 7-hydroxycoumarin and 7-hydroxycoumarin-glucuronide were applied to 
the column in a methanol mobile phase. These experiments helped to establish the 
separation methodologies applied later, such as pump speeds, flow rates, collection 
intervals etc. Initially, both samples were shown to elute within the first 10 ml of mobile 
phase, so rapid purification times could be established. However, in the mobile phase 
used, inadequate differences in retentions of the two components were found.
The conditions of the mobile phase in the initial isocratic HPLC separation were applied 
to the preparative column. In this case, 7-hydroxycoumarin-glucuronide and 7- 
hydroxycouamarin were seen to separate very well. However, 7-hydroxycoumarin- 
glucuronide eluted in the void volume and could not be successfully fractionated from the 
column. Under these conditions, the mobile phase was too polar to bring about adequate 
retardation of the water soluble glucuronide on the column. The coumarin contaminant of 
7-hydroxycoumarin was not important in these separations because either its concentration 
was too small to be noted in chromatograms, or it coeluted with 7-hydroxycoumarin under 
the conditions applied.
A more simple mobile phase of methanol:water was applied to the separation. It was 
found that with higher methanol concentrations, 7-hydroxycoumarin-glucuronide was 
significantly retarded on the column. Decreases in methanol concentration further retarded 
7-hydroxycoumarin on the column. At 50:50 methanol:water (v/v), good separation and 
retention of both components could be established. Good separation also occurred at 60:40 
methanol:water (v/v).
Having established separations for pure mixtures of 7-hydroxycoumarin and 7- 
hydroxycoumarin-glucuronide, the methodology was applied to the separation of crude
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reaction mixtures. A range of volumes of the reaction mixture were applied to the column 
up to 400 pi, which brought about concomitant increases in the peaks of both 7- 
hydroxycoumarin and 7-hydroxycoumarin-glucuronide. The two compounds were still 
resolvable with 400 pi sample volumes.
The second readily available source of 7-hydroxycoumarin-glucuronide was the 
administration of coumarin to a healthy human volunteer and harvesting of the urine 
samples subsequent to this. Studies of the pharmacokinetics of coumarin metabolism in 
humans has shown its rapid excretion as 7-hydroxycoumarin-glucuronide in the urine, 
which takes place within 24 h, with maximum excretion approximately 2 h post­
administration (Pelkonen et al., 1997). Thus, urine from control and treated healthy 
volunteers was taken, the latter 2 h after administration of 1 g p.o. coumarin in 10 x 100 
mg tablets. These were separated by the same analytical technique as the enzymatic 
mixtures. In this case, no 7-hydroxycoumarin peak was noted. In the control urine, a 
significant 254 nm absorbance peak was noted in the same position as would be found 
7-hydroxycoumarin-glucuronide, indicating the presence of glucuronides, but with a low 
320 nm absorbance, suggesting non-coumarin-derived glucuronides. When the control 
urine was spiked with 7-hydroxycoumarin-glucuronide, the 320 nm signal showed an 
increase at the same position as the 254 nm glucuronide peak. This suggested that natural 
glucuronides present in the urine were coeluting with 7-hydroxycoumarin-glucuronide. 
When treated urine was separated, a larger 254/320 nm peak also eluted at the same 
position as in the control urine sample. The higher 320/254 nm ratio also indicated that 
this was, indeed, the position at which 7-hydroxycoumarin-glucuronide was eluting.
As has been stated, many natural metabolic waste products are excreted as glucuronides, 
notably bilirubin and testosterone, and other hormones (Reid and Leppard, 1983). It is 
clear from this that the separation technique employed was not applicable for the direct 
separation of 7-hydroxycoumarin-glucuronide from treated urine samples because it does 
not separate glycone derivatives of different compounds.
Although simple to analyse directly, water-miscible glucuronide compounds are difficult 
to purify using liquid/liquid separation methodologies as they are not easily extracted with
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organic solvents. The presence of the 7-hydroxycoumarin moiety would, however, endow 
them with some lipophilicity. An attempt was made to exploit this by the development 
of an extraction procedure for 7-hydroxycoumarin-glucuronide. This was based on an 
organic phase composed of dichloromethane (DCM) and methanol. These were chosen 
because the polar methanol would dissolve in the water-immiscible DCM, but could still 
dissolve quantities of 7-hydroxycoumarin-glucuronide. Various ratios of DCM:methanol 
were tested against pure samples of 7-hydroxycoumarin-glucuronide using equal volumes 
of the organic and inorganic mixtures. The presence of the glucuronide was analysed by 
the 320 nm absorbance of the dried, rehydrated samples. Maximum 320 nm readings were 
at a DCM:methanol ratio of 70:30 (v/v).
The extraction procedure was applied to the enzymatic reaction mixtures and urine 
samples containing 7-hydroxycoumarin glucuronide. As compared with unextracted 
enzyme mixtures, the yield of 7-hydroxycoumarin-glucuronide decreased significantly, 
whereas the level of 7-hydroxycoumarin in these samples was significantly increased. In 
urine, the yield of glucuronide in the sample had also decreased substantially, although 
the glucuronide that was present did show a high 320 nm absorbance. This may indicate 
that the extraction methodology was more efficient at extracting 7-hydroxycoumarin- 
glucuronide than other glucuronides present in the urine.
Overall, employment of an extraction methodology resulted in inefficient extraction of the 
7-hydroxycoumarin-glucuronide, both from enzyme reaction mixtures and from samples. 
The availability of large volumes of urine, however, may allow for an improvement in the 
extraction methodology. Using large volumes of urine and small volumes of organic 
mixture may increase the partitioning of significant quantities of 7-hydroxycoumarin- 
glucuronide into the organic phase. This may also remove significant quantities of other 
glucuronides from the sample that do not possess lipophilic functional groups.
When extracted, separated samples from treated urine were analysed by HPLC, 7- 
hydroxycoumarin-glucuronide was shown to be present in significant amounts with only 
minimal contaminants present and was considered acceptable for use in further 
experimental procedures.
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5.11 Physical analysis of 7-hydroxycoumarin-glucuronide
Some physical characteristics of the 7-hydroxycoumarin-glucuronide were analysed by 
HPLC. The molecule exhibited good thermal stability at 60°C. Of note was the sensitivity 
of the glucuronide to alkaline pH. Even mildly alkaline conditions brought about 
degradation of the conjugate, but this was significant above pH 10. This finding is 
substantially in accordance with other glucuronides which undergo rapid alkaline 
hydrolysis of the (3-D ether linkage (Wilson et al., 1983). Indeed, this lability is of 
importance when analysing such metabolites in urine. The composition and pH of the 
urine can vary substantially depending on dietary habits and the administration of other 
drugs such as antacids which make urine basic and may lead to deconjugation. Also, urine 
loses carbon dioxide upon standing and becomes alkaline. This results in the precipitation 
of salts such as inorganic phosphates and may also bring about deconjugation of 7- 
hydroxycoumarin-glucuronide and precipitation of insoluble 7-hydroxycoumarin leading 
to inaccurate results. This is important when data derived from such metabolic studies is 
related to the phase II inter-individual variability in humans and possible associated 
hepatotoxic effects (Bogan, 1996). Such analyses may benefit by being acidified upon 
collection.
5.12 Conjugate production
For the production of antibodies to small haptens - as has already been illustrated several 
times throughout this thesis - it is necessary to conjugate them to large immunogens such 
as proteins. As has also been demonstrated, coumarin and 7-hydroxycoumarin lack any 
functional groups that can be readily applied to a conjugation reaction. Production of 
amino derivatives of coumarin and 7-hydroxycoumarin have been used to produce 
conjugates for the purpose of antibody production (Egan, 1993; Bogan, 1996).
Of concern is the orientation of the hapten as displayed to the antigen-binding site. It 
might be thought that orientation of coumarin and 7-hydroxycoumarin in directions that 
leave the pyrone ring proximal to the antigen-binding site may bring about associated 
cross-reactivities with the resulting antibodies. For this reason, conjugation of coumarin
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was at the 6 position and 7-hydroxycoumarin at the 3 position, resulting in opposing 
orientations (Egan, 1993; Bogan, 1996). This did yield antibodies that showed no cross­
reactivity to either species.
The same concerns were initially applied to the conjugation of 7-hydroxycoumarin- 
glucuronide to proteins such as bovine serum albumin. The only functional group 
available for attachment with this molecule is the carboxyl group present on the 
glucuronic acid moiety. This coupling methodology of drug glucuronides has been 
successfully used (Abbott Laboratories, 1984). However, conjugation at the glucuronic 
acid moiety may orient the hapten with the 7-hydroxycoumarin pyrone ring proximal to 
the antigen-binding site, again leading to concerns of cross-reactivity. To circumvent this, 
glucuronide conjugates of 7-hydroxycoumarin with functional groups would be desirable 
such as 3-amino-7-hydroxycoumarin-glucuronide. In this way, the hapten could be 
oriented with its glucuronic acid component greatly exposed to the antibody, theoretically 
minimising cross reactivity.
Conjugate synthesis required the production of 3-amino-7-hydroxycoumarin from 3- 
acetylamino-7-acetocoumarin, previously synthesised by Bogan (1996). Infrared analysis 
of the product was in accordance with Bogan (1996). HPLC analysis, however, showed 
that the reaction was not complete and contaminants of 3-acetylamino-7-acetocoumarin 
remained. This two component mixture was applied to in vitro glucuronidation. 
Identification of the components by HPLC, coupled with photodiode array detection 
yielded 5 components in the reaction mixture. Two of these were the original components 
of the sample. Three new derivatives of significance were found in the mixture. These all 
had lower retention times, so greater polarity than the parent molecules. Two of these 
possessed photodiode array spectra similar to the two parental species and a third, which 
also appeared to be a coumarin derivative due to its absorbance at 320 nm, but otherwise, 
not significantly recognising the parental components.
It was presumed that glucuronidation of the parental components did take place in this 
mixture and that this resulted in the hydrophillic components produced. However, because 
no definitive identification of the components could be made without significant further
283
production, purification and anlysis by a methodology such as nuclear magnetic resonance, 
no further characterisation of these species was attempted. However, the potential clearly 
exists for the in vitro metabolic production of a glycone derivative of 3-amino-7- 
hydroxycoumarin.
Since pursuance of the production of a 3-amino- derivative of 7-hydroxycoumarin- 
glucuronide was found to be prohibitively complex, production of a conjugate of 7- 
hydroxycoumarin-glucuronide, coupled via the glucuronic acid moiety was pursued, with 
due regard given to the potential of such a methodology to result in antibodies that would 
be cross-reactive with either 7-hydroxycoumarin or coumarin.
The well established chemistry of l-ethyl-3(3-dimethylaminopropyl)carbodiimide 
(EDC)/N-hydroxysuccinimide (NHS) was shown to be applicable to the linkage of 
glucuronide conjugates to proteins (Abbott Laboratories, 1984). The method adopted for 
7-hydroxycoumarin-glucuronide conjugation initially used a high pH of 9.6. Although 
awareness was given to the instability of 7-hydroxycoumarin-glucuronide at elevated pH, 
this was most pronounced above pH 10, and a high pH would ensure full dissociation of 
the carboxyl group of the glucuronic acid for full reactivity. When analysed by photodiode 
array and compared to controls, the approximately 66 kDa species was shown to possess 
a 320 nm absorbance peak, indicating attachment of a coumarin moiety to the protein. 
Since linkage could only be via the glucuronic acid, this suggested attachment of an in 
tact 7-hydroxycoumarin-glucuronide molecule to bovine serum albumin. This conjugate 
could be used in the production of antibodies to 7-hydroxycoumarin-glucuronide.
CONCLUSIONS
A method for the in vitro glucuronidation of 7-hydroxycoumarin using liver-isolated UDP- 
glucuronyltransferase was established. This also led to the development of two analytical 
techniques for the measurement of the enzymatic process based on HPLC and CE. 
Chromatographic techniques were also developed for the purification of 7- 
hydroxycoumarin from enzymatic reaction mixtures and urine.
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Attempts were made to produce in vitro glucuronidated conjugates of 3-amino-7- 
hydroxycoumarin, but the complex mixtures produced meant that this was not a viable 
option. Instead, conjugation was performed via the carboxyl group of the glucuronide 
using EDC/NHS coupling chemistry. This resulted in stable 7-hydroxycoumarin- 
glucuronide-BSA conjugates with the potential to be used in the production of antibodies, 
either as polyclonal sera, or the selection and screening of clones from antibody phage 
display libraries.
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6. OVERALL CONCLUSIONS
The purpose of this research was the development of genetic techniques for the production 
of antibodies to the experimental chemotherapeutic agent, coumarin, and its major human 
phase I metabolite, 7-hydroxycoumarin. Also, this research studied the phase II 
metabolism of 7-hydroxycoumarin to 7-hydroxycoumarin-glucuronide.
The first system for the production of antibody fragments to coumarin and 7- 
hydroxycoumarin to be evaluated was the pComb3 system for the production of Fab 
antibody fragments. The system required the production of light and heavy chain gene 
libraries from the splenocytes of immunised mice. These heavy and light chain gene 
libraries were successfully created in the cloning vector pGEM-T. However, all attempts 
to transfer these libraries to the phagemid vector pComb3 failed. Initially, it was thought 
that problems lay with restriction-digestion of the light and heavy chain genes. However, 
this was eventually shown not to be the case as these could be transferred to and from the 
pGEM-T vector. From my own results and the experiences of others (Burioni et al., 
1997), it became clear that difficulties in cloning were due to the characteristics of the 
vector, pComb3. Modified versions of this plasmid have been created, but time did not 
allow for their use in this instance.
As an alternative to the pComb3 vector system, work was developed using an alternative, 
naive human library, commonly referred to as the Nissim library (Nissim et al., 1994). 
Here, a complete human antibody repertoire in the form of single chain scFv antibodies 
was present, along with increased diversity brought about by the presence of a random 
CDR sequence on the antibody heavy chain.
The library was evaluated at various stages for its ability to produce antibodies to 
coumarin and 7-hydroxycoumarin. It became evident that the conditions used for both 
affinity selection and screening would have a crucial impact on the quantity and type of 
antibody clones that would be selected from the library. This was particularly so for the 
small hydrophobic haptens that were being investigated, i.e., coumarin and 7- 
hydroxycoumarin. It became clear that the design of the hapten-protein conjugates 
required for selection and screening was of great significance. At low hapten coupling 
ratios, antibodies to the hapten were not sufficiently enriched over clones recognising the
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carrier protein. At higher hapten coupling ratios, however, clones were successfully 
isolated that bound to the hapten-protein conjugate, but not to the carrier protein alone. 
Also, alternating the carrier protein used in affinity selection resulted in antibody clones 
with the same characteristics. Other methods of selection were also briefly explored, such 
as the use of haptens coupled directly to solid phases and use of BIAcore as an affinity 
selection system.
Detailed analysis of the clones derived from the affinity selection strategies, however, 
showed that these antibodies possessed only poor affinities to the hapten and bound 
predominantly to a combined protein-hapten epitope via a weak electrostatic interaction. 
Further characterisation suggested that this was most probably an interaction with the 
amino acid by which the hapten was attached to the parent protein. The structural 
simplicity and hydrophobic nature of these haptens militated against producing antibodies 
recognising free drug alone. To avoid this, conjugates utilising different conjugate 
chemistries would be desirable. In this way, selection would not be made predominantly 
against the type of linkage between hapten and carrier protein, but to the hapten alone. 
The other strategy of direct attachment of haptens may also be useful in this regard.
In vitro methods for the production of 7-hydroxycoumarin-glucuronide were developed 
using liver UDP-glucuronyl transferase from both bovine and porcine sources. These 
methods were accompanied by the development of methods for the analysis of 7- 
hydroxycoumarin-glucuronide using HPLC and CE. Methods were also developed for the 
purification of 7-hydroxycoumarin-glucuronide, from in vitro enzymatic synthesis, and 
from the urine of patients treated with coumarin. Finally, different means of producing 
protein conjugates of the glucuronide were investigated. An in vitro enzymatic synthesis 
route was found not to be viable due to the complexity of the reaction product. Linkage 
of the 7-hydroxycoumarin-glucuronide via the carboxyl group of the glucuronide residue 
using EDC/NHS chemistry was simpler and resulted in a higher yield of pure product, 
which could then be used for antibody production in either the ways previously discussed, 
or through the more traditional means of polyclonal and hybridoma production.
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In summary, this work has contributed to the understanding of the mechanisms at work 
during affinity selection strategies to small, hydrophobic haptens, and has illustrated the 
special considerations required when working with such molecules. A significant 
contribution has also been made to the study of phase II metabolism of coumarin, by the 
development of in vitro metabolic methodologies and the analytical tools to accompany 
them. Also, the production of conjugates with which to produce antibodies to the phase 
II metabolite leaves possible further immunoanalytical research in this area.
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APPENDIX 
Prize winning essays in Biochemistry
The Antibody Army: Friend or Foe?
Royal Irish Academy, National Committee for Biochemistry, Scince Writing Competition Winner, 1996.
A n tib o d ie s !  Even my five year old nephew has 
heard of them: some alien superhero producing 
antibodies against a mutant virus created by an evil 
scientist to destroy the world...and all that on a 
children’s cartoon. But what are they? They are 
protein molecules found in your bloodstream. Their 
function is to seek out foreign bodies such as 
viruses and bacteria and mark them for destruction. 
Hence the name ’anti-bodies’. The antibody army is 
a large one with an estimated one hundred million 
million million antibody molecules circulating in the 
body.
The shape of antibody molecules (also called 
immunoglobulins) is essential to the way they seek 
out alien invaders in the bloodstream. Their basic 
structure is often thought of in terms of the shape 
of the letter Y. The two arms of the Y are identical 
to one another. Each is able to attach to the foreign 
invader which is now called an antigen. The stem 
part of the Y interacts with the rest of the body’s 
immune system, which results in the destruction of 
the foreign body.
Although all antibodies have the same basic 
structure, they can combine to form larger 
molecules that each perform slightly different jobs 
(Figure 1). The mainstay of the antibody army is 
the single Y molecule, called IgG (meaning 
immunoglobulin G). Another single Y molecule is 
called IgE. IgE have a special function in helping to 
combat parasitic infections. These have gained 
much attention because of their link with allergic 
responses, something we will return to later. IgA 
molecules are made up of two Ys linked tail to tail. 
These are important in protecting the external 
linings of the body, most importantly, the lungs and 
the alimentary canal. The biggest Ig molecule is 
IgM. Here, five Ys join in a ring structure. These 
are produced early on in the body’s response to 
infection and so are weaker than the IgG molecules 
that are produced later. The presence of 10 places 
at which to attach the enemy invader helps to 
compensate for this weakness.
So how do these molecules seek out enemy 
invaders and go about having them destroyed, and 
how can they tell whether they are enemy invaders 
or not? Although the basic structure of each 
antibody is the same, the areas at the tips of the Y 
arms are different from one antibody to the next.
Figure 1. Antibody subclasses. IgG is the main 
antibody present in the body, accounting for 70- 
75%. IgA accounts for between 15 and 20%, and 
IgM makes up about 10%. IgE is only present in 
trace quantities.
Each antibody is produced by a different antibody- 
producing cell called a B cell. It is reckoned that 
the body can generate more than one hundred 
million different antibody molecules in this way. 
These will all attach themselves to slightly different 
chemical structures including those present in the 
body. Early in human development, before birth, the 
immune system is in a learning mode. Protected by 
the mother’s immune system, and so being free of 
any foreign bodies, the only molecules present are 
that of the growing infant. These are called ’self 
antigens. Many of the antibodies produced will 
attach to these self antigens. These antibodies are 
then removed from the immune system, or rather 
the B cells that produce them are removed. All that 
should remain are B cells that produce antibodies to 
molecules not already present in the body. This still 
leaves many millions of combinations that can seek 
out and bind to antigens present on viruses, bacteria 
and parasites. The immune system is now ready to 
take on all comers. However, it still has a lot to 
learn.
If the body becomes infected with, for example, a 
bacteria it has never encountered before, then 
somewhere in the immune system there is an 
antibody or even several antibodies that can bind to 
it. These could be spread out through the blood 
stream and lymphatic system. Lymph nodes are like 
busy market places for cells of the immune system. 
Here, many B cells can come into close contact 
with other immune cells, along with the invading 
bacteria. In this way, the bacteria has more chance
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of coming into contact with B cells that produce 
antibodies which can attach to it. When this 
happens, the B cells producing these antibodies are 
triggered to multiply very rapidly and produce more 
antibody against the bacteria. So, often the first sign 
of infection can be the swelling of lymph nodes due 
to this extra activity. Most people are familiar with 
the swelling of their tonsils in response to a 
bacterial infection.
The antibodies produced at this early stage do not 
bind to the foreign body that strongly, so IgM 
molecules are used which can bind at 10 sites per 
molecule. In the meantime, the B cells undergo 
further changes that ’fine tune’ the structure of the 
antibody so as to bind more and more strongly to 
the foreign antigen. This strength of antibody 
binding is called affinity. Eventually, the low 
affinity IgM molecules are replaced by high affinity 
IgG molecules. To become active, these IgG 
molecules must attach at both arms. This then 
allows the stem of the antibody to attach to other 
cells and molecules of the immune system. One 
important set of such molecules is called 
’complement’. Binding of antibody to the bacteria 
causes a series of changes in the complement 
molecules, one result of which is the Membrane 
Attack Complex, where a hole is formed in the 
membrane of the bacteria, allowing its contents to 
spill out and be destroyed (Figure 2). Many other 
cells also attack foreign bodies such as cytotoxic T 
cells (Tc) which recognize antigen and natural killer 
(NK) cells which recognize the stem part of the 
antibody that is bound to antigen. These produce 
cocktails of enzymes that can also attack and break 
down bacteria and parasites. If the immune system 
wins the batde, all the foreign invaders are 
destroyed. Many of the B cells that produced the 
antibodies now go on to form memory cells. These 
are long-lived B cells that stay dormant, but are 
activated when the same invader tries to attack 
again. This is thankfully why, with most diseases, 
we only suffer them once.
Understanding the workings of the immune system 
allows us to go one step further and prevent the 
body from ever having to suffer a disease. This is 
the principle of vaccination. Here, the body is 
allowed to encounter the enemy on safer territory. 
In the case of viral immunizations, such as the 
measles, mumps and rubella viruses (MMR), the 
body is supplied either with virus that has been 
killed or virus that has been severely disabled, so 
making it incapable of causing disease. Antibodies 
are still produced against it and this results in
Figure 2. Antibody-mediated destruction o f a 
bacterial cell. Antibodies attract proteins in the 
blood called complement. These form a ring 
structure in the membrane surrounding the bacterial 
cell causing its contents to leak out. It also attracts 
other cells to the bacteria which release enzymes 
that break down the bacteria. The B cells producing 
these antibodies can go on to form long-lived B 
cells.
subsequent resistance to disease.
So the antibody army keeps us alive from moment 
to moment. Its surveillance of our body for foreign 
invaders is constant and unceasing and goes on 
mosdy without us noticing. The antibodies of our 
immune system are something we take for granted. 
The immune system is, however, extremely 
complex, and much of it remains undiscovered and 
poorly understood. Such complexity also leads to 
fallibility, and the immune system can fail to 
function in many ways. Many of these relate to how 
the antibody carries out its functions. In these 
instances, the antibody is guilty of treachery, 
turning on the body and inflicting damage.
Disease brought about by the failure of antibodies 
to function correctly can be broadly categorized into 
two groups between which there is considerable 
overlap. These are hypersensitivity and 
autoimmunity. Hypersensitivity refers to the 
misguided or exaggerated immune response, 
whereas autoimmunity refers to the attack by the 
immune system upon its own body.
The most common form of hypersensitivity is that 
of the allergic reaction. Most allergies are against 
substances in the environment that are of little or no 
harm, such as pollen, dust, penicillin and nut oils. 
The immune system, for reasons that are poorly 
understood, designates these as dangerous foreign 
invaders and mounts an immunological attack 
against them. In these cases the allergic response is
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led by IgE antibodies. These are particularly 
powerful activators of immune cells called mast 
cells. These cells are stimulated to release 
extremely powerful and fast acting chemicals such 
as histamines, heparin, and prostaglandins. These 
bring about an immediate and extreme 
inflammatory response. In hay fever, the symptoms 
are runny nose, streaming eyes, itching, etc. This 
response is quite localized and not life threatening. 
Many people are also allergic to the dust mite, or 
rather its faeces. When these enter the lungs in 
airborne dust, an asthmatic response may result 
which inflames the airways, restricting breathing. 
This can, in the most extreme of circumstances, 
close the airways completely. The Asthma Society 
of Ireland estimate that a quarter of a million Irish 
people currently suffer with asthma. The incidence 
is much higher among children where 1 in 7 are 
thought to be affected, compared with 1 in 20 adult 
sufferers. Other more severe allergic responses are 
against antigens such as bee venom, certain nut oils 
and penicillin. Challenge with these antigens results 
in a systemic effect known as anaphylaxis. Here, 
mast cells are stimulated by IgE throughout the 
body. The most severe result of this is the loss of 
fluid from the blood stream into the surrounding 
tissues. This can result in the collapse of the 
circulation which may cause heart failure and death. 
An injection of adrenalin reverses most of these 
effects, along with a drip to restore blood volume.
The production of IgE antibodies is believed to be 
important in the battle against parasitic infections 
such as worms. Modern Western man is less prone 
to parasitic disease, and so this element of our 
immune system is less used. It is not yet clear why 
the body decides to make IgE antibodies to 
substances such as pollen, penicillin and nut oils, 
and not to other substances in the environment, or 
more importantly, why it makes them at all. Many 
believe that modem day environmental factors such 
as pollution and diet may be contributing to the 
allergic response. Whatever their cause, allergies are 
increasing in our modern world.
Another disease brought about by the misguided 
production of antibodies is haemolytic disease of 
the newborn. This can occur when a mother has a 
different blood group to her unborn infant. This 
occurs predominantly with an antigen found on red 
blood cells called Rhesus D. if the unborn infant 
has the Rhesus D antigen (Rh+) and the mother 
does not (Rh‘), the mother will produce antibodies 
to the infant’s Rhesus antigen. At the birth of a first 
child, some of the infant’s red blood cells can be
passed back into the mother’s circulation. This is 
the time at which the mother’s immune system 
produces anti-Rhesus antibodies. If the mother has 
subsequent Rh+ babies, these anti-Rhesus IgG 
antibodies will cross the placenta and attack the 
growing infant’s red blood cells, causing 
widespread symptoms, damaging the spleen and 
liver which becomes enlarged and results in 
jaundice. These symptoms can be prevented by the 
administration of an anti-D antibody to the mother 
following the birth of her first Rh+ child. These 
antibodies clear up any of the infant’s blood cells 
that may have entered her body and so a response 
is not mounted by the mother’s immune system. 
This has greatly reduced the incidence of, and 
resulting death from this disease since the 
introduction of anti-D in the 1970s.
Autoimmunity can result in many diseases that 
attack various parts of the person’s own body. 
Three such diseases are myasthenia gravis, 
rheumatoid arthritis and multiple sclerosis.
Figure 3. Myasthenia gravis. In a normal nerve 
impulse, the signal reaches the motor neuron end 
plate and causes the release of acetylcholine (ACh) 
which then crosses the synapse and binds to ACh 
receptors on the muscle. Autoantibodies associated 
with myasthenia gravis bind to the ACh receptors 
and prevent the binding o f ACh. The impulse is 
weakened and this leads to decreased muscular 
movement.
Myasthenia gravis is a very rare disease which 
results in extreme muscular weakness. In this 
condition, ’self’ antibodies (also called 
autoantibodies) are produced that cause the blocking 
of signals that are transmitted by nerve cells 
(neurons) from the nervous system to the muscles 
(Figure 3). To allow a muscle to move, an electrical 
impulse must pass from the nervous system 
(initially from the brain) to a muscle. To do this, it 
must travel from one neuron to the next. These
322
neurons have gaps between them called synapses. 
For the signal to pass from the end of one neuron 
to the start of the next, several types of transmitter 
chemical can be released from the neuron carrying 
the signal which travels across the synapse and 
stimulates the next neuron to trigger an impulse. 
One of these chemicals is called acetylcholine 
(ACh). In myasthenia gravis, antibodies are 
produced that bind to the receptors of ACh on the 
last nerve that connects to the muscle. Not as much 
ACh is allowed to reach the muscle, and this results 
in a weakened signal which impairs muscle 
movement.
Rheumatoid arthritis is a familiar disease to many. 
It results in the inflammation of the joints, often 
those in the hands, wrists and elbows. Other joints 
are also affected. This all results in limited joint 
movement, pain and joint deformation which can 
often be permanent. According to the Arthritis 
Foundation of Ireland, 1% of the Irish population 
are affected by rheumatoid arthritis, with women 
being three times more susceptible than men.
It is believed that rheumatoid arthritis is caused by 
an autoantibody of the IgM class. This antibody is, 
itself directed against an altered IgG antibody called 
rheumatoid factor. One theory suggests that an IgG 
antibody is initially produced to combat damage due 
to injury or infection at the joint. This IgG may 
itself become damaged as a result of the 
inflammatory response. This damaged IgG may 
then be seen by the immune system as foreign, 
whereupon, it produces an IgM antibody against it.
This would lead to further damage due to 
inflammation and further modification of antibody 
(Figure 4). This cyclical pattern of inflammation 
leads to the long-term, progressively worsening 
symptoms that are characteristic of rheumatoid 
arthritis.
Multiple sclerosis (MS) is another disease that 
affects cells of the nervous system. This time, the 
cells affected are those of the central nervous 
system, namely the brain and the spinal cord. These 
areas are also made up of neurons. These neurons 
in particular have a protective coating called 
myelin. This acts like an insulator and helps the 
passage of electrical impulses along neurons. MS is 
caused by the production of autoantibodies to this
myelin layer. This results in its destruction and the 
impaired functioning of the nerves themselves when 
damaged myelin is replaced by scar tissue (Figure 
5). Symptoms resulting from this are lack of 
muscular control, or loss of movement. The disease 
is slow but progressive. It is characterized by 
unpredictable periods of remission and exacerbation 
and has also been known to spontaneously clear up 
completely. MS is a very relevant Irish problem. Its 
prevalence is particularly high here, with 
approximately 1 in 1,000 suffers.
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Figure 4. Rheumatoid arthritis. Initially, IgG 
present in the joints becomes damaged in some 
way. This rheumatoid factor (RF) causes the 
production o f an IgM antibody against it. This IgM 
recruits immune chemicals to the region which 
damage surrounding tissue such as cartilage and 
the synovial membrane. They also further damage 
IgG producing more rheumatoid factor, and so 
producing more anti-RF IgM antibody.
Figure 5. Multiple sclerosis. Autoantibodies are 
produced to the myelin sheath surrounding nerves 
of the central nervous system. These result in 
damage which is repaired by scar tissue. This 
damaged tissue impairs the quality o f the myelin 
sheath and reduces the quality o f the nerve 
impulses.
The cause of MS is still very unclear. Most now 
believe it is a result of a combination of factors. 
These may be a viral infection and an 
environmental factor. Genetic predisposition may 
also be involved. Many candidates for both the viral 
and environmental cause have been put forward. 
The most popular viral culprit at present is the
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measles virus. In some instances, measles infection 
may bring about damage of myelin. This damaged 
myelin may then be seen by the immune system as 
foreign which then produces antibodies against it. 
These antibodies may cause the myelin further 
damage. Some believe that parts of the measles 
virus look like myelin, and so in producing 
antibodies against the virus, the same antibodies 
also cause damage to the myelin. The relationship 
between measles virus and MS is made hard to 
study because disease symptoms do not occur until 
many years after measles infection. Attempts to 
unequivocally link the two have not yet proved 
possible.
Antibody soldiers are very powerful and have at 
their disposal the considerable resources of the 
immune system. This gives them the strength to
defend us from very many bacteria, viruses and 
parasites. They do, however, carry a double-edged 
sword, which, when turned upon the body can 
inflict considerable damage, and even kill. Research 
in immunology is some of the most exciting and 
fast moving in modern science. The untold 
complexity of the immune system ensures this will 
be a long task. As more becomes known, however, 
ways of directing the immune system to even 
greater good will be discovered. One such exciting 
area is the immunotherapy of many cancers. Further 
knowledge of the immune system will no doubt 
help us in the fight against many diseases. This 
knowledge will also show why the immune system 
sometimes turns on itself, causing what seems to be 
needless self destruction. In understanding this, 
even better cures for autoimmune diseases such as 
rheumatoid arthritis, myasthenia gravis and multiple 
sclerosis will inevitably follow. We wait.
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It’s Life Jim, but not as we Know it!
Royal Irish Academy, National Committee for Biochemistry, Science Writing Competition, Runner up, 1997.
With the discovery of viruses just over 100 years ago, and with the more recent 
discoveries of viroids (naked nucleic acids) and prions (the cause of BSE or mad cow 
disease), these biologically simple creations are challenging the traditional definitions of 
that elusive entity...LIFE!
MERRING! No its not a Serbo-Croatian swear word, but an acronym used to teach the characteristics possessed 
by all living things: Movement, Excretion, Respiration, Reproduction, Irritability, Nutrition and Growth. All 
living things can move in some way, whether towards a stimulus such as food or light in plants, or by 
locomotion as in animals and humans. Excretion involves the removal of harmful waste products from an 
organism. Everyone is familiar with the waste product produced by yeast fermentation, alcohol. To produce 
energy with which to carry out the processes of life, all living things must perform respiration. This involves 
the release of energy from energy-rich molecules such as glucose. Although carbon-containing (organic) sources 
of energy are the most common, many microorganisms can use non-carbon (inorganic) sources such as sulphur 
bacteria in hot volcanic springs. To perpetuate themselves, all organisms must also possess the most important 
quality of life. Its ability to reproduce. This can be in the simple form of asexual reproduction from a single 
parent, or sexual reproduction with one offspring resulting from two parents. Both result in the perpetuation of 
the species and also introduce genetic diversity, resulting in its evolution. Irritability involves the sensing of, and 
response to the environment. In higher mammals such as humans, this is extremely complex and is controlled 
through our nervous system, but it is also present in extremely simple forms of life, for example when an 
amoeba responds to the presence of a harmful substance in its surroundings and move away from it. Nutrition 
is the intake of all the chemical substances required for the life processes of an organism which it is incapable 
of producing for itself. Nutritional complexity tends to increase with the complexity of the organism. Humans 
must take in large numbers of nutrients including carbon-containing compounds for energy and biosynthesis, the 
building blocks of life. Plants, however, require only carbon dioxide, oxygen, water, energy from the sun and 
several other inorganic components from which they synthesise all the materials with which they need to survive. 
Finally, a result of these combined life processes is an increase in the size and complexity of all living things, 
simply referred to as growth. Growth periods vary enormously from as little as 20 minutes for some bacteria 
to hundreds of years for some of our oldest trees.
However diverse, all forms of life on our planet have these seven traditionally defined characteristics. They have 
also all been found to carry out these life processes using the same fundamental building blocks. Cells. Alone, 
or in combination with other cells, all these functions can be performed.
The Cell - The Protein Factory
lust as diverse forms of life perform these same basic functions, so too all cell types, no matter how different, 
also cany out the same fundamental processes, the most important one of which is the production of proteins. 
Nearly all the functions of the cell are carried out using some protein or other. They are either structural or 
enzymes which direct and control all the reactions that take place within the cell. So important are they that the 
cell directs large amounts of resources to their production. In fact a quarter of the cell’s dry mass is made up 
of the protein-making machinery, ribosomes. These are like individual self-contained assembly lines for proteins 
in the giant protein factory which is the cell (Figure 1). All the genetic information for the production of all these 
proteins is contained in the nucleus of the cell in the form of DNA (deoxyribonucleic acid). The DNA is like 
a permanent record of what the cell does and how it does it, and is extremely precious as it must be replicated 
faithfully to each generation. It is too precious to be used again and again to promote protein production directly. 
Much like an important piece of computer software, the DNA is used as the master copy for the production of 
working copies of the information. In a cell, these working copies for protein production are called RNA 
(ribonucleic acids), and though different from DNA in many ways, still encode the same information for protein 
production. Another reason for the presence of RNA is that DNA contains not only the information necessary 
for that cell, but also the information for every cell in the body. Obviously not all this information is required 
for our single cell, and only the information necessary is converted into RNA. The RNA molecules then travel
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to the ribosome protein assembly line and the RNA is read into the ribosome like a punch tape. The information 
is read off the RNA in sequence, three nucleic acids at a time, each triplet encoding for a different amino acid 
to be joined to the growing chain. Eventually, the whole protein is synthesized, correctly folded and transported 
off to the part of the cell where it performs its function. All these proteins contribute to the performance of all 
our ’life’ tasks: movement, excretion...etc. In this way a basic mechanism for the existence of life can be seen 
in this three step process of DNA to RNA to protein. However, nature has found ways of producing much 
simpler forms of reproductive structure that are clearly ’life’, but do not conform to the basic cellular definition.
Figure 1. The Cell -The Protein Factory
DNA in the nucleus is transcribed to RNA which is read by ribosomes and converted into protein sequences. 
These proteins become folded and undergo further modifications and are transported to the region o f the cell 
where they perform their function.
Viruses
Before the invention of the microscope, the cause of microbial disease remained unknown. All that could be 
shown was that certain tissues from infected individuals remained ’infectious’ when brought into contact with 
healthy individuals, but when passed through fine clays, many such infectious tissues were rendered innocuous. 
Then with the invention of the light microscope, the cause of so many of these diseases (bacteria and other 
microorganisms) could now be seen directly.
It was a Russian scientist, Iwanowsky, who first observed that some infections still remained upon filtration. 
These smaller infectious agents he called viruses. And although most of the characteristics of viruses were 
defined indirectly, they were only visualized directly for the first time in 1942 with the invention of the electron 
microscope, the only device capable of visualizing these extremely small entities.
If viruses are not cells, what are they? They are basically composed of a nucleic acid (DNA or RNA), 
surrounded by a protein coat called a capsid. The capsid is composed mostly of repeating protein subunits which
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tend to give viruses the most fascinating geometric shapes (Figure 2), but which protects the nucleic acid from 
environmental hazards such as ultraviolet radiation. Some viruses also surround themselves with a membrane 
called an envelope which they ’steal’ from other cells. In fact everything a virus has, it has stolen from a cell.
Viruses carry out only one of our seven life functions; reproduction. When a virus comes into contact with some 
suitable uninfected host cells, (for example, influenza viruses in the air when someone sneezes for instance). 
These get carried to the cells of the lungs. Viruses have then developed clever ways of getting the cell to bring 
it inside. When this occurs, the cell is now doomed to become a slave to the viruses voracious reproductive 
appetite. The viral nucleic acid has been specially designed to hijack all the assembly line machinery of the cell 
to producing its own proteins and replicating its own nucleic acids. These then assemble into mature virus 
particles called virions. Eventually the cell becomes full to bursting with virus particles. The cell bursts (and 
dies), leaving the virions to go off and infect neighbouring cells or to be passed to other individuals.
Viruses have ’discovered’, if you like, that they do not need all the machinery for reproducing themselves They 
can just borrow it (steal it?) from cells that do. This brings us closer to a definition of what constitutes life: that 
which can perpetuate itself. Many may argue with such a definition for various reasons, but all those things that 
we clearly agree are life exhibit this characteristic at least.
I
Figure 2. The Adenovirus
The adenovirus is composed o f an icosahedral capsid encapsidating a DNA nucleic acid.
Viroids
Several plant diseases had been studied for which no infectious agent (fungal, bacterial or viral) could be 
identified. The only component that could be found in diseased extracts was RNA. After much study, it became 
clear that these plants were being infected by another new agent never seen before; a naked nucleic acid. This 
they called a viroid.
327
Viroid RNA is fascinating in that it alone is able to redirect the plant cell for its own reproduction. It is 
extremely resistant to the environment such as ultraviolet radiation and is at a lesser risk that animal viruses 
because of the absence of a plant immune system. The viroid RNAs are also inclined to bend and fold producing 
much secondary structure, which may allow them to behave like a protein and actually ’do things’, rather than 
just get replicated. In fact, the RNA in cells also possess much secondary structure which is all involved in the 
control of protein production. The RNA from plant viroids is extremely similar to some of the plant’s own 
nucleic acid. It is likely that the viroid ’evolved’ to become separated from the plant RNA and developed the 
ability to be replicated by the plant’s cells in much the same way as viruses are.
Now we see two very important elements to our new definition of life: reproduction and evolution. What is 
occurring is that as these viroids and viruses (and indeed cells) replicate, they do so quite faithfully, but not so 
faithfully as mistakes cannot happen. This leads to minor changes that may or may not be an improvement on 
the previous generation. Those changes that are an improvement - that is they help survival and further 
reproduction - may result in those individuals doing better than others in the population and so replicate more 
successfully. Evolution is just a result of the demand put on a faulty replication mechanism to improve.
Many have speculated that these RNA molecules could have been the first forms of life on our planet. Only they 
have been shown to possess the ability to carry information in the form of the genetic code, but also like proteins 
to ’do things’, because of their secondary structure.
Viruses and viroids both fit our new definition. But is there anything else out there that doesn’t conform to these 
rules? A group of diseases called the spongiform encephalopathies were thought for a time to be either the result 
of viruses or viroids, but no genetic material could ever be found associated with the disease. Their cause has 
only been seriously established in the last decade or so.
Prions
An isolated tribe were discovered in Papua New Guinea in 1957 who still practised cannibalism. It was also a 
male dominated society, and at meal times, the men would get all the good quality muscle tissue, but the women 
and children would be left with the offal and brains to eat. Accordingly, there was a high incidence of a disease 
in the women and children called Kura. This is a neurological disorder, very similar to diseases in the Western 
world such as Creutzfeldt-Jacob’s disease (CJD) and Gerstmann-Straussler syndrome (GSS). These 
neurodegenerative disorders are ultimately fatal. A similar disease in sheep, scrapie, has also resulted in the 
infection of cattle via dietary supplements which resulted in the cattle epidemic bovine spongiform 
encephalopathy (BSE) or mad cow disease. Spread of the disease to humans from meat containing infected offal 
has also been identified. The disease reached epidemic proportions in the United Kingdom, but due to strict 
control measures in Ireland, only isolated cases have occurred with no transmission to man having occurred here.
Out of any infectious disease this group of diseases has probably seen the most argument and debate as to their 
cause. Doctors who had studied patients with these diseases knew it to have a genetic component (nucleic acid), 
because diseases such as fatal familial insomnia (as the name suggests), were passed on in families. (Diseases 
such as CJD are familial and have also been contracted from infected growth hormone extract injected to treat 
dwarfism). Other scientists, however, could also demonstrate that these diseases were infectious and could be 
passed from one individual to the next, but that the infectious material did not contain any nucleic acids at all.
Following much intensive research, it has been found that the infectious component of this group of diseases is 
a protein, and for this reason they were termed prions (protein infectious agents). Prior to this, only agents 
carrying genetic information were shown to be capable of causing infectious disease. How was a protein able 
to bring about its own propagation, and what is the involvement of the genetic component that has been shown 
to exist?
I am sure much detail has still to be worked out, but the basic, underlying mechanism has now been elucidated 
sufficiently (Figure 3). The prion protein is a normal protein produced by cells in the brain. Its exact function 
has not been concluded yet. Genetic mutations in the DNA that codes for this protein have been shown to be 
linked with many of the cases of the disease that are passed down through families. These mutations bring about
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an incorrect, misfolded version of the protein. Normally, such misshaped proteins would be destroyed, but in 
this instance, the changes in the protein’s shape lead to several interesting characteristics. The protein becomes 
insoluble, which also renders it resistant to biochemical breakdown by protein-digesting enzymes called 
proteases. This insoluble, indigestible protein material builds up in areas of the brain forming crystalline 
structures which gradually damage brain tissue in small, discrete patches, giving the brain a sponge-like 
appearance, hence spongiform encephalopathies. This, however, is only half the story. If a healthy, uninfected 
individual ingests (or injects) some of this material into their body, the harmful protein resists any attempts at 
digestion and enters the body. When it reaches the brain, the ’bad’ prion protein comes into contact with ’good’ 
prion protein. The two proteins join together to form a complex in some way, which results in the bad prion 
protein changing the shape of the good protein. In a sense, bad prion protein has brought about its own 
replication. These two molecules of bad prion protein now come into contact with others, also resulting in their 
conversion. This process moves relentlessly on until enough damage accrues, causing death. No cure is yet 
available for these diseases, although drugs are available which slow their progression.
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Figure 3.
Mechanism of Prion Replication
Misfolded ’bad’ prion protein from either infectious or genetic sources comes into contact with correctly 
folded prion protein. Following complex formation, the correctly folded prion protein becomes misfolded. Now 
both proteins can go on to form complexes with correctly folded protein.
Does the prion fit our definition of life? Well it can reproduce itself using the components of a cell, just as 
viruses do. It does not, however, control its own evolution. This is selected for by genetic changes in a protein 
gene in the original ’host’ individual, in whom such a mutation is of no evolutionary benefit. Once having left 
its original ’host’, however, it does not appear to require an evolutionary mechanism by which to be sustained. 
But lacking the ability to mutate and change with the times, measures to control infection and genetic screening 
to reduce familial propagation of the disease may bring about their demise.
'GOOD'
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Thus, viruses and viroids do get safely into our definition of what is life. The prion is on shakier ground, 
however, but maybe if discovered on another planet, in another galaxy, we would hear that now familiar trekky 
phrase "It’s life Jim, but not as we know it."
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